Top

Anil K. Sood, M.D.

Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery

Meet Anil Sood, M.D.

In the News

Power blush, bronzer, and eye shadow with makeup brushes

Is talc in makeup safe?

Cancerwise blog post: Dr. Anil Sood discusses ovarian cancer symptoms, diagnosis and treatment, as well as MD Anderson's Ovarian Cancer Moon Shot.

Ovarian cancer diagnosis and treatment: What’s new

Present Title & Affiliation

Primary Appointment

American Cancer Society Professor, The University of Texas MD Anderson Cancer Center, Houston, Texas

Frank McGraw Memorial Chair in Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Co-Director, Women's Cancer Moonshot Program, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Director, Blanton-Davis Ovarian Cancer Research Program, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Vice Chairman, Translational Research, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Co-Director, Center for RNA Interference and Non-Coding RNA (Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer), The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Graduate Faculty, Regular Member, Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Texas

Education & Training

Postgraduate Training

1995-1998	Fellow, Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
1991-1995	Resident, Obstetrics and Gynecology, University of Florida, Gainesville, Florida

Licenses & Certifications

2011	NCI Investigator
2002	Texas Medical Board
2001	American Board of Obstetrics and Gynecology, Certification of Special Qualifications in Gynecologic Oncology
1999	American Board of Obstetrics and Gynecology
1993	Florida Licensure
1991	Federation Licensing Examination

Experience & Service

Administrative Appointments/Responsibilities

Member, Research Council, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2013

Director, Journal Club, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2012

Director, Fellow Education, Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA, 2000 - 2002

Other Professional Positions

Member, Panel for developing guidelines on the management of adolescents and young adults suffering from non-epithelial ovarian cancers, The European Society of Gynaecological Oncology (ESGO) with the European Reference Network for Rare Adult Solid Cancers (EURACAN), Gynecoligic Cancer InterGroup (GCIG) and European Society for Paediatric Oncology Europe (SIOPe), 2026 - 2027

Rare gynecologic tumors registry, International Gynecologic Cancer Society, 2026

Board of Directors (North American Regional board representative), International Gynecologic Cancer Society (IGCS), 2025 - 2028

Member, Expert Panel on PARP Inhibitors in the Management of Ovarian Cancer Guideline, American Society of Clinical Oncology, Alexandria, Virginia, 2025 - 2026

SGO Pathways to Progress: A State-of-the-Science Research Summit in Gynecologic Oncology, Baltimore, MD, Society of Gynecologic Oncology, Baltimore, MD, 2025

Member, Ethics Committee, Society of Gynecologic Oncology, Chicago, Illinois, 2024 - 2026

Member, SGO and FWC strategic planning retreat, 2024

Co-Chair, Translational Research (TR) Sub-Committee, Gynecologic Oncology Group (GOG) Partners Investigators Council (IC), 2023 - Present

Member, SGO CEO Search Committee, Society of Gynecologic Oncology, Chicago, Illinois, 2023 - 2024

Scientific Program Steering Committee, Society of Gynecologic Oncology (2024 Meeting), 2023 - 2024

NCI NCTN Core Correlative Sciences Committee (NCTN-CCSC), NCI, 2022 - Present

Mentor and speaker, SGO Bridges Course, 2022 - Present

Pelotonia-AACR Women’s Cancer Initiative Scientific Advisory Committee (SAC),, AACR, 2022 - Present

Board of Directors, Society of Gynecologic Oncology (SGO), 2021 - 2024

Scientific Program Committee, and Co-Chair of Master Session on Ovarian Cancer, International Gynecologic Cancer Society (IGCS) 2022 Annual Global Meeting, 2021 - 2022

Chair, Executive Committee, Reproductive Scientist Development Program, 2020 - Present

Member, Honors & Awards Committee, SGO, Chicago, Illinois, 2020 - 2022

Member, Research Management Task Force, SGO, 2020 - 2021

Member, Conquer Cancer Foundation Grants Selection Committee, ASCO, Alexandria, Virginia, 2019 - 2022

Workshop on “Difficult questions in ovarian cancer research”,, IARC and NCI, Lyon, 2019

Nominating Committee, SGO, Chicago, Illinois, 2018 - 2020

Member, FDA-AACR-SGO Workshop on Drug Development in Gynecologic Malignancies, SGO, Chicago, Illinois, 2018

Ad hoc reviewer, External Advisory Board (EAB), Dana Farber/Harvard Cancer Center, 2017

Member, Fellowship Committee, American Gynecological & Obstetrical Society, 2016 - 2018

Member, Program Committee and Executive Advisory Board Member, The Nano/Molecular Medicine and Engineering Conference, 2016 - 2018

Clinical Trials Planning Meeting on Moving Forward in Endometrial Cancer: Designing Targeted Trials for Targeted Endometrial Cancer Populations using Targeted Agents, NCI GCSC, Rockville, Maryland, 2016

Panel on Opportunities for Cancer Prevention during Early Adulthood: Putting Scientific Evidence into Public Health Practice, Centers for Disease Control (CDC) and the National Association of Chronic Disease Directors (NACDD), Atlanta, GA, 2016

Scientific Advisory Committee, Ovarian Cancer Research Fund Alliance (OCRFA), 2016

Member, External Advisory Board, Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina, 2015 - 2019

Member, Scientific Program Committee, 47th Annual Meeting on Women’s Cancer (SGO, 2016), 2015 - 2016

Member, Search Committee for Vice President, Therapeutics Discovery, 2015 - 2016

Judy’s Mission Advisory Committee, The Judith Liebernthal Robinson Ovarian Cancer Foundation, 2015

Session Chairman: Metastatic Cell Plasticity, An AACR Special Conference on Tumor Metastasis, 2015

External Advisory Committee, Department of Biomedical Engineering, Rice University, 2014 - 2016

Member, Institute of Medicine Committee on the State of the Science in Ovarian Cancer Research, 2014 - 2015

Scientific and Medical Advisory Board, Ovarian Cancer National Alliance, Washington, District of Columbia, 2013 - 2016

AACR Surgical Oncology Task Force, AACR, Philadelphia, Pennsylvania, 2013 - 2015

Chair, Education Session: Pathways in Gynecologic Malignancies, 2013 Annual Meeting of the American Society of Clinical Oncology, 2013

Chairman, Awards Committee, Foundation for Women's Cancer, 2012 - 2021

Scientific Program Committee and Steering Committee, 44th Annual Meeting on Women's Cancer (SGO, 2013), 2012 - 2013

Clinical Trials Committee, 2012 Annual meeting of the American Association for Cancer Research, 2012

Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2011

Co-Organizer, Biobehavioral Research Network, NCI, 2010 - 2017

Internal Advisory Board, Breast Cancer SPORE, MD Anderson Cancer Center, 2010 - 2015

External Advisory Board, Ovarian cancer SPORE Application, Memorial Sloan Kettering Cancer Center, New York, New York, 2010 - 2014

Member, Membership Committee, Society of Gynecologic Oncology, Chicago, Illinois, 2010 - 2014

Member,, Ovarian Task Force for the Gynecologic Cancer Scientific Steering Committee (GCSC) of the National Cancer Institute (NCI), 2010 - 2013

Chair, Ovarian Cancer Section - Research Summit, Society of Gynecologic Oncology, Chicago, Illinois, 2010 - 2011

Faculty, Vail Methods in Clinical Cancer Research Workshop Sponsored by ASCO and AACR, Vail, CO, 2009 - 2015

External Advisory Board, Mayo Clinic, Rochester, MN, 2009 - 2012

Scientific Program Committee, American Association for Cancer Research (100th meeting; Experimental and Molecular Therapeutics Section), Denver, Colorado, 2009

Invited Judge for Resident Research Day, Medical University of South Carolina Cancer Center, Charleston, South Carolina, 2009

External Advisory Board, Ovarian Cancer SPORE, Fox Chase Cancer Center, 2008 - 2012

Chairman, Internal Advisory Committee, U54 Puerto Rico Cancer Center/MD Anderson Cancer Center Partnership for Excellence in Cancer Research, 2007 - 2012

Awards Committee, Gynecologic Cancer Foundation, 2007 - 2012

Organizing Committee, The 37th Annual Meeting of the Felix Rutledge Society, Houston, TX, 2007

Scientific Program Committee, 11th Biennial Meeting of the International Gynecologic Cancer Society, Santa Monica, California, 2006 - Present

Executive Committee, Reproductive Scientist Development Program, 2006 - Present

Member, Gynecologic Cancer Scientific Steering Committee (GCSC), National Cancer Institute (NCI), Bethesda, MD, 2006 - 2010

Chair, Reproductive Scientist Development Program Scholar's Fund Committee, 2006 - 2008

Program Steering Committee, U54 Puerto Rico Cancer Center/MD Anderson Cancer Center Partership for Excellence in Cancer Research, 2006 - 2007

Scientific Program Committee, 11th Biennial Meeting of the International Gynecologic Cancer Society, Santa Monica, CA, 2006

Committee Member, Preparation of the 2006 Gynecologic Oncology (GO) Written Examination, American Board of Obstetrics and Gynecology, Dallas, TX, 2005 - 2009

Task Force on Behavioral Science and Cancer, American Association For Cancer Research, Philadelphia, Pennsylvania, 2005 - 2008

Consultantships, MedImmune, Inc, Gaithersburg, MD, 2005

Scientific Program Committee, Combined meeting of the Western Association of Gynecologic Oncologists and the Felix Rutledge Society, 2004

Member-at-Large, Western Association of Gynecologic Oncologists, 2003 - 2005

Member, Women’s Cancer Network (WCN) Editorial Committee, Gynecologic Cancer Foundation, 2002 - Present

Member, Education Committee, Society of Gynecologic Oncology, Chicago, Illinois, 2002 - 2010

Candidate member, Education Committee, Society of Gynecologic Oncologists, 2001 - 2002

Scientific Program Committee, Western Association of Gynecologic Oncologists, 2001

Gynecologic Oncology Group, Committee on Experimental Medicine, 1999 - Present

Candidates Task Force, Society of Gynecologic Oncologists, 1999 - 2002

Scientific Program Committee, Western Association of Gynecologic Oncologists, 1999

Extramural Institutional Committee Activities

Member, MSTP Board, The University of Texas MD Anderson Cancer Center, 2023 - Present

Chair, Cancer Biology Program (CBP) Faculty Application Review Committee, UTHealth and MD Anderson Cancer Center Graduate School of Biomedical Sciences (GSBS), 2023 - Present

Member, Executive Oversight Committee for the Advanced Microscopy Core facility, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, Steering Committee, Cancer Biology Program, UT MD Anderson UTHealth Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, Sabin Family Foundation Fellow Award Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

M.D./Ph.D. Program Board, UTHealth and MD Anderson Cancer Center Graduate School of Biomedical Sciences (GSBS), The University of Texas MD Anderson Cancer Center, 2014 - Present

Member, IAB, CCSG, Flow Cytometry / Confocal Microscopy Core Lab, The University of Texas MD Anderson Cancer Center, 2011 - Present

Member, Steering Committee, T32 Training Grant in Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 2005 - Present

Member, Fellowship Admissions Committee, The University of Texas MD Anderson Cancer Center, 2004 - Present

Member, Executive Committee, Blanton-Davis Ovarian Cancer Research Program, The University of Texas MD Anderson Cancer Center, 2004 - Present

Member, Fellowship Planning Committee, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 2003 - Present

Member, Tumor Bank Committee, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 2002 - Present

Editorial Activities

Editorial Board, Extracellular Vesicles and Circulating Nucleic Acids, 2024 - Present

Editorial Board, SN (Springer-Nature) Comprehensive Clinical Medicine, 2019 - Present

Editorial Board, Investigational New Drugs, 2017 - Present

Associate Editor, Nanomedicine: Nanotechnology, Biology, and Medicine, 2016 - Present

Editorial Board, Non-Coding RNA, 2014 - Present

Editorial Board Member, Journal of Ovarian Research, 2012 - Present

Editorial Board, Frontiers in Genetics (Non-Coding RNA), 2011 - 2024

Editorial Board, Cancer Hallmarks, 2011 - 2013

Editorial Board, American Journal of Cancer Research, 2010 - Present

Editorial Board, Journal of Clinical Oncology, 2010 - 2012

Associate Editor, Journal of Ovarian Research, 2010 - 2012

Deputy Editor, Gynecologic Oncology, 2008 - 2022

Editorial Board, Obstetrics and Gynecology International, 2008 - 2016

Editorial Board, International Journal of Women's Health, 2008 - 2015

Advisory Panel, US Obstetrics and Gynecology, 2007 - 2014

Editor, Prognostic and Predictive Factors in Gynecologic Cancers, 2006 - 2014

Editorial Board, Obstetrics and Gynecology, 2006 - 2010

Editorial Board, Gynecologic Oncology, 2006 - 2008

Editorial Board, Cancer Biology and Therapy, 2005 - 2019

Editorial Board, Current Women's Health Reviews, 2004 - Present

Editorial Advisory Board, Cancer, 2003 - 2018

Honors & Awards

2025 - Present	Waun Ki Hong Award for Excellence in Team Science – as member of the “Translational Nanotherapies Team”, The University of Texas MD Anderson Cancer Center
2024	Elected, National Academy of Inventors (NAI)
2024	Society of Gynecologic Oncology's 2024 Gynecologic Oncology Innovation Award, Society of Gynecologic Oncology
2023	Distinguished Alumnus Award, University of Iowa
2021	Elected, National Academy of Medicine (NAM)
2017	American Cancer Society Research Professor Award, American Cancer Society
2017	Elected, Association of American Physicians (AAP)
2015	Outstanding Achievement Award, Society of American Asian Scientists in Cancer Research (SAASCR)
2015	Making a Difference Award, The Belinda Sue Fund
2014	Rosalind Franklin Ovarian Cancer Research award, Ovarian Cancer National Alliance
2014	Society for Gynecologic Investigation President's Achievement Award, Society for Gynecologic Investigation
2012	Elected Fellow, The American Association for the Advancement of Science
2011 - 2012	America's Top Doctors for Cancer, Castle Connolly Medical Ltd. (U.S. News & World Report rankings)
2011	Dallas/Fort Worth Living Legend Faculty Achievement Award in Basic Research, MD Anderson Cancer Center
2011	GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher
2010	Elected, Fellow of the Academy of Behavioral Medicine, Academy of Behavioral Medicine
2009	Elected Member, The American Society for Clinical Investigation
2009	Excellence in Teaching Award, Association of Professors of Gynecology and Obstetrics, The University of Texas M.D. Anderson Cancer Center
2008	Elected Fellow, The American Gynecological and Obstetrical Society
2008	Elected, Alpha Omega Alpha Honor Medical Society
2007	Educator of the month, The University of Texas M.D. Anderson Cancer Center
2007	Excellence in Ovarian Cancer Research Award, The Gynecologic Cancer Foundation/Margaret Greenfield/Carmel Cohen, MD
2006 - 2009	Faculty Scholar Award, The University of Texas M.D. Anderson Cancer Center
2005	Educator of the Month, UT M.D. Anderson Cancer Center
2004	James F. Nolan Award for the best overall research presentation, Western Association of Gynecologic Oncologists and the Felix Rutledge Society, Monterey, CA
2003	Outstanding educator, The University of Texas M. D. Anderson Cancer Center
2003	Charles A. Hunter, Jr. Prize Thesis Award, The American Gynecological and Obstetrical Society, Napa, CA
2002	James F. Nolan Award for the best overall research presentation, The Annual Meeting of the Western Association of Gynecologic Oncologists, Newport Beach, CA
2002	Invited expert for the Biological Mechanisms of Psychosocial Effects on Disease (BiMPED) Conference, Sponsored by the Basic Biobehavioral Research Branch (BBRB), N.C.I., Bethesda, Maryland
1998	Young Investigator Award, Fourth Joint Conference of the American Association for Cancer Research (AACR) and the Japanese Cancer Association Meeting
1997	Best All-Around Clinical Poster, The 28th Annual Meeting of the Society of Gynecologic Oncologists (SGO)
1996	J.G. Moore Award for the best research presentation by a fellow, The Annual Meeting of the Western Association of Gynecologic Oncologists, San Diego, CA
1995	Outstanding Laparoendoscopic Resident Surgeon, University of Florida
1994 - 1995	Outstanding Performance on CREOG Exam Award
1992 - 1995	Outstanding Student Teaching Award, University of Florida

Professional Memberships

National Academy of Inventors

2024 - Present

National Academy of Medicine

2021 - Present

Association of American Physicians

2017 - Present

American Association for the Advancement of Science

2012 - Present

Academy of Behavioral Medicine Research

2010 - Present

American Gynecological and Obstetrical Society

2009 - Present

American Society for Biochemistry and Molecular Biology (ASBMB)

2009 - Present

Scientific Program Committee, Society of Gynecologic Oncologists

2006 - 2006

Reproductive Scientist Development Program

2006 - Present

Task Force on Behavioral Science and Cancer, American Association for Cancer Research 2006Scientific Program Committee, Society of Gynecologic Oncologists

2005 - 2008

Combined meeting of the Western Association of Gynecologic Oncologists and the Felix Rutledge Society

2004

American Psychosomatic Society

2003

Gynecologic Cancer Foundation

2002 - Present

Felix Rutledge Society, Member

2002 - Present

Psycho-Neuro-Immunology Research Society, Member

2002 - Present

American College of Surgeons

2002 - Present

International Gynecologic Cancer Society

2002 - Present

Society of Gynecologic Oncologists

2002 - 2010

Western Association of Gynecologic Oncologists

2001 - Present

Society of Gynecologic Oncologists, Education Committee

2001 - 2002

Western Association of Gynecologic Oncologists

1999 - Present

Gynecologic Oncology Group

1999 - 2014

American Society of Clinical Oncology

1998 - Present

American Association for Cancer Research

1995 - Present

American College of Obstetricians and Gynecologists

1995 - Present

Society of Gynecologic Oncologists

1995 - Present

North Carolina Society Medical Student Section, American Medical Association

1988 - 1991

Selected Presentations & Talks

Local Presentations

2024. Catalyzing change: The ovarian cancer moon shot journey. Invited. NCI Division of Extramural Activities (DEA) Brown Bag Seminar (Online), US.
2024. Therapeutic applications of non-coding RNAs. Invited. 5th Annual Non-Coding RNA Symposium. Chicago, Illinois, US.
2024. Rare tumors. Invited. SGO 2024 Allied Health Professionals Meeting. Charlotte, North Carolina, US.
2024. Unraveling ovarian cancer complexity with spatial analyses. Invited. 31st Annual Precision Med TRI-CON Meeting. San Diego, CA, US.
2024. Therapeutic applications of non-coding RNAs. Invited. Medicine Grand Rounds. Pittsfield, MA, US.
2023. Extracellular vesicles as biomarkers and drivers of biology in ovarian cancer. Invited. Translational and Basic Science Research Program in Early Lesions (TBEL). Houston, Texas, US.
2023. Catalyzing change: Ovarian cancer Moon Shot Journey. Invited. Leaders in the Field Seminar. Los Angeles, CA, US.
2023. Capitalizing on adaptive changes in the tumor microenvironment. Invited. TRANSCEND Cancer Initiative Symposium. Houston, Texas, US.
2023. Opportunities across kingdoms for RNAi delivery. Invited. Gordon Research Conference FNA Nanotechnology: RNA self-assembly, packaging, imaging and therapeutics. Ventura, CA, US.
2022. Effects of neuroendocrine stress hormones on ovarian cancer growth and progression. Invited. Cardiology Grand Rounds. Houston, Texas, US.
2022. Extracellular vesicles as biomarkers and drivers of biology in ovarian cancer. Invited. Cancer Biomarkers in Vesicles & Beyond. Houston, Texas, US.
2022. Emerging opportunities for enhancing immune therapy. Invited. Ovarian cancer Research Group Think Tank Meeting. Denver, CO, US.
2022. Sharpening the scalpel with molecular biology. Invited. International Gynecologic Cancer Society (IGCS) Annual Global Meeting. New York, NY, US.
2022. Updates from the Ovarian Cancer Moon Shot Program. Invited. Kelly Society Lecture. Baltimore, MD, US.
2022. Therapeutic applications of non-coding RNAs. Invited. Seminar. West Lafeyette, IN, US.
2021. Overcoming adaptive changes in the tumor micronvironment. Invited. Grand Rounds. Houston, Texas, US.
2021. Understanding the mechanisms of adaptive resistance to anti-angiogenesis drugs. Invited. Grand Rounds. Houston, Texas, US.
2021. Bench-to-bedside (and back): Collaboration between physicians and scientists. Invited. Faculty Development Session. Milwaukee, WI, US.
2021. Overcoming adaptive changes in the tumor microenvironment. Invited. Distinguished Lecture Series in Experimental Therapeutics. Houston, Texas, US.
2020. 1) Lessons learned from the Ovarian Cancer Moon Shot program; 2) The platelet lifeline to cancer. Invited. 2020 Ob/Gyn Residents' and Fellows' Research Day. Rochester, MN, US.
2020. Dangerous liaisons between platelets and cancer. Invited. New Haven, CT, US.
2020. Bench-to-bedside (and back): Adaptive changes in the tumor microenvironment. Invited. The Stephenson Cancer Center 2020 Cancer Research Symposium. Oklahoma City, OK, US.
2019. Stress, nerves, and RNAi therapy. Invited. Distinguished Speakers Seminar Series. Buffalo, NY, US.
2019. Advances and obstacles in RNAi therapy. Invited. 2nd Conference on Biomotors, Virus Assembly, and Nanobiotechnology Applications (in conjunction with Bi-annual Meeting of the International Society of RNA Nanotechnology and Nanomedicine. Columbus, OH, US.
2019. Lessons learned from the Ovarian Cancer Moon Shot Program. Invited. International Ovarian Cancer Research Consortium and International Symposium on Tumor Microenvironment, US.
2019. The platelet lifeline to cancer. Invited. NCI 7th Molecular and Cellular Characterization of Screen-Detected Lesions (MCL) Consortium. Nashville, TN, US.
2019. Lessons learned from the Ovarian Cancer Moon Shot Program. Invited. Grand Rounds. Boston, MA, US.
2019. Ovarian cancer metastasis: Mechanisms and therapy. Invited. Inaugural Symposium on Cancer Metastasis in Honor of Isaiah J. Fidler, Celebrating 50 years of cancer metastasis research. Houston, Texas, US.
2019. 1) Keynote address - Updates from the ovarian cancer Moon Shot program; 2) Grand rounds - Dangerous liaisons between platelets and cancer. Invited. Gynecologic Oncology Research Retreat. Cleveland, Ohio, US.
2018. Metronomic therapy: Lessons from the lab and clinic. Invited. Sixth International Meeting of Metronomic Chemotherapy in Oncology. Grand Rapids, MI, US.
2018. Overcoming adaptive changes in the tumor microenvironment. Invited. The American Cancer Society Jiler Professors & Fellows Conference. Minneapolis, MN, US.
2018. Therapeutic applications of non-coding RNAs. Invited. Omaha, NE, US.
2018. Dangerous liaisons between platelets and cancer. Invited. Tampa, FL, US.
2018. Emerging opportunities in rare gynecologic cancers. Invited. Workshop on drug development in gynecologic malignancies. Silver Spring, MD, US.
2018. Targeting the tumor microenvironment in ovarian cancer metastasis. In the Session RAOS09 - Ovarian cancer metastasis. Invited. Annual Meeting of the American Association for Cancer Research. Chicago, IL, US.
2018. The platelet lifeline to cancer. Invited. 9th Symposium on Hemostasis: Advances in the clinical and basic sciences of coagulation. Chapel Hill, NC, US.
2018. Dangerous liaisons between platelets and cancer. Invited. Oncology Grand Rounds. Houston, Texas, US.
2018. Personalized surgical algorithm for advanced ovarian cancer. Invited. The Farr Nezhat Surgical Innovation Session on Surgical Decision Making in Advanced Ovarian Cancer. 49th Annual Meeting of Society of Gynecologic Oncology. New Orleans, LA, US.
2018. Dangerous liaisons between platelets and cancer. Invited. Grand Rounds. Bryan, Texas, US.
2018. 1) Therapeutic applications of non-coding RNAs. 2) Dangerous liaisons between platelets and cancer. Invited. Reproductive Sciences Seminar; Ob-Gyn Clinical Grand Rounds. Denver, CO, US.
2017. Role of platelets in adaptive changes to anti-angiogenesis therapy. In session on: New Innovations in Platelet Regulation of Tumor Growth and Metastasis. Invited. 59th Annual Meeting of the American Society of Hematology. Atlanta, GA, US.
2017. 1) New drugs for targeted therapy in gynecologic oncology; 2) Crucial conversations: You get what you negotiate; 3) Lessons learned from the ovarian cancer Moon Shot program; 4) Dangerous liaisons between platelets and cancer. Visiting. Ob/Gyn postgraduate conference: Advances in gynecologic cancers. Iowa City, IA, US.
2017. Lecture in Gynecology: Dangerous liaisons between platelets and cancer. Invited. The 22nd Annual Robert C. Knapp, M.D. Boston, MA, US.
2017. Leveraging the stress response in ovarian cancer management. Invited. State-of-the-Art Ovarian Cancer Conference. New York, NY, US.
2017. 1) IOM recommendations, recent advances in ovarian cancer; 2) New directions in targeting angiogenesis. Invited. An AACR Special Conference; Addressing Critical Questions in Ovarian Cancer Research and Treatment. Pittsburgh, PA, US.
2017. Selective targeting of tumor angiogenesis. Invited. 15th International Nanomedicine & Drug Delivery Symposium. Ann Arbor, MI, US.
2017. 1) Crucial conversation: You get what you negotiate; 2) Successful grantsmanship. Invited. SGO Early Career Educational Summit. Chicago, IL, US.
2017. Therapeutic applications of non-coding RNAs. Invited. First Conference on Biomotors, Virus Assembly, and Nanobiotechnology Applications. Columbus, OH, US.
2017. Prolactin and ovarian cancer. Invited. Federation of American Societies for Experimental Biology (FASEB) meeting on "Growth hormone/prolactin family in biology and disease. Steamboat Springs, CO, US.
2017. Systemic in vivo delivery using biocompatible nanoparticles. Invited. 16th Annual World Preclinical Congress. Boston, MA, US.
2017. Emerging concepts in stress, inflammation, and tumor microenvironment. Invited. 24th Annual Scientific Meeting of the PsychoNeuroImmunology Research Society. Galveston, Texas, US.
2017. Multi-level approaches to cancer. Invited. Integrated Multi-Level Approaches to Psychosocial Processes & Health. Boston, MA, US.
2016. Ovarian cancer metastasis: Mechanisms and therapy. Invited. Metastatic Cancer Task Force Testimony and Operational Meeting. Tysons Corner, VA, US.
2016. Overcoming adaptive changes in the tumor microenvironment. Invited. The Rivkin Center for Ovarian Cancer and the AACR - 11th Biennial Ovarian Cancer Research Symposium. Seattle, WA, US.
2016. New approaches for targeting tumor angiogenesis. Invited. Gordon Research Conference: Drug Carriers in Medicine and Biology. Waterville Valley, NH, US.
2016. State of anti-angiogenic therapies and adaptive changes. Invited. SPORE Workshop on Translational Research in Ovarian/GYN Cancers. Shady Grove, Rockville, MD, US.
2016. Promises and challenges of RNAi therapeutics. Invited. Center for Targeted Therapies Seminar Series. Nashville, TN, US.
2016. Stress, nerves and cancer. Invited. Panel on Opportunities for Cancer Prevention during Early Adulthood: Putting Scientific Evidence into Public Health. Atlanta, GA, US.
2016. Emerging approaches for targeted and sustained delivery of ncRNAs. Invited. Workshop on RNA Nanobiology. Rockville, MD, US.
2016. About Trousseau, platelets, angiogenesis, and cancer patients. Invited. Miami, FL, US.
2015. Hematogenous metastasis of ovarian cancer: Rethinking mode of spread. Invited. An AACR Special Conference on Tumor Metastasis. Austin, Texas, US.
2015. Promises and challenges of RNAi therapeutics. Invited. Symposium on Drug Discovery & Development. Lexington, KY, US.
2015. A framework for personalized approaches to ovarian cancer. Invited. iBRIGHT 2015 (Integrative Biostatics Research for Imaging Genomics, & High-throughput Technologies in Precision Medicine. Houston, Texas, US.
2015. Adaptation to anti-angiogenesis therapy. Invited. An AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities. Orlando, FL, US.
2015. Adaptation to anti-angiogenesis therapy. Invited. Symposia on cancer Research: Emerging Concepts in Host Response to Cancer. Houston, Texas, US.
2015. Drugging the undruggable: New directions in RNAi therapeutics. Invited. Annual University Retreat for Research, US.
2015. About stress, nerves, and cancer metastasis. Invited. Seattle, WA, US.
2015. Drugging the undruggable: New directions in RNAi therapeutics. Invited. Grand Rounds, CT, US.
2015. About stress, nerves, and cancer metastasis. Invited. Workshop on the Role of Nerves in Cancer Progression. Rockville, MD, US.
2015. Targeting IncRNA in ovarian cancer. Invited. Cambridge Healthtech Institute's Extracellular Biomarkers Summit. Boston, MA, US.
2015. Small RNAs: From biomarkers to cancer therapy. Invited. Houston, Texas, US.
2015. Molecular predictors of residual disease after cytoreduction. Invited. Symposium on Neoadjuvant chemotherapy for ovarian cancer - Clinical considerations and research opportunities. Gynecologic Oncology Group Winter 2015 Meeting. San Diego, CA, US.
2015. New approaches for targeted and sustained delivery of ncRNAs. Invited. Gordon Research Conference: RNA Nanotechnology. Ventura, CA, US.
2014. Unmet Needs for Imaging in Cancer Patients and Cancer Biology. Invited. Workshop on Current Topics in Cancer Systems Biology: Multi-Scale Imaging for Cancer Biology. Houston, Texas, US.
2014. Clinical perspectives of metabolism research. Invited. Symposium on Metabolism in Cancer. Houston, Texas, US.
2014. From science to practice: Bridging the gap with translational research. Invited. 4th Annual Postdoctoral Science Symposium. Houston, Texas, US.
2014. Mater microRNA regulatory networks in ovarian cancer. Invited. Systems Medicine and Bioengineering Seminar Series. Houston, Texas, US.
2014. 1) Crucial conversations: You get what you negotiate; 2) Grantsmanship and Career Development Proposals. Invited. SGO Early Career Educational Summit. Chicago, IL, US.
2013. Causes and consequences of cancer-associated thrombocytosis. Invited. In session on: Platelets and Cancer, 55th Annual Meeting of the American Society of Hematology. New Orleans, LA, US.
2013. Master microRNA regulatory networks in ovarian cancer. Invited. Houston, Texas, US.
2012. Promises and challenges with use of RNA interference for therapy. Invited. 28th Southern Biomedical Engineering Conference. Houston, Texas, US.
2012. Integrated translational research in gynecologic cancers. Invited. Education Forum III: Critical pathways in gynecologic cancers. The 2012 Annual Meeting on Women's Cancer, US.
2012. Exploiting ovarian cancer microenvironment and metabolic circuits for therapeutic purposes. Invited. Capitalizing on Biology to Develop Novel Prevention and Treatment Approaches to Gynecologic Cancer, Gynecologic Oncology Group 84th Semi-Annual Meeting. San Diego, CA, US.
2012. Interfering with tumor vasculature. Invited. Grand Rounds. New Orleans, LA, US.
2012. Mechanisms of stress effects on cancer. Invited. Cancer Survivorship Research: Translating Science to Care (6th Biennial Cancer Survivorship Research Conference. Alexandria, VA, US.
2012. Therapeutic gene silencing in vivo using RNA interference. Invited. TechConnect Summit & Expo. Santa Clara, CA, US.
2012. Promises and challenges of RNAi Therapeutics. Invited. 2nd Annual Trainees' Research Retreat. Houston, Texas, US.
2011. New directions in anti-angiogenesis therapy. Invited. The 9th International Conference on Ovarian Cancer. Austin, Texas, US.
2011. Interfering with tumor vasculature. Invited. New York, NY, US.
2011. Interfering with tumor vasculature. Invited. Roswell Park Cancer Institute Faculty Forum. Buffalo, NY, US.
2011. Neuroendocrine influences on cancer metastasis. Invited. Hematology/Oncology Cancer Epidemiology, Prevention & Control Grand Rounds. Detroit, MI, US.
2011. RNAi therapeutics: Challenges and future directions. Invited. The Leukemia Research Meeting. Houston, Texas, US.
2011. RNAi therapeutics: Translation from bench to bedside. Invited. In: Next-Generation Therapeutic Targets and Drugs: 47th Annual Meeting. Chicago, IL, US.
2011. Stromal influences of stress in cancer: The role of macrophages. Invited. In: NCI Symposium: PNI and Cancer: Role of the Tumor Macro(phage)-Environment. 18th Annual Meeting of the PsychoNeuroImmunology Research Society. Chicago, IL, US.
2011. Stress effects on tumor microenvironment. Invited. In: NCI Symposium: Cancer Mechanisms. Annual Meeting of the Academy of Behavioral Medicine Research. Deer Valley, UT, US.
2011. Neuroendocrine influences on cancer metastasis. Invited. Iowa City, IA, US.
2011. Neuroendocrine influences on cancer metastasis. Invited. In Stress and Disease: Lessons for Research on Cancer. Boston, MA, US.
2011. Interfering with tumor vasculature. Invited. Boston, MA, US.
2011. Targeting the EphA2 axis in uterine carcinoma. Invited. 7th Annual Uterine Cancer Biology Symposium. Houston, Texas, US.
2011. Bad blood: The role of platelets in ovarian carcinoma. Invited. 12th International Forum on Ovarian Cancer, Helene Harris Memorial Trust. Hallandale, FL, US.
2011. Translational Progress Towards personalized Medicine in Gynecologic Cancers. Invited. New Trends in Managing Gynecologic Cancers: The Need for Personalized Medicine, US.
2011. Regulation of tumor angiogenesis by EZH2. Invited. The 13th International Symposium on Anti-Angiogenic Agents. San Diego, CA, US.
2011. Molecular targeting of metastatic cancer. Invited. Symposium on Mechanisms and Management of Tumor Metastasis. 58th Annual Meeting of the Society for Gynecologic Investigation. Miami, FL, US.
2011. Neuroendocrine influences on cancer metastasis. Invited. First Annual Kidney Cancer Collaborative Symposium. Houston, Texas, US.
2011. Adrenergic regulation of tumor microenvironment. Invited. In Major Symposium, "Neuroendocrine influences on cancer progression", the 102nd Annual Meeting of the American Society for Cancer Research. Orlando, FL, US.
2011. Translational research: Training and beyond. Invited. In Professional Advancement Series Session, "Translational Research: Where do you fit in and what you need to succeed", the 102nd Annual Meeting of the American Society for Cancer Research. Orlando, FL, US.
2010. New concepts in therapeutic targets and platforms. Invited. SGO's 2010 State of the Art Conference. Chicago, IL, US.
2010. Neuroendocrine influences on cancer metastasis. Invited. Epidemiology of Psychological and Social Influences on Cancer Outcome, A Think Tank meeting. Los Angeles, CA, US.
2010. Ovarian Cancer: Clinical Aspects. Invited. Ultrasound in the New Millennium: The Cancer Patient. Houston, Texas, US.
2010. Angiogenesis, Invasion, and Metastasis. Invited. A Primer on Cancer Biology and Plausible Mechanisms and Pathways for Stress-Mediated Effects on Cancer Biology. 68th Annual Meeting of the American Psychosomatic Society. Portland, OR, US.
2010. Systemic Regulation of Tumor Progression II: Sympathetic Nervous System. Invited. A Primer on Cancer Biology and Plausible Mechanisms and Pathways for Stress-Medicated Effects on Cancer Biology. 68th Annual Meeting of the American Psychosomatic Society. Portland, OR, US.
2010. Interfering with Tumor Vasculature. Invited. First Global Congress on NanoEngineering for Medicine and Biology (NEMB), American Society of Mechanical Engineers (ASME). Session on Challenges in Biomedicine for Engineers. Houston, Texas, US.
2009. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kB pathway. Invited. Symposium: Complementary and alternative medicine approaches to health and wellness. The 16th Annual Meeting of the Psychoneuroimmunology Research Society. Breckenridge, CO, US.
2009. Targeting angiogenesis in ovarian carcinoma. Invited. New York, NY, US.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited. New York, NY, US.
2009. Effects of chronic stress on cancer metastasis. Invited. In Educational Session "Biological consequences of stress" Eighth Annual International Conference of Frontiers in Cancer Prevention Research. Houston, Texas, US.
2009. Biological approaches to ovarian cancer therapy. SGO Special Symposia: Ovarian Cancer Translational Research. Prospects for Advances in Genetic Risk Assessment, Screening, and Biological Therapy. Invited. Society of Gynecologists 40th Annual Meeting on Women's Cancer. San Antonio, Texas, US.
2009. SiRNA targeting of the tumor vasculature. Invited. The 11th International Symposium on Anti-Angiogenic Agents. San Diego, CA, US.
2008. Impact of microenvironment on tumor growth: Mechanisms and targets. Invited. Educational Short Course. The 15th Annual Meeting of the Psychoneuroimmunology Research Society. Madison, WI, US.
2008. Interfering with cancer: An update on siRNA therapeutics. Invited. The 99th Annual Meeting of the American Association for Cancer Research. San Diego, CA, US.
2008. Therapeutic gene silencing in vivo using RNA interference. Invited. Grand Rounds. Houston, Texas, US.
2008. Selectivity Filters for Molecular Therapy. Invited. Sunrise Session 7: State of the Science - Ovarian Cancer, The 39th Annual Meeting of the Society of Gynecologic Oncologists. Tampa, FL, US.
2008. On the Horizon: Developing Therapeutics. Invited. 7th Biennial Ovarian Cancer Research Symposium. Seattle, WA, US.
2008. Research forecast 2009: Novel therapeutics and developing therapies. Invited. Oncology Nursing Society (ONS) 9th Annual Institutes of Learning Program; Recurrent Ovarian Cancer: Challenges and Management Strategies. Seattle, WA, US.
2007. Translational Research in Ovarian Carcinoma. Invited. Houston, TX, US.
2007. Emerging anti-angiogenesis strategies for gynecologic malignancies. Invited. The 37th Annual Meeting of the Felix Rutledge Society. Houston, TX, US.
2007. Influence of Biobehavioral Factors on Tumor Biology: Pathway and Mechanisms. Invited. Integrative Medicine Program Lecture. Houston, Texas, US.
2006. Neuroendocrine influences on tumor growth processes. Short Course, PNI and Disease Processes: Fundamentals and clinical perspectives. Invited. The 13th Annual Meeting of the Psychoneuroimmunology Research Society. Miami, FL, US.
2006. Therapeutic gene silencing in vivo using RNA interference in the session entitled "Dissecting the Genomic Architecture of Cancer. Invited. 97th Annual Meeting of the American Association for Cancer Research. Washington, DC, US.
2006. Principles of Targeted Therapy. Invited. The 37th Annual Meeting of the Society of Gynecologic Oncologists. Palm Springs, CA, US.
2006. Therapeutic gene silencing with siRNA. Plastic Surgery Seminar Series. Houston, Texas, US.
2006. Targeted therapy in ovarian cancer. Invited. 5th Annual Clinical Cancer Update. North Lake Tahoe, CA, US.
2006. Stress and its effect on the treatment of ovarian cancer. Invited. San Diego, CA, US.
2006. Angiogenesis: Emerging therapeutic targets. Invited. Gynecologic Oncology Group Semi-Annual Meeting. San Diego, CA, US.
2005. Effects of behavioral factors and stress on tumor microenvironment. Invited. Sixth Annual International Conference on Ovarian Cancer. New York, NY, US.
2005. Therapeutic targeting of EphA2 in ovarian cancer. Invited. San Diego, CA, US.
2005. Antiangiogenic approaches in ovarian carcinoma: Opportunities and challenges. Invited. Ovarian Cancer State of the Science Meeting. Rockville, MD, US.
2005. Multidisciplinary models of neuroendocrine modulation of tumor progression: Integrative views and historical perspectives on immunological and non-immunological mechanisms. Invited. The 12th Annual Meeting of the Psychoneuroimmunology Research Society. Denver, CO, US.
2005. Modified vertical rectus abdominis myocutaneous (VRAM) flap for pelvic reconstruction. Invited. 2005 Winter Meeting of the Society of Gynecologic Oncologists: Controversies in Gynecologic Oncology, US.
2005. Anti-angiogenic therapy for treatment of ovarian cancer. Invited. The 7th International Symposium on Anti-Angiogenic Agents: Recent Advances and Future Directions in Cell Biology and Clinical Research. San Diego, CA, US.
2004. Neuroendocrine modulation of tumor metastasis. Invited. Teton Village, WY, US.
2004. The seed and soil of cancer metastasis. Invited. Exploring the Integration of Psychoneuroimmunology and Tumor Immunology in Cancer Control Research Conference. Bethesda, Maryland, US.
2004. Cox-2 in ovarian carcinoma. Invited. The 35th Annual Meeting of the Society of Gynecologic Oncologists. San Diego, CA, US.
2003. Angiogenesis and beyond in ovarian carcinoma. Invited. Fourth Annual International Conference on Ovarian Cancer. New York, NY, US.
2003. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Charles A. Hunter, Jr. Prize Thesis Award Presentation. Napa, CA, US.
2003. The complexity of tumor vascularity: Role of tumor cell plasticity. Invited. Grand Rounds. Galveston, Texas, US.
2002. Operative notes and dictations. Invited. Resident Lecture Series, Iowa, US.
2002. Genetic Screening for Gynecologic Malignancies. Invited. The 50th Annual College Meeting of the American College Obstetricians and Gynecologists. Los Angeles, CA, US.
2002. Molecular determinants of ovarian cancer plasticity. Invited. Grand Rounds. Houston, Texas, US.
2002. High expression of tumor necrosis factor-related apoptosis-inducting ligand (TRAIL) is associated with favorable survival in ovarian cancer. Invited. The 33rd Annual Meeting of the Society of Gynecologic Oncologists. Miami, FL, US.
2001. Genetic Insights into Gynecologic Disorders: Genetic screening for gynecologic malignancies. Invited. The 49th Annual College Meeting of the American College of Obstetricians and Gynecologists. Chicago, IL, US.
2001. Genetic Insights into Gynecologic Disorders: Prophylactic options for gynecologic malignancies. Invited. The 49th Annual College Meeting of the American College of Obstetricians and Gynecologists. Chicago, IL, US.
2001. Genetic Insights into Gynecologic Disorders: Future prospects for molecular treatments. Invited. The 49th Annual College Meeting of the American College of Obstetricians and Gynecologists. Chicago, IL, US.
2000. Genetic screening for women's malignancies. Invited. 7th Annual Current Topics in Ob/Gyn, Women's Malignancies - Year 2000 Update. Rootstown, Ohio, US.
2000. 7th Annual Current Topics in Ob/Gyn Cancer of the ovary: Surgical prevention. Invited. Women's Malignancies - Year 2000 Update. Rootstown, Ohio, US.

Regional Presentations

2018. Personalized surgical algorithm for advanced ovarian cancer. Invited. The 2018 Regional Meeting of the AAGL. Chongqing, CN.
2011. Therapeutic gene silencing using RNA interference. Invited. 67th Southwest Regional Meeting of the American Chemical Society. Austin, Texas, US.

National Presentations

2024. Promises and challenges of RNAi therapeutics. Invited. Duke Cancer Institute Seminar Series. Durham, NC, US.

International Presentations

2024. Opportunities across kingdoms for RNAi delivery. Invited. Global Conference on Research and Application of Chinese Herbal Medicine-derived Extracellular Vesicles. Guangzhou, CN.
2023. Therapeutic applications of non-coding RNAs. Invited. International Conference on Molecular Oncology and Precision Medicine. Riyadh, SA.
2022. Effects of neuroendocrine stress hormones on ovarian cancer growth and progression. Invited. Global Gynecological Oncology Summit (virtual meeting), CN.
2022. Capitalizing on adaptive changes in the tumor microenvironment. Invited. International Conference on Advanced Biomedical Sciences. Taichung, TW.
2022. 1) Can we detect and overcome PARPi resistance? 2) Capitalizing on vulnerabilities from adaptive changes to anti-angiogenesis drugs. Invited. 23rd European Congress on Gynecological Oncology. Berlin, DE.
2021. Understanding the mechanisms of adaptive resistance to anti-angiogenesis drugs. Invited. 9th CCBIO Annual Symposium 2021 (Virtual). Bergen, NO.
2019. Therapeutic considerations for ovarian carcinomas and adaptive changes. Invited. Tumor seminar on Difficult Questions in Ovarian Cancer Research, Joint meeting of the International Agency for Research on Cancer (IARC) and the NCI. Lyon, FR.
2019. 1) About Trousseau, platelets, angiogenesis, and cancer patients; 2) Updates from the ovarian cancer Moon Shot program. Invited. 61st Annual Meeting of the Japan Society of Gynecologic Oncology (JSGO). Niigata, JP.
2019. Overcoming adaptive changes in the tumor microenvironment. Invited. The 5th Red House Forum, International Obstetrics & Gynecology Summit. Shanghai, CN.
2019. 1) The role and therapeutic implications of thrombocytosis in ovarian cancer; 2) MD Anderson Moon Shot effort in ovarian cancer: Rationale, surgical triage and updates; 3) Adaptive changes from antiangiogenic drugs; 4) New therapeutic strategies: RNA inhibitors and combinations with PARP inhibitors. Invited. Next Frontiers to Cure Cancer Annual Meeting. Sao Paulo, BR.
2019. Overcoming adaptive changes in the tumor microenvironment. Invited. 71st Annual Congress of the Japan Society of Obstetrics and Gynecology. Nagoya, JP.
2019. Overcoming adaptive changes in the tumor microenvironment. Invited. The UT MD Anderson Cancer Center Global Academic Programs and Israel Joint Symposium on Collaborative Cancer Research in the Era of Precision Medicine. Tel Aviv, IL.
2018. Updates from the Ovarian Cancer Moon Shot. Invited. Joint meeting between the European Society of Gynecological Oncology (ESGO - SEGO) and the Felix Rutledge Society (FRS). Barcelona, ES.
2018. Therapeutic applications of non-coding RNAs. Invited. 2nd China International Medical Technology Conference. Lianyungang, CN.
2018. Overcoming adaptive changes in the tumor microenvironment. Invited. Global Academic Programs Conference 2018. Stockholm, SE.
2018. Ovarian cancer moon shot program. Invited. 6th MD Anderson International Meeting in Gynecologic Oncology: Embracing New Standards of Care in Gynecologic Cancers. Madrid, ES.
2018. Overcoming adaptive changes in the tumor microenvironment. Invited. 20th annual MITO meeting. Naples, IT.
2017. 1) Dangerous liaisons between platelets and cancer; 2) Lessons learned from the ovarian cancer Moon Shot Program. Invited. Cambridge, GB.
2017. 1) Updates from the ovarian cancer moon shot program; 2) Dangerous liaisons between platelets and cancer. Invited. 8th Trope - Kolstad meeting: Updates and Controversies in Gynecologic Oncology. Oslo, NO.
2017. Impact of stress on cancer biology. Invited. XXIII Congreso Latinoamericano de Bioquimica Clinica. Punta del Este, UY.
2017. 1) New drugs for targeted therapy in gynecologic oncology; 2) New advances in chemotherapy for ovarian cancer. Invited. The 4th Red House Forum, International Obstetrics & Gynecology Summit. Shanghai, CN.
2017. 1) A framework for personalized approaches to ovarian cancer; 2) Targeting the undruggable: Advances and obstacles in RNAi therapy. Invited. ANZ-GOG Annual Scientific Meeting. Melbourne, AU.
2017. Emerging role of platelets in adaptive changes to anti-angiogenesis therapy. Invited. Gordon Research Conference: Cell Biology of Megakaryocytes & Platelets. Lucca (Barga), IT.
2016. 1) About Trousseau, platelets, angiogenesis and cancer patients; 2) Personalized surgical therapy in ovarian cancer; 3) New drugs for targeted therapy in gynecologic oncology; 4) Peritoneal Carcinomatosis - Role of Hyperthermic intraperitoneal chemotherapy (HIPEC). Invited. 1st South Southeast Congress of Brazilian Society of Surgical Oncology. Florianopolis, BR.
2016. Lessons learned from the Moonshot Program: A team approach to advance patient care. Invited. The 6th MD Anderson Cancer Center - China Sister Institute Pathology Conference. Shanghai, CN.
2016. Pathologist-surgeon communications on frozen section diagnosis. Invited. The 6th MD Anderson Cancer Center - China Sister Institute Pathology Conference. Shanghai, CN.
2016. Lessons learned from the Moonshot program. Invited. Copenhagen, DK.
2016. Drugging the undruggable: New directions in RNAi therapeutics. Invited. Tel Aviv, IL.
2016. Drugging the undruggable: new directions in RNAi therapeutics. Invited. 8th Canadian Conference of Ovarian Cancer Research. Niagra, Ontario, CA.
2016. Clinical and Translational Pathways. Invited. Bergen, NO.
2016. Targeting stress neuroendocrine pathways in cancer. Invited. 5th MD Anderson International Meeting in Gynecologic Oncology: Tailoring Cancer-Therapy in the Era of Personalized Medicine. Madrid, ES.
2016. Predictors of residual disease in patients with ovarian cancer. Invited. 5th MD Anderson International Meeting in Gynecologic Oncology: Tailoring Cancer-Therapy in the Era of Personalized Medicine. Madrid, ES.
2016. Targeting angiogenesis in ovarian cancer: Overcoming adaptive responses. Invited. 5th MD Anderson International Meeting in Gynecologic Oncology: Tailoring Cancer-Therapy in the Era of Personalized Medicine. Madrid, ES.
2016. Framework for overcoming resistance. Invited. Cancer Translational Research Initiative Planning Workshop. Toronto, CA.
2015. A framework for personalized approaches to ovarian cancer. Invited. 4th Oncosalud International Symposium. Lima, PE.
2015. Novel agents for targeted therapy in gynecologic oncology. Invited. 4th Oncosalud International Symposium. Lima, PE.
2015. A framework for personalized approaches to ovarian cancer. Invited. The 3rd International Red House Forum. Shanghai, CN.
2015. What have we learned from the Cancer Genome Atlas. Invited. The 3rd International Red House Forum. Shanghai, CN.
2015. A framework for personalized approaches to ovarian cancer. Invited. 3rd Lowy Symposium - Drug Discovery to Personalized Medicine. Sydney, AU.
2015. Promises and challenges of RNAi therapeutics. Invited. Molecular Pathways to Therapeutics: Paradigms and Challenges in Oncology. Mumbai, IN.
2015. Hematogenous metastasis of ovarian cancer. Invited. Helene Harris Memorial Trust, 13th International Forum on Ovarian Cancer. Toledo, ES.
2014. RNAi strategies in future therapeutics of ovarian cancer. Invited. IV MD Anderson International Meeting in Gynecologic Oncology: Emerging Therapies in Gynecological Cancer. Madrid, ES.
2014. The cancer genome atlas (TCGA): Innovations in ovarian and uterine cancer. Invited. IV MD Anderson International Meeting in Gynecologic Oncology: Emerging Therapies in Gynecological Cancer. Madrid, ES.
2013. Anti-angiogenesis therapy for ovarian cancer: Moving beyond VEGF. Invited. The 3rd Biennial Meeting of the Asian Society of Gynecologic Oncology. Kyoto, JP.
2013. What have we learned from the cancer genome atlas?. Invited. The 3rd Biennial Meeting of the Asian Society of Gynecologic Oncology. Kyoto, JP.
2013. New directions in targeting the tumor microenvironment. Invited. Niigata, JP.
2013. Personalized therapy in gynecologic oncology: Biology, strategy, and assessment. Invited. 18th International Meeting of the European Society of Gynecological Oncology (ESGO). Liverpool, GB.
2012. Targeting tumor angiogenesis using RNA interference. Invited. Oligonucleotide Delivery: Biology, Engineering and Development. Hernstein, AT.
2012. Targeting tumor microenvironment in gynecologic cancers. Invited. In Educational Symposium: What is individualized medicine? The 14thth Biennial Meeting of the International Gynecologic Cancer Society (IGCS). Vancouver, CA.
2012. Translational research in gynecological oncology. Invited. The 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS). Vancouver, CA.
2012. Integrated genomic analysis in ovarian cancer: The Cancer Genome Atlas. Invited. Molecular Biology of Gynecologic Cancers: The Basic Principles of Translational Research. III M. D. Anderson International Conference in Gynecologic Oncology. Madrid, ES.
2012. Novel agents for targeted therapy in gynecologic oncology. Invited. Molecular Biology of Gynecologic Cancers: The Basic Principles of Translational Research. III M. D. Anderson International Conference in Gynecologic Oncology. Madrid, ES.
2012. Small interfering RNA: Promises for treatment and problems in delivery. Invited. Delivering on the Promise of the Human Genome Project. 178th Meeting of the American Association for the Advancement of Science. Vancouver, CA.
2011. Interfering with tumor vasculature. Invited. Oxford, GB.
2010. Microenvironment and pathogenesis of epithelial ovarian cancer. Invited. The Sixth International Symposium on Hormonal Oncogenesis. Tokyo, JP.
2010. Molecular and Biological Effects of Stress on Cancer Metastasis. Invited. NCI Symposium: The role of host factors in the development and progression of neoplastic disease> The 17th Annual Meeting of the Psychoneuroimmunology Research Society. Dublin, IE.
2010. Novel Therapies in Ovarian Cancer. Invited. II M. D. Anderson International Conference in Gynecologic Oncology. Madrid, ES.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited. 4th International Liposome Society Conference: Liposome Advances: Progress in Drug and Vaccine Discovery. London, GB.
2009. Targeted gene silencing in vivo using rHDL nanoparticles. Invited. 4th International Liposome Society Conference: Liposome Advances: Progress in Drug and Vaccine Discovery. London, GB.
2009. Angiogenesis as a therapeutic target in gynecologic malignancies. Invited. Fertility 2009 (6th Biannual Conference of the UK Fertility Societies). Edinburgh, GB.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited. Tel Aviv, IL.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited. Gyeongju City, KR.
2009. Toxicities of targeted therapy. Invited. The 8th Korean Gynecologic Oncology Group Meeting. Daegu, KR.
2009. Effects of neuroendocrine pathways on ovarian cancer growth and progression. Invited. The 8th Korean Gynecologic Oncology Group Meeting. Daegu, KR.
2009. Anti-angiogenesis agents. Invited. The 24th Annual Meeting of the Korean Society of Gynecologic Oncology and Colposcopy. Daegu, KR.
2009. Emerging therapeutic approaches. Invited. The 24th Annual Meeting of the Korean Society of Gynecologic Oncology and Colposcopy. Daegu, KR.
2008. Neuroendocrine influences on cancer metastasis. Invited. From Molecules to Societies: The Psychobiological Determinants of Health and Well-Being Workshop. British Columbia, CA.
2006. Angiogenesis mechanisms in ovarian cancer. Invited. 1st International Conference on Ovarian Cancer: State of the Art an Future Directions, GR.

Formal Peers

2017. “Of Zebras and Lions: How stress influences cancer metastasis.”. Invited. Philadelphia, Pennsylvania, US.
2016. A framework for personalized approaches to ovarian cancer. Invited. Philadelphia, Pennsylvania, US.
2016. Of Zebras and Lions: How stress influences cancer metastasis. Invited. Sioux Falls, SD, US.
2016. Metabolic fingerprint of stress influences in cancer. Invited. Rockville, MD, US.
2016. Lessons learned from the Moonshot program. Invited. Detroit, MI, US.
2016. About Trousseau, platelets, angiogenesis, and cancer patients. Invited. Baltimore, MD, US.
2015. Promises and challenges of RNAi therapeutics. Invited. Fort Worth, TX, US.
2015. A framework for personalized approaches to ovarian cancer. Invited. St. Louis, MO, US.
2015. Promises and challenges of RNAi therapeutics. Invited. St. Louis, MO, US.
2015. Ovarian cancer metastasis: Re-thinking mode of spread. Invited. Detroit, MI, US.
2014. Fred Benjamin, MD Memorial Lectureship, “About Trousseau, platelets, and ovarian cancer.”. Visiting. New Hyde Park, NY, US.
2014. “Promises and challenges of RNAi therapeutics.”. Invited. Durham, NC, US.
2014. “Drugging the undruggable: New directions in RNAi therapeutics.”. Invited. Pittsburgh, PA, US.
2014. “Novel developments in targeted therapy in advanced epithelial ovarian cancer.”. Invited, CO.
2014. “Targeting stress signaling in ovarian cancer.”. Invited. Medellin, CO.
2014. “Master microRNA regulatory networks in ovarian cancer.”. Invited. Houston, TX, US.
2014. “Biological validatin of lethality targets using nanotechnology.”. Invited. Bethesda, MD, US.
2014. “Master microRNA regulatory networks in ovarian cancer”. Invited. Shanghai, Shanghai, CN.
2014. “Promises and challenges of RNAi therapeutics.” , . Invited. Dallas, TX, US.
2014. “Neuroendocrine influences on cancer metastasis”. Invited. Changsha, CN.
2014. “Nanotechnology from a clinician’s point of view”. Application of nanotechnology to the treatment of cancer patients. Invited. San Diego, CA, US.
2014. President’s Achievement Award presentation: Targeting the undruggable: New directions in RNA interference and tumor microenvironment. Invited. Florence, IT.
2014. “New directions in targeting the tumor microenvironment”. Invited. Milan, IT.
2014. Promises and challenges of RNAi therapeutics. Invited. Cincinnati, OH, US.
2013. About Trousseau, platelets, microenvironment and cancer patients. Invited. New York, NY, US.
2013. New directions in targeting the tumor microenvironment. Invited. New York, NY, US.
2013. Causes and consequences of cancer-associated thrombocytosis. Visiting. Minneapolis, MN, US.
2013. Collection and analysis of “omic” data to provide accurate diagnosis and treatment. Invited. Bethesda, MD, US.
2013. About George Engel and Mechanisms of Stress Effects on Cancer Metastasis. Invited. Chicago, IL, US.
2013. Causes and consequences of paraneoplastic thrombocytosis. Invited. Miami, FL, US.
2013. About Trousseau, platelets and ovarian cancer. Invited. Philadelphia, PA, US.
2013. “Promises and challenges of RNAi therapeutics”. Invited. Milan, IT.
2013. “Two new directions: Metformin and stress signaling". Invited. Chicago, IL, US.
2013. Smith-Errington Lecture, Promises and challenges of RNAi therapeutics. Visiting. London.
2013. “Neuroendocrine influences on cancer metastasis”. Invited. Shanghai, CN.
2013. “New directions in targeting the tumor microenvironment”. ,. Invited. Greenville, SC, US.
2013. “Targeting tumor angiogenesis using RNA interference. Invited. Albuquerque, NM, US.
2013. “Mechanisms of paraneoplastic thrombocytosis”. Invited. Greenville, SC, US.
2013. “Targeting tumor angiogenesis using RNA interference". Invited. Indianapolis, IN, US.
2013. “Therapeutic gene silencing in vivo using biocompatible nanoparticles”. Invited. San Francisco, CA, US.
2013. “Bad blood: The role of platelets in ovarian carcinoma.”. Invited. Boston, US.
2013. “Interfering with tumor vasculature.”. Invited. San Diego, CA, US.
2012. “Promises and challenges of RNAi therapeutics”. Invited. South Bend, IN, US.
2012. Targeting tumor angiogenesis using RNA interference. Invited. Chicago, IL, US.
2012. Promises and challenges of RNAi therapeutics. Invited. Oklahoma City, OK, US.
2012. Targeting tumor angiogenesis using RNA interference. Invited. Galveston, TX, US.
2012. Neuroendocrine influences on cancer metastasis. Invited. Charlottesville, VA, US.
2012. Neuroendocrine influences on cancer metastasis. Invited. Sacramento, CA, US.
2012. Targeted therapy for ovarian cancer. Invited. Houston, TX, US.
2012. Promises and challenges with use of RNA interference for therapy. Invited. Seattle, WA, US.
2012. Interfering with tumor vasculature. Invited. New Orleans, LA, US.
2012. Interfering with tumor vasculature. Invited. Boston, MA, US.
2011. Neuroendocrine influences on tumor microenvironment. Invited. Houston, TX, US.
2011. Interfering with tumor vasculature. Invited. Charleston, SC, US.
2011. Neuroendocrine influences on cancer metastasis. Visiting. New York, NY, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Salt Lake City, UT, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Denver, CO, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Cincinnati, OH, US.
2010. Effects of Chronic Stress on Cancer Metastasis. Invited. Orlando, FL, US.
2010. Neuroendocrine Influences on Cancer Metastasis. Invited. Winston Salem, NC, US.
2009. "Interfering with tumor vasculature". Invited. Mayaguez, PR.
2009. Angiogenesis and tumor microenvironment in gynecologic malignancies. Invited. Madison, WI, US.
2009. New directions in anti-angiogenesis therapy. Invited. New York, NY, US.
2009. "Therapeutic targeting of angiogenesis in vivo using RNA interference". Invited. Rochester, MN, US.
2009. "Therapeutic gene silencing in vivo using RNA interference". Invited. Frederick, MD, US.
2009. Interfering with tumor vasculature. Invited. Morgantown, WV, US.
2009. Therapeutic gene silencing in vivo using RNA interference. Invited. New York, NY, US.
2009. "Therapeutic gene silencing in vivo using RNA interference". Invited, PA, US.
2009. "Therapeutic gene silencing in vivo using RNA interference". Invited, PA, US.
2009. "Therapeutic targeting of angiogenesis". Invited. Charleston, SC, US.
2009. "Therapeutic targeting of angiogenesis in vivo using RNA interference". Invited. Rochester, MN, US.
2008. "Effects of neuroendocrine pathways on ovarian cancer growth and progression". Invited. Bethesda, MD, US.
2008. Angiogenesis and tumor microenvironment in gynecologic malignancies. Invited. Minneapolis, MN, US.
2008. Therapeutic gene silencing in vivo using RNA interference. Invited. Houston, TX, US.
2008. Neuroendocrine Influences on Cancer Metastasis. Invited. Chapel Hill, NC, US.
2008. "Therapeutic gene silencing in vivo using RNA interference". Invited. San Francisco, CA, US.
2008. Probstein Lecturer, "Therapeutic targeting of angiogenesis". Visiting. St. Louis, MO, US.
2008. "Angiogenesis and tumor microenvironment in gynecologic malignancies". Invited. Gainesville, FL, US.
2008. Probstein Lecturer, "Neuroendocrine influences on cancer metastasis". Visiting. St. Louis, MO, US.
2007. "Antivascular therapy for ovarian cancer". Invited. Charlotte, NC, US.
2007. "Angiogenesis and tumor microenvironment in gynecologic malignancies". Invited. Charlotte, NC, US.
2007. "Antivascular therapy for ovarian cancer". Invited. Nashville, TN, US.
2007. "Neuroendocrine Influences of Cancer Metastasis". Invited. Bethesda, MD, US.
2007. "Anti-Vascular Therapy for Ovarian Cancer". Invited. Detroit, MI, US.
2007. "Therapeutic Gene Silencing In Vivo using RNA Interference". Invited. New York, NY, US.
2007. "Therapeutic Targeting of Focal Adhesion Kinase (FAK) using In Vivo RNA Interference". Invited. Reno, NV, US.
2007. "Effects of chronic stress on cancer growth and progression". Invited. Bethesda, MD, US.
2007. "Role of VEGF and angiogenesis in gynecologic cancer". Invited. Atlanta, GA, US.
2006. "Neuroendocrine influences on cancer metastasis". Invited. San Francisco, CA, US.
2006. "Anti-vascular therapy in ovarian carcinoma". Invited. Los Angeles, CA, US.
2006. "Effects of chronic stress on cancer metastasis". Invited. Los Angeles, CA, US.
2005. "Therapeutic silencing of Eph2 in ovarian cancer". Invited. Columbus, OH, US.
2005. "Effects of chronic stress on cancer metastasis". Invited. Columbus, OH, US.
2005. "Therapeutic silencing of Eph2 in ovarian cancer". Invited. San Diego, CA, US.
2005. "Therapeutic Targeting of Eph2 in Ovarian Carcinoma". Invited. Philadelphia, PA, US.
2005. "Anti-vascular therapy for ovarian carcinoma". Invited. Davis, CA, US.
2005. "Molecular biology of ovarian carcinoma". Invited. Davis, CA, US.
2002. "Molecular determinants of ovarian cancer plasticity". Invited. Gainesville, FL, US.
2001. "Genetic screening for ovarian cancer: Medicolegal implications". Invited. Iowa City, IA, US.
2001. "Ovarian Cancer: Genetic Insights and Management". Invited. Iowa City, IA, US.
2001. "Benign and malignant vulvar neoplasms". Invited. Sioux City, IA, US.
2001. "Prophylactic approaches for ovarian cancer". Invited. St. Louis, MO, US.
2001. "Genetic screening and medicolegal ramifications". Invited. St. Louis, MO, US.
2001. "Methods to Repair Obstetric Lacerations". Invited. Iowa City, IA, US.
2000. "Vasculogenic mimicry in ovarian carcinoma". Invited. Amana, IA, US.
2000. "Clinical trials for gynecological malignancies". Invited. Davenport, IA, US.
2000. "Ovarian cancer: Clinical and research perspectives". Invited. Charlotte, NC, US.
2000. "Clinical trials in ovarian cancer". Invited. Des Moines, IA, US.
1999. "Prophylactic Oophorectomy: For Whom?". Invited. Iowa City, IA, US.
1999. "Issues in Gynecologic Cancer". Invited. Iowa City, IA, US.
1999. "Ovarian cancer: An update". Invited. Des Moines, IA, US.
1999. "Gynecologic Cancers". Invited. Iowa City, IA, US.
1999. "Indications for prophylactic oophorectomy". Invited. Mason City, IA, US.
1998. "Clinical Trials". Invited. Iowa City, IA, US.
1998. "Ovarian cancer: An update". Invited. Chicago, IL, US.
1998. "Menopause in the Cancer Patient". Invited. Waterloo, IA, US.
1998. "Ovarian Cancer: The role for primary surgical cytoreduction". Invited. Iowa City, IA, US.
1997. "Management of Menopause". Invited. Iowa City, IA, US.
1996. "Menopausal Concerns in the Oncology Patient". Invited. Williamsburg, IA, US.
1996. "Molecular Prognostic Factors for Breast Cancer". Invited. Iowa City, IA, US.
1994. "Evaluation of a pelvic mass". Invited. Gainesville, FL, US.

Less

Grant & Contract Support

Date:	2025 - 2026
Title:	Green Medicine: Plant Vesicles in Cancer Treatment
Funding Source:	Lyda Hill Philanthropies
Role:	PI
ID:	FP00023072

Date:	2025 - 2030
Title:	Development of the MasSpec Pen Technology to Guide Surgical Decisions in the Care for Patients with Ovarian Cancer
Funding Source:	BCM/NIH
Role:	PI
ID:	R01 CA306089

Date:	2025 - 2026
Title:	Overcoming adaptive resistance to tisotumab vedotin in gynecologic cancers
Funding Source:	Pfizer
Role:	PI
ID:	LS2025-00064478

Date:	2025 - 2027
Title:	Mapping the Molecular Landscape of Mucinous Ovarian Cancer: Unveiling Tumor-Stroma Dynamics
Funding Source:	Mucinous Ovarian Cancer Coalition (MOCC)
Role:	PI
ID:	AWD00009079

Date:	2024 - 2027
Title:	Innovative cell therapy approaches for hematological and solid malignancies
Funding Source:	CPRIT
Role:	Co-PI
ID:	RP240439

Date:	2024 - 2028
Title:	Platelet Pathophysiology in Resistance to Antiangiogenic Therapy Against Ovarian Cancer Evaluated in a Vascularized TME-Chip
Funding Source:	DOD
Role:	PI
ID:	OC230122P1

Date:	2024 - 2026
Title:	Cancer Center Support (Core) Grant
Funding Source:	NIH/NCI
Role:	Co-Leader
ID:	P30 CA016672 (Pisters)

Date:	2024 - 2027
Title:	Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging
Funding Source:	CPRIT
Role:	Co-I
ID:	RP240311

Date:	2024 - 2026
Title:	AI-guided single-cell transfer learning model to predict precision medicine in ovarian cancer
Funding Source:	Ovarian Cancer Research Alliance (OCRA)
Role:	PI
ID:	CRDGAI-2024-3-1387

Date:	2023 - 2028
Title:	The University of MD Anderson Cancer Center Spore in Ovarian Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	P50 CA217685 (Sood and Bast)

Date:	2023 - 2028
Title:	Novel Biomarkers Predicting Blood Clots in Ovarian Cancer
Funding Source:	NIH
Role:	PI
ID:	CA275762

Date:	2022 - 2026
Title:	Defining mechanisms of immune suppression via special transcriptomics
Funding Source:	American Cancer Society
Role:	PI
ID:	RP21-155-06COUN

Date:	2021 - 2023
Title:	Theranostic Heterodimer Eph-Targeting Peptides for Ovarian & Breast Cancer
Funding Source:	Emerson Collective Cancer Research Fund
Role:	PI
ID:	710509-80-124339-19

Date:	2021 - 2026
Title:	Multimodal imaging and therapy of Ovarian Cancer
Funding Source:	University of Maryland
Role:	PI
ID:	R01CA247224

Date:	2021 - 2024
Title:	Rational combination therapy with EGFL6 antibodies
Funding Source:	Top Alliance Biosciences Inc
Role:	PI
ID:	AWD00005900

Date:	2021 - 2026
Title:	Training of Academic Gynecologic Oncologists
Funding Source:	NIH/NCI
Role:	PI
ID:	CA101642

Date:	2021 - 2023
Title:	Understanding and targeting myeloid populations in ovarian cancer for enhancing therapeutics effects
Funding Source:	The University of Arkansas
Role:	PI
ID:	813467

Date:	2020 - 2021
Title:	RA200395 - Rational restoration of p53-dependent antitumor drug response in chemoresistant rare ovarian cancer subtype
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	GRANT13249696

Date:	2019 - 2023
Title:	Development and application of a scalable workflow for immunomagnetic separation of exRNA carrier subclasses and molecular analysis of their cargo
Funding Source:	University of California San Diego/NIH
Role:	Co-I
ID:	1UG3 CA241687 (Laurent, L)

Date:	2019 - 2022
Title:	Rational development of immune therapy for low-grade ovarian serous carcinoma to overcome MEK inhibitor resistance
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	OC180177 (Wong, KK)

Date:	2019 - 2024
Title:	Role of RNA activation in Tumor Progression and Metastasis
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01 CA22907 (Chaluvally-Raghavan)

Date:	2019 - 2021
Title:	Blocking Adaptive Resistance to Anti-Angiogenesis Drugs
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	OC180136 (Hu, Wei)

Date:	2018 - 2024
Title:	Platelets promote growth of ovarian cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01 CA177909

Date:	2018 - 2023
Title:	Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer
Funding Source:	University of Michigan
Role:	Co-I
ID:	R01 CA227622 (Nagrath)

Date:	2018 - 2021
Title:	Mass Spectrometry Imaging to Uncover Predictive Metabolic Markers of Ovarian Cancer Surgical Outcome and Treatment Response
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP180381 (Eberlin)

Date:	2017 - 2024
Title:	Harnessing the power of exosomes for non-coding RNA delivery
Funding Source:	NCI
Role:	PI
ID:	R35 CA209904-02

Date:	2017 - 2022
Title:	Targeted Therapeutics for Ovarian Cancer and Its Microenvironment - treatment and theoretical modeling
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	U01 CA213759 (MPI; Lopez)

Date:	2017 - 2021
Title:	Non-coding RNA Cancer Therapeutics
Funding Source:	American Cancer Society (ACS)
Role:	PI
ID:	RP-16-240-01-TBG

Date:	2016 - 2021
Title:	EphA2 targeting in uterine carcinoma (Project 3 - UT MDACC SPORE in Uterine Cancer)
Funding Source:	NIH/NCI
Role:	PI
ID:	P50 CA098258

Date:	2016 - 2019
Title:	Targeting adaptive changes following anti-angiogenesis therapy in ovarian cancer
Funding Source:	Gateway Foundation
Role:	Co-PI
ID:	G-16-100 (Sood)

Date:	2016 - 2021
Title:	Biobehavioral Influences on Ovarian Cancer Progression. Role of Chemoresistance
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01CA193249

Date:	2015 - 2019
Title:	Targeting adaptive changes following anti-angiogenesis therapy in ovarian cancer
Funding Source:	V Foundation
Role:	Co-PI
ID:	VFoundation-2015 (Sood, Coleman)

Date:	2015 - 2018
Title:	Microenvironmental control of premalignant lesions in ovarian cancer
Funding Source:	Ovarian Cancer Research Fund Alliance, Inc
Role:	Principal Investigator-MDACC

Date:	2014 - 2018
Title:	Selective Tumor Delivery of Anti-Cancer Agents in Ovarian Cancer Therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	DP 150091 (Lacko)

Date:	2014 - 2017
Title:	Ovarian Cancer: Mechanisms of neuroendocrine regulation
Funding Source:	NIH/NCI
Role:	PI
ID:	2R01-CA109298-10

Date:	2013 - 2018
Title:	Platelets Promote Growth of Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01 CA177909-01 (Afshar-Karghan)

Date:	2013 - 2018
Title:	Novel Extra Cellular RNA-based Combinatorial RNA Inhibition Therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	UH3 TR000943

Date:	2013 - 2016
Title:	Consortium to Study Long-Term Survivors of Ovarian Cancer
Funding Source:	Development of Ovarian Cancer Outcome Consortium
Role:	PI
ID:	OC120547

Date:	2013 - 2017
Title:	Power of Platelets in ovarian cancer
Funding Source:	Ovarian Cancer Research Fund
Role:	Principal Investigator-MDACC

Date:	2011 - 2018
Title:	Clinical Translation of Therapeutic siRNA in Solid Malignancies
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP120214 (Coleman)

Date:	2011 - 2013
Title:	Disrupting BRCA1/2 DNA Damage Response by Blocking the Centrosomal Protein STIL(SIL): A novel strategy for treatment of ovarian cancer
Funding Source:	Department of Defense (DOD)
Role:	Co-PI
ID:	OC100237

Date:	2011 - 2017
Title:	Circumventing Platinum Resistance Using siRNA Transfer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Principal Investigator-MDACC
ID:	RP110595-P2

Date:	2011 - 2013
Title:	Role of platelets in ovarian cancer pathogenesis
Funding Source:	BCM/MDACC MRP
Role:	PI

Date:	2010 - 2017
Title:	Texas Center for Cancer Nanomedicine
Funding Source:	NIH/NCI
Role:	PI
ID:	1U54 CA151668-01

Date:	2010 - 2016
Title:	Targeting Dll4-Notch signaling in ovarian cancer (Project 2 - UT MDACC SPORE in Ovarian Cancer)
Funding Source:	NIH/NCI
Role:	PI
ID:	NIH 2 P50 CA083639-11

Date:	2010 - 2013
Title:	New Reagents for Synthesis of High Potency siRNAs
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	R44 GM084442-03

Date:	2010 - 2015
Title:	Molecular Targeting of PPAR-delta in colon cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01 CA142969-01A1

Date:	2010 - 2013
Title:	Identification and Validation of Biomarkers for Predicting Response to VEGF-Targeted Therapy
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	W81XWH-10-1-0158

Date:	2009 - 2014
Title:	Biobehavioral-cytokine interactions in ovarian cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01-CA1045-01 (Supplement

Date:	2009 - 2014
Title:	Toward individualized breast cancer therapy: leveraging molecular medicine with multistage vector technology
Funding Source:	DoD/BCRP
Role:	Co-I
ID:	W81XWH-08-BCRP-INNOV

Date:	2009 - 2013
Title:	Novel siRNA based therapeutic approaches for ovarian carcinoma Program Project Development Grant
Funding Source:	Ovarian Cancer Research Fund
Role:	PI

Date:	2008 - 2012
Title:	Nanovectors for Characterization and Destruction of Breast Tumor Vasculature
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	R01-CA128797

Date:	2006 - 2015
Title:	Anti-vascular therapy for ovarian cancer
Funding Source:	The Marcus Foundation
Role:	PI

Date:	2005 - 2008
Title:	Novel siRNA based therapeutic approaches for ovarian carcinoma, Program Project Development Grant
Funding Source:	Ovarian Cancer Research Fund, Inc
Role:	PI

Date:	2005 - 2010
Title:	Cell-specific targeting of ovarian cancer vasculature SPORE (Project 2)
Funding Source:	NIH
Role:	PI
ID:	CA083639-06A1

Date:	2004 - 2006
Title:	Anti-Vascular effects of AVE8062 in ovarian carcinoma
Funding Source:	Sanofi-Aventis, Inc
Role:	PI

Date:	2004 - 2006
Title:	Biobehavioral-cytokine interactions in ovarian cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01-CA1045-01 (Supplement)

Date:	2004 - 2011
Title:	Tumor metastasis: Biobehavioral mechanisms
Funding Source:	National Cancer Institute - NIH
Role:	PI
ID:	5R01-CA110793-05

Date:	2004 - 2008
Title:	Role of EphA2 in Ovarian Cancer Development and Progression
Funding Source:	Department of Defense Ovarian Cancer Research Program
Role:	PI
ID:	W81XWH-04-1-0227

Date:	2003 - 2004
Title:	Role of Focal Adhesion Kinase on Taxotere activity in ovarian cancer
Funding Source:	Aventis, Inc
Role:	PI

Date:	2002 - 2004
Title:	Functional Role of MMPs in Ovarian Tumor Cell Plasticity Properties
Funding Source:	UT M.D. Anderson Cancer Center Ovarian Cancer SPORE Career Development Award
Role:	PI

Date:	2002 - 2004
Title:	Neuroendocrine Regulation of VEGF and IL-6 in Ovarian Carcinoma
Funding Source:	The Donna Marie Cimitile Fotheringham Award for Ovarian Cancer Research
Role:	PI

Date:	2001 - 2002
Title:	Role of FAK expression in Invasion and Cisplatin Resistance in Ovarian Cancer
Funding Source:	Gynecologic Cancer Foundation - National Ovarian Cancer Coalition Award
Role:	PI

Date:	2001 - 2005
Title:	Molecular Mechanisms of Ovarian Cancer Plasticity
Funding Source:	Reproductive Scientist Development Program
Role:	PI

Date:	2001 - 2002
Title:	Development of teaching materials regarding operative dictations for residents and medical students
Funding Source:	Council on Teaching, University Iowa
Role:	PI

Date:	2001 - 2002
Title:	Hormonal stimulation of tumor angiogenesis in ovarian cancer
Funding Source:	Oberman Center for Advanced Studies Interdisciplinary Research Grant
Role:	Co-PI

Date:	2000 - 2002
Title:	Biobehavioral-Immune Interactions in Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	R21 CA88293-01

Date:	2000
Title:	ON-Q Pain Management System in Patients Undergoing Abdominal Surgery for Gynecologic Malignancies
Funding Source:	Ethicon Endo-Surgical (EES)
Role:	Co-PI

Date:	1999 - 2001
Title:	A Randomized, Double-Blind, Placebo-Controlled, Phase IIB Study of the Safety and Efficacy of OVAREX (TM) Mab-B43.13 in Ovarian Cancer Patients with an Elevated Serum CA 125 but without Other Evidence of Disease
Funding Source:	ALTAREX Corporation
Role:	PI

Date:	1999 - 2001
Title:	Phase II Trial of Intraperitoneal Topotecan/Oral Etoposide in Ovarian Cancer
Funding Source:	SmithKline Beecham, Inc
Role:	PI

Date:	1999 - 2001
Title:	Molecular Mechanisms Resulting in Distant Metastases in Ovarian Cancer
Funding Source:	Reproductive Scientist Development Program
Role:	PI

Date:	1998 - 1999
Title:	Distant Metastases in Ovarian Cancer
Funding Source:	American Cancer Society Seed Grant
Role:	PI

Date:	1997 - 1998
Title:	Genomic Instability: Why the Guardian Fails in Ovarian Cancer
Funding Source:	ACOG/Ortho Academic Training Fellowship Grant
Role:	Co-PI

Date:	1997 - 1998
Title:	The Use of Anorectal Manometry to Assess Rectal Dysfunction in Patients following Radical Hysterectomy
Funding Source:	American Cancer Society Seed Grant to Dr. Ingrid Nygaard
Role:	Co-PI

Date:	1992 - 1993
Title:	Human Papillomavirus (HPV) DNA in LEEP Plume
Funding Source:	Southern Medical Association Research Project Grant
Role:	Co-I

Date:	1988 - 1989
Title:	Type Specific Detection of Human Papilomavirus (HPV) in Cervical Neoplasia
Funding Source:	Southern Medical Association Research Project Grant
Role:	Co-I

Selected Publications

Peer-Reviewed Articles

Eyada, M, Michael, V, Patel, S, How, JA, Wilke, RN, Jazaeri, AA, Fleming, N, Soliman, PT, Sood, AK, Westin, SN, Sims, TT. Oral cyclophosphamide combined with bevacizumab in recurrent heavily pre-treated ovarian cancer. International Journal of Gynecological Cancer 36(8), 2026. e-Pub 2026. PMID: 42259216.
Powers-James, C, Christie, AJ, Arun, BK, Austin, T, Babiera, G, Basen-Engquist, KM, Carmack, CL, Chaoul, MA, Connelly Newton, L, Haddad, R, Harrison, CA, Leung, CH, Li, Y, Mallaiah, S, Nagarathna, R, Parker, PA, Perkins, GH, Spelman, AR, Sood, AK, Wagner, R, Yang, P, Yeung, SJ, Cohen, L. Lifestyle Program for Breast Cancer Improves Body Composition, Fitness, and Patient-Reported Outcomes. Cancers 18(11), 2026. e-Pub 2026. PMID: 42279341.
Uekusa, R, Yokoi, A, Ukai, M, Yoshida, K, Chattrairat, K, Yasui, T, Inokuma, Y, Kitagawa, M, Asano-Inami, E, Yoshihara, M, Tamauchi, S, Yoshikawa, N, Niimi, K, Matsuzaki, J, Ochiya, T, Sood, AK, Yamamoto, Y, Kajiyama, H. DNA Copy Number Profiling in Extracellular Vesicles as Clinical Biomarkers of High-Grade Serous Ovarian Carcinoma. Journal of Extracellular Vesicles 15(5), 2026. e-Pub 2026. PMID: 42139280.
Telles R, Thaker PH, Goodheart MJ, Penedo FJ, K Lutgendorf AKSS. Rethinking depression diagnosis in ovarian cancer: The role of somatic symptoms. Cancer 132(10):e70344, 2026. e-Pub 2026. PMID: 42108834.
Brodsky, AL, Asare, A, Fellman, B, Anderson, K, Yao, J, Lee, S, Tran, HT, Xu, X, Liu, J, Celestino, J, Hajek, RA, Morgan, M, Mohammad, MM, Soliman, PT, Shafer, A, Sood, AK, Bodurka, DC, Fleming, N, Grinsfelder, MO, Milojevic, L, Jazaeri, AA, Mills, GB, Coleman, R, Westin, SN. Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA). Clinical Cancer Research 32(7):1234-1245, 2026. e-Pub 2026. PMID: 41528970.
Piha-Paul, SA, Tseng, C, Thompson, E, Stafford, RJ, Le, H, Kang, L, Fu, S, Tsimberidou, AM, Blumenschein, GR, Rodon Ahnert, J, Slopis, JM, Hong, DS, Naing, A, Meric-Bernstam, F, Ng, CS, Westin, SN, Sood, AK. Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies. Oncologist 31(3), 2026. e-Pub 2026. PMID: 41389341.
Hollis, RL, Miller, A, Lankes, HA, Wong, KK, Rodgers, WH, Millan, D, Carty, K, Coleman, R, Moore, KM, Secord, AA, O’Malley, DM, Chan, J, Hagemann, AR, Gaillard, S, Guntupalli, SR, Edelson, M, Rose, PG, Dorigo, O, Banerjee, S, Ewing, A, Churchman, M, Sood, AK, Herrington, CS, Gourley, C, Gershenson, DM. Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS. Clinical Cancer Research 32(4):724-734, 2026. e-Pub 2026. PMID: 41378992.
Lee, H, Sager, B, Sood, AK, Afshar-Kharghan, V, Cho, MS. Platelets induce VISTA expression and modulate the ovarian tumor microenvironment. Platelets 37(1), 2026. e-Pub 2026. PMID: 41841642.
Sims TT, Sood AK, Westin SN, Rangel K, Fleming ND. Correlation of BRCA and homologous recombination deficiency status with clinical and survival outcomes in patients with advanced-stage ovarian cancer undergoing frontline therapy. Int J Gynecol Cancer 19(7):104494, 2026. e-Pub 2026. PMID: 41680019.
Phi, LH, Cheng, Y, Funakoshi, Y, Bertucci, F, Finetti, P, Van Laere, S, Zou, F, Long, JP, Ogata, S, Krishnamurthy, S, Reuben, JM, Foulks, JM, Warner, SL, Rosenbluth, JM, Sood, AK, Tripathy, D, Ueno, NT, Wang, X. AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization. Breast Cancer Research 27(1), 2025. e-Pub 2025. PMID: 40329335.
Ma, X, Hsu, YC, Asare, A, Zhang, K, Glassman, D, Handley, KF, Foster, KI, Sharma, K, Westin, SN, Jazaeri, AA, Fleming, N, Bhattacharya, PK, Jiang, X, Sood, AK, Shams, S. A pioneering artificial intelligence tool to predict treatment outcomes in ovarian cancer via diagnostic laparoscopy. Scientific reports 15(1):14437, 2025. e-Pub 2025. PMID: 40281006.
Tarney, CM, Mhawech-Fauceglia, P, Ogata, JD, Oliver, J, Abulez, T, Branton, PA, Movahedi-Lankarani, S, Hood, BL, Conrads, KA, Rosalik, K, Wong, KK, Gershenson, DM, Lee, S, Sood, AK, Bast Jr, RC, Darcy, KM, Phippen, NT, Maxwell, GL, Conrads, TP, Bateman, NW. Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers. Clinical Proteomics 22(1), 2025. e-Pub 2025. PMID: 41053579.
Stur, E, Peng, F, Teng, PN, Bayraktar, E, Hu, M, Corvigno, S, Brown, DJ, Lee, S, Moore, KN, Bateman, NW, Darcy, KM, Maxwell, GL, P. Conrads, T, Sahni, N, Vázquez-García, I, Shah, S, Celestino, J, D. Fleming, N, Navin, N, Wang, L, Sood, AK. The dynamic immune behavior of primary and metastatic ovarian carcinoma. npj Precision Oncology 9(1):120, 2025. e-Pub 2025. PMID: 40281242.
Wilke, RN, Liu, J, Westin, SN, Fellman, B, Sims, TT, Pham, MM, Rangel, KM, Sey, E, Rauh-Hain, JA, Lu, KH, Sood, AK, Fleming, N. The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy. International Journal of Gynecological Cancer 35(11), 2025. e-Pub 2025. PMID: 39414313.
Tahan, E, Brodsky, AL, Gonzales, N, Bercow, AS, Sood, AK, Ramondetta, LM, Gershenson, DM, Hillman, RT. Survival outcomes in patients with recurrent mixed sex cord-stromal tumors of the ovary. International Journal of Gynecological Cancer 35(10), 2025. e-Pub 2025. PMID: 40815979.
Knisely, A, Dai, Y, Barlow, GL, Lee, S, Lawson, BC, Clark, HD, Fellman, B, Yuan, Y, Lu, W, Lubo Julio, IC, Lazcano, RN, Chelvanambi, M, Melendez, B, Singh, BB, Singh, B, Wani, K, Chen, J, Yeh, CC, Gao, J, Barnes, S, Shi, O, Khan, KB, Serrano, A, Gomez Bolanos, L, Scalise, CB, Cheung, SK, Dutta, P, Velichko, S, ElNaggar, AC, Liu, MC, Wilke, RN, How, JA, Ramondetta, LM, Boruta II, DM, Richardson, G, Shafer, A, Westin, SN, Sims, TT, Sood, AK, Ramirez, PT, Lazar, A, Soliman, PT, Lu, KH, Haymaker, CL, Solis Soto, LM, Wargo, J, Grisham, RN, Wucherpfennig, K, Wang, L, Jazaeri, AA. Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy. Clinical Cancer Research 31(19):4122-4135, 2025. e-Pub 2025. PMID: 40748258.
Bayraktar, E, Rodriguez-Aguayo, C, Stur, E, Kumar, S, Mangala, LS, Jennings, NB, Bayram, NN, Corvigno, S, Asare, A, Ivan, C, Kim, MS, Vu, TC, Hanjra, P, Kim, SB, Lankenau Ahumada, A, Wu, W, Lee, S, Szymanowska, A, Oztatlici, H, Estecio, MR, Lee, JS, Jain, A, Sahni, N, Hagan, J, Baylin, SB, Liu, J, Lopez Berestein, G, Pradeep, S, Sood, AK. Epigenetic modulation of BARD1 to enhance anti-VEGF therapy. Cell Reports Medicine 6(9), 2025. e-Pub 2025. PMID: 40907495.
Nie, H, Liao, L, Zielinski, RJ, Gomez, JA, Basi, A, Seeley, E, Tan, L, Bilecz, AJ, Zhou, W, Liu, H, Wang, C, Wu, S, Qi, Y, Miyamoto, T, Severi, F, Goldman, AR, Gu, S, Sood, AK, Jazaeri, AA, Drapkin, R, Claiborne, DT, Zhang, N, Lorenzi, PL, Burks, JK, Lengyel, E, Gottlieb, E, Zhang, R. Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer Research 85(18):3471-3489, 2025. e-Pub 2025. PMID: 40658600.
Dai, Y, Knisely, A, Yano, M, Dang, M, Hinchcliff, EM, Lee, S, Welp, A, Chelvanambi, M, Lastrapes, M, Liu, H, Yuan, Z, Wang, C, Nie, H, Jean, S, Montaner, LJ, Hou, J, Patel, A, Patel, S, Fellman, B, Yuan, Y, Sun, B, Pandurengan, RK, Cuentas, EP, Celestino, J, Liu, Y, Liu, J, Hillman, RT, Westin, SN, Sood, AK, Soliman, PT, Shafer, A, Meyer, LA, Gershenson, DM, Vining, D, Ganeshan, DM, Lu, KH, Wargo, J, Peng, W, Zhang, R, Wang, L, Jazaeri, AA. PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature 644(8076):537-546, 2025. e-Pub 2025. PMID: 40604275.
Lin, N, Huang, T, Patel, CJ, Poole, EM, Clish, CB, Armaiz Pena, GN, Nagaraja, AS, Eliassen, AH, Shutta, KH, Balasubramanian, R, Kubzansky, LD, Hankinson, SE, Zeleznik, O, Sood, AK, Tworoger, SS. Plasma and ovarian metabolomic responses to chronic stress in female mice. Metabolomics 21(4), 2025. e-Pub 2025. PMID: 40593273.
Brodsky, AL, Flores Legarreta, A, Fellman, B, Glassman, D, How, JA, Vuttaradhi, VK, Sood, AK, Ramondetta, LM, Gershenson, DM, Hillman, RT. TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors. International Journal of Gynecological Cancer 35(8), 2025. e-Pub 2025. PMID: 39395821.
Li D, Shi S, Cao Q, Sood AK, Molldrem JJ, Ma Q, Li C. Copper Sulfide Nanoparticle-Mediated Photothermolysis Induces Immunogenic Cell Death in Ovarian Cancer Cells. bioRxiv, 2025. e-Pub 2025. PMID: 40777257.
Brodsky, AL, Flores Legarreta, A, How, JA, Vuttaradhi, VK, Sood, AK, Ramondetta, LM, Gershenson, DM, Hillman, RT. Survival outcomes comparing minimally invasive versus open cytoreductive surgery in recurrent adult-type granulosa cell tumors. American journal of obstetrics and gynecology 233(1):51.e1-51.e10, 2025. e-Pub 2025. PMID: 39824329.
Matsuo, K, Lee, MW, Furey, KB, Yang, JL, Roman, LD, Klar, M, Sood, AK, Wright, JD. Estimating high-grade serous fallopian tubal carcinoma in the era of tubal hypothesis. International Journal of Gynecological Cancer 35(4), 2025. e-Pub 2025. PMID: 39955182.
Asare, A, Previs, RA, Spinosa, D, Fellman, B, Scott, AL, Mulder, I, Mahmoud, M, Enbaya, A, Siedel, J, Cobb, LP, Soliman, PT, Sood, AK, Coleman, R, Secord, AA, Westin, SN. Bevacizumab beyond progression. Gynecologic oncology 194:112-118, 2025. e-Pub 2025. PMID: 39987772.
Chelariu-Raicu, A, Vu, TC, Umamaheswaran, S, Stur, E, Hanjra, P, Han, Y, Hu, M, Lin, J, Lawson, BC, Liu, J, Sood, AK, Wen, Y. IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer. Cancer Research Communications 5(4):512-526, 2025. e-Pub 2025. PMID: 40029935.
Welte, T, Vuttaradhi, VK, Khlebus, E, Brodsky, AL, Legarreta, A, Celestino, J, Powell, RT, Stephan, C, Nguyen, N, Li, J, Takamatsu, S, Calzoncinth, K, Sood, AK, Gershenson, DM, Futreal, A, Lawson, BC, Hillman, RT. Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors. Cancer Research 85(5):875-893, 2025. e-Pub 2025. PMID: 39652611.
Ahmed, J, Stephen, B, Khawaja, MR, Yang, Y, Salih, I, Barrientos Toro, E, Raso, G, Karp, DD, Piha-Paul, SA, Sood, AK, Ng, CS, Johnson, A, Soliman, PT, Meric-Bernstam, F, Lu, KH, Naing, A. A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. Gynecologic oncology 193:73-80, 2025. e-Pub 2025. PMID: 39787747.
Zhang, Y, Barkdull, S, Kontoyiannis, PD, Legarreta, A, Gershenson, DM, Ramalingam, P, Frumovitz, M, Sood, AK. TP53 and KRAS co-mutations are associated with worse outcomes in mucinous ovarian carcinomas. Frontiers in Oncology 15, 2025. e-Pub 2025. PMID: 40896434.
Corvigno, S, Yao, J, Asare, A, Zhao, L, Celestino, J, Hajek, RA, Goette, EA, Rogers, RT, Montoya, RN, Song, P, Zhang, Q, Song, X, Mohammad, MM, Shaw, KR, Zhang, J, Lu, KH, Jazaeri, AA, Westin, SN, Sood, AK, Lee, S. Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer. Frontiers in Oncology 15(1538446):1538446, 2025. e-Pub 2025. PMID: 40365343.
Guo, S, Liu, X, Cheng, X, Jiang, Y, Ji, S, Liang, Q, Koval, A, Li, Y, Owen, L, Kim, IK, Aparicio, A, Lee, S, Sood, AK, Kopetz, S, Shen, JY, Weinstein, JN, DeAngelis, MM, Chen, R, Wang, W. A deconvolution framework that uses single-cell sequencing plus a small benchmark data set for accurate analysis of cell type ratios in complex tissue samples. Genome Research 35(1):147-161, 2025. e-Pub 2025. PMID: 39586714.
van Wietmarschen, HA, Area-Gomez, E, Picard, M, Goodheart, M, Sood, AK, Lutgendorf, SK. Metabolic Effects of Healing Touch During Cervical Cancer Treatment. Integrative cancer therapies 24, 2025. e-Pub 2025. PMID: 40908655.
van Wietmarschen HA, Area-Gomez E, Picard M, Goodheart MJ, Sood AK, Lutgendorf SK. Metabolic Effects of Healing Touch During Cervical Cancer Treatment: An Exploratory Analysis. Integr Cancer Ther 24:15347354251367793, 2025. e-Pub 2025. PMID: 40908656.
Tarney CM, Mhawech-Fauceglia P, Ogata JD, Oliver J, Abulez T, Branton PA, Movahedi-Lankarani S, Hood BL, Conrads KA, Rosalik K, Wong KK, Gershenson DM, Lee S, Sood AK, Bast RC, Darcy KM, Phippen NT, Maxwell GL, Conrads TP, Bateman NW. Qualitative proteomics identifies conserved proteins and latered regulation of mucin-16 in low grade serous ovarian cancers. Clinical Proteomics 22:33, 2025. e-Pub 2025.
Awasthi, S, Dobrolecki, LE, Sallas, C, Zhang, X, Li, Y, Khazaei, S, Ghosh, S, Jeter, CR, Liu, J, Mills, GB, Westin, SN, Lewis, MT, Peng, W, Sood, AK, Yap, TA, Yi, SS, McGrail, DJ, Sahni, N. UBA1 inhibition sensitizes cancer cells to PARP inhibitors. Cell Reports Medicine 5(12), 2024. e-Pub 2024. PMID: 39626673.
Bateman, NW, Abulez, T, Soltis, AR, McPherson, A, Choi, S, Garsed, DW, Pandey, A, Tian, C, Hood, BL, Conrads, KA, Teng, PN, Oliver, J, Gist, G, Mitchell, D, Litzi, T, Tarney, CM, Crothers, BA, Mhawech-Fauceglia, P, Dalgard, C, Wilkerson, MD, Pierobon, M, Petricoin, EF, Yan, C, Meerzaman, D, Bodelon, C, Wentzensen, N, Lee, JS, Huntsman, DG, Shah, S, Shriver, CD, Phippen, NT, Darcy, KM, Bowtell, DD, Conrads, TP, Maxwell, GL, Makohon-Moore, S, Barakat, W, Zhang, X, Hunt, AL, Ao, W, Lytle-Gabbin, SL, Casablanca, Y, Hamilton, CA, Newell, M, Wells, J, Sukumar, G, Bacikova, D, Freyman, J, Cohn, DE, Berchuck, A, Havrilesky, LJ, Duska, L, Odunsi, A, Sood, AK, Brenton, JD, Sala, E, Annunziata, C, Dorigo, O, Nelson, B, Cochrane, DR, Moore, K, Baldelli, E, Chen, QR, Hu, Y, Fereday, S, Traficante, N, Defazio, A, Goode, EL. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 38480868.
Czopik, A, McNamee, EN, Vaughn, V, Huang, X, Bang, IH, Clark, T, Wang, Y, Ruan, W, Nguyen, T, Masterson, JC, Tak, E, Frank, S, Collins, CB, Li, H, Rodriguez-Aguayo, C, Lopez Berestein, G, Gerich, ME, Furuta, GT, Yuan, X, Sood, AK, De Zoeten, EF, Eltzschig, H. HIF-2α-dependent induction of miR-29a restrains TH1 activity during T cell dependent colitis. Nature communications 15(1):8042, 2024. e-Pub 2024. PMID: 39271652.
Murray, CE, Kornepati, AV, Ontiveros, C, Liao, YJ, de la Peña Avalos, B, Rogers, CM, Liu, Z, Deng, Y, Bai, HY, Kari, S, Padron, AS, Boyd, JT, Reyes, R, Clark, CA, Svatek, RS, Li, R, Hu, Y, Wang, M, Conejo-Garcia, JR, Byers, LA, Ramkumar, K, Sood, AK, Lee, JM, Burd, CE, Vadlamudi, RK, Gupta, HB, Zhao, W, Dray, E, Sung, P, Curiel, TJ. Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors. Molecular cancer 23(1), 2024. e-Pub 2024. PMID: 39478560.
Brown, J, Miller, A, Holman, LL, Backes, F, Nagel, C, Bender, D, Miller, DS, Powell, MA, Westin, SN, Bonebrake, AJ, Muller, CY, Secord, AA, Crane, EK, Schorge, JO, Tew, WP, Sood, AK, Bookman, M, Aghajanian, C, Gershenson, DM. Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors. Gynecologic oncology 190:283-290, 2024. e-Pub 2024. PMID: 39265466.
Lemieux, M, Telles, R, Goodheart, M, Dahmoush, L, Hagemann, IS, Penedo, FJ, Nandakumar, R, Cole, SW, Sood, AK, Lutgendorf, SK, Thaker, PH. Quality of life and survivorship in patients with low-grade ovarian cancer. Gynecologic oncology 190:96-103, 2024. e-Pub 2024. PMID: 39173565.
Reihanisaransari, R, Gajjela, CC, Wu, X, Ishrak, R, Corvigno, S, Zhong, Y, Liu, J, Sood, AK, Mayerich, D, Berisha, S, Reddy, RK. Rapid Hyperspectral Photothermal Mid-Infrared Spectroscopic Imaging from Sparse Data for Gynecologic Cancer Tissue Subtyping. Analytical Chemistry 96(40):15880-15887, 2024. e-Pub 2024. PMID: 39312212.
Matsuo, K, Chen, L, Klar, M, Roman, LD, Sood, AK, Gershenson, DM, Wright, JD. Primary Cytoreduction and Survival for Patients with Less-Common Epithelial Ovarian Cancer. JAMA Network Open 7(6):e2417775, 2024. e-Pub 2024. PMID: 38900429.
Lee MW, Anderson ZS, Girma AM, Klar M, Roman LD, Carlson JW, Wright JD, Sood AK, Matsuo K. Diagnosis Shift in Site of Origin of Tubo-Ovarian Carcinoma. Obstet Gynecol 143(5):660-669, 2024. e-Pub 2024. PMID: 38513238.
Vo, D, Liu, Y, Sood, AK, Rezvani, K, Jazaeri, AA, Liu, J. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma. Cancer Biomarkers 39(4):289-298, 2024. e-Pub 2024. PMID: 38250760.
Reihanisaransari R, Gajjela CC, Wu X, Ishrak R, Corvigno S, Zhong Y, Liui J, Sood AK, Mayerich D, Berisha S, Reddy R. Rapid hyperspectral photothermal mid-infrared spectroscopic imaging from sparse data for gynecologic cancer tissue subtyping. ArXiv, 2024. e-Pub 2024. PMID: 38463509.
Lutgendorf SK, Telles RM, Whitney B, Thaker PH, Slavich GM, Goodheart MJ, Penedo FJ, Noble AE, Cole SW, Sood AK, Corn BW. The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients. Brain Behav Immun 116:362-369, 2024. e-Pub 2024. PMID: 38081436.
Eyada, M, Michael, V, Fellman, B, Patel, S, Soliman, PT, How, JA, Jazaeri, AA, Fleming, N, Sood, AK, Westin, SN, Sims, TT. Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Kim MS, Corvigno S, Foster K, Hanjra P, Vu TC, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. International Journal of Molecular Sciences 25(2), 2024. e-Pub 2024. PMID: 38279277.
Telles R, Zimmerman MB, Thaker PH, Slavich GM, Ramirez ES, Zia S, Goodheart MJ, Cole SW, Sood AK, Lutgendorf SK. Rural-urban disparities in psychosocial functioning in epithelial ovarian cancer patients. Gynecol Oncol 184:139-145, 2024. e-Pub 2024. PMID: 38309031.
Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer 130(7):1061-1071, 2024. e-Pub 2024. PMID: 38009662.
Barnard ME, Poole EM, Huang T, Sood AK, Kubzansky LD, Tworoger SS. Caregiver burden and risk of epithelial ovarian cancer in the Nurses’ Health Studies. American Journal of Epidemiology 194(2):362-369, 2024. e-Pub 2024. PMID: 38973733.
Knisely A, Hinchcliff EM, Gardner E, Lito K, Fellman B, Yuan Y, Sood AK, Westin SN, Lu KH, Jazaeri AA. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience 27(5), 2024. e-Pub 2024. PMID: 38726365.
Ghosh LD, Mathur T, Tronolone JJ, Chuong A, Rangel K, Corvigno S, Sood AK, Jain A. Angiogenesis-Enabled Human Ovarian Tumor Microenvironment-Chip Evaluates Pathophysiology of Platelets in Microcirculation. Adv Healthc Mater:e2304263, 2024. e-Pub 2024. PMID: 38553940.
Telles R, Zia S, Greteman BB, Thaker PH, Penedo F, Charlton ME, Goodheart MJ, Armer JS, Noble A, Sood AK, Lutgendorf SK. Well-being and stress vulnerability in ovarian cancer survivors during the COVID-19 pandemic. J Psychosoc Oncol 42(3):1-16, 2024. e-Pub 2024. PMID: 37587850.
Aris M, Sood AK, Zaslavsky A. Editorial: Platelets in tumor biology: From molecular mechanisms to clinical applications. Front Cell Dev Biol 12, 2024. e-Pub 2024. PMID: 38415273.
How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Curentas EP, Schmeler KM, Nick A, Lu KH, Coleman RL, Wang L, Jazaeri A. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med 5:1-14, 2024. e-Pub 2024. PMID: 39151421.
Kim MS, Glassman D, Handley KF, Ahumada AL, Jennings NB, Bayraktar E, Foster K, Joseph R, Lee S, Coleman RL, Sood AK. Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Med 13(15):e70031, 2024. e-Pub 2024. PMID: 39114948.
How JA, Legarreta AF, Handley KF, Fellman B, Foster KI, Glassman D, Vuttaradhi VK, Brodsky AL, Lawson B, Frumovtiz M, Westin SN, Ramondetta LM, Gershenson DM, Sood AK, Hillman RT. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol 230(5):544.e1-544.e13, 2024. e-Pub 2024. PMID: 38191019.
Corvigno S, Liu Y, Bayraktar E, Stur E, Bayram NN, Ahumada AL, Nagaraju S, Rodriguez-Aguayo C, Chen H, Vu TC, Wen Y, Liang H, Zhao L, Lee S, Lopez-Berestein G, Sood AK. Enhanced plant-derived vesicles for nucleotide delivery for cancer therapy. NPJ Precis Oncol 8(1):86, 2024. e-Pub 2024. PMID: 38582949.
Knisely A, Hinchcliff E, Fellman B, Mosley A, Lito K, Hull S, Westin SN, Sood AK, Schmeler KM, Taylor JS, Huang SY, Sheth RA, Lu KH, Jazaeri AA. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med 5(4):311-320.e3, 2024. e-Pub 2024. PMID: 38471508.
Li, Y, Dobrolecki, LE, Sallas, C, Zhang, X, Kerr, TD, Bisht, D, Wang, Y, Awasthi, S, Kaundal, B, Wu, S, Peng, W, Mendillo, ML, Lu, Y, Jeter, CR, Peng, G, Liu, J, Westin, SN, Sood, AK, Lewis, MT, Das, J, Yi, S, Bedford, MT, McGrail, DJ, Sahni, N. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell Reports Medicine 4(12), 2023. e-Pub 2023. PMID: 38118413.
McGrail DJ, Li Y, Smith RS, Feng B, Dai H, Hu L, Dennehey B, Awasthi S, Mendillo ML, Sood AK, Mills GB, Lin SY, Yi SS, Sahni N. Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins. Cell Rep Med 4(11):101255, 2023. e-Pub 2023. PMID: 37909041.
Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AK. In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy. NPJ Precis Oncol 7(1):115, 2023. e-Pub 2023. PMID: 37923835.
Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih IM, Westin SN, Wong KK, Gershenson DM. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer 33(9):1331-1344, 2023. e-Pub 2023. PMID: 37591609.
Zhang X, Yao J, Li X, Niu N, Liu Y, Hajek RA, Peng G, Westin S, Sood AK, Liu J. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci Adv 9(29):eadf7195, 2023. e-Pub 2023. PMID: 37478190.
Gajjela CC, Brun M, Mankar R, Corvigno S, Kennedy N, Zhong Y, Liu J, Sood AK, Mayerich D, Berisha S, Reddy R. Leveraging mid-infrared spectroscopic imaging and deep learning for tissue subtype classification in ovarian cancer. Analyst 148(12):2699-2708, 2023. e-Pub 2023. PMID: 37218522.
Foster KI, Handley KF, Glassman D, Sims TT, Javadi S, Palmquist SM, Saleh MM, Fellman BM, Fleming ND, Bhosale PR, Sood AK. Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study. Int J Gynecol Cancer 33(6):937-943, 2023. e-Pub 2023. PMID: 36948527.
Foster KI, Shaw KRM, Jin J, Westin SN, Yap TA, Glassman DM, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Liu Y, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer 129(11):1672-1680, 2023. e-Pub 2023. PMID: 36930815.
Foster KI, Flores Legarreta A, Kamat R, Handley KF, Glassman D, How JA, Lawson BC, Westin SN, Ramondetta LM, Frumovitz M, Gershenson DM, Sood AK, Hillman RT. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol 228(6):724.e1-724.e9, 2023. e-Pub 2023. PMID: 36907533.
Conley AB, Fournier KF, Sood AK, Frumovitz M. Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer. Obstet Gynecol 141(5):1019-1023, 2023. e-Pub 2023. PMID: 37023452.
Liu, Y, Ahumada, AL, Bayraktar, E, Schwartz, P, Chowdhury, MA, Shi, S, Sebastian, MM, Khant, H, de Val, N, Bayram, NN, Zhang, G, Vu, TC, Jie, Z, Jennings, NB, Rodriguez-Aguayo, C, Swain, J, Stur, E, Mangala, LS, Wu, Y, Nagaraju, S, Ermias, B, Li, C, Lopez Berestein, G, Braam, J, Sood, AK. Enhancing oral delivery of plant-derived vesicles for colitis. Journal of Controlled Release 357:472-483, 2023. e-Pub 2023. PMID: 37031740.
Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, Dutta P, Kingsley CV, Foster KI, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, Sood AK. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience 26(2):106020, 2023. e-Pub 2023. PMID: 36824283.
Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci 24(4):3915, 2023. e-Pub 2023. PMID: 36835335.
Zhang X, Yao J, Niu N, Li X, Liu Y, Huo L, Euscher ED, Wang H, Bell D, Sood AK, Wang G, Lawson BC, Ramalingam P, Malpica A, Sahin AA, Ding Q, Liu J. SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas. Mod Pathol 36(2):100001, 2023. e-Pub 2023. PMID: 36853778.
Li X, Zhong Y, Zhang X, Sood AK, Liu J. Spatiotemporal view of malignant histogenesis and macroevolution via formation of polyploid giant cancer cells. Oncogene 42(9):665-678, 2023. e-Pub 2023. PMID: 36596845.
Kalra K, Kaur R, Gupta P, Sood AK. COVID-19 Vaccine Acceptance During Pregnancy, Women's Views, and Influencing Factors. Cureus 15(1):e34039, 2023. e-Pub 2023. PMID: 36814747.
Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol 168:76-82, 2023. e-Pub 2023. PMID: 36423446.
Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist 28(12):e1100-e1292, 2023. e-Pub 2023. PMID: 37311055.
LaFargue CJ, Amerov P, Noh K, Mangala S, Lu C, Cho M, Pradeep S, Wan Y, Hu W, Rupaimoole R, Coleman RL, Zhang N, An Z, Lopez-Bernstein G, De Franciscis V, Sood AK. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nature Communications 14(1):2407, 2023. e-Pub 2023. PMID: 37100807.
Lutgendorf SK, Thaker PH, Goodheart MJ, Arevalo JMG, Chowdhury MA, Noble AE, Dahmoush L, Slavich GM, Penedo FJ, Sood AK, Cole SW. Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression. Cancer 128(23):4157-4165, 2022. e-Pub 2022. PMID: 36251340.
Jensen DM, Han P, Mangala LS, Lopez-Berestein G, Sood AK, Liu J, Kriegel AJ, Usa K, Widlansky ME, Liang M. Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications. Mol Ther 30(11):3462-3476, 2022. e-Pub 2022. PMID: 35965413.
Ruiz M, Zhang N, Sood AK, An Z. Antibody therapeutics for epithelial ovarian cancer. Expert Opin Biol Ther 22(11):1379-1391, 2022. e-Pub 2022. PMID: 36302510.
Handley KF, Sims TT, Bateman NW, Glassman D, Foster KI, Lee S, Yao J, Yao H, Fellman BM, Liu J, Lu Z, Conrads KA, Hood BL, Barakat W, Zhao L, Zhang J, Westin SN, Celestino J, Rangel KM, Badal S, Pereira I, Ram PT, Maxwell GL, Eberlin LS, Futreal PA, Bast RC, Fleming ND, Conrads TP, Sood AK. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open 5(10):e2236626, 2022. e-Pub 2022. PMID: 36239936.
Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Nie L, Chan LC, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Hung MC. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer 3(10):1211-1227, 2022. e-Pub 2022. PMID: 36253486.
Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]. EBioMedicine 83:104194, 2022. e-Pub 2022. PMID: 35914489.
Stur E, Bayraktar E, Dal Molin GZ, Wu SY, Mangala LS, Yao H, Wang Y, Ram PT, Corvigno S, Chen H, Liang H, Tworoger SS, Levine DA, Lutgendorf SK, Liu J, Moore KN, Baggerly KA, Karlan BY, Sood AK. Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma. Cancers (Basel) 14(17):4198, 2022. e-Pub 2022. PMID: 36077735.
Zhao L, Corvigno S, Ma S, Celestino J, Fleming ND, Hajek RA, Lankenau Ahumada A, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer. Cancers (Basel) 14(15), 2022. e-Pub 2022. PMID: 35892848.
Handley KF, Sood AK, Molin GZD, Westin SN, Meyer LA, Fellman B, Soliman PT, Coleman RL, Fleming ND. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol 166(1):50-56, 2022. e-Pub 2022. PMID: 35599168.
Gershenson DM, Sun CC, Westin SN, Eyada M, Cobb LP, Nathan LC, Sood AK, Malpica A, Hillman RT, Wong KK. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol 165(3):560-567, 2022. e-Pub 2022. PMID: 35606067.
Cho MS, Lee H, Gonzalez-Delgado R, Li D, Sasano T, Carlos-Alcalde W, Ma Q, Liu J, Sood AK, Afshar-Kharghan V. Platelets Increase the Expression of PD-L1 in Ovarian Cancer. Cancers (Basel) 14(10), 2022. e-Pub 2022. PMID: 35626102.
Wu Y, Jennings NB, Sun Y, Dasari SK, Bayraktar E, Corvigno S, Stur E, Glassman D, Mangala LS, Lankenau Ahumada A, Westin SN, Sood AK, Hu W. Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. J Cancer Res Clin Oncol 148(4):803-821, 2022. e-Pub 2022. PMID: 35094142.
LaFargue CJ, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, AABA DC, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AK. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol 165(1):82-89, 2022. e-Pub 2022. PMID: 35216808.
Stur E, Corvigno S, Xu M, Chen K, Tan Y, Lee S, Liu J, Ricco E, Kraushaar D, Castro P, Zhang J, Sood AK. Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. iScience 25(3):103923, 2022. e-Pub 2022. PMID: 35252817.
Glassman D, Bateman NW, Lee S, Zhao L, Yao J, Tan Y, Ivan C, Rangel KM, Zhang J, Conrads KA, Hood BL, Abulez T, Futreal PA, Fleming ND, Afshar-Kharghan V, Maxwell GL, Conrads TP, Chen K, Sood AK. Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers (Basel) 14(6):1496, 2022. e-Pub 2022. PMID: 35326647.
Asare, A, Yao, H, Lara, OD, Wang, Y, Zhang, L, Sood, AK. Race-associated Molecular Changes in Gynecologic Malignancies. Cancer Research Communications 2(2):99-109, 2022. e-Pub 2022. PMID: 35992327.
Wen Y, Chelariu-Raicu A, Umamaheswaran S, Nick AM, Stur E, Hanjra P, Jiang D, Jennings NB, Chen X, Corvigno S, Glassman D, Lopez-Berestein G, Liu J, Hung MC, Sood AK. Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Rep 38(4):110301, 2022. e-Pub 2022. PMID: 35081345.
El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G. CORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal 89:110147, 2022. e-Pub 2022. PMID: 34772589.
Sasano T, Gonzalez-Delgado R, Muñoz NM, Carlos-Alcade W, Cho MS, Sheth RA, Sood AK, Afshar-Kharghan V. Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. J Thromb Haemost 20(1):104-114, 2022. e-Pub 2022. PMID: 34608736.
Wong KK, Bateman NW, Ng CW, Tsang YTM, Sun CS, Celestino J, Nguyen TV, Malpica A, Hillman RT, Zhang J, Futreal PA, Rojas C, Conrads KA, Hood BL, Dalgard CL, Wilkerson MD, Phippen NT, Conrads TP, Maxwell GL, Sood AK, Gershenson DM. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. Journal of Translational Medicine 20(1), 2022. e-Pub 2022. PMID: 36528667.
Wu J, Lakomy DS, Fellman BM, Salcedo MP, Sood AK, Jhingran A, Klopp AH, Iyer RB, Jimenez C, Colbert LE, Eifel PJ, Schmeler KM, Lin LL. Longitudinal changes in bone mineral measurements inside and outside radiation fields used for cervical cancer treatment. Pract Radiat Oncol 12(5):e423-e433, 2022. e-Pub 2022. PMID: 35390531.
Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther 20(12):2352-2361, 2021. e-Pub 2021. PMID: 34583979.
McGuire MH, Dasari SK, Yao H, Wen Y, Mangala LS, Bayraktar E, Ma W, Ivan C, Shoshan E, Wu SY, Jonasch E, Bar-Eli M, Wang J, Baggerly KA, Sood AK. Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Mol Cancer Res 19(11):1917-1928, 2021. e-Pub 2021. PMID: 34348992.
Wood CA, Han S, Kim CS, Wen Y, Sampaio DRT, Harris JT, Homan KA, Swain JL, Emelianov SY, Sood AK, Cook JR, Sokolov KV, Bouchard RR. Clinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates. Nat Commun 12(1):5410, 2021. e-Pub 2021. PMID: 34518530.
Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 27(15):4454, 2021. e-Pub 2021. PMID: 34341059.
Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJC. Editor's Note: The Paradoxical Expression of Maspin in Ovarian Carcinoma. Clin Cancer Res 27(15):4456, 2021. e-Pub 2021. PMID: 34341061.
Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK. Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor alpha Blockade in Uterine Cancer. Clin Cancer Res 27(15):4449, 2021. e-Pub 2021. PMID: 34341054.
Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MMK, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK. Editor's Note: Targeting Src in Mucinous Ovarian Carcinoma. Clin Cancer Res 27(15):4450, 2021. e-Pub 2021. PMID: 34341055.
Saha B, Mathur T, Tronolone JJ, Chokshi M, Lokhande GK, Selahi A, Gaharwar AK, Afshar-Kharghan V, Sood AK, Bao G, Jain A. Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer. Sci Adv 7(30), 2021. e-Pub 2021. PMID: 34290095.
Joseph R, Soundararajan R, Vasaikar S, Yang F, Allton KL, Tian L, den Hollander P, Isgandarova S, Haemmerle M, Mino B, Zhou T, Shin C, Martinez-Paniagua M, Sahin AA, Rodriguez-Canales J, Gelovani J, Chang JT, Acharya G, Sood AK, Wistuba II, Gibbons DL, Solis LM, Barton MC, Varadarajan N, Rosen JM, Zhang XH, Mani SA. CD8(+) T cells inhibit metastasis and CXCL4 regulates its function. Br J Cancer 125(2):176-189, 2021. e-Pub 2021. PMID: 33795809.
How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs 39(3):829-835, 2021. e-Pub 2021. PMID: 33415580.
Bindra S, McGill MA, Triplett MK, Tyagi A, Thaker PH, Dahmoush L, Goodheart MJ, Ogden RT, Owusu-Ansah E, Karan K, Cole S, Sood AK, Lutgendorf SK, Picard M. Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors. Scientific Reports 11(1):11595, 2021. e-Pub 2021. PMID: 34078919.
Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol 161(1):56-62, 2021. e-Pub 2021. PMID: 33536126.
Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol 161(1):104-112, 2021. e-Pub 2021. PMID: 33551196.
Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol 160(3):777-785, 2021. e-Pub 2021. PMID: 33563487.
Lee S, Zhao L, Little LD, Westin SN, Jazarei AA, Fleming ND, Zhang J, Futreal PA, Sood AK. Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. iScience 24(2):102053, 2021. e-Pub 2021. PMID: 33537658.
Elsayed AM, Bayraktar E, Amero P, Salama SA, Abdelaziz AH, Ismail RS, Zhang X, Ivan C, Sood AK, Lopez-Berestein G, Rodriguez-Aguayo C. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. Int J Mol Sci 22(4), 2021. e-Pub 2021. PMID: 33668685.
Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AK. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Rep 34(6):108726, 2021. e-Pub 2021. PMID: 33567287.
Zhong Y, Liu J, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman BM, Coleman RL, Sood AK, Fleming ND. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel) 13(4), 2021. e-Pub 2021. PMID: 33572451.
Matsuo K, Matsuzaki S, Nusbaum DJ, Maoz A, Oda K, Klar M, Roman LD, Sood AK. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. Gynecol Oncol 160(1):32-39, 2021. e-Pub 2021. PMID: 33196436.
Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene 40(2):384-395, 2021. e-Pub 2021. PMID: 33149280.
Sasano T, Cho MS, Rodriguez-Aguayo C, Bayraktar E, Taki M, Afshar-Kharghan V, Sood AK. Role of tissue-factor bearing extracellular vesicles released from ovarian cancer cells in platelet aggregation in vitro and venous thrombosis in mice. Thrombosis Update 2 2:100020, 2021. e-Pub 2021.
Cueno MG, Szeto A, Schrepf A, Thaker PH, Goodheart M, Cole SW, Sood AK, McCabe PM, Mendez AJ, Lutgendorf SK. Positive psychosocial factors and oxytocin in the ovarian tumor microenvironment. Psychosomatic Medicine 83(5):417-422, 2021. e-Pub 2021. PMID: 34080583.
Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol 162(1):65-71, 2021. e-Pub 2021. PMID: 33838925.
Nitecki R, Fleming ND, Fellman B, Meyer B, Meyer LA, Sood AK, Lu KH, Rauh-Hain A. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 161(3):660-667, 2021. e-Pub 2021. PMID: 33867146.
Cho MS, Li J, Gonzalez-Delgado R, Lee H, Vasquez M, He T, He Y, Liu K, Sasano T, Numberg B, Sood AK, Wong STC, Afshar-Kharghan V. The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer 5(7):1947-1951, 2021. e-Pub 2021. PMID: 33821990.
Wagner MJ, Lyons YA, Siedel JH, Dood R, Nagaraja AS, Haemmerle M, Mangala LS, Chanana P, Lazar AJ, W-L W, Ravi V, Holland EC, Sood AK. Combined VEGFR and MAPK pathway inhibition in angiosarcoma. Scientific Reports 11(1):9362, 2021. e-Pub 2021. PMID: 33931674.
Amero P, Lokesh GLR, Chaudhari RR, Cardenas-Zuniga R, Schubert T, Attia YM, Motanvo-Gonzalez E, Elsayed AM, Ivan C, Wang Z, Cristini V, de Franciscis V, Zhang S, Volk DE, Mitra R, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G. Conversion of RNA aptamer into modified DNA aptamers provides for prolonged stability and enhanced antitumor activity. Journal of the American Chemical Society 143(20):7655-7670, 2021. e-Pub 2021. PMID: 33988982.
Niu N, Shen W, Zhong Y, Bast RC, Jazaeri A, Sood AK, Liu J. Expression of B7-H4 and IDO1 is associated with drug resistance and prognosis in high-grade serous ovarian carcinomas. Human Pathology 113:20-27, 2021. e-Pub 2021. PMID: 33887301.
Gao C, Jin G, Forbes ME, Mangala LS, Wang Y, Rodriguez-Aguayo C, Amero P, Bayraktar E, Yan Y, Lopez-Berestein G, Broaddus RR, Sood AK, Xue F, Zhang W. Inactivating mutations of the IK gene weaken Ku80/Ku70-mediated DNA repair and sensitize endometrial cancer to chemotherapy. Cancers 13(10):2487, 2021. e-Pub 2021. PMID: 34065218.
Secord AA, O’Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and anti-angiogenic treatment in advanced epithelial ovarian cancer. Gynecologic Oncology 162(2):482-495, 2021. e-Pub 2021. PMID: 34090705.
Saha B, Tronolone JJ, Chokshi M, Oney S, Lokhande G, Gaharwar AK, Barondeau DP, Afshar-Kharghan V, Sood AK, Bao G, Jain A. Human Tumor MicroEnvironment-Chip evaluates the consequences of platelet extravasation and antitumor-antiplatelet therapy in ovarian cancer. Science Advances 7(30):eabg 5283, 2021. e-Pub 2021.
Virani S, Baiocchi G, Bowtell D, Cabasag C, Cho KR, Fortner RT, Fujiwara K, Kim JW, Kobel M, Kurtz JE, Levine DA, Menon U, Norquist BM, Pharoah PDP, Sood AK, Tworoger SS, Wentzensen N, Chanock SJ, Brennan P, Trabert B. Joint IARC/NCI International Cancer Seminar Series Report: Expert consensus on future directions for ovarian carcinoma research. Carcinogenesis 42(6):785 – 793. e-Pub 2021.
Hunt AL, Bateman NW, Barakat W, Makohorn-Moore S, Hood BL, Conrads KA, Zhou M, Calvert V, Pierobon M, Loffredo J, Litzi TJ, Oliver J, Mitchell D, Gist G, Rojas C, Blanton B, Robinson EL, Odunsi K, Sood AK, Casablanca Y, Darcy KM, Shriver CD, Petricoin EF, Rao UNM, Maxwell GL, Conrads TP. Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. iScience 24(7):102757, 2021. e-Pub 2021.
Kanikarla-Marie P, Fowlkes NW, Afshar-Kharghan V, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG. The provocative roles of platelets in liver disease and cancer. Frontiers in Oncology, Molecular and Cellular Oncology 11:643815, 2021. e-Pub 2021. PMID: 34367949.
Lutgendorf SK, Ramirez E, Schrepf A, Valentine MC, Charlton M, Zimmerman MB, Goodheart MJ, Zia S, Sood AK, Thaker PH. Rural residence is related to shorter survival in epithelial ovarian cancer patients. Gynecologic Oncology 163(1):22-28, 2021. e-Pub 2021. PMID: 34400004.
Wu Y, Huang J, Ivan C, Sun Y, Ma S, Mangala LS, Fellman BM, Urbauer DL, Jennings NB, Ram P, Coleman RL, Sood AK. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecologic Oncology 163(1):181-190, 2021. e-Pub 2021. PMID: 34391578.
Ma S, Mangala LS, Hu W, Bayraktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar –Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AK. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Reports 36(7), 2021. e-Pub 2021. PMID: 34407412.
Westin SN, Labrie M, Litton J, Blucher A, Fang Y, Vellano C, Marszalek JR, Feng N, Ma XY, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clinical Cancer Research 27(23), 2021. e-Pub 2021. PMID: 34518313.
Niu N, Yao J, Qi L, Bast RC, Sood AK, Liu J. IL-6 promotes drug resistance through of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis 10(9):65, 2021. e-Pub 2021. PMID: 34588424.
Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AK. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. Journal of Cancer Research and Clinical Oncology 147(12):3545-3555, 2021. e-Pub 2021. PMID: 34476576.
Huang T, Townsend MK, Dood RL, Sood AK, Tworoger SS. Antihypertensive medication use and ovarian cancer survival. Gynecologic Oncology 163(2):342-347, 2021. e-Pub 2021. PMID: 34556331.
George J, Li Y, Kadembari IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen CL, Ghosh C, Sun Y, Ramchandran R, Rader JS, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan P. RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to translation start site. Cell Reports 37(5):109934, 2021. e-Pub 2021. PMID: 34731628.
Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK. Rational combination of CRM1 inhibitor selinexor and olaparib shows synergy in ovarian cancer cell lines and mouse models. Molecular Cancer Therapeutics 20(12), 2021. e-Pub 2021.
Ketcher D, Lutgendorf SK, Leighton S, Matzo M, Carter J, Peddireddy A, Karlan B, Tew WP, Sood AK, Shinn EH. Attributions of survival and methods of coping of long-term ovarian cancer survivors: A qualitative study. BMC Women’s Health 21(1):376, 2021. e-Pub 2021. PMID: 34711227.
Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa JK, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. International Journal of Gynecologic Cancer(31:92 – 97), 2021. e-Pub 2021.
Lei G, Zhang Y, Hong T, Zhang X, Liu X, Mao C, Yan Y, Koppula P, Chen W, Sood AK, Liu J, Gan B. Ferroptosis as a mechanism to mediate p53 function in tumor radioresistance. Oncogene 40:3533-3547, 2021. e-Pub 2021.
Bailey CD, Previs RA, Fellman B, Zaid TM, Huang M, Brown A, Enbaya A, Balakrishnan N, Broaddus RR, Bodurka DC, Soliman PT, Fleming ND, Nick AM, Sood AK, Westin SN. Pathologic distribution at the time of interval tumor reductive surgery informs personalized ovarian cancer surgery for high-grade ovarian cancer. International Journal of Gynecologic Cancer(31:232 – 237), 2021. e-Pub 2021. PMID: 33122243.
Garvin L, Slavich GM, Schrepf A, Davis LZ, Thaker PH, Goodheart MJ, Cole SW, Sood AK, Lutgendorf SK. Chronic difficulties are associated with poorer psychosocial functioning in the first year post-diagnosis in epithelial ovarian cancer patients. Psycho-Oncology 30:954-961, 2021. e-Pub 2021. PMID: 33760306.
Zhong Y, Liu L, Li X, Westin SN, Malpica A, Lawson BC, Lee S, Fellman B, Coleman RL, Sood AK, Fleming N. A modified 2-tier chemotherapy response score (CRS) and other histopathologic features for predicting outcomes of patients with advanced extrauterine high-grade serous carcinoma after neoadjuvant chemotherapy. Cancers, 2021.
Patel AB, Iyer P, Matsuzaki S, Matsuo K, Sood AK, Fleming ND. Emerging trends in neoadjuvant chemotherapy for ovarian cancer. Cancers, 2021.
Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecologic Oncology, 2021.
Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings N, Liu J, Lopez-Berestein G, Ram P, Sood AK. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Reports, 2021.
How J, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Naing A. Phase II study of the clinical efficacy and safety of single-agent pembrolizumab in patients with granulosa cell tumors of the ovary. Investigational New Drugs, 2021.
Elsayed AM, Bayraktar E, Amero P, Salama SA, Abdelaziz AH, Ismail RS, Ivan C, Zhang X, Sood AK, Lopez-Berestein G, Rodriguez-Aguayo C. PRKAR1B-AS2 long noncoding RNA promotes tumorigenesis, survival, and chemoresistance via PI3K/AKT/mTOR pathway. International Journal of Molelcular Sciences, 2021.
Coleman RL, Hu W, Soliman P, Nick A, Ramirez P, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer L, Sood AK. Dasatinib, paclitaxel and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic Oncology, 2021.
Joseph R, Soundararajan R, Vasaikar S, Yang F, Tian L, den Hollander P, Isgandarova S, Haemmerle M, Mino B, Zhou T, Shin C, Martinez M, Sahin AS, Canales JR, Gelovani J, Chang J, Acharya G, Sood AK, Wistuba II, Gibbons DL, Soto LMS, Varadarajan N, Rosen JM, Zhang XH, Mani SA. CD8+ T cells inhibit metastasis and CXCL4 regulates its function. British Journal of Cancer, 2021.
Lee S, Zhao L, Little LD, Westin SN, Jazaeri AA, Fleming ND, Zhang J, Futreal PA, Sood AK. Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. iScience, 2021.
Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK. Clinical significance of homologous recombination deficiency score testing in endometrial cancer. Gynecologic Oncology(160:777 – 785), 2021. e-Pub 2021.
Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK. The hidden role of paxillin: Localization to nucleus promotes tumor angiogenesis. Oncogene 40:384-395, 2021. e-Pub 2021.
Hong B, Chapa V, Saini U, Modgil P, Cohn DE, He G, Siddik ZH, Sood AK, Yan Y, Karuppaiyah S, Pei G, Zhao Z, Yoo JY, Kaur B. Oncolytic HSV therapy modulates vesicular trafficking inducing cisplatin sensitivity and anti-tumor immunity. Clinical Cancer Research 27(2):542-553, 2021. e-Pub 2021.
Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G. Long non-coding RNAs in ovarian cancer: Expression profile and functional spectrum. RNA Biology: Noncoding RNAs in Cancer(11):1523 – 1534, 2020. e-Pub 2020. PMID: 31847695.
Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer. Mol Cancer Ther 19(11):2396-2406, 2020. e-Pub 2020. PMID: 32943548.
Wen Y, Wang Y, Chelariu-Raicu A, Stur E, Liu Y, Corvigno S, Bartsch F, Redfern L, Zand B, Kang Y, Liu J, Baggerly K, Sood AK. Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer. Mol Cancer Ther 19(9):1943-1954, 2020. e-Pub 2020. PMID: 32737156.
Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther 19(8):1727-1735, 2020. e-Pub 2020. PMID: 32499298.
Saha B, Mathur T, Handley KF, Hu W, Afshar-Kharghan V, Sood AK, Jain A. OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer. Blood Adv 4(14):3329-3342, 2020. e-Pub 2020. PMID: 32717032.
Li Y, Yang S, Sadaoui NC, Hu W, Dasari SK, Mangala LS, Sun Y, Zhao S, Wang L, Liu Y, Ramondetta LM, Li K, Lu C, Kang Y, Cole SW, Lutgendorf SK, Sood AK. Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. iScience 23(7):101289, 2020. e-Pub 2020. PMID: 32623336.
Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget 11(29):2819-2833, 2020. e-Pub 2020. PMID: 32754300.
Salcedo MP, Sood AK, Jhingran A, Eifel PJ, Klopp AH, Iyer RB, Fellman BM, Jimenez C, Schmeler KM. Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. Cancer 126(11):2607-2613, 2020. e-Pub 2020. PMID: 32125711.
Han C, Wang C, Chen Y, Li K, Wu Y, Xu X, Hilton T, Cai W, Zhao Z, Houck K, Liu L, Sood AK, Wu X, Xue F, Li M, Zhang J, J-F D. Placenta-derived microvesicles induce preeclampsia in mouse models. Hematologica 105(6):1686-1694, 2020. e-Pub 2020. PMID: 31439676.
Cata JP, Gorur A, Yuan X, Berg NK, Sood AK, Eltzschig H. Role of microRNA for pain after surgery – narrative review of animal and human studies. Anesthesia & Analgesia 130(6):1638-1652, 2020. e-Pub 2020. PMID: 32384350.
Coleman RL, Handley K, Burger R, Dal Molin GZ, Stagg R, Sood AK, Moore KN. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecologic Oncology 157:386-391, 2020. e-Pub 2020. PMID: 32037195.
Maoz A, Matsuo K, Ciccone M, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM. Molecular pathways and targeted therapies for malignant ovarian germ cell tumors and sex cord-stromal tumors: a contemporary review. Cancer 12(6):1398, 2020. e-Pub 2020. PMID: 32485873.
Matsuo K, Chang EJ, Matsuzaki S, Mandelbaum RS, Matsushima K, Grubbs BH, Klar M, Roman LD, Sood AK, Wright JD. Minimally invasive surgery for early-stae ovarian cancer. Association between hospital surgical volume and short-term perioperative outcomes. Gynecologic Oncology 158(59-65), 2020. e-Pub 2020. PMID: 32402635.
Srinivasan S, Yeri AS, Cheah PS, Chung A, Danielson K, DeHoff P, Filant J, Laurent CD, Laurent LD, Magee R, Moeller C, Nejad P, Paul A, Rigoutsos I, Rodosthenous R, Shah R, Simonson B, To C, Wong D, Yan IK, Zhang X, Balaj L, Breakefield XO, Gandhi R, Lapidus J, Londin E, Murthy V, Patel T, Raffai R, Sood AK, Das S, Laurent LC. Small RNA sequencing across diverse biofluids identifies optimal methods for exRNA isolation. Cell 177(2):446-462.e.16, 2020. e-Pub 2020. PMID: 30951671.
Matsuo K, Machida H, Matsuzaki S, Grubbs BH, Klar M, Roman LD, Sood AK, Gershenson DM, Wright JD. Evolving population-based statistics for rare epithelial ovarian cancers. Gynecologic Oncology 157:3-11, 2020. e-Pub 2020.
Matsuo K, Machida H, Grubbs BH, Matsuzaki S, Frimer M, Roman LD, Sood AK, Gershenson DM. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. Gynecologic Oncology 157:21-28, 2020. e-Pub 2020. PMID: 31954535.
Cao Q, Wang W, Zhou M, Huang Q, Wen X, Zhao J, Shi S, Geng K, Li F, Hatakeyama H, Xu C, Piwnica-Worms D, Peng W, Zhou D, Sood AK, Li C. Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition. Nanomedicine, 2020. e-Pub 2020. PMID: 32059873.
El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Alama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cellular Sinalling, 2020. e-Pub 2020. PMID: 31935430.
Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular analysis of clinical defined subsets of high-grade serous ovarian cancer. Cell Reports, 2020. e-Pub 2020. PMID: 32294438.
Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O’Malley D, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernandez ML, Gershenson DM. Low-grade serous ovarian cancer: State of the science. Gynecologic Oncology 156:715-725, 2020. e-Pub 2020. PMID: 31969252.
Wi TI, Byeon Y, Won JE, Lee JM, Kang TH, Lee JW, Lee YJ, Sood AK, Han HD, Par YM. Selective tumor-specific antigen delivery to dendritic cells using mannose-labeled PLGA nanoparticles for cancer immunotherapy. Journal of Biomedical Nanotechnology 16(2):201-211, 2020. e-Pub 2020. PMID: 32252881.
Xiong C, Wen Y, Zhao J, Yin D, Xu L, Yao C, Liu J, Chaudhari RR, Zhang S, Sood AK, Li C. Targeting forward and reverse EphB4/EFNB2 signaling by a peptide with dual functions. Scientific Reports 10:520, 2020. e-Pub 2020. PMID: 31949258.
Handley KF, Sood AK. A solution to the dilution: The role for biomarkers in advanced ovarian cancer. Clinical Cancer Research 26:9-10, 2020. e-Pub 2020. PMID: 31672769.
Kim MS, Ma S, Chelariu-Raicu A, Leushner C, Alila HW, Lee S, Coleman RL, Sood AK. Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer. Molecular Cancer Therapeutics, 2020.
Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget, 2020.
Li Y, Yang S, Sadaoui NC, Hu W, Dasari SK, Mangala LS, Sun Y, Zhao S, Wang L, Liu Y, Ramondetta LM, Li K, Lu C, Kang Y, Cole SW, Lutgendorf SK, Sood AK. Sustained adrenergic activation of YAP1 induces anoikis resistance in cervical cancer cells. iScience, 2020.
Prathipati P, Rodriguez-Aguayo C, Walton BL, Sood AK, Greaver J, Janssen CF, Lopez-Berestein G. A retrospective analysis for different routes of administration in mice-percutaneous retro-orbital, jugular, catheter, tail vein and femoral cut down injections. Journal of Biosciences and Medicines 8:131-141, 2020. e-Pub 2020.
Miyake TM, Pradeep S, Wu SY, Gharpure KM, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. NRG1/ErbB3 pathway activation induces acquired resistance to XPO1 inhibitors. Molecular Cancer Therapeutics, 2020.
Matsuo K, Huang Y, Matsuzaki S, Klar M, Roman LD, Sood AK, Wright JD. Minimally invasive surgery and increased risk of capsule rupture for early-stage ovarian cancer. Journal of the American Medical Association Oncology 6(7):1110-1113, 2020. e-Pub 2020.
Nusbaum DJ, Mandelbaum RS, Machida H, Roman LD, Sood AK, Gershenson DM, Matsuo K. Significance of lymph node ratio on survival of women with borderline ovarian tumors. Archives of Gynecology and Obstetrics 301:1289-1298, 2020. e-Pub 2020.
Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Fernandez FM, Nephew KP, Karpf AR, Widschwendter M, Sood AK, Bast RC, Godwin AK, Miller KD, Cho CH, Kim J. Targeting progesterone signaling prevents metastatic ovarian cancer. Proc Natl Acad Sci U S A 117(50):31993-32004, 2020. e-Pub 2020. PMID: 33262282.
Seiler A, Sood AK, Jenewein J, Fagundes C. The impact of stress and the role of the tumor microenvironment in the formation of brain metastases. Brain Behavior and Immunity 87:860 – 880, 2020. e-Pub 2020.
Lara OD, Wang Y, Asare A, Xu T, H-S S, Liu Y, Hu W, Sumazin P, Uppal S, Zhang L, Rauh-Hain JA, Sood AK. Pan-cancer clinical and molecular analysis of racial disparities. Cancer 126:800 – 807, 2020. e-Pub 2020. PMID: 31730714.
Lutgendorf SK, Thaker PH, Arevalo JMG, Goodheart MJ, Dahmoush L, Penedo F, Slavich GM, Sood AK, Cole SW. Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. Cancer 126(19):4407-4413, 2020. e-Pub 2020. PMID: 32691853.
Liu Y, Wu S, Koo Y, Yang A, Dai Y, Osman S, Chowdhury M, Kim M, Nguyen M, Wei H, Tang E, Ma S, Duc-Hiep B, Chehab EW, Braam J, Sood AK. Characterization of and isolation methods for plant leaf nanovesicles and exosomes. Nanotechnology, Biology, and Medicine 29:102271, 2020. e-Pub 2020.
Wen Y, Wang Y, Chelariu-Raicu A, Stur E, Liu Y, Corvigno S, Bartsch F, Redfern L, Zand B, Kang Y, Liu J, Baggerly KA, Sood AK. Blockade of the short form of prolactin receptor induces FOXO3a/EIF-4EBP1-mediated cell death in uterine cancer. Molecular Cancer Therapeutics, 2020.
Saha B, Mathur T, Handley KF, Hu W, Afshar Kharghan V, Sood AK, Jain A. OvCa-chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer. Blood Advances, 2020.
Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin S, Sood AK, Wong KK, Silva EG, Gershenson DM. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative resistance. Gynecologic Oncology 158:653-658, 2020.
Peres LC, Sinha S, Townsend MK, Fridley BL, Karlan BY, Lutgendorf SK, Shinn E, Sood AK, Tworoger SS. Predictors of survival trajectories among women with epithelial ovarian cancer. Gynecol Oncol 156(2):459-466, 2020. PMID: 31839342.
Matsuo K, Matsuzaki S, Nusbaum DJ, Maoz A, Oda K, Klar M, Roman LD, Sood AK. Neoadjuvant chemotherapy for advanced ovarian cancer: Recent trends and outcomes in the United States. Gynecologic Oncology 160:32-39, 2020. e-Pub 2020.
Parashar D, Geethadevi A, Ragle-Aure M, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P. MiRNA551b-3p activates an oncostatin signaling module for the progression of triple-negative breast cancer. Cell Reports 29:4389-4406, 2019. e-Pub 2019. PMID: 31875548.
Kurnit KC, Sinno A, Fellman BM, Varghese A, Stone RL, Sood AK, Gershenson DM, Schmeler KM, Fader AN, Frumovitz M. The impact of gastrointestinal adjuvant chemotherapy regimens in women with mucinous ovarian cancer. Obstetrics and Gynecology 134(6):1253-1259, 2019. e-Pub 2019. PMID: 31764736.
Trudel-Fitzgerald C, Poole EM, Sood AK, Okerke OI, Kawachi I, Kubzansky LD, Tworoger SS. Social integration, marital status, and ovarian cancer risk: A 20-year prospective cohort study. Psychosomatic Medicine 81:833-840, 2019. e-Pub 2019. PMID: 31592935.
Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Y-H T, Rodriguez-Aguao C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H. A-to-I edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. Journal of Clinical Investigation 129(12):5343-5356, 2019. e-Pub 2019. PMID: 1682236.
Lara OD, Krishnan S, Wang Z, Corvigno S, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin S, Fleming N, Cristini V, Rao A, Burks J, Sood AK. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Scientific Reports 9:17589, 2019. e-Pub 2019. PMID: 31772388.
Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, Money R, Liu J, Roszik J, Clise-Dwyer K, Burks JK, O’Halloran TJ, Laurent LC, Sood AK. Mechanisms of nuclear content loading to exosomes. Science Advances 5(11):eaax8849, 2019. e-Pub 2019. PMID: 31799396.
Shi S, Li T, Wen X, Wu SY, Xiong C, Zhao J, Lincha VR, Chow DS, Liu Y, Sood AK, Li C. Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention. Bioconjug Chem 30(10):2675-2683, 2019. e-Pub 2019. PMID: 31560538.
Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Berestein G, Sood AK. Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biology and Therapy 12(2):147-156, 2019. e-Pub 2019. PMID: 31640461.
Yang H, Zhang S, Jiang Y, Mao W, Pang L, Redwood A, Jennings N, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Xiao-Feng L, Jones P, Ahmed AA, Piwnica-Worms H, Sood AK, Bast RC, Lu Z. A glycolytic enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2), regulates paclitaxel sensitivity in ovarian and breast cancer cells and xenografts with WT p53 25(18):5702-5716, 2019. e-Pub 2019. PMID: 31391192.
Bach DH, Zhang W, Sood AK. Chromosomal Instability in Tumor Initiation and Development. Cancer Research 79:3995-4002, 2019. e-Pub 2019. PMID: 31350294.
Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene 38:6095-6108, 2019. e-Pub 2019. PMID: 31289363.
Shuford S, Rayner M, Millard M, Mattingly C, Lotstein A, Smith A, Guo Q, O’Donnell L, Elder J, Puls L, Weroha J, Nick A, Barnett J, Maxwell L, Conrads T, Corless C, Sood AK, Orr D, Holmes L, Gevaert M, Crosswell HE, DesRochers TM. Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. Scientific Reports 9(1):11153, 2019. e-Pub 2019. PMID: 31371750.
Cueno MG, Szeto A, Schrepf A, Kinner E, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Sood AK, Cole SW, McCabe PM, Lutgendorf SK, Mendez AJ. Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. Psychoneuroendocrinology 106:244-251, 2019. e-Pub 2019. PMID: 31005045.
Zhaorigetu S, Prathipati P, Rodriguez-Aguayo C, Walton BL, Sood AK, Lopez-Berestein G. Fatty acid binding protein-4 silencing attenuates atherosclerosis progression by affecting macrophage apoptosis and autophagy. Journal of Biosciences and Medicines 7:99-109, 2019. e-Pub 2019.
Gunaratne PH, Rao AK, Lin C, Hernandez-Herrera A, Pan Y, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH. Activating p53-family member Tap63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer:2409 – 2422, 2019. e-Pub 2019.
Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JM, Dizon T, Coleman RL, Cole SW, Sood AK. Prospective combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation of its impact on circulating immune cell gene expression. Gynecologic Oncology 154:524-530, 2019. e-Pub 2019. PMID: 31353053.
Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical Questions in Ovarian Cancer Research and Treatment: Report of an American Association for Cancer Research Special Conference. Cancer 125(12):1963-1972, 2019. e-Pub 2019. PMID: 30835824.
Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, Pecot CV. Quaking Orchestrates a Post-Transcriptional Regulatory Network of Endothelial Cell Cycle Progression Critical to Angiogenesis and Metastasis. Oncogene 38(26):5191-5210, 2019. e-Pub 2019. PMID: 30918328.
Duc-Hiep B, Lee SK, Sood AK. Circular RNAs in cancer. Molecular Therapy – Nucleic Acids 16:118-129, 2019. e-Pub 2019. PMID: 30861414.
Sans M, Zhang J, Lin JQ, Feider CL, Giese N, Breen MT, Sebastian K, Liu J, Sood AK, Eberlin LS. Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. Clin Chem 65(5):674-683, 2019. e-Pub 2019. PMID: 30770374.
Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DM. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. Gynecol Oncol 153(2):230-237, 2019. e-Pub 2019. PMID: 30797590.
McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, Lopez-Berestein G, Baggerly KA, Sood AK. Pan-cancer genomic analysis links 3’UTR DNA methylation with increased gene expression in T cells. EBio Medicine, 2019. e-Pub 2019. PMID: 31056473.
Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget:3533-3546, 2019. e-Pub 2019. PMID: 31191824.
Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther 18(5):969-979, 2019. e-Pub 2019. PMID: 30926640.
Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer 125(14):2409-2422. e-Pub 2019. PMID: 31012964.
Murillo OD, Thistlethwaite W, Rozowsky J, Subramanian SL, Lucero R, Shah N, Jackson AR, Srinivasan S, Chung A, Laurent CD, Kitchen RR, Galeev T, Warrell J, Diao JA, Welsh JA, Hanspers K, Riutta A, Burgstaller-Muehlbacher S, Shah R, Yeri A, Jenkins LM, Ahsen ME, Cordon-Cardo C, Dogra N, Gifford SM, Smith JT, Stolovitzky G, Tewari AK, Wunsch BH, Yadav KK, Danielson KM, Filant J, Moeller C, Nejad P, Paul A, Simonson B, Wong DK, Zhang X, Balaj L, Gandhi R, Sood AK, Alexander RP, Wang L, Wu C, Wong D, Galas DJ, Van Keuren-Jensen K, Patel T, Jones JC, Das S, K-H C, Pico A, Su AI, Raffai RL, Laurent LC, Roth ME, Gerstein MB, Milosavljevic A. ExRNA atlas analysis reveals distinct extracellular RNA cargo types present across human biofluids. Cell 177:463-477, 2019. e-Pub 2019. PMID: 30951672.
Das S, Communication Consortium TER, Sood AK. The extracellular RNA communication consortium: Establishing foundational knowledge and technologies for extracellular RNA research. Cell 177:231-242, 2019. e-Pub 2019. PMID: 30951667.
An J, Du Y, Fan X, Wang Y, Ivan C, Zhang XG, Sood AK, An Z, Zhang N. EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene 38(12):2123-2134, 2019. e-Pub 2019. PMID: 30455428.
Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS, Dhanasekaran DN. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Lett 442:464-474, 2019. e-Pub 2019. PMID: 30503552.
Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine 40:290-304, 2019. e-Pub 2019. PMID: 30655206.
Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK. Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Mol Cancer Ther 18(2):421-436, 2019. e-Pub 2019. PMID: 30420565.
Salcedo MP, Sood AK, Dos Reis R, Ramalingam P, Chen C, Frumovitz M, Jhingran A, Pitcher B, Ramirez PT, Schmeler KM. Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases. Gynecol Oncol 152(1):101-105, 2019. e-Pub 2019. PMID: 30396690.
Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther 18(1):162-172, 2019. e-Pub 2019. PMID: 30305341.
Salcedo MP, Sood AK, dos Reis R, Ramalingam P, Chen C, Frumovitz M, Jhingran A, Pitcher B, Urbauer D, Ramirez PT, Schmeler KM. Clinical implications of perineural invasion (PNI) in vulvar carcinoma. Gynecologic Oncology 152:101-105, 2019. e-Pub 2019.
Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ. Advancing Drug Development in Gynecologic Malignancies. Clin Cancer Res 25(16):4874-4880, 2019. e-Pub 2019. PMID: 31126961.
Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol 151(3):428-432, 2018. e-Pub 2018. PMID: 30366647.
Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine 38:100-112, 2018. e-Pub 2018. PMID: 30487062.
Kim GH, Won JE, Byeon Y, Kim MG, Wi TI, Lee JM, Park YY, Lee JW, Kang TH, Jung ID, Shin BC, Ahn HJ, Lee YJ, Sood AK, Han HD, Park YM. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Drug Deliv 25(1):1394-1402, 2018. e-Pub 2018. PMID: 29890852.
Byeon Y, Lee JW, Choi WS, Won JE, Kim GH, Kim MG, Wi TI, Lee JM, Kang TH, Jung ID, Cho YJ, Ahn HJ, Shin BC, Lee YJ, Sood AK, Han HD, Park YM. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer. Cancer Res 78(21):6247-6256, 2018. e-Pub 2018. PMID: 30115698.
González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martín-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, García MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, Sánchez-Rovira P, Chang JC, Granados-Principal S. Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. Clin Cancer Res 24(22):5697-5709, 2018. e-Pub 2018. PMID: 30012564.
Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol 4(11):1519-1526, 2018. e-Pub 2018. PMID: 29860375.
Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24(20):5072-5084, 2018. e-Pub 2018. PMID: 30084832.
Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, Fan Y, Xu X, Morgan MA, Long M, Zhang Y, Zhang R, Sood AK, Rebbeck TR, Dang CV, Zhang L. Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34(4):549-560.e9, 2018. e-Pub 2018. PMID: 30300578.
Inoue K, Deng Z, Chen Y, Giannopoulou E, Xu R, Gong S, Greenblatt MB, Mangala LS, Lopez-Berestein G, Kirsch DG, Sood AK, Zhao L, Zhao B. Bone protection by inhibition of microRNA-182. Nat Commun 9(1):4108, 2018. e-Pub 2018. PMID: 30291236.
Haldar R, Shaashua L, Lavon H, Lyons YA, Zmora O, Sharon E, Birnbaum Y, Allweis T, Sood AK, Barshack I, Cole S, Ben-Eliyahu S. Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain Behav Immun 73:294-309, 2018. e-Pub 2018. PMID: 29800703.
Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer 28(8):1485-1490, 2018. e-Pub 2018. PMID: 30036226.
Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev 37(2-3):439-454, 2018. e-Pub 2018. PMID: 30112590.
Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol 132(3):545-554, 2018. e-Pub 2018. PMID: 30095787.
Umamaheswaran S, Dasari SK, Yang P, Lutgendorf SK, Sood AK. Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev 37(2-3):203-211, 2018. e-Pub 2018. PMID: 29948328.
Armer JS, Clevenger L, Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Sood AK, Cole SW, Slavich GM, Lutgendorf SK. Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer 124(16):3401-3408, 2018. e-Pub 2018. PMID: 29905941.
Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9(1):2923, 2018. e-Pub 2018. PMID: 30050129.
McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin EL, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Manrique SZ, Liu C, Huang L, Chen Y, M-A F, Haymaker C, Bernatchez C, Satani N, Muller FL, Roszik J, Kalra AV, Heffernan TP, Sood AK, Hu J, Amaria R, Davis RE, Hwu P. The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy. Journal of the National Cancer Institute 11(7):777-786, 2018. e-Pub 2018. PMID: 29267866.
Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK. Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78(12):3233-3242, 2018. e-Pub 2018. PMID: 29661830.
Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AK. ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget 9(38):25115-25126, 2018. e-Pub 2018. PMID: 29861857.
Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN, Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, Lopez-Berestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y, Yang X, Sun D, Sun Y, Hung MC, Ma L. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Rep 23(3):823-837, 2018. e-Pub 2018. PMID: 29669287.
Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Research Network CGA, Weinstein JN, Mills GB, Levine DA, Akbani R. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell 33(4):690-705.e9, 2018. e-Pub 2018. PMID: 29622464.
Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Research Network CGA, Sood AK, Gunaratne PH, Sumazin P. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Rep 23(1):297-312.e12, 2018. e-Pub 2018. PMID: 29617668.
Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley K, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN. LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res 78(8):1923-1934, 2018. e-Pub 2018. PMID: 29386184.
Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 37(1):107-124, 2018. e-Pub 2018. PMID: 29243000.
Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 9(1):476, 2018. e-Pub 2018. PMID: 29396402.
Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol 4(2):196-202, 2018. e-Pub 2018. PMID: 29242937.
Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17(2):464-473, 2018. e-Pub 2018. PMID: 29237804.
Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 37(6):722-731, 2018. e-Pub 2018. PMID: 29059175.
Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW. Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer 124(3):580-586, 2018. e-Pub 2018. PMID: 29112229.
Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest 128(2):589-606, 2018. e-Pub 2018. PMID: 29251630.
Velazquez-Torres G, Shoshan E, Ivan C, Huang L, Fuentes-Mattei E, Paret H, Kim SJ, Rodriguez-Aguayo C, Xie V, Brooks D, Jones SJM, Robertson AG, Calin G, Lopez-Berenstein G, Sood AK, Bar-Eli M. A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9(1):461, 2018. e-Pub 2018. PMID: 29386624.
Matsuo K, Machida H, Roman LD, Sood AK, Gershenson. Trends of low-grade serous ovarian carcinoma between 1973 and 2013 in the United States. Journal of Gynecologic Oncology 29(1):e15, 2018. e-Pub 2018. PMID: 28185273.
Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, DeMarzo AM, Sood AK, Zhang L, Dang CV. MYC targeted long non-coding RNA DANCR promotes cancer in part by reducing p21 levels. Cancer Res 78(1):64-74, 2018. e-Pub 2018. PMID: 29180471.
Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS. Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol Cell Neurosci 86:65-71, 2018. e-Pub 2018. PMID: 29180229.
Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JC. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports 10(1):212-227, 2018. e-Pub 2018. PMID: 29249663.
Vu HT, Kotla S, Ko KA, Fujii Y, Tao Y, Medina J, Thomas T, Hada M, Sood AK, Singh PK, Milgrom SA, Krishnan S, Fujiwara K, Le NT, Abe JI. Ionizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation. Front Cardiovasc Med 5:23, 2018. e-Pub 2018. PMID: 29594152.
Liu Q, Lu C, Dai W, Li K, Xu J, Huang Y, Li G, Kang Y, Sood AK, Xu C. Association of biobehavioral factors with non-coding RNAs in cervical cancer. Biosci Trends 12(1):24-31, 2018. e-Pub 2018. PMID: 29553098.
Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol 8:9, 2018. e-Pub 2018. PMID: 29456965.
Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol 117(2), 2018. e-Pub 2018. PMID: 28787528.
Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores ER, Sood AK, Huang S, Yu D, Yang L, Lin C. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest 127(12):4498-4515, 2017. e-Pub 2017. PMID: 29130936.
Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids 15(9):251-262, 2017. e-Pub 2017. PMID: 29246304.
Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep 21(10):2785-2795, 2017. e-Pub 2017. PMID: 29212026.
Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget 8(57):96496-96505, 2017. e-Pub 2017. PMID: 29228548.
Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res 23(22):7034-7046, 2017. e-Pub 2017. PMID: 28855350.
Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Sci Transl Med 9(415), 2017. e-Pub 2017. PMID: 29118262.
Trudel-Fitzgerald C, Poole EM, Idahl A, Lundin E, Sood AK, Kawachi I, Kubzansky LD, Tworoger SS. The association of work characteristics with ovarian cancer risk and mortality. Psychosom Med 79(9):1059-1067, 2017. e-Pub 2017. PMID: 28306624.
Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W. Erratum to: MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol 10(1):163, 2017. e-Pub 2017. PMID: 28985752.
Yasukawa M, Liu Y, Hu L, Cogdell D, Gharpure KM, Pradeep S, Nagaraja AS, Sood AK, Zhang W. ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. Oncotarget 8(51):88410-88420, 2017. e-Pub 2017. PMID: 29179445.
Fleming ND, Coleman RL, Tung C, Westin SN, Hu W, Sun Y, Bhosale P, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol 147(1):41-46, 2017. e-Pub 2017. PMID: 28774461.
Cuneo MG, Schrepf A, Slavich GM, Thaker PH, Goodheart M, Bender D, Cole SW, Sood AK, Lutgendorf SK. Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. Psychoneuroendocrinology 84:139-142, 2017. e-Pub 2017. PMID: 28711723.
Cho MS, Noh K, Haemmerle M, Li D, Park H, Hu Q, Hisamatsu T, Mitamura T, Mak SLC, Kunapuli S, Ma Q, Sood AK, Afshar-Kharghan V. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood 130(10):1235-1242, 2017. e-Pub 2017. PMID: 28679740.
Pu T, Xiong L, Liu Q, Zhang M, Cai Q, Liu H, Sood AK, Li G, Kang Y, Xu C. Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging. Oncol Lett 14(3):2869-2877, 2017. e-Pub 2017. PMID: 28928826.
Hu Q, Hisamatsu T, Haemmerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong STC, Sood AK, Afshar-Kharghan V. Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer. Clin Cancer Res 23(18):5611-5621, 2017. e-Pub 2017. PMID: 28611202.
Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 2(16):e93076. e-Pub 2017. PMID: 28814667.
Li L, Zheng H, Huang Y, Huang C, Zhang S, Tian J, Li P, Sood AK, Zhang W, Chen K. DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer. Carcinogenesis 38(8):797-805, 2017. e-Pub 2017. PMID: 28637314.
Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun 8(1):310, 2017. e-Pub 2017. PMID: 28827520.
Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AK. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst 109(7), 2017. e-Pub 2017. PMID: 28376174.
Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, Sood AK. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. Gynecol Oncol 146(1):101-108, 2017. e-Pub 2017. PMID: 28527672.
Wang Y, Xu X, Yu S, Jeong KJ, Zhou Z, Han L, Tsang YH, Li J, Chen H, Mangala LS, Yuan Y, Eterovic AK, Lu Y, Sood AK, Scott KL, Mills GB, Liang H. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res 27(7):1112-1125, 2017. e-Pub 2017. PMID: 28411194.
Tseng JH, Bisogna M, Hoang LN, Olvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA, Jelinic P. miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Sci Rep 7(1):3614, 2017. e-Pub 2017. PMID: 28620240.
Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA. Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res 23(11):2891-2904, 2017. e-Pub 2017. PMID: 27903673.
Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, Chang Q, Lazar AJ, Sood AK, Drapkin R, DePinho R, Draetta G, Chin L. PRKCI promotes immune suppression in ovarian cancer. Genes Dev 31(11):1109-1121, 2017. e-Pub 2017. PMID: 28698296.
Sans M, Gharpure K, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood RL, Sood AK, Eberlin LS. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Res 77(11):2903-2913, 2017. e-Pub 2017. PMID: 28416487.
Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK. Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA). Mol Cancer Ther 16(6):1114-1123, 2017. e-Pub 2017. PMID: 28265009.
Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodríguez-Aguayo C, López-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer. Mol Cancer Ther 16(5):966-976, 2017. e-Pub 2017. PMID: 28223424.
Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, Novikov I, Huertas P, Rottapel R, Sood AK, Izraeli S. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget 8(16):27380-27392, 2017. e-Pub 2017. PMID: 28423708.
Pi F, Zhang H, Li H, Thiviyanathan V, Gorenstein DG, Sood AK, Guo P. RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery. Nanomedicine 13(3):1183-1193, 2017. e-Pub 2017. PMID: 27890659.
Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget 8(12):20145-20164, 2017. e-Pub 2017. PMID: 28423620.
Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Lee JS, Sood AK, Kim MP, Mills GB, Ram PT. Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene 36(10):1339-1350, 2017. e-Pub 2017. PMID: 27669434.
Arun B, Austin T, Babiera GV, Basen-Engquist K, Carmack CL, Chaoul A, Cohen L, Connelly L, Haddad R, Harrison C, Li Y, Mallaiah S, Nagarathna R, Parker PA, Perkins GH, Reuben JM, Shih YT, Spelman A, Sood AK, Yang P, Yeung SJ. A Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience. Integr Cancer Ther 16(1):3-20, 2017. e-Pub 2017. PMID: 27903842.
Matsuo K, Machida H, Takiuchi T, Grubbs BH, Roman LD, Sood AK, Gershenson DM. Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecol Oncol 144(3):496-502, 2017. e-Pub 2017. PMID: 28131526.
Harjes U, Bridges E, Gharpure KM, Roxanis I, Sheldon H, Miranda F, Mangala LS, Pradeep S, Lopez-Berestein G, Ahmed A, Fielding B, Sood AK, Harris AL. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene 36(7):912-921, 2017. e-Pub 2017. PMID: 27568980.
Yatsenko SA, Mittal P, Wood-Trageser MA, Jones MW, Surti U, Edwards RP, Sood AK, Rajkovic A. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. Fertil Steril 107(2):457-466.e9, 2017. e-Pub 2017. PMID: 27889101.
Gangwar R, Meena AS, Shukla PK, Nagaraja AS, Dorniak PL, Pallikkuth S, Kalyanaraman B, Waters C, Sood AK, Rao RK. Calcium-Mediated Oxidative Stress: a Common Mechanism in Tight Junction Disruption by Different Types of Cellular Stress. Biochemical Journal 474(5):731-749, 2017. e-Pub 2017. PMID: 28057718.
Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi I. Metastasis regulation by PPARD expression in cancer cells. JCI Insight 2(1):e91419, 2017. e-Pub 2017. PMID: 28097239.
Hu Q, Cho MS, Thiagarajan P, Aung FM, Sood AK, Afshar-Kharghan V. A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. Platelets 28(1):99-102, 2017. e-Pub 2017. PMID: 27534811.
Sun Y, Ji P, Chen T, Zhou X, Yang D, Guo Y, Liu Y, Hu L, Xia D, Liu Y, Multani AS, Shmulevich I, Kucherlapati R, Kopetz S, Sood AK, Hamilton SR, Sun B, Zhang W. MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. J Pathol 241(1):67-79, 2017. e-Pub 2017. PMID: 27741356.
Wagner MJ, Ravi V, Menter DG, Sood AK. Endothelial cell malignancies: new insights from the laboratory and clinic. NPJ Precis Oncol 1(1):11, 2017. e-Pub 2017. PMID: 29872699.
Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RASaxis in chemotherapy-resistant ovarian cancer. Cell Discov 3:17029, 2017. e-Pub 2017. PMID: 28904816.
Denizli M, Aslan B, Mangala LS, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK. Chitosan Nanoparticles for miRNA Delivery. Methods Mol Biol 1632:219-230, 2017. e-Pub 2017. PMID: 28730442.
Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS. TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY) 8(12):3507-3519, 2016. e-Pub 2016. PMID: 27992857.
Han HD, Byeon Y, Jang JH, Jeon HN, Kim GH, Kim MG, Pack CG, Kang TH, Jung ID, Lim YT, Lee YJ, Lee JW, Shin BC, Ahn HJ, Sood AK, Park YM. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Sci Rep 6:38348, 2016. e-Pub 2016. PMID: 27910914.
Hu Q, Wang M, Cho MS, Wang C, Nick AM, Thiagarajan P, Aung FM, Han X, Sood AK, Afshar-Kharghan V. Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. BBA Clin 6:76-81, 2016. e-Pub 2016. PMID: 27453821.
Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons Y, Pradeep S, Hu W, Previs RA, Hansen JM, Fang D, Dorniak PL, Filant J, Dial EJ, Shen F, Hatakeyama H, Sood AK. Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Mol Cancer Ther 15(12):2894-2904, 2016. e-Pub 2016. PMID: 27638860.
Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC, Sood AK, Nagrath D. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab 24(5):685-700, 2016. e-Pub 2016. PMID: 27829138.
Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang R. BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Res 76(21):6320-6330, 2016. e-Pub 2016. PMID: 27803105.
Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, Shim J, Dorniak PL, Mangala LS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, Lopez-Berestein G, Li C, Sood AK. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep 17(6):1621-1631, 2016. e-Pub 2016. PMID: 27806300.
Zhou M, Melancon M, Stafford RJ, Li J, Nick AM, Tian M, Sood AK, Li C. Precision Nanomedicine Using Dual Positron Emission Tomography and Magnetic Resonance Temperature Imaging-Guided Photothermal Therapy. J Nucl Med 57(11):1778-1783, 2016. e-Pub 2016. PMID: 27283932.
Feng S, Kroll MH, Nick AM, Sood AK, Afshar-Kharghan V. Platelets are not hyperreactive in patients with ovarian cancer. Platelets 27(7):716-718, 2016. e-Pub 2016. PMID: 27185008.
Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GL, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight 1(17):e87754, 2016. e-Pub 2016. PMID: 27777972.
Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y, Cogdell D, Liu J, Sood AK, Broaddus R, Xue F, Zhang W. MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. J Hematol Oncol 9(1):112, 2016. e-Pub 2016. PMID: 27760566.
Abeydeera ND, Egli M, Cox N, Mercier K, Conde JN, Pallan PS, Mizurini DM, Sierant M, Hibti FE, Hassell T, Wang T, Liu FW, Liu HM, Martinez C, Sood AK, Lybrand TP, Frydman C, Monteiro RQ, Gomer RH, Nawrot B, Yang X. Evoking picomolar binding in RNA by a single phosphorodithioate linkage. Nucleic Acids Res 44(17):8052-64, 2016. e-Pub 2016. PMID: 27566147.
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers 2:16061, 2016. e-Pub 2016. PMID: 27558151.
Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene 35(33):4312-20, 2016. e-Pub 2016. PMID: 26725326.
Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AA. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell 30(2):273-289, 2016. e-Pub 2016. PMID: 27478041.
Huang T, Poole EM, Eliassen AH, Okereke OI, Kubzansky LD, Sood AK, Forman JP, Tworoger SS. Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. Int J Cancer 139(2):291-9, 2016. e-Pub 2016. PMID: 26934358.
Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, McCrae KR, Palumbo JS, Raskob GE, Chan AT, Sood AK. Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Res 76(13):3671-5, 2016. e-Pub 2016. PMID: 27527638.
Matsuo K, Cahoon SS, Yoshihara K, Shida M, Kakuda M, Adachi S, Moeini A, Machida H, Garcia-Sayre J, Ueda Y, Enomoto T, Mikami M, Roman LD, Sood AK. Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer. Obstet Gynecol 128(1):127-37, 2016. e-Pub 2016. PMID: 27275802.
Whiting N, Hu J, Zacharias NM, Lokesh GL, Volk DE, Menter DG, Rupaimoole R, Previs R, Sood AK, Bhattacharya P. Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer. J Med Imaging (Bellingham) 3(3):036001, 2016. e-Pub 2016. PMID: 27547777.
Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Platelet FAK is a critical regulator of tumor growth after withdrawal of anti-angiogenic therapy. Journal of Clinical Investigation, 2016. e-Pub 2016.
Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget 7(23):35132-43, 2016. e-Pub 2016. PMID: 27147567.
Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER. ∆Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell 29(6):874-888, 2016. e-Pub 2016. PMID: 27300436.
Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol Cancer Ther 15(6):1344-52, 2016. e-Pub 2016. PMID: 27009216.
Christensen DK, Armaiz-Pena GN, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart MJ, Bender D, Thaker PH, Ahmed A, Penedo FJ, DeGeest K, Mendez L, Domann F, Sood AK, Lutgendorf SK. SSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget 7(22):33179-91, 2016. e-Pub 2016. PMID: 27121207.
Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Rep 15(7):1493-504, 2016. e-Pub 2016. PMID: 27160903.
Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, Rodriguez-Aguayo C, Yang P, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene 35(18):2390-7, 2016. e-Pub 2016. PMID: 26257064.
Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget 7(18):25930-48, 2016. e-Pub 2016. PMID: 27036018.
Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 126(5):1885-96, 2016. e-Pub 2016. PMID: 27064283.
Bhalwal AB, Nick AM, Dos Reis R, Chen CL, Munsell MF, Ramalingam P, Salcedo MP, Ramirez PT, Sood AK, Schmeler KM. Carcinoma of the Bartholin Gland: A Review of 33 Cases. Int J Gynecol Cancer 26(4):785-9, 2016. e-Pub 2016. PMID: 26844611.
Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol 141(2):260-3, 2016. e-Pub 2016. PMID: 26968641.
Poole EM, Kubzansky LD, Sood AK, Okereke OI, Tworoger SS. A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes Control 27(5):661-8, 2016. e-Pub 2016. PMID: 27023470.
Di Guilmi J, Salvo G, Nick A, Sood AK, Coleman RL, Lu KH, Mehran R, Vaporciyan A, Ramirez PT. Role of viedo-assisted thorascopy in advanced ovarian cancer. A literature review. International Journal of Gynecologic Cancer 26(4):801-806, 2016. e-Pub 2016. PMID: 26937753.
Timsah Z, Ahmed Z, Ivan C, Berrout J, Gagea M, Zhou Y, Pena GN, Hu X, Vallien C, Kingsley CV, Lu Y, Hancock JF, Liu J, Gladden AB, Mills GB, Lopez-Berestein G, Hung MC, Sood AK, Bogdanov M, Ladbury JE. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene 35(17):2186-96, 2016. e-Pub 2016. PMID: 26212011.
Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget 7(15):20825-39, 2016. e-Pub 2016. PMID: 26959114.
Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram P, Sehgal V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clin Cancer Res 22(7):1713-24, 2016. e-Pub 2016. PMID: 26581245.
Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JW. Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. Mol Cancer Ther 15(4):618-27, 2016. e-Pub 2016. PMID: 26861249.
Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecol Oncol 141(1):57-64, 2016. e-Pub 2016. PMID: 27016230.
Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun 7:11169, 2016. e-Pub 2016. PMID: 27041221.
Mitamura T, Gourley C, Sood AK. Prediction and failure of anti-angiogenesis escape. Gynecologic Oncology, 2016. e-Pub 2016. PMID: 26748214.
Rupaimoole R, Calin GA, Lopez-Berestein, Sood AK. MicroRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discovery, 2016. e-Pub 2016. PMID: 26865249.
Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget 7(12):15093-104, 2016. e-Pub 2016. PMID: 26918603.
Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology 63(3):864-79, 2016. e-Pub 2016. PMID: 26599259.
Zhang S, Mercado-Uribe I, Sood AK, Bast RC, Liu J. Coevolution of neoplastic epithelial cells and multilineage stroma via polyploidy giant cells during immortalization and transformation of mullerian epithelial cells. Genes and Cancer 7((3-4)):60-72, 2016. e-Pub 2016.
Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, Pecot C, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene 35(6):691-701, 2016. e-Pub 2016. PMID: 25639871.
Nagaraja AS, Sadaoui NC, Dorniak PL, Lutgendorf SK, Sood AK. SnapShot: Stress and Disease. Cell Metab 23(2):388-388.e1, 2016. e-Pub 2016. PMID: 26863488.
Cho MS, Rupaimoole R, Choi HJ, Noh K, Chen J, Hu Q, Sood AK, Afshar-Kharghan V. Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition. J Immunol 196(3):1412-8, 2016. e-Pub 2016. PMID: 26718342.
Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst 108(6):djv426, 2016. e-Pub 2016. PMID: 26819345.
Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, Lopez-Berestein G, Jeong W, Park IS, Park YN, Sood AK, Mills GB, Lee JS. YAP1 and TAZ Activates mTORC1 Pathway by Regulating Amino Acid Transporters in hepatocellular carcinoma. Hepatology 63(1):159-72, 2016. e-Pub 2016. PMID: 26389641.
Kendricks A, Pageon LR, Craig SL, Wen Y, Sood AK, Lockworth CR. Severe polyarthritis with implanted ovarian carcinoma cells in a mouse. Journal of the American Veterinary Medical Association 249(10):1149-1151, 2016. e-Pub 2016.
Shinn EH, Valentine A, Jethanandani A, Basen-Engquist K, Fellman B, Urbauer D, Atkinson E, Yusuf SW, Lenihan D, Woods ML, Kies MS, Sood AK, Carmack C, Morrison WH, Gillenwater A, Sturgis EM, Garden AS. Depression and oropharynx cancer outcome. Psychosom Med 78(1):38-48, 2016. e-Pub 2016. PMID: 26632757.
Han HD, Byeon Y, Kang TH, Jung ID, Lee JW, Shin BC, Lee YJ, Sood AK, Park YM. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. Int J Nanomedicine 11:5729-5742, 2016. e-Pub 2016. PMID: 27843314.
Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Lyons Y, Hu W, Previs RA, Hansen JM, Fang D, Dorniak PL, Filant J, Dial EJ, Shen F, Hatakeyama H, Sood AK. Anti-tumor and anti-angiogenic effects of aspirin-PC in ovarian cancer. Molecular Cancer Therapeutics 15(12):2894-904, 2016. e-Pub 2016.
Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han Z, Pathak S, Multani AS, Kuang J, Bast RC, Sood AK, Hung MC, Liu J. Linking genomic reorganization to tumor inititation via the giant cell cycle. Oncogenesis 5(12):e281, 2016. e-Pub 2016.
Ravoori M, Singh S, Bhavane R, Sood AK, Anvari B, Bankson J, Annapragada A, Kundra V. Multimodal magnetic resonance and near infrared-fluorescent imaging of intraperitoneal ovarian cancer using a dual-mode dual-gadolinium liposomal contrast agent. Scientific Reports 6:38991, 2016. e-Pub 2016.
Wang H, Li X, Volk DE, Lokesh GL, Elizondo-Riojas MA, Li L, Nick AM, Sood AK, Rosenblatt KP, Gorenstein DG. Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery. Biotechniques 61(5):249-259, 2016. e-Pub 2016. PMID: 27839510.
Kanlikilicer P, Saber M, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res 76(24):7194-7207, 2016. e-Pub 2016. PMID: 27742688.
Huang T, Tworoger SS, Hecht JL, Rice MS, Sood AK, Kubzansky LD, Poole EM. Association of ovarian tumor β2-adrenergic receptor status with ovarian cancer risk factors and survival. Cancer Epidemiol Biomarkers Prev 25(12), 2016. e-Pub 2016. PMID: 27587791.
Chung JF, Yoon CJ, Cheon SA, Seo ES, Park SH, Yang JS, Kim B, Joo MY, Park TJ, Kim KH, Sood AK, Lee SJ. NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. Oncotarget 7(30):47576-47585, 2016. e-Pub 2016. PMID: 27374093.
Chung JF, Lee SJ, Sood AK. Immunological and pleiotropic effects of individual β-blockers and their relevance in cancer therapies. Expert Opin Investig Drugs 25(5):501-5, 2016. e-Pub 2016. PMID: 26954371.
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. e-Pub 2016. PMID: 26799652.
Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 1402:189-97, 2016. e-Pub 2016. PMID: 26721492.
Zand B, Previs RA, Zacharias NM, Rupaimoole R, Nagaraja AS, Guindani M, Dalton HJ, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala, LS, Rodriguez-Aguayo C, Taylor M, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Bar Eli M, Lopez-Berestein G, Bhattacharya PK, Sood AK. Role of increased n-acetylaspartate levels in ovarian carcinoma. Journal of the National Cancer Institute 108(6):djv426, 2016. e-Pub 2016.
Hou MH, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Coleman RL, Sood AK, Tsimberidou A, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenesis beyond tumor progression in patients with recurrent high-grade epithelial ovarian cancer: Phase I trial experience. Oncotarget 7(23):35132-35143, 2016. e-Pub 2016.
Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar R, Li L, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Maiti SN, Cooper LJN, Bulayeva N, Choi HJ, Dorniak PL, Rosenblatt KP, Tanaka T, Lopez-Berestein G, Gorenstein D, Sood AK. Improving tumor vascular maturation using non-coding RNAs increases anti-tumor effect of chemotherapy. Journal of Clinical Investigation Insight 1(17):e87754, 2016. e-Pub 2016.
Han HD, Byeon Y, Jeon HN, Kang TH, Jung ID, Shin BC, Lopez-Berestein G, Sood AK, Park YM. TLR-3-induced immune response by PLGA nanoparticles for dendritic cell-based cancer immunotherapy. International Journal of Nanomedicine 11:5729-5742, 2016. e-Pub 2016.
Shields BB, Pecot CV, Gao H, McMillan E, Potts M, Nagel C, Purinton S, Wang Y, Ivan C, Kim HS, Borkowski RJ, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, Lea J, Gazdar A, Baggerly KA, Sood AK, White MA. A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Mol Syst Biol 11(12):842, 2015. e-Pub 2015. PMID: 26655797.
Rupaimoole R, Previs RA, Lee J, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Zacharias Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK. Novel long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis pathway. Cell Report 13:2395-2402, 2015. e-Pub 2015. PMID: 26686630.
Sercombe L, Veerati T, Mohemani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology 6:286, 2015. e-Pub 2015. PMID: 26648870.
Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK. Dual metronomic chemotherapy with Nab-paclitaxel and topotecan has potent anti-angiogenic activity in ovarian cancer. Molecular Cancer Therapeutics 14(12):2677-2786, 2015. e-Pub 2015. PMID: 26516159.
Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin stimulates tumor growth via EphB4. Cancer Cell 28(5):610-22, 2015. e-Pub 2015. PMID: 26481148.
Wang R, Stone RL, Rochat RH, Nick AM, Vijayan V, Afshar-Kharghan V, Schmid MF, Dong JF, Sood AK, Chiu. Electron cryo-tomography reveals ultrastructure alterations in platelets from ovarian cancer patients. Proceedings of the National Academy of Sciences 112(46):14266-14271, 2015. e-Pub 2015. PMID: 26578771.
Bayer JL, Spitz DR, Christensen D, McCormick ML, Farley D, DeGeest K, Damoush L, Aust S, Sood AK, Lutgendorf SK. Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. Brain Behav Immun 50:58-62, 2015. e-Pub 2015. PMID: 25989110.
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15(11):668-79, 2015. e-Pub 2015. PMID: 26493647.
Davis LZ, Slavich GM, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Farley DM, Markon KE, Penedo FJ, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer 121(19):3543-50, 2015. e-Pub 2015. PMID: 26096769.
Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer 121(19):3444-51, 2015. e-Pub 2015. PMID: 26301456.
Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE. Targeting c-MYC in platinum-resistant ovarian cancer. Mol Cancer Ther 14(10):2260-9, 2015. e-Pub 2015. PMID: 26227489.
Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L. Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell 28:529-540, 2015. e-Pub 2015. PMID: 26461095.
Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget 6(30):29161-77, 2015. e-Pub 2015. PMID: 26313360.
Jiang L, Nick AM, Sood AK. Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period?. Curr Anesthesiol Rep 5(3):250-256, 2015. e-Pub 2015. PMID: 26388704.
Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Stone RL, Previs RA, Hansen JM, Ikeda Y, Miyara A, Hiramatsu K, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Roman LD, Gabra H, Fotopoulou C, Sood AK. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur J Cancer 51(14):1978-88, 2015. e-Pub 2015. PMID: 26238017.
Cole SW, Nagaraja AS, Lutgendorf SK, McDonald PG, Sood AK. Sympathetic nervous system regulation of the tumour microenvironment. Nature Review Cancer 15(9):563-572, 2015. e-Pub 2015. PMID: 26299593.
Graybill W, Sood AK, Monk BJ, Coleman RL. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecol Oncol 138(2):223-6, 2015. e-Pub 2015. PMID: 26166806.
Matsuo K, Hom MS, Moeini A, Machida H, Takeshima N, Roman LD, Sood AK. Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. Gynecol Oncol 138(2):332-8, 2015. e-Pub 2015. PMID: 26013698.
Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res 21(14):3286-97, 2015. e-Pub 2015. PMID: 25878333.
Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol 1(4):486-94, 2015. e-Pub 2015. PMID: 26181259.
Zhou M, Li J, Liang S, Sood AK, Li C. CuS nanodots with ultrahigh efficient renal clearance for positron emission tomography imaging and image-guided photothermal therapy. ACS Nano 9(7):7085-7096, 2015. e-Pub 2015. PMID: 26098195.
Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RC. CDK5 regulates paclitaxel sensitivity in ovarian cancer cells by regulation of activation of AKT, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosis. PLoS 10(7), 2015. e-Pub 2015. PMID: 26146988.
Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst 107(7):djv108, 2015. e-Pub 2015. PMID: 25995442.
Thanapprapasr D, Previs RA, Hu W, Ivan C, Armaiz-Pena GN, Dorniak PL, Hansen JM, Rupaimoole R, Huang J, Dalton HJ, Ali-Fehmi R, Coleman RL, Sood AK. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther 14(6):1466-75, 2015. e-Pub 2015. PMID: 25833835.
Bullock MD, Silva AM, Kanlikilicer P, Filant J, Rashed MH, Sood AK, Lopez-Berestein G, Calin GA. Exosomal non-coding RNAs: Diagnostic, prognostic and therapeutic applications in cancer. Non-Coding RNA. Noncoding RNA:53-68, 2015. e-Pub 2015. PMID: 29861415.
Liu G, Yang D, Pecot CV, Sun Y, Li X, Ji P, Cogdell D, Hu L, De Cecco L, Mezzanzanica D, Rodriguez-Aguayo C, Lopez-Berestein G, Xue F, Sood AK, Zhang W. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. Journal of the National Cancer Institute 107(7), 2015. e-Pub 2015.
Gonzalez-Villasana V, Fuentes-Mattei E, Dalton H, Rodriguez-Aguayo C, Aslan B, Valazquez-Torres G, Previs R, Pradeep S, Ivan C, Kahraman N, Kanlikilicer P, Sood AK, Lopez-Berestein G. Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer. Clinical Cancer Research 21(9):2127-2137, 2015. e-Pub 2015. PMID: 25595279.
Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 520(7549):697-701, 2015. e-Pub 2015. PMID: 25901683.
Previs RA, Coleman RL, Harris AL, Sood AK. Molecular pathways: Translational and therapeutic implications of the Notch signaling pathway in cancer. Clinical Cancer Research 21(5):955-961, 2015. e-Pub 2015. PMID: 25388163.
Jin Y, Wang L, Qu S, Kristian A, Maelandsmo GM, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, Lopez-Berestein G, Fazil L, Rennie PS, Risberg B, Waehre H, Dalielsen HE, Ozpolat B, Saatcioglu F. STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO. Molecular Medicine 7:315-331, 2015. e-Pub 2015. PMID: 25680860.
Schrepf A, Goodheart MJ, Bender D, Dahmoush L, Penedo F, Lucci JA, Thaker PT, Mendez L, Slavich G, Lubaroff DM, Cole SW, SSchrepf A, Goodheart MJ, Bender D, Dahmoush L, Penedo F, Lucci JA, Thaker PT, Mendez L, Slavich G, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK ood AK, Lutgendorf SK. Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology 53:256-267, 2015. e-Pub 2015. PMID: 25647344.
Choi HJ, Armaiz-Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer and Metastasis Reviews 34(1):19-40, 2015. e-Pub 2015. PMID: 25544368.
Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJM, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Robertson AG, Calin GA, Markel G, Fidler IJ, Bar-Eli M. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nature Cell Biology 17(3):311-321, 2015. e-Pub 2015. PMID: 25686251.
Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein G. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget 6(6):4266-73, 2015. e-Pub 2015. PMID: 25738355.
Yang X, Shen F, Hu W, Coleman RL, Sood AK. New ways to successfully target tumor vasculature in ovarian cancer. Current Opinion in Obstetrics and Gynecology 27(1):58-65, 2015. e-Pub 2015.
Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, Sood AK. Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res 21(3):602-10, 2015. e-Pub 2015. PMID: 25473001.
Matsuo K, Yoshino K, Hasegawa K, Murakami R, Ikeda Y, Adachi S, Hiramatsu K, Yokoyama T, Nishimura M, Sheridan TB, Enomoto T, Fujiwara K, Matsumura N, Konishi I, Fotopoulou C, Roman LD, Sood AK. Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. Gynecologic Oncology 136:198-204, 2015. e-Pub 2015. PMID: 25497604.
Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for personalized surgical approach to ovarian cancer. Nature Reviews Clinical Oncology 12:239-245, 2015. e-Pub 2015. PMID: 25707631.
Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Sehgal V, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res 21(2):448-59, 2015. e-Pub 2015. PMID: 25416196.
Wen Y, Graybill WS, Previs RA, Hu W, Ivan C, Sehgal V, Mangala LS, Zand B, Nick AM, Jennings NB, Dalton HJ, Ram P, Lee JS, Vivas-Mejia PE, Coleman RL, Sood AK. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clinical Cancer Research 21(2):448-59, 2015. e-Pub 2015.
Sun Y, Guo F, Bognoli M, Xue F, Sun B, Shmulevich I, Mezzanzanica D, Chen K, Sood AK, Yang D, Zhang W. The key nodes of a microRNA network associated with integrated mesenchymal subtype of high-grade serous ovarian cancer. Chinese Journal of Cancer:28-40, 2015. e-Pub 2015. PMID: 25556616.
Shields BB, Pecot CV, Gao H, McMillan E, Potts M, Nagel C, Purinton S, Wang Y, Ivan C, Kim HS, Borkowski RJ, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, Lea J, Gazdar AF, Baggerly KA, Sood AK, White MA. A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Molecular Systems Biology 11(12):842, 2015. e-Pub 2015.
Huang T, Poole EM, Okereke OI, Kubzansky LD, Eliassen AH, Sood AK, Wang M, Tworoger SS. Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies. Gynecol Oncol 139(3):481-6, 2015. e-Pub 2015. PMID: 26449316.
Ravoori M, Singh S, Lu C, Han L, Pradeep S, Choi HJ, Bankson J, Sood AK, Kundra V. Tumor T1 relaxation time for assessing response to bevacizumab anti-angiogenic therapy in a mouse ovarian cancer model. PLoS One 10(6):e0131095, 2015. e-Pub 2015.
Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Lutgendorf SK, Sood AK, Lopez-Berestein G. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. Feb 28; 6(6):4266-73, 2015. e-Pub 2015.
Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun 6(7351):1-12, 2015. e-Pub 2015. PMID: 26081979.
Srivastava A, Filant J, Moxley KM, Sood AK, McMeekin S, Ramesh R. Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment. Current Gene Therapy 15(2):182-92, 2015. e-Pub 2015.
Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 235(1):25-36, 2015. e-Pub 2015. PMID: 25230372.
Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MC, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AK. XPO1/CRM1 inhibition causes anti-tumor effects by mitochondrial accumulation of eIF5A. Clinical Cancer Research 21(14):3286-3297, 2015. e-Pub 2015.
Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer D, Matsuo K, Squires K, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK. Clinical impact of selective and non-selective beta-blockers on survival in ovarian cancer patients. Cancer 121(19):3444-3451, 2015. e-Pub 2015.
Moss TJ, Luo Z, Seviour EG, Sehgal V, Lu Y, Hill SM, Rupaimoole R, Lee JS, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Azencott R, Gray JW, Mukherjee S, Mills GB, Ram PT. Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. NPJ Syst Biol Appl 1:15001, 2015. e-Pub 2015. PMID: 28725457.
Davis LZ, Slavich GM, Thaker PH, Goodheart MJ, Bender D, Lubaroff DM, Dahmoush L, Farley D, Markon KE, Cole SW, Sood AK, Lutgendorf SK. Eudaimonic well-being is associated with lower tumor norepinephrine in epithelial ovarian cancer patients. Cancer 121(19):3543-3550, 2015. e-Pub 2015.
Liu Y, Sato M, Zhao Y, Hu L, Cogdell D, Zheng H, Broaddus R, Gharpure KM, Pradeep S, Nagaraja AS, Shmulevich I, Chen K, Sood AK, Zhang W. Association of somatic mutations of ADAMTS family genes with improved chemotherapy sensitivity and survival in serous ovarian carcinoma. Journal of the American Medical Association Oncology 1(4):486-494, 2015. e-Pub 2015.
Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Borresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell 26(6):863-879, 2014. e-Pub 2014. PMID: 25490449.
Wu SY, Lopez-Berestein G, Calin GA, Sood AK. Targeting the undruggable: Advances and obstacles in current RNAi therapy. Science Translational Medicine 6(240):240ps7, 2014. e-Pub 2014. PMID: 24920658.
Chaoul A, Milbury K, Sood AK, Prinsloo S, Cohen L. Mind-body practices in cancer care. Current Oncology Reports 16(12):417, 2014. e-Pub 2014. PMID: 25325936.
Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, Hu Y, Ang KH, Chen J, Ma L. MiR-205 acts as a tumor radiosensitizer by targeting ZEB1 and Ubc13. Nature Communications 5(5):5671, 2014. e-Pub 2014. PMID: 25476932.
van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, Starmans MHW, Yao CQ, Ivan M, Ivan C, Pecot CV, Boutros PC, Sood AK, Koritzinsky M, Wouters BG. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun 5:5203, 2014. e-Pub 2014. PMID: 25351418.
Leung CS, T-L Y, K-P Y, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena G, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium Dependent FAK/CREB/TNNC1 Signaling Mediates the Effect of Stromal MFAP5 on Ovarian Cancer Metastatic Potential. Nature Communication 5:5092, 2014. e-Pub 2014. PMID: 25277212.
Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst 106(9):dju245, 2014. e-Pub 2014. PMID: 25214561.
Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK. Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biol Ther 15(8):1061-7, 2014. e-Pub 2014. PMID: 24841852.
Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26(1):77-91, 2014. e-Pub 2014. PMID: 25026212.
Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, Yee C, Lee KM, Kim TW. API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res 74(13):3556-66, 2014. e-Pub 2014. PMID: 24769442.
Gharpure KM, Chu KS, Bowerman C, Miyake T, Pradeep S, Mangala LS, Han HD, Rupaimoole R, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AK. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Molecular Cancer Therapeutics, 2014. e-Pub 2014. PMID: 24755199.
Menter DG, Swank MW, Patterson SL, Logsdon C, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: Are we there yet?. Cancer Prevention Research 7(10):973-92, 2014. e-Pub 2014. PMID: 25060262.
Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, Gonzalez A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK. Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: Emerging Therapies in Gynecologic Cancer. Gynecologic Oncology, 2014. e-Pub 2014. PMID: 24952408.
Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res 20(12):3280-8, 2014. e-Pub 2014. PMID: 24756370.
Rytelewski M, Tong J, Buensuceso A, Leong HS, Vareki SM, Figueredo R, Di Cresce C, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers A, Vincent M, Ferguson PJ, Koropatnick J. BRCA2 inhibition modulates tumor proliferation, metabolic response and metastatic frequency following cisplatin treatment. Molecular Oncology 8(8):1429-1440, 2014. e-Pub 2014. PMID: 24974076.
Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 pathway alterations in ovarian cancer. Cancer Res 74(12):3282-93, 2014. e-Pub 2014. PMID: 24743243.
Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD, Im DD, Rosenshein NB, Roman LD, Sood AK. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol Oncol 133(3):473-9, 2014. e-Pub 2014. PMID: 24674832.
Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50(9):1638-48, 2014. e-Pub 2014. PMID: 24709487.
Roh JW, Huang J, Hu W, Yang X, Jennings NB, Sehgal V, Sohn BH, Han HD, Lee SJ, Thanapprapasr D, Bottsford-Miller J, Zand B, Dalton HJ, Previs RA, Davis AN, Matsuo K, Lee JS, Ram P, Coleman RL, Sood AK. Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. Clin Cancer Res 20(10):2740-50, 2014. e-Pub 2014. PMID: 24634380.
Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen ST. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis 35(5):1100-9, 2014. e-Pub 2014. PMID: 24379240.
Matsuo K, Yoshino K, Hiramatsu K, Banzai C, Hasegawa K, Yasuda M, Nishimura M, Sheridan TB, Ikeda Y, Shiki Y, Mabuchi S, Enomoto T, Kimura T, Fujiwara K, Roman LD, Sood AK. Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer. Obstet Gynecol 123(5):957-65, 2014. e-Pub 2014. PMID: 24785846.
Guo F, Cogdell D, Hu L, Yang D, Sood AK, Xue F, Zhang W. MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep 31(5):2021-8, 2014. e-Pub 2014. PMID: 24677166.
Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7(2):488-500, 2014. e-Pub 2014. PMID: 24703838.
Joshi HP, Subramanian IV, Schnettler EK, Ghosh G, Rupaimoole R, Evans C, Saluja M, Jing Y, Cristina I, Roy S, Zeng Y, Shah VH, Sood AK, Ramakrishnan S. Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc Natl Acad Sci U S A 111(14):5331-6, 2014. e-Pub 2014. PMID: 24706848.
Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D, Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L, Deavers MT, Broaddus R, Coleman RL, Sood AK. Cross-talk between EphA2 and BRaf/CRaf Is a Key Determinant of Response to Dasatinib. Clin Cancer Res 20(7):1846-55, 2014. e-Pub 2014. PMID: 24486585.
Davis A, Afshar-Kharghan V, Sood AK. Platelet effects on ovarian cancer. Seminars in Oncology 41(3):378-384, 2014. e-Pub 2014. PMID: 25023353.
Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan V. Autocrine effects of tumor-derived complement. Cell Rep 6(6):1085-95, 2014. e-Pub 2014. PMID: 24613353.
Cata JP, Villarreal J, Keerty D, Thakar DR, Liu DD, Sood AK, Gottumukkala V. Perioperative beta-blocker use and survival in lung cancer patients. J Clin Anesth 26(2):106-17, 2014. e-Pub 2014. PMID: 24480297.
Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer and Metastasis Review 33:231-269, 2014. e-Pub 2014. PMID: 24696047.
Dalton HJ, Armaiz-Pena G, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK. Monocyte subpopulations in angiogenesis. Cancer Research 74(5):1-7, 2014. e-Pub 2014. PMID: 24556724.
Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol 132:166-175, 2014. e-Pub 2014. PMID: 24183729.
Guo F, Parker Kerrigan BC, Yang D, Hu L, Shmulevich I, Sood AK, Xue F, Zhang W. Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. J Hematol Oncol 7:19, 2014. e-Pub 2014. PMID: 24598126.
Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun 5:3459, 2014. e-Pub 2014. PMID: 24619206.
Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, Degeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK. Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther 15(7):919-929, 2014. e-Pub 2014. PMID: 24755674.
Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol 10:728, 2014. e-Pub 2014. PMID: 24799285.
Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DS, Mills GB, Sood A, Lee JS. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res 34(2):811-7, 2014. e-Pub 2014. PMID: 24511017.
Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Pecot CV, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK. Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biol Ther 8:1061-7, 2014. e-Pub 2014.
Han C, Liu Y, Wan G, Choi HJ, He X, Ivan C, Sood AK, Zhang X, Lu X. The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibitors ovarian tumor progression. Cell Rep 8(5):1447-60, 2014. e-Pub 2014. PMID: 25176654.
Van den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, Starmans MHW, Yao CQ, Ivan M, Ivan C, Pecot CV, Boutros PC, Sood AK, Koritzinsky M, Wouters BG. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun 5:5203, 2014. e-Pub 2014.
Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Jeong LH, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous metastasis of ovarian cancer: Rethinking mode of spread. Cancer Cell 26(1):77-91, 2014. e-Pub 2014.
Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G, Walton BL. Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. J Liposome Res 24(3):182-90, 2014. e-Pub 2014. PMID: 24443972.
Jag UR, Patel HA, Gharbaran R, Tanaka T, Sood AK, Hu W, Lu J, Patwa R, Kowalski J, Shah S, Blake P, Liang M, McCue P, Goy A, Pecora A, Suh KS. Kallikrein family proteases KLK6 and KLK7 are early detection and diagnostic biomarkers for serous and papillary serous subtypes of ovarian cancer. J Ovarian Res 7:109, 2014. e-Pub 2014.
Gizzatov A, Stigliano C, Ananta JS, Sethi R, Xu R, Guven A, Ramirez M, Shen H, Sood A, Ferrari M, Wilson LJ, Liu X, Decuzzi P. Geometrical confinement of Gd(DOTA) molecules in mesoporous silicon nanoconstructs for cancer imaging. Cancer Letters 352:97-101, 2014. e-Pub 2014.
Krzeszinski JY, Wei W, Huynh HD, Chang TC, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y. Mir-34a suppresses osteoporosis and cancer bone metastasis by inhibiting osteoclastogenesis and targeting Tgif2. Nature 512:431-435, 2014. e-Pub 2014.
Guo F, Cogdell D, Hu L, Yang D, Sood AK, Xue F, Zhang W. MiR-101 suppresses epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep 31(5):2021-8, 2014. e-Pub 2014.
Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, Xue F, Zhang W. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol 233:308-318, 2014. e-Pub 2014. PMID: 24604117.
Rupaimoole R, Ivan C, Pecot CV, Wu S, Pradeep S, Zand B, Nagaraja AS, Gharpure KM, Armaiz-Pena GN, Lu C, Sadaoui NC, Mangala LS, Taylor M, Dalton HJ, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK. Hypoxia mediated downregulation of miRNA biogenesis leads to increased tumor progression. Nat Commun 5:5202, 2014. e-Pub 2014.
Pecot CV, Wu S, Bellister S, Bhattacharya R, Maharaj A, Rodriguez-Aguayo C, Morelli MP, Rupaimoole R, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther 13(12):2876-85, 2014. e-Pub 2014. PMID: 25281617.
Noh KH, Kim SH, Kim JH, Song KH, Kim K, Lee YH, Kang TH, Han HD, Sood A, Ng J, Sonn CH, Kuman V, Yee C, Lee KM, Kim TW. API5 confers tumor immune resistance through an FGF2/FGFR/PKCδ-dependent cell survival pathway. Cancer Res. Jul 1; 74(13):3556-66, 2014. e-Pub 2014.
Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Deng D, Fuentes-Mattei E, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Aslan B, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein G. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound Paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther 13(11):2583-94, 2014. e-Pub 2014. PMID: 25193509.
Hsu YH, Wu TJ, Chan LC, Chen CT, Hsu JL, Yao J, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Li CW, Shen J, Wang MY, Sahin AA, Sood AK, Mills G, Yu D, Hortobagyi GN, Hung MC. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res 74(17):4822-35, 2014. e-Pub 2014.
Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton M, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Liu W, Venkatanarayan A, Krohn M, Lopez-Berestein G, Kristensen VN, Gagea M, Ram P, Lorenzi PL, A-L B, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell 26(6):863-79, 2014. e-Pub 2014.
Wu SY, Yang X, Gharpure K, Hatakeyama H, Egli M, McGuire M, Nagaraja AS, Miyake T, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena G, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton H, Kowali C, Keyomarsi K, McMillan NAJ, Overwijk WW, Liu J, Lee JS, Baggerly K, Lopez-Berestein G, Ram P, Nawrot B, Sood AK. 2’-OMe-phosphorodithioate siRNAs show increased loading into the RISC complex and enhanced anti-tumor activity. Nature Communications 5:3459, 2014. e-Pub 2014.
Tucker SL, Gharpure K, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. Molecular predictors of residual disease after cytoreductive surgery in patients with high-grade serous ovarian cancer. Clinical Cancer Research 20(12):3280-3288, 2014. e-Pub 2014.
Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Rupaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D. Metabolic shifts toward glutamine regulates aggressive tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology 10(5):728, 2014. e-Pub 2014.
Matsuo K, Yoshino K, Hiramatsu K, Banzai C, Hasegawa K, Yasuda M, Nishimura M, Sheridan TB, Ideda Y, Shiki Y, Mabuchi S, Enomoto T, Kimura T, Fujiwara K, Roman LD, Sood AK. Impact of lymphovascular space invasion on survival of stage I epithelial ovarian cancer patients. Obstetrics and Gynecology 123(5):957-965, 2014. e-Pub 2014.
Tamir A, Jag UR, Schindewolf CD, Tanaka T, Gharbaran R, Sarojini S, Paten HA, Sood AK, Hu W, Patwa R, Blake PM, Lim H, Goy AH, Pecora AH, Suh KS. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous subtypes of ovarian cancer. The Journal of Ovarian Research 7:109, 2014. e-Pub 2014.
Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK. Targeting Src and tubulin in mucinous ovarian carcinoma. Clin Cancer Res 19(23):6532-43, 2013. e-Pub 2013. PMID: 24100628.
Wang H, Heijnen CJ, van Velthoven CT, Willemen HL, Ishikawa Y, Zhang X, Sood AK, Vroon A, Eijkelkamp N, Kavelaars A. Balancing GRK2 and Epac1 levels preventions and relieves chronic pain. J Clin Invest 123(12):5023-5034, 2013. e-Pub 2013. PMID: 24231349.
Lutgendorf SK, Slavich GM, Degeest K, Goodheart M, Bender D, Thaker PH, Penedo F, Zimmerman B, Lucci J, Mendez L, Collins K, Sood AK. Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients. Gynecol Oncol 131:667-673, 2013. e-Pub 2013. PMID: 24096110.
Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov 3(11):1302-15, 2013. e-Pub 2013. PMID: 24002999.
Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondetta LM, Sood AK. β-blockers: a new role in cancer chemotherapy?. Expert Opin Investig Drugs 22(11):1359-63, 2013. e-Pub 2013. PMID: 23919278.
Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK. Role of Focal Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer. J Natl Cancer Inst 105(19):1485-95, 2013. e-Pub 2013. PMID: 24062525.
Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs 31(5):1192-200, 2013. e-Pub 2013. PMID: 23907406.
Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, Dahmoush L, Penedo F, Lucci J, Thaker PH, Mendez L, Sood AK, Slavich GM, Lutgendorf SK. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer 119(17):3234-41, 2013. e-Pub 2013. PMID: 23797955.
Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. Poor survival with wild-type TP53 ovarian cancer?. Gynecol Oncol 130(3):565-9, 2013. e-Pub 2013. PMID: 23800698.
Gharpure KM, Sood AK. Neighborhood matters: response to EZH2 methyltransferase inhibitors. Cell Cycle 12(15):2345, 2013. e-Pub 2013. PMID: 23887388.
Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer 23(5):815-22, 2013. e-Pub 2013. PMID: 23669443.
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 123(5):2119-30, 2013. e-Pub 2013. PMID: 23585472.
Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia 15(5):502-10, 2013. e-Pub 2013. PMID: 23633922.
Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res 19(7):1806-15, 2013. e-Pub 2013. PMID: 23386691.
Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J. Interleukin-1beta promotes ovarian tumorigenesis through a p53/NF-kappaB-mediated inflammatory response in stromal fibroblasts. Neoplasia 15(4):409-20, 2013. e-Pub 2013. PMID: 23555186.
Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol 129(1):86-91, 2013. e-Pub 2013. PMID: 23321064.
Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Penedo F, Lucci JA 3rd, Ganjei-Azar P, Mendez L, Markon K, Lubaroff DM, Thaker PH, Slavich GM, Sood AK, Lutgendorf SK. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain Behav Immun 30 Suppl(0):S126-34, 2013. e-Pub 2013. PMID: 22884960.
Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res 19(4):809-20, 2013. e-Pub 2013. PMID: 23344261.
Zhou J, Roh JW, Bandyopadhyay S, Chen Z, Munkarah AR, Hussein Y, Alosh B, Jazaerly T, Hayek K, Semaan A, Sood AK, Ali-Fehmi R. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol 128(2):344-8, 2013. e-Pub 2013. PMID: 22871469.
Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK, Sood AK. Why stress is BAD for cancer patients. J Clin Invest 123(2):558-60, 2013. e-Pub 2013. PMID: 23348736.
Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res 19(1):170-82, 2013. e-Pub 2013. PMID: 23147994.
Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC Jr, Fu S, Hu W, Sood AK. Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol 3:58, 2013. e-Pub 2013. PMID: 23519775.
Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One 8(11):e79167, 2013. e-Pub 2013. PMID: 24236104.
Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK. Tumour angiogenesis regulation by the miR-200 family. Nat Commun 4:2427, 2013. e-Pub 2013. PMID: 24018975.
Clevenger L, Schrepf A, DeGeest K, Bender D, Goodheart M, Ahmed A, Dahmoush L, Penedo F, Lucci J, Thaker P, Mendez L, Sood AK, Slavich GM, Lutgendorf SK. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year post diagnosis. Cancer 119(17):3234-3241, 2013. e-Pub 2013.
Yang D, Sun Y, Hu L, Ji P, Pecot CV, Zheng H, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang W. Integrated analysis reveals a poor prognostic mesenchymal subtype driven by a key microRNA network in serous ovarian cancer. Cancer Cell 23:186-199, 2013. e-Pub 2013.
Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt R, Kwan SY, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of fibroblast growth factor receptor 4 (FGFR4) as a prognostic marker and a potential therapeutic target for advanced-stage high-grade serous ovarian cancer. Clinical Cancer Research 19(4):809-820, 2013. e-Pub 2013.
Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Penedo F, Lucci JA, Ganjei-Azar P, Mendez L, Markon K, Lubaroff DM, Kirschbaum C, Sood AK, Lutgendorf SK. Cortisol and interleukin-6 in ovarian cancer patients following primary treatment: Relationships with depression, fatigue, and disability. Brain Behav Immun:S126-34, 2013. e-Pub 2013.
Tekedereli I, Akar U, Alpay SN, Sood AK, Lopez-Berestein G, Ozpolat B. Therapeutic silencing of Bcl-2 by siRNA in vivo inhibits tumor growth through induction of apoptosis and autophagy. Molecular Therapy Nucleic Acids 10:2:e121, 2013. e-Pub 2013. PMID: 24022053.
Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Wu Z, English RD, Soman KV, Shahazad MMK, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK. Src activation by β-adrenoreceptors is a key switch for tumor metastasis. Nature Communications 4:1403, 2013. e-Pub 2013.
Zhou J, J-W R, Bandyopadhyay S, Chen Z, Munkarah A, Hussein Y, Alosh B, Jazaerly T, Sood AK, Ali-Fehmi R. Overexpression of enhancer of zesteh 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecologic Oncology 128:344-348, 2013. e-Pub 2013.
Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AK. Biological significance of HORM-A domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett 330(2):123-129, 2013. e-Pub 2013. PMID: 22776561.
Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol 128(3):506-511, 2013. e-Pub 2013. PMID: 23200915.
Thaker PH, Melhem-Bertrandt A, Sood AK, Ramondetta LM. Importance of adrenergic pathways in women’s cancers. Cancer Biomarkers 13(3):145-54, 2013. e-Pub 2013. PMID: 23912486.
Masiero M, Simoes FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FM. A core primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 24(2):229-41, 2013. e-Pub 2013. PMID: 23871637.
Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J. Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia 15(4):409-20, 2013. e-Pub 2013.
Jin Y, Qu S, Teslkova M, Wang L, Kristian A, Maelandsmo GM, Kong H, Zhang T, Jeronimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood A, Lopez-Berestein G, Danielsen HE, Ozpolat B, Danielsen HE, Saatcioglu F. A molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proceedings of the National Academy of Sciences 110(28):E2572-E2581, 2013. e-Pub 2013.
Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Alpaugh K. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomas: A Gynecologic Oncology Group (GOG) study. Gynecologic Oncology 129(1):86-91, 2013. e-Pub 2013.
Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst K, Kurzrock AK. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Investigational New Drugs 31(5):1192-1200, 2013. e-Pub 2013.
Zhang X, Lu X, Lopez G, Sood AK, Calin G. In situ hybridization-based detection of microRNAs in human diseases. MicroRNA Diagnostics and Therapeutics doi: 10.2478/micmat-2013-0002.MICRNAT:12-23, 2013. e-Pub 2013.
Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, J-S L, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK. Tumor angiogenesis regulation by the miR-200 family. Nature Communications 4:2427(doi: 10.1038/ncomms3427):1-14, 2013. e-Pub 2013.
Wan G, Hu X, Liu Y, Han C, Sood AK, Calin GA, Zhang X, Lu X. A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. The EMBO Journal 32(21):2833-47, 2013. e-Pub 2013. PMID: 24097061.
Shinn EH, Lenihan DJ, Urbauer D, Basen-Engquist K, Valentine A, Palmero L, Woods M, Patel P, Nick AM, Shahzad MMK, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK. Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiology, Biomarkers & Prevention 22(11):2102-09, 2013. e-Pub 2013. PMID: 24045927.
Nishimura M, E-J J, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discovery 3:1302-1315, 2013. e-Pub 2013.
Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Rodriguez-Aguayo C, Lopez-Berestein G, Toombs JE, Wei S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis RJ, Roth MG, Minna JD, White MA. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155(3):552-566, 2013. e-Pub 2013. PMID: 24243015.
Miller DF, Yan PS, Buechlein A, Rodriguez BA, Yilmaz AS, Goel S, Lin H, Collins-Burow B, Rhodes LV, Braun C, Pradeep S, Rupaimoole R, Dalkilic M, Sood AK, Burow ME, Tang H, Huang TH, Liu Y, Rusch DB, Nephew KP. A new method for stranded whole transcriptome RNA-seq. Methods 63(2):126-34, 2013. e-Pub 2013. PMID: 23557989.
Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. Tat-activation regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology 58(1):182-191, 2013. e-Pub 2013.
Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS ONE 8(11):e79167, 2013. e-Pub 2013.
Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, Sood AK, Afshar-Kharghan V. Platelets increase the proliferation of ovarian cancer cells. Blood 120(24):4869-72, 2012. e-Pub 2012. PMID: 22966171.
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 127(3):538-43, 2012. e-Pub 2012. PMID: 22922531.
Kloc M, Tejpal N, Sidhu J, Ganachari M, Flores-Villanueva P, Jennings NB, Sood AK, Kubiak JZ, Ghobrial RM. Inverse relationship between TCTP/RhoA and p53 /cyclin A/actin expression in ovarian cancer cells. Folia Histochem Cytobiol 50(3):358-67, 2012. e-Pub 2012. PMID: 23042265.
Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, Roh J, Han HD, Lopez-Berestein G, Ali-Fehmi R. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol 43(10):1638-44, 2012. e-Pub 2012. PMID: 22436627.
Clevenger L, Schrepf A, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Penedo F, Lubaroff DM, Sood AK, Lutgendorf SK. Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. Brain Behav Immun 26(7):1037-44, 2012. e-Pub 2012. PMID: 22543257.
Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 127(1):70-4, 2012. e-Pub 2012. PMID: 22710075.
Matsuo K, Sheridan TB, Yoshino K, Miyake T, Hew KE, Im DD, Rosenshein NB, Mabuchi S, Enomoto T, Kimura T, Sood AK, Roman LD. Significance of lymphovascular space invasion in epithelial ovarian cancer. Cancer Med 1(2):156-64, 2012. e-Pub 2012. PMID: 23342265.
Kloc M, Tejpal N, Sidhu J, Ganachari M, Flores-Villanueva P, Jennings NB, Sood AK, Kubiak JZ, Ghobrial RM. Inverse relationship between TCTP/RhoA and p53/cyclin A/actin expression in ovarian cancer cells. Folia Histochemica Et Cytobiologica 50(3):358-67, 2012. e-Pub 2012.
Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics 13(13):1523-35, 2012. e-Pub 2012. PMID: 23057551.
Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33(10):1843-53, 2012. e-Pub 2012. PMID: 22581827.
You J, Zhang R, Xiong C, Zhong M, Melancon M, Gupta S, Nick AM, Sood AK, Li C. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res 72(18):4777-86, 2012. e-Pub 2012. PMID: 22865457.
Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther 13(11):1034-41, 2012. e-Pub 2012. PMID: 22895067.
Zhou HY, Chen SR, Byun HS, Chen H, Li L, Han HD, Lopez-Berestein G, Sood AK, Pan HL. N-methyl-D-aspartate receptor- and calpain-mediated proteolytic cleavage of K+-Cl- cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain. J Biol Chem 287(40):33853-64, 2012. e-Pub 2012. PMID: 22854961.
Lee SJ, Ghosh SC, Han HD, Stone RL, Bottsford-Miller J, Shen de Y, Auzenne EJ, Lopez-Araujo A, Lu C, Nishimura M, Pecot CV, Zand B, Thanapprapasr D, Jennings NB, Kang Y, Huang J, Hu W, Klostergaard J, Sood AK. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin Cancer Res 18(15):4114-4121, 2012. e-Pub 2012. PMID: 22693353.
Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126(1):47-53, 2012. e-Pub 2012. PMID: 22487539.
Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous carcinoma of the ovary using a two-tier grading system: A Gynecologic Oncology Group study. Cancer 118(12):3087-94, 2012. e-Pub 2012. PMID: 22072418.
Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol 125(3):640-645, 2012. e-Pub 2012. PMID: 22387451.
Schmeler KM, Sood AK, Bell-McGuinn KM, Coleman RL, Frumovitz M, Sonoda Y, Ramirez PT, Gershenson DM, Barakat RR, Gardner GJ. Proceedings from the 9th International Conference on Ovarian Cancer. Gynecol Oncol 125(1):5-7, 2012. e-Pub 2012. PMID: 22210309.
Berger JL, Westin SN, Fellman B, Rallapali V, Frumovitz M, Ramirez PT, Sood AK, Soliman PT. Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: An analysis of surgical outcomes. Gynecol Oncol 125(1):252-255, 2012. e-Pub 2012. PMID: 22166844.
Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 2012. e-Pub 2012. PMID: 22966490.
Frumovitz M, Kriseman ML, Sun CC, Blumenthal-Barby J, Sood AK, Bodurka DC, Soliman PT. Unverifiable accomplishments and publications on applications for gynecologic oncology fellowships. Obstet Gynecol 119(3):504-8, 2012. e-Pub 2012. PMID: 22353948.
Li L, Cao XH, Chen SR, Han HD, Lopez-Berestein G, Sood AK, Pan HL. Up-regulation of Cavβ3 subunit in primary sensory neurons increases voltage-activated Ca2+ channel activity and nociceptive input in neuropathic pain. J Biol Chem 287(8):6002-13, 2012. e-Pub 2012. PMID: 22187436.
Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366(7):610-618, 2012. e-Pub 2012. PMID: 22335738.
Wu SY, Sood AK. New roles opined for OPCML. Cancer Discov 2(2):115-6, 2012. e-Pub 2012. PMID: 22585855.
Frumovitz M, Kriseman ML, Sun CC, Blumenthal-Barby J, Bodurka DC, Sood AK, Soliman PT. Unverifiable academic accomplishments and publications on applications for gynecologic oncology fellowships. Obstetrics & Gynecology, 2012. e-Pub 2012.
Liu Y, Sun Y, Broaddus R, Liu J, Sood AK, Shmulevich I, Zhang W. Integrated analysis of gene expression profile and tumor nuclear images associated with chemotherapy response in serous ovarian adenocarcinoma. PLoS One 7(5):e36383, 2012. e-Pub 2012.
Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann M. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors (2012). Clinical Cancer Research 18(24):6648-6657, 2012. e-Pub 2012.
You J, Zhang R, Zhang G, Zhong M, Liu Y, Van Pelt CS, Liang D, Wei W, Sood AK, Li C. Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: A platform for near-infrared light-triggered drug release. Journal of Controlled Release 158:319-328, 2012. e-Pub 2012.
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh K, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) study. . Gynecologic Oncology 127:538-543, 2012. e-Pub 2012.
Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, Bitar BS, Roh J, Han HD, Lopez-Berestein G, Ali-Fehmi R. Clinical and biological relevance of EZH2 in triple negative breast cancer. Human Pathology 43(10):1638-1644, 2012. e-Pub 2012.
J-P G, Calcagno AM, Varma S, Davidson B, Elstrand MB, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM. Multidrug resistance-linked gene signature predicts overall survival of patients with ovarian primary serous carcinoma. Clinical Cancer Research 18(11):3197-3206, 2012. e-Pub 2012.
Lutgendorf SK, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Zimmerman MB, Penedo FJ, Lucci JA, Ganjei-Azar P, Thaker PH, Mendez L, Lubaroff DM, Slavich GM, Cole S, Sood AK. Social influences on clinical outcome of ovarian cancer patients. Journal of Clinical Oncology 30(23):2885-2890, 2012. e-Pub 2012.
Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: Role of inflammatory signaling. PLoS One 7(8):e42324, 2012. e-Pub 2012. PMID: 22870317.
Wu CC, Yang TY, Yu CTR, Phan L, Ivan C, Sood AK, Hsu SL, Lee MH. P53 negatively regulates Aurora-A via transcriptional and post-translational regulation. Cell Cycle 11(18):3433-3442, 2012. e-Pub 2012.
Matsuo K, Sheridan TB, Yoshiro K, Miyake T, Hew KE, Im DD, Rosenshein NB, Mabuchi S, Enomoto T, Kimura T, Sood AK, Roman LD. Significance of lymphovascular invasion in epithelial ovarian cancer. Cancer Medicine 1(2):156-164, 2012. e-Pub 2012.
Cho MS, Bottsford-Miller J, Vasquez HG, Stone RL, Zand B, Kroll M, Sood AK, Afshar-Kharghan V. Platelets increase the proliferation of ovarian cancer cells in vitro and in vivo. Blood 120(2):4869-4872, 2012. e-Pub 2012.
Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology 127(1):70-74, 2012. e-Pub 2012.
Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, Liang S, Tanyi JL, Sood AK, Zhang L. Genomic DNA copy-number alterations of the let-7 family in human cancers. PLoS One 7(9):e44399, 2012. e-Pub 2012. PMID: 22970210.
You J, Zhang R, Xiong C, Zhong M, Melancon M, Gupta S, Nick AM, Sood AK, Li C. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Research 72(18):4777-4786, 2012. e-Pub 2012.
Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One 7(7):e41171, 2012. e-Pub 2012. PMID: 22911754.
You J, Zhang R, Zhang GD, Zhong M, Van Pelt CS, Sood AK, Li C. Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: A platform for laser-triggered drug release with low systemic toxicity. Journal of Controlled Release 158:319-328, 2012. e-Pub 2012.
Liu Y, Sun Y, Broaddus R, Liu J, Sood AK, Shmulevich I, Zhang W. Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma. PLoS One 7(5):e36383, 2012. e-Pub 2012. PMID: 22590536.
Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res 14(4):R108, 2012. e-Pub 2012. PMID: 22812534.
Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AK. A novel platform for detection of CK+ and CK- CTCs. Cancer Discov 1(7):580-6, 2011. e-Pub 2011. PMID: 22180853.
Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Silencing of p130Cas in ovarian carcinoma: A novel mechanism for tumor cell death. J Natl Cancer Inst 103(21):1596-612, 2011. e-Pub 2011. PMID: 21957230.
Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 12(12):1109-17, 2011. e-Pub 2011. PMID: 21992853.
Gillet JP, Calcagno AM, Varma S, Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proceedings of the National Academy of Sciences 108(46):18708-13, 2011. e-Pub 2011. PMID: 22068913.
Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LM. Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine Tumors. Gastroenterology 141(5):1728-37, 2011. e-Pub 2011. PMID: 21806944.
Matsuo K, Ahn EH, Bond VK, Im DD, Rosenshein NB, Sood AK. Multi-drug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian, and peritoneal cancer. American Journal of Clinical Oncology 5:488-93, 2011. e-Pub 2011. PMID: 20921883.
Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Journal of the American Medical Association 306(14):1557-65, 2011. e-Pub 2011. PMID: 21990299.
Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11(10):719-25, 2011. e-Pub 2011. PMID: 21941283.
Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of the delta family notch ligand dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 71(18):6030-9, 2011. e-Pub 2011. PMID: 21795478.
Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res 17(17):5674-85, 2011. e-Pub 2011. PMID: 21753153.
Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK. Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res 17(16):5367-78, 2011. e-Pub 2011. PMID: 21737505.
Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol 8(8):467-77, 2011. e-Pub 2011. PMID: 21647195.
Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645-52, 2011. e-Pub 2011. PMID: 21632501.
Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AK. Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res 17(11):3649-59, 2011. e-Pub 2011. PMID: 21531818.
Research Network TCGA. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609-15, 2011. e-Pub 2011. PMID: 21720365.
Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing surviving splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer 17(11):3716-26, 2011. e-Pub 2011. PMID: 21512144.
Han HD, Mora EM, Roh JW, Nishimura M, Lee SJ, Stone RL, Bar-Eli M, Lopez-Berestein G, Sood AK. Chitosan hydrogel for localized gene silencing. Cancer Biology & Therapy 11(9):839-45, 2011. e-Pub 2011. PMID: 21358280.
Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 13(5):393-405, 2011. e-Pub 2011. PMID: 21532880.
Rodriguez H, Torres-Lugo M, Rinaldi-Ramos C, Mendez J, Lee J, Sood AK, Lopez-Berestein G. Enhanced synergism in human colon cancer cells between magnetic fluid hyperthermia and the anticancer drug cis-diamminedichloroplatinum. Nano Letters 5:4153-7, 2011. e-Pub 2011. PMID: 21780419.
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase Ib-IIa study to reverse platinum resistance by the use of a hypomethylating agent azacitidine in platinum-resistant or refractory epithelial ovarian cancer. Cancer 117(8):1661-9, 2011. e-Pub 2011. PMID: 21472713.
Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 17(7):1713-21, 2011. e-Pub 2011. PMID: 21300758.
Chakravarty D, Roy SS, Babu CR, Dandamudi R, Vivas-Mejia P, Curiel TJ, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res 17(8):2250-9, 2011. e-Pub 2011. PMID: 21421858.
Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez-Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AK. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 13(4):309-19, 2011. e-Pub 2011. PMID: 21472135.
Lamkin DM, Lutgendorf SK, Lubaroff D, Sood AK, Beltz TG, Johnson AK. Cancer induces inflammation and depressive-like behavior in the mouse: Modulation by social housing. Brain Behav Immun 25(3):555-64, 2011. e-Pub 2011. PMID: 21182930.
Wang E, Bhattacharya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One 6(3):1-9, 2011. e-Pub 2011. PMID: 21445297.
Lutgendorf SK, DeGeest K, Dahmoush L, Farley D, Penedo F, Bender D, Goodheart M, Buekers TE, Mendez L, Krueger G, Clevenger L, Lubaroff DM, Sood AK, Cole SW. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun 25(2):250-5, 2011. e-Pub 2011. PMID: 20955777.
Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK. Clinical and Biological Impact of EphA2 Overexpression and Angiogenesis in Endometrial Cancer. Cancer Biol Ther 10(12):1306-14, 2011. e-Pub 2011. PMID: 20948320.
Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK, Levenson V. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol 120(1):113-20, 2011. e-Pub 2011. PMID: 21056906.
Pecot CV, Bischoff FZ, Mayer JA, Wong K, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AK. Novel platform for detection of CK+ and CK-CTCs. Cancer Discovery 1(7):580-586, 2011. e-Pub 2011.
Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Rodriguez-Aguayo C, Lopez-Berestein G, Plowman G, Bagri A, Sood AK, Ellis LM. Neuropilin-2 mediated β-catenin signaling and survival in human gastrointestinal cancer cell lines. PLoS One 6(10):e23208, 2011. e-Pub 2011. PMID: 22028766.
Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 6(7):e21121, 2011. e-Pub 2011. PMID: 21754983.
Liggett T, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK, Levenson V. Unique cell-free plasma DNA methylation patterns in women with malignant ovarian tumors. Gynecologic Oncology 120:113-120, 2011. e-Pub 2011.
Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9(12):3186-99, 2010. e-Pub 2010. PMID: 20889728.
Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, Levenback CF, Munsell MF, Jung M, Wolf JK. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer 116(21):4973-9, 2010. e-Pub 2010. PMID: 20665499.
Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. Stress effects on FosB and interleukin-8 (IL-8) driven ovarian cancer growth and metastasis. J Biol Chem 285(46):35462-70, 2010. e-Pub 2010. PMID: 20826776.
Lutgendorf SK, Mullen-Houser E, Russell D, Degeest K, Jacobson G, Hart L, Bender D, Anderson B, Buekers TE, Goodheart MJ, Antoni MH, Sood AK, Lubaroff DM. Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun 24(8):1231-40, 2010. e-Pub 2010. PMID: 20600809.
Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs 19(11):1339-54, 2010. e-Pub 2010. PMID: 20815774.
Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik A. Suppression of relaxin receptor decreases prostate cancer growth and metastasis. Endocrine Related Cancer 17(4):1021-33, 2010. e-Pub 2010. PMID: 20861284.
Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70(18):7042-52, 2010. e-Pub 2010. PMID: 20823155.
Weinrib AZ, Sephton SE, Degeest K, Penedo F, Bender D, Zimmerman B, Kirschbaum C, Sood AK, Lubaroff DM, Lutgendorf SK. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer 116(18):4410-9, 2010. e-Pub 2010. PMID: 20564155.
Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 16(15):3910-22, 2010. e-Pub 2010. PMID: 20538762.
Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18(2):185-97, 2010. e-Pub 2010. PMID: 20708159.
Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Study Group AOC, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18(2):109-21, 2010. e-Pub 2010. PMID: 20708153.
Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 9(8):2377-88, 2010. e-Pub 2010. PMID: 20682653.
Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol 116(2 Pt 1):269-73, 2010. e-Pub 2010. PMID: 20664385.
Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol 117(3):491-6, 2010. e-Pub 2010. PMID: 20332054.
Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 120(5):1515-1523, 2010. e-Pub 2010. PMID: 20389021.
Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 70(9):3687-96, 2010. e-Pub 2010. PMID: 20430760.
Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 16(9):2562-70, 2010. e-Pub 2010. PMID: 20388851.
Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer 116(8):1918-25, 2010. e-Pub 2010. PMID: 20166213.
Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9(4):985-95, 2010. e-Pub 2010. PMID: 20371710.
Cole SW, Arevalo JM, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, Sheridan JF, Seeman TE. Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A 107(12):5681-6, 2010. e-Pub 2010. PMID: 20176930.
Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16(4):1119-1128, 2010. e-Pub 2010. PMID: 20145172.
Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz M, Bodurka DC, Sood AK. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer 116(3):625-30, 2010. e-Pub 2010. PMID: 20052724.
Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 9(3):176-82, 2010. e-Pub 2010. PMID: 20009575.
Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res 16(1):184-94, 2010. e-Pub 2010. PMID: 20028751.
Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol 116(1):61-5, 2010. e-Pub 2010. PMID: 19840886.
Mann AP, Somasunderam A, Nieves-Alicea R, Li X, Hu A, Sood AK, Ferrari M, Gorenstein DG, Tanaka T. Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One 5(9), 2010. e-Pub 2010. PMID: 20927342.
Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves RA, Mann AP, Mora E, H-D H, Shahzad MMK, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin, Stone RL, Nick AM, Lopez-Berestein G, Sood AK. Sustained siRNA delivery by porous silicon particles for cancer treatment. Cancer Research 70(9):3687-3696, 2010. e-Pub 2010.
Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz M, Bodurka DC, Sood AK. Pelvic fractures following radiation therapy for cervical cancer: Implications for survivors 116(3):625-630, 2010. e-Pub 2010.
Mann A, Somasunderam A, Nieves-Alicea R, Li X, Hu A, Sood AK, Ferrari M, Gorenstein D, Tanaka T. A novel antagonistic thioaptamer ligand against E-selectin. PLoS One 5(9):e13050, 2010. e-Pub 2010.
Cole SW, Arevalo JM, Sung CY, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, Sheridan JF, Seeman TE. Computational modeling of gene-environment interaction identifies the human IL6 locus as a genetic moderator of socio-environmental mortality risk. Proceedings of the National Academy of Sciences 107(12):5681-5686, 2010. e-Pub 2010.
Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan B, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. Plasma cell-free DNA in ovarian cancer: An independent predictive biomarker of clinical outcome. Cancer 116:1918-1925, 2010. e-Pub 2010.
Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK. Combined anti-angiogenic therapy against VEGF and integrin alpha(V)beta(3) in an orthotopic model of ovarian cancer. Cancer Biol Ther 8(23):2261-70, 2009. e-Pub 2009. PMID: 19829059.
Cai YQ, Chen SR, Han HD, Sood AK, Lopez-Berestein G, Pan HL. Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats. J Neurochem 111(4):1000-10, 2009. e-Pub 2009. PMID: 19780895.
Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 114(3):431-6, 2009. e-Pub 2009. PMID: 19524286.
Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 immunoconjugate a molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 101(17):1193-1205, 2009. e-Pub 2009. PMID: 19641174.
Shinn EH, Taylor CL, Kilgore K, Valentine A, Bodurka DC, Kavanagh J, Sood A, Li Y, Basen-Engquist K. Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients. Palliat Support Care 7(3):299-306, 2009. e-Pub 2009. PMID: 19788771.
Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic Properties of Metronomic Topotecan in Ovarian Carcinoma. Cancer Biol Ther 8(16):1596-603, 2009. e-Pub 2009. PMID: 19738426.
Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48-52, 2009. e-Pub 2009. PMID: 19361839.
Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK. EphA2 Overexpression is Associated with Lack of Hormone Receptor Expression and Poor Outcome in Endometrial Cancer. Cancer 115(12):2684-92, 2009. e-Pub 2009. PMID: 19396818.
Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 15(11):3770-80, 2009. e-Pub 2009. PMID: 19470734.
Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma. Future Oncol 5(5):591-600, 2009. e-Pub 2009. PMID: 19519199.
Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 8(11):1027-1034, 2009. e-Pub 2009. PMID: 19395869.
Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AK. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res 15(9):2971-8, 2009. e-Pub 2009. PMID: 19383821.
Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 15(8):2695-702, 2009. e-Pub 2009. PMID: 19351748.
Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM. Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted?. Gynecol Oncol 113(1):86-90, 2009. e-Pub 2009. PMID: 19162310.
Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 124(5):1045-53, 2009. e-Pub 2009. PMID: 19058181.
Lamkin DM, Spitz DR, Zimmerman B, Lenihan, DeGeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK. Glucose as a prognostic factor in ovarian carcinoma. Cancer 115(5):1021-7, 2009. e-Pub 2009. PMID: 19156916.
Lutgendorf SK, McGinn S, Sung CY, Arevalo JM, DeGeest K, Penedo F, Lucci J, Lubaroff, Sood AK, Cole SW. Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun 23(2):176-83, 2009. e-Pub 2009. PMID: 18550328.
Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CD. The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One 4(10):e7502, 2009. e-Pub 2009. PMID: 19847298.
Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous carcinoma of the ovary is relatively chemoresistant. Gynecologic Oncology 114(1):48-52, 2009. e-Pub 2009.
Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 14(24):8143-51, 2008. e-Pub 2008. PMID: 19088029.
Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2641-50, 2008. e-Pub 2008. PMID: 19092150.
Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli M. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 68(21):9078-86, 2008. e-Pub 2008. PMID: 18974154.
Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, DeGeest K, Langley RR, Lucci JA, Cole SW, Lubaroff DM, Sood AK. Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res 14(21):6839-46, 2008. e-Pub 2008. PMID: 18980978.
Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennings NB, Kinch MS, Tice D, Sood AK. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10(11):1259-67, 2008. e-Pub 2008. PMID: 18953435.
Nick AM, Sood AK. The ROC 'n' role of the multiplex assay for early detection of ovarian cancer. Nat Clin Pract Oncol 5(10):568-9, 2008. e-Pub 2008. PMID: 18695710.
Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 14(17):5437-46, 2008. e-Pub 2008. PMID: 18765535.
Lutgendorf SK, Lamkin DM, DeGeest K, Anderson B, Dao M, McGinn S, Zimmerman B, Maiseri H, Sood AK, Lubaroff DM. Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun 22(6):890-900, 2008. e-Pub 2008. PMID: 18276105.
Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 68(14):5849-58, 2008. e-Pub 2008. PMID: 18632639.
Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, Sood AK. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 7(7):1098-103, 2008. e-Pub 2008. PMID: 18443431.
Sood AK, Birrer MJ. Highlights from the 2008 Annual Meeting of the American Association for Cancer Research. Gynecol Oncol 110(1):5-6, 2008. e-Pub 2008. PMID: 18595162.
Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 14(11):3372-9, 2008. e-Pub 2008. PMID: 18519766.
Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 198(4):477.e1-9; discussion 477.e9-10, 2008. e-Pub 2008. PMID: 18395047.
Lamkin DM, Lutgendorf SK, McGinn S, Dao M, Maiseri H, DeGeest K, Sood AK, Lubaroff DM. Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun 22(1):65-73, 2008. e-Pub 2008. PMID: 17643954.
X-F L, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC. Specific blockade of VEGF and HER2 pathways results in additive inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 7(23):3747-3758, 2008. e-Pub 2008.
Villares GJ, Zigler M, Wang H, Wu H, Melnikova VO, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli. Targeting melanoma growth and metastasis with liposomal incorporated PAR-1 siRNA. Cancer Research 68(21):9078-9086, 2008. e-Pub 2008.
Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES. Lyn activation contributes to the growth and metastasis of Ewing’s sarcoma. Molecular Cancer Therapeutics 7(7):1807-16, 2008. e-Pub 2008.
Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 7(23):3747-58, 2008. e-Pub 2008. PMID: 19029832.
Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. In vivo therapeutic targeting of the transcriptional regulator inhibitor of DNA-binding (Id2) by siRNA reduces tumor growth and survival of human colorectal carcinoma cells in the liver. Oncogene 27:7192-7200, 2008. e-Pub 2008.
Han LY, Fletcher MS, Deavers MT, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth W, DeGeest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK. HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clinical Cancer Research 14(11):3372-3379, 2008. e-Pub 2008.
Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DD. The previously un-described ZKSCAN3 (ZNF306) is a novel “driver” of colorectal cancer progression. Cancer Research 68(11):4321-30, 2008. e-Pub 2008.
Lutgendorf SK, Weinrib A, Penedo F, Costanzo E, Henderson P, DeGeest K, Russell D, Kirschbaum C, Sephton S, Sood AK, Lubaroff DM. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 26(29):4820-7, 2008. e-Pub 2008. PMID: 18779606.
Lutgendorf SK, Lamkin DM, Jennings NB, Penedo F, DeGeest K, Langley RR, Lucci JA, Cole S, Lubaroff DM, Sood AK. Behavioral influences on MMP expression in ovarian cancer. Clinical Cancer Research 14(21):6839-6846, 2008. e-Pub 2008.
Guan H, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES. Lyn activation contributes to the growth and metastasis of Ewing's sarcoma. Molecular Cancer Therapeutics 7(7):1807-16, 2008. e-Pub 2008.
Ren W, Korchin B, Lahat G, Wei, C, Bolshakov S, Nguyen T, Merritt WM, Dicker A, Lazar A, Sood AK, Pollock RE, Lev D. Combined VEGFR/EGFR blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clinical Cancer Research 14(17):5466-5475, 2008. e-Pub 2008.
Gray MJ, Van Buren G, Dallas NA, Xia L, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CL, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of neuropilin-2 by siRNA reduces in vivo tumor progression in colorectal carcinoma cells in a murine orthotopic model. Journal of the National Cancer Institute 100:109-120 (Published with commentary by M. Narazake, M. Segarra, a, 2008. e-Pub 2008.
Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley R, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on anti-angiogenic therapy in ovarian cancer. Am J Obstet Gynecol 198:477.e1-744.e10, 2008. e-Pub 2008.
Lamkin DM, Lutgendorf SK, McGinn S, Dao M, Maiseri H, Degeest K, Sood AK, Lubaroff DM. Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun[Epub ahead of print] 22:65-73, 2008. e-Pub 2008.
Landen CN, Birrer MJ, Sood AK. Early genetic events in the pathogenesis of epithelial ovarian cancer. J Clin Onc 26(6):995-1005, 2008. e-Pub 2008.
Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene 27(57):7192-200, 2008. e-Pub 2008. PMID: 18806828.
Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, DeGeest K, Langley R, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK. Effects of IL-8 targeted therapy with liposome incorporated siRNA on ovarian cancer growth. J Natl Cancer Inst 100:359-372, 2008. e-Pub 2008.
Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan, Mehta K. Inhibition of tissue transglutaminase promotes gemcitabine efficacy and blocks pancreatic cancer growth and metastasis in mice. Clin Cancer Res 14(8):2476-2483, 2008. e-Pub 2008.
Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Shavrin A, Qin C, Maxwell D, Ma J, Trent J, Lin YG, Gelovani J, Bornmann W, Sood AK, Lopez-Berestein G. Curbing cardiotoxicity of anti-cancer drug imatinib through rational molecular re-engineering: From in silico design to animal model. J Clinl Invest 117(12):4044-4054, 2007. e-Pub 2007.
Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67(22):10976-83, 2007. e-Pub 2007. PMID: 18006843.
Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 282(41):29919-26, 2007. e-Pub 2007. PMID: 17716980.
Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt W, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK. Anti-tumor and anti-vascular effects of AVE8062 in ovarian carcinoma. Cancer Research 67(19):9337-45, 2007. e-Pub 2007. PMID: 17909042.
Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Arevalo J, Lutgendorf SK, Gallick GG, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate IL-6 expression by ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 282(41):29919-29926, 2007. e-Pub 2007.
Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 13:4209-17, 2007. e-Pub 2007. PMID: 17634550.
Landen CN, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson DM, Brinkley WR, Sood AK. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 13:4098-104, 2007. e-Pub 2007. PMID: 17634535.
Zhang W, Yang D, Sood AK. Exploring clinical and molecular differences between BRCA1 and BRCA2 mutations in serous ovarian carcinoma. Journal of the American Medical Association 56(5):601-5, 2007. e-Pub 2007.
Spannuth WA, Thaker PH, Sood AK. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer. American Journal of Obstetrics and Gynecology 196(4):e6-e9, 2007. e-Pub 2007. PMID: 17403394.
Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 96:1083-91, 2007. e-Pub 2007. PMID: 17353927.
Milam MR, Sood AK, King S, Bassett RL, Lu KH, Slomovitz BM, Coleman RL, Ramirez PT. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol 109(3):641-6, 2007. e-Pub 2007. PMID: 17329515.
Frumovitz M, Sood AK. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol 104(3):768-78, 2007. e-Pub 2007. PMID: 17306693.
Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67(4):1757-68, 2007. e-Pub 2007. PMID: 17308118.
Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67(1):281-8, 2007. e-Pub 2007. PMID: 17210709.
Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109:332-40, 2007. e-Pub 2007. PMID: 17154180.
Frumovitz M, Bodurka DC, Broaddus RR, Coleman RL, Sood AK, Gershenson DM, Burke TW, Levenback CF. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol 104:100-3, 2007. e-Pub 2007. PMID: 16963111.
Kamat AA, Merritt WM, Coffey D, Lin YG, Broaddus R, Nugent E, Han LY, Patel PR, Landen CN, Spannuth W, Coleman RL, Gershenson DM, Sood AK. Clinical and biological significance of vascular endothelial growth factor (VEGF) in endometrial cancer. Clin Cancer Res 13(24):7487-7495, 2007. e-Pub 2007.
Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Kamat AA, Armaiz-Pena GN, Spannuth WA, Gershenson DM, Aggarwal BB, Sood AK. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the NF-КB pathway. Clin Cancer Res (*Cover Illustration) 13:3423-30, 2007. e-Pub 2007. PMID: 17545551.
Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Sood AK. Therapeutic efficacy of a novel FAK inhibitor TAE226 in ovarian carcinoma. Cancer Res 67(*Highlighted in Nature Reviews Cancer)(22):10976-10983, 2007. e-Pub 2007.
Landen CN, Lin YG, Das P, Arevalo JMG, Kamat AA, Han LY, Jennings NB, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Neuroendocrine modulation of STAT3 in ovarian cancer. Cancer Res 67(21):10389-10396, 2007. e-Pub 2007. PMID: 17974982.
Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS. The receptor tyrosine kinase EphB4 is over-expressed in ovarian cancer, provides survival signals and predicts poor outcome. British Journal of Cancer 96:1083-1091, 2007. e-Pub 2007.
Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal Delivery of Liposomal siRNA for Therapy of Advanced Ovarian Cancer. Cancer Biol Ther 5:1708-13, 2006. e-Pub 2006. PMID: 17106249.
Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, Lemeshow S, Glaser R. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66:10357-64, 2006. e-Pub 2006. PMID: 17079456.
Landen CN, Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 98:1558-70, 2006. e-Pub 2006. PMID: 17077358.
Merritt WM, Thaker PH, Landen CN, Jr, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK. Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther 5:1357-60, 2006. e-Pub 2006. PMID: 16969087.
Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN, Jr, Lu C, Gershenson DM, Simpson JL, Sood AK. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 5:1369-74, 2006. e-Pub 2006. PMID: 16969071.
Sood AK. Second look laparotomy for ovarian germ cell tumors: to do or not to do?. J Postgrad Med 52(4):246-7, 2006. e-Pub 2006. PMID: 17191357.
Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Ann N Y Acad Sci 1075:230-4, 2006. e-Pub 2006. PMID: 17108216.
Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther 5(9):1136-41, 2006. e-Pub 2006. PMID: 16855388.
Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA, rd, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 66:8633-9, 2006. e-Pub 2006. PMID: 16951177.
Halder J, Kamat AA, Landen CN, Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12:4916-24, 2006. e-Pub 2006. PMID: 16914580.
Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108:361-8, 2006. e-Pub 2006. PMID: 16880307.
Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939-44, 2006. e-Pub 2006. PMID: 16862152.
Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB, Reinthaller A. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 103(2):512-517, 2006. e-Pub 2006. PMID: 16750560.
Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN, Jr, Han L, Gershenson DM, Sood AK. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 12:1707-14, 2006. e-Pub 2006. PMID: 16551853.
Han LY, Landen CN, Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 24:755-61, 2006. e-Pub 2006. PMID: 16380413.
Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12(2):369-75, 2006. e-Pub 2006. PMID: 16428474.
Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI. The role of relaxin in endometrial cancer. Cancer Biol Ther 5:71-7, 2006. e-Pub 2006. PMID: 16322684.
Rose SL, Bunten CE, Geisler JP, Sood AK, Sorosky JI. Mesh erosion into the bowel and vagina following abdominal sacral colpopexy: A case-report. Journal of Pelvic Medicine & Surgery 12(1):45-48, 2006. e-Pub 2006.
Han LY, Landen CN, Trevino JG, Kamat AA, T-J K, Merritt WM, Lin YG, Sawyer TK, Shakespeare WC, Coleman RL, Gershenson DM, Gallick GE, Sood AK. Anti-angiogenic and anti-tumor effects of Src inhibition in ovarian carcinoma. Cancer Research 66(17):8633-8639, 2006. e-Pub 2006.
Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker PH, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK. Efficacy and anti-vascular mechanisms of EphA2 downregulation with agonistic antibodies in ovarian cancer. Journal of the National Cancer Institute 98(21):1558-1570, 2006. e-Pub 2006.
Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Heinze G, Six L, Sliutz G, Tempfer CB, Reinthaller A. The clinical value of preoperative vascular endothelial growth factor in ovarian cancer: A multicenter study. Gynecologic Oncology 103(2):512-517, 2006. e-Pub 2006.
Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI. Relaxin promotes migration and invasion of endometrial cancer. Cancer Biology & Therapy 5(1):71-77, 2006. e-Pub 2006.
Halder J, Landen CN, Jr, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AK. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 11(24 Pt 1):8829-36, 2005. e-Pub 2005. PMID: 16361572.
Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65(22):10602-12, 2005. e-Pub 2005. PMID: 16288054.
Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol 23(28):7105-13, 2005. e-Pub 2005. PMID: 16192594.
Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11(19 Pt 1):6966-71, 2005. e-Pub 2005. PMID: 16203789.
Landen CN, Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65(15):6910-8, 2005. e-Pub 2005. PMID: 16061675.
Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 104(2):305-13, 2005. e-Pub 2005. PMID: 15954082.
Thaker PH, Yokoi K, Jennings NB, Li Y, Rebhun RB, Rousseau DL, Jr, Fan D, Sood AK. Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist nembutal. Cancer Biol Ther 4(7):753-8, 2005. e-Pub 2005. PMID: 15970706.
Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 11(13):4923-33, 2005. e-Pub 2005. PMID: 16000591.
Sood AK, Coleman RL, Wolf JK, Gershenson DM. Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. Expert Opin Pharmacother 6(7):1269-75, 2005. e-Pub 2005. PMID: 15957979.
Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM. Fifth International Conference on Ovarian Cancer: challenges and opportunities. Gynecol Oncol 97(3):916-23, 2005. e-Pub 2005. PMID: 15907981.
Sood AK, Cooper BC, Sorosky JI, Ramirez PT, Levenback C. Novel modification of the vertical rectus abdominis myocutaneous flap for neovagina creation. Obstet Gynecol 105(3):514-8, 2005. e-Pub 2005. PMID: 15738017.
Sood AK, Cooper BC, Sorosky JI, Ramirez PT, Levenback C. Novel modification of the vertical rectus abdominis myocutaneous (VRAM) flap for neovagina creation. Obstetrics and Gynecology 105:514-518, 2005. e-Pub 2005.
Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. VEGF Trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clinical Cancer Research 11:6966-6971, 2005. e-Pub 2005.
Landen CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting by in vivo liposomal siRNA delivery. Cancer Research 65(15):6910-6918, 2005. e-Pub 2005.
Landen CN, Klingelhutz A, Coffin JE, Sorosky JI, Sood AK. Genomic instability is associated with lack of telomerase activation in ovarian cancer. Cancer Biol Ther 3(12):1250-3, 2004. e-Pub 2004. PMID: 15477760.
Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 165(4):1087-95, 2004. e-Pub 2004. PMID: 15466376.
Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res 10(18 Pt 1):6080-5, 2004. e-Pub 2004. PMID: 15447993.
Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10(15):5145-50, 2004. e-Pub 2004. PMID: 15297418.
Frausto SD, Geisler JP, Fletcher MS, Sood AK. Late recurrence of juvenile granulosa cell tumor of the ovary. Am J Obstet Gynecol 191(1):366-7, 2004. e-Pub 2004. PMID: 15295395.
Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM, Hendrix MJ. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 190(4):899-909, 2004. e-Pub 2004. PMID: 15118611.
Eichholz AC, Van Voorhis BJ, Sorosky JI, Smith BJ, Sood AK. Operative note dictation: should it be taught routinely in residency programs?. Obstet Gynecol 103(2):342-6, 2004. e-Pub 2004. PMID: 14754706.
Hsu Y, Sood AK, Sorosky JI. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol 27(1):14-8, 2004. e-Pub 2004. PMID: 14758127.
Lowe MP, Cooper BC, Sood AK, Davis WA, Syrop CH, Sorosky JI. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol 91(3):569-72, 2003. e-Pub 2003. PMID: 14675678.
Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer 98(10):2199-206, 2003. e-Pub 2003. PMID: 14601090.
Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Rainwater K, Ritchie JM, Yang M, Sood AK. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 9(12):4514-21, 2003. e-Pub 2003. PMID: 14555525.
Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J Clin Oncol 21(15):2856-9, 2003. e-Pub 2003. PMID: 12885801.
Bender DP, Sorosky JI, Buller RE, Sood AK. Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma. Am J Obstet Gynecol 189(1):113-7, 2003. e-Pub 2003. PMID: 12861147.
Chun ML, Buekers TE, Sood AK, Sorosky JI. Postoperative wound infection with Pasteurella multocida from a pet cat. Am J Obstet Gynecol 188(4):1115-6, 2003. e-Pub 2003. PMID: 12712125.
Eichholz AC, Geisler JP, Sood AK. Metastatic breast cancer to the uterus and cervix. Journal of Gynecologic Surgery 19(3):145-148, 2003. e-Pub 2003.
Chun ML, Buekers TE, Sood AK, Sorosky, JI. Postoperative wound infection with Pasteurella multocida from pet cats. American Journal of Obstetrics and Gynecology 188:1115-1116, 2003. e-Pub 2003.
Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman J. Phase II study of oxaliplatin in recurrent, platinum resistant and refractory ovarian cancer: A gynecologic oncology group study. Journal of Clinical Oncology 21:2856-2859, 2003. e-Pub 2003.
Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AK. In situ profiling reveals metabolic alterations in the tumor microenvironment of high-grade serous ovarian tumors after neoadjuvant chemotherapy. NPJ Precision Oncology 7:115, 2003. e-Pub 2003.
Bender D, Sorosky, JI, Buller RE, Sood AK. Serum CA-125 is an independent prognostic factor in cervical adenocarcinoma. The American Journal of Obstetrics and Gynecology 189:113-117, 2003. e-Pub 2003.
Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJ. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther 1(6):661-4, 2002. e-Pub 2002. PMID: 12642690.
Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 8(10):3193-7, 2002. e-Pub 2002. PMID: 12374688.
Sood AK, Nygaard I, Shahin MS, Sorosky JI, Lutgendorf SK, Rao SS. Anorectal dysfunction after surgical treatment for cervical cancer. J Am Coll Surg 195(4):513-9, 2002. e-Pub 2002. PMID: 12375757.
Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJ. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 8(9):2924-32, 2002. e-Pub 2002. PMID: 12231537.
Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz A. p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. Cancer Biol Ther 1:511-7, 2002. e-Pub 2002. PMID: 12496479.
Lutgendorf SK, Johnsen EL, Cooper B, Anderson B, Sorosky JI, Buller RE, Sood AK. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 95(4):808-15, 2002. e-Pub 2002. PMID: 12209725.
Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 100(1):59-64, 2002. e-Pub 2002. PMID: 12100804.
Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE. Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol 86(1):85-90, 2002. e-Pub 2002. PMID: 12079305.
Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 20(7):1832-7, 2002. e-Pub 2002. PMID: 11919241.
Lowe MP, Bender D, Sood AK, Davis W, Syrop CH, Sorosky JI. Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction. Fertil Steril 77(1):188-9, 2002. e-Pub 2002. PMID: 11779615.
Lutgendorf SK, Anderson B, Ullrich P, Johnsen EL, Buller RE, Sood AK, Sorosky JI, Ritchie J. Quality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer 94(1):131-40, 2002. e-Pub 2002. PMID: 11815969.
Lowe MP, Cooper B, Sood AK, Davis WA, Syrop CH, Sorosky JI. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Fertility & Sterility 77:188-189, 2002. e-Pub 2002.
Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J. Randomized trial of cisplatin and Ifosfamide versus cisplatin, Ifosfamide, and bleomycin in advanced squamous cell carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Journal of Clinical Oncology 20:1832-1832, 2002. e-Pub 2002.
Sood AK, Shahin MS, Sorosky JI. Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol 83(3):599-600, 2001. e-Pub 2001. PMID: 11733979.
Geisler JP, Sorosky JI, Duong HL, Buekers TE, Geisler MJ, Sood AK, Anderson B, Buller RE. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol 83(3):501-3, 2001. e-Pub 2001. PMID: 11733962.
Sood AK, Holmes R, Hendrix MJ, Buller RE. Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer. Cancer Res 61(11):4371-4, 2001. e-Pub 2001. PMID: 11389062.
Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AK. p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang. Am J Obstet Gynecol 184(5):891-902; discussion 902-3, 2001. e-Pub 2001. PMID: 11303196.
Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE, Hendrix MJ. Molecular determinants of ovarian cancer plasticity. Am J Pathol 158(4):1279-88, 2001. e-Pub 2001. PMID: 11290546.
Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky JI, Kirby PA. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res 7(4):831-8, 2001. e-Pub 2001. PMID: 11309330.
Lowe MP, Ault KA, Sood AK. Recurrent carcinoma in situ of a neovagina. Gynecol Oncol 80(3):403-4, 2001. e-Pub 2001. PMID: 11263940.
Mayr NA, Yuh WT, Arnholt JC, Ehrhardt JC, Sorosky JI, Magnotta VA, Berbaum KS, Zhen W, Paulino AC, Oberley LW, Sood AK, Buatti JM. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 12(6):1027-33, 2000. e-Pub 2000. PMID: 11105046.
Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89(9):2006-17, 2000. e-Pub 2000. PMID: 11064359.
Minassian VA, Sood AK, Lowe P, Sorosky JI, Al-Jurf AS, Buller RE. Long-term central venous access in gynecologic cancer patients. J Am Coll Surg 191(4):403-9, 2000. e-Pub 2000. PMID: 11030246.
Zhang SH, Sood AK, Sorosky JI, Anderson B, Buller RE. Preservation of the saphenous vein during inguinal lymphadenectomy decreases morbidity in patients with carcinoma of the vulva. Cancer 89(7):1520-5, 2000. e-Pub 2000. PMID: 11013366.
Lutgendorf SK, Anderson B, Rothrock N, Buller RE, Sood AK, Sorosky JI. Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer. Cancer 89(6):1402-11, 2000. e-Pub 2000. PMID: 11002237.
Sood AK, Sorosky JI, Mayr N, Anderson B, Buller RE, Niebyl J. Cervical cancer diagnosed shortly after pregnancy: prognostic variables and delivery routes. Obstet Gynecol 95(6 Pt 1):832-8, 2000. e-Pub 2000. PMID: 10831976.
Pertzborn S, Buekers TE, Sood AK. Hematogenous skin metastases from cervical cancer at primary presentation. Gynecol Oncol 76(3):416-7, 2000. e-Pub 2000. PMID: 10684721.
Harms SA, Sood AK, Shahin M, Mayr N, Sorosky JI. Bowel surgery after intraperitoneal 32P: Is it safe to perform low colorectal anastomosis?. Journal of Gynecologic Techniques 6:65-67, 2000. e-Pub 2000.
Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE. Distant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res 5(9):2485-90, 1999. e-Pub 1999. PMID: 10499623.
Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS. RESPONSE: Re: Association Between Nonrandom X-Chromosome Inactivation and BRCA1 Mutation in Germline DNA of Patients With Ovarian Cancer. J Natl Cancer Inst 91:1508-1509, 1999. e-Pub 1999. PMID: 10469756.
Sood AK, Sorosky JI, Squatrito RC, Skilling JS, Anderson B, Buller RE. Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies. Neoplasia 1(2):118-22, 1999. e-Pub 1999. PMID: 10933045.
Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS. Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Inst 91(4):339-46, 1999. e-Pub 1999. PMID: 10050867.
Hsu Y, Lallas TA, Hodges K, Sood AK, Sorosky JI. Primary ovarian leiomyoma: A case report and review of the literature. Journal of Gynecologic Surgery 15:55-59, 1999. e-Pub 1999.
Minassian V, Sood AK, Metcalf A, Anderson B, Mayr N, Buller RE. Complications related to radiotherapy for cervical cancer in a patient with Crohn's disease. Journal of Pelvic Surgery 5:36-39, 1999. e-Pub 1999.
Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, Benda JA, Morgan LS. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer 82(9):1731-7, 1998. e-Pub 1998. PMID: 9576296.
Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ. Field cancerization: why late "recurrent" ovarian cancer is not recurrent. Am J Obstet Gynecol 178(4):641-9, 1998. e-Pub 1998. PMID: 9579425.
Signore CC, Sood AK, Richards DS. Second-trimester vaginal bleeding: correlation of ultrasonographic findings with perinatal outcome. Am J Obstet Gynecol 178(2):336-40, 1998. e-Pub 1998. PMID: 9500496.
Olson JK, Sood AK, Sorosky JI, Anderson B, Buller RE. Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol 68(1):25-8, 1998. e-Pub 1998. PMID: 9454655.
Sood AK, Pardubsky PD, Gacuson M, Kumar GC, Sum Ping ST. Nasoenteric tube complications: A case report of tip displacement. Nutrition in Clinical Practice 13:40-42, 1998. e-Pub 1998.
Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 90(3):441-7, 1997. e-Pub 1997. PMID: 9277659.
Sood AK, Sorosky JI, Mayr N, Krogman S, Anderson B, Buller RE, Hussey DH. Radiotherapeutic management of cervical carcinoma that complicates pregnancy. Cancer 80(6):1073-8, 1997. e-Pub 1997. PMID: 9305707.
Rasmussen CC, Sood AK, Sorosky JI, Anderson B. Posterior exenteration through groin incision in a patient with stage III vulvar carcinoma. Gynecol Oncol 66(2):331-4, 1997. e-Pub 1997. PMID: 9264586.
Sood AK, Skilling JS, Buller RE. Ovarian cancer genomic instability correlates with p53 frameshift mutations. Cancer Res 57(6):1047-9, 1997. e-Pub 1997. PMID: 9067268.
Buller RE, Sood AK, Fullenkamp C, Sorosky J, Powills K, Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Therapy 4(4):239-245, 1997. e-Pub 1997.
Sood AK, Sorosky JI, Krogman S, Anderson B, Benda J, Buller RE. Surgical management of cervical cancer complicating pregnancy: a case-control study. Gynecol Oncol 63:294-8, 1996. e-Pub 1996. PMID: 8946861.
Sood AK, Buller RE. Genomic instability in ovarian cancer: A reassessment using arbitrarily primed polymerase chain reaction. Oncogene 13:2499-2504, 1996. e-Pub 1996. PMID: 8957095.
Sood AK, Stone IK. Myoglobinuric acute renal failure associated with the Maylard incision: A case report. Journal of Pelvic Surgery 2:42-43, 1996. e-Pub 1996.
Skilling JS, Sood AK, Neiman T, Lager DJ, Buller RE. An abundance of p53 null mutations in ovarian carcinoma. Oncogene 13:117-123, 1996. e-Pub 1996.
Sood AK, Yancey M, Richards D. Prediction of fetal macrosomia using humeral soft tissue thickness. Obstet Gynecol 85(6):937-40, 1995. e-Pub 1995. PMID: 7770263.
Sood AK, Gelder MS, Huang SW, Morgan LS. Anaphylaxis to carboplatin following multiple previous uncomplicated courses. Gynecol Oncol 57:131-2, 1995. e-Pub 1995. PMID: 7705695.
Sood AK, Bahrani-Mostafavi Z, Stoerker J, Stone IK. Human papillomavirus DNA in LEEP plume. Infectious Diseases in Obstetrics and Gynecology 2(4):167-170, 1994. e-Pub 1994.
Sood AK. Cigarette smoking and cervical cancer: meta-analysis and critical review of recent studies. Am J Prev Med 7:208-13, 1991. e-Pub 1991. PMID: 1836735.
Sood AK, Stoerker J, Watts SL. Type-specific detection of human papillomaviruses in archival cervical neoplasia samples using the polymerase chain reaction. Fax 4:5-9, 1989. e-Pub 1989.
Welte T, Vuttaradhi VK, Khlebus E, Brodsky A, Legarreta AF, Celestino J, Powell RT, Stephan C, Nguyen N, Li J, Takamatsu S, Calzoncinth KM, Sood AK, Gershenson DM, Futreal A, Lawson BC, Hillman RT. Gain-of-function chromatin remodeling activity of oncogenic FOXL2-C134W reprograms glucocorticoid receptor occupancy to drive granulosa cell tumors. Cancer Research. e-Pub 1900.
Zeleznik OA, Huang T, Patel C, Poole EM, Clish CB, Armaiz-Pena GN, Nagaraja AS, Eliassen AH, Balasubramanian R, Kubzansky LD, Hankinson SE, Sood AK, Tworoger SS. Plasma and ovarian metabolomic responses to chronic stress in female mice.

Review Articles

Erfani, H, Martynova, A, Matsuzaki, S, Matsuo, K, Roman, LD, Sood, AK, Kurnit, KC, Westin, SN. Androgen receptor as a therapeutic target in endometrial cancer. International Journal of Gynecological Cancer 36(6), 2026. e-Pub 2026. PMID: 42070324.
Fleming, N, Wolfe, CA, Keating, MF, Sans, M, Rangel, KM, Sunny, C, Westin, SN, Jazaeri, AA, Soliman, PT, Taylor, JS, Hillman, RT, How, JA, Lawson, BC, Sood, AK, Eberlin, LS. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery. Journal of Clinical Oncology 42:5573, 2024. e-Pub 2024.
Matsuo K, Matsuzaki S, Maeda M, Rau AR, Yoshihara K, Tamura R, Shimada M, Machida H, Mikami M, Klar M, Roman LD, Wright JD, Sood AK, Gershenson DM. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas. JAMA Netw Open 6(6):e2318602, 2023. e-Pub 2023. PMID: 37326992.
Mateescu B, Jones JC, Alexander RP, Alsop E, An JY, Asghari M, Boomgarden A, Bouchareychas L, Cayota A, Chang HC, Charest A, Chiu DT, Coffey RJ, Das S, De Hoff P, deMello A, D'Souza-Schorey C, Elashoff D, Eliato KR, Franklin JL, Galas DJ, Gerstein MB, Ghiran IH, Go DB, Gould S, Grogan TR, Higginbotham JN, Hladik F, Huang TJ, Huo X, Hutchins E, Jeppesen DK, Jovanovic-Talisman T, Kim BYS, Kim S, Kim KM, Kim Y, Kitchen RR, Knouse V, LaPlante EL, Lebrilla CB, Lee LJ, Lennon KM, Li G, Li F, Li T, Liu T, Liu Z, Maddox AL, McCarthy K, Meechoovet B, Maniya N, Meng Y, Milosavljevic A, Min BH, Morey A, Ng M, Nolan J, De Oliveira Junior GP, Paulaitis ME, Phu TA, Raffai RL, Reátegui E, Roth ME, Routenberg DA, Rozowsky J, Rufo J, Senapati S, Shachar S, Sharma H, Sood AK, Stavrakis S, Stürchler A, Tewari M, Tosar JP, Tucker-Schwartz AK, Turchinovich A, Valkov N, Van Keuren-Jensen K, Vickers KC, Vojtech L, Vreeland WN, Wang C, Wang K, Wang Z, Welsh JA, Witwer KW, Wong DTW, Xia J, Xie YH, Yang K, Zaborowski MP, Zhang C, Zhang Q, Zivkovic AM, Laurent LC. Phase 2 of extracellular RNA communication consortium charts next-generation approaches for extracellular RNA research. iScience 25(8):104653, 2022. e-Pub 2022. PMID: 35958027.
Corvigno S, Johnson AM, Wong KK, Cho MS, Afshar-Kharghan V, Menter DG, Sood AK. Novel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles. Mol Cancer Ther 21(7):1067-1075, 2022. e-Pub 2022. PMID: 35545008.
Liu J, Niu N, Li X, Zhang X, Sood AK. The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. Semin Cancer Biol 81:132-144, 2022. e-Pub 2022. PMID: 34670140.
Menter DG, Afshar-Kharghan V, Shen JP, Martch SL, Maitra A, Kopetz S, Honn KV, Sood AK. Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer Metastasis Rev 41(1):147-172, 2022. e-Pub 2022. PMID: 35022962.
Patel A, Iyer P, Matsuzaki S, Matsuo K, Sood AK, Fleming ND. Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. Cancers (Basel) 13(4), 2021. e-Pub 2021. PMID: 33562443.
Matsuzaki S, Klar M, Matsuzaki S, Roman LD, Sood AK, Matsuo K. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol 160(2):586-601, 2021. e-Pub 2021. PMID: 33183764.
Cata JP, Sood AK, Eltzschig HK. Anesthetic drugs and cancer progression: Fact or fiction. Anesthesiology 133:698-699, 2020. e-Pub 2020.
LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 20(1):e15-e28, 2019. e-Pub 2019. PMID: 30614472.
Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol 151(2):374-380, 2018. e-Pub 2018. PMID: 30213435.
Zhang L, Peng D, Sood AK, Dang CV, Zhong X. Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer. Mol Cancer Ther 17(9):1816-1823, 2018. e-Pub 2018. PMID: 30181330.
Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, López JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler H. Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis. Res Pract Thromb Haemost 2(3):407-428, 2018. e-Pub 2018. PMID: 30046746.
Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 33(6):965-983, 2018. e-Pub 2018. PMID: 29657130.
Hu X, Sood AK, Dang CV, Zhang L. The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15, 2018. e-Pub 2018. PMID: 29054012.
Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM. Aspirin use and endometrial cancer risk and survival. Gynecol Oncol 148(1):222-232, 2018. e-Pub 2018. PMID: 29132875.
Dal Molin GZ, Omatsu K, Sood AK, Coleman RL. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Ther Adv Med Oncol 10:1758835918778483, 2018. e-Pub 2018. PMID: 29977351.
Ma S, Pradeep S, Hu W, Zhang D, Coleman R, Sood AK. The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Res 7:326, 2018. e-Pub 2018. PMID: 29560266.
Chung JF, Lee SJ, Sood AK. Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. Oncotarget 8(40):69047-69061, 2017. e-Pub 2017. PMID: 28978180.
Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev 36(2):199-213, 2017. e-Pub 2017. PMID: 28730545.
Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn 16(12):1337-1351, 2016. e-Pub 2016. PMID: 27828713.
Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA Therapeutics in Cancer - An Emerging Concept. EBioMedicine 12:34-42, 2016. e-Pub 2016. PMID: 27720213.
Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol 12(12):1439-56, 2016. e-Pub 2016. PMID: 27087632.
Srivastava A, Babu A, Filant J, Moxley KM, Ruskin R, Dhanasekaran D, Sood AK, McMeekin S, Ramesh R. Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer. J Biomed Nanotechnol 12(6):1159-73, 2016. e-Pub 2016. PMID: 27319211.
Mitamura T, Gourley C, Sood AK. Prediction of anti-angiogenesis escape. Gynecol Oncol 141(1):80-5, 2016. e-Pub 2016. PMID: 26748214.
Hansen JM, Coleman RL, Sood AK. Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer 56:131-43, 2016. e-Pub 2016. PMID: 26849037.
Barata P, Sood AK, Hong DS. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev 50:35-47, 2016. e-Pub 2016. PMID: 27612280.
Jenner Z, Sood AK, Coleman RL. Rucaparib and next-generation sequencing-based companion diagnostic evaluation in the current PARP inhibitor landscape for recurrent ovarian cancer treatment. Future Oncology 12(12):1439-1456, 2016. e-Pub 2016.
Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AK. Nanotechnology: Future of Oncotherapy. Clin Cancer Res 21(14):3121-30, 2015. e-Pub 2015. PMID: 26180057.
Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87:108-19, 2015. e-Pub 2015. PMID: 25666164.
Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol 137(3):553-8, 2015. e-Pub 2015. PMID: 25827290.
Yang X, Shen F, Hu W, Coleman RL, Sood AK. New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol 27(1):58-65, 2015. e-Pub 2015. PMID: 25502429.
Bowtell D, Boehm S, Ahmed A, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer B, Blagden S, Bookman MA, Brenton J, Chiappinelli KB, Correia Martins F, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman, Iwanicki M, Karlan B, Kaye A, Lengyel E, Levine DA, Lu K, McNeish I, Menon U, Narod S, Nelson BH, Nephew K, Pharoah P, Powell D, Ramos P, Romero I, Scott C, Sood AK, Stronach EA, Balkwill F. Rethinking ovarian cancer II: A roadmap for reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer 15:668-679, 2015. e-Pub 2015.
Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 66:110-6, 2014. e-Pub 2014. PMID: 24384374.
Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. J Drug Target 21(10):904-13, 2013. e-Pub 2013. PMID: 24079419.
Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10(4):211-24, 2013. e-Pub 2013. PMID: 23381004.
Armaiz-Pena GN, Cole SW, Lutgendorf SK, Sood AK. Neuroendocrine influences on cancer progression. Brain Behav Immun 30 Suppl(Suppl):S19-25, 2013. e-Pub 2013. PMID: 22728325.
Miyake TM, Sood AK, Coleman RL. Contemporary use of bevacizumab in ovarian cancer. Expert Opin Biol Ther 13(2):283-94, 2013. e-Pub 2013. PMID: 23190436.
Zand B, Coleman RL, Sood AK. Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am 26(3):543-63, viii, 2012. e-Pub 2012. PMID: 22520979.
Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18(5):1201-6, 2012. e-Pub 2012. PMID: 22186256.
Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from anti-angiogenesis therapy: Clinical implications and future strategies. Journal of Clinical Oncology 30(32):4026-4034, 2012. e-Pub 2012.
Kang Y, Lutgendorf SK, Hu W, Cole SW, Sood AK. Stress related neuroendocrine influences in ovarian cancer. Current Cancer Therapy Reviews 8:100-109, 2012. e-Pub 2012.
Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des 18(19):2713-9, 2012. e-Pub 2012. PMID: 22390757.
Lutgendorf SK, Sood AK. Biobehavioral factors and cancer progression: physiological pathways and mechanisms. Psychosom Med 73(9):724-30, 2011. e-Pub 2011. PMID: 22021459.
Sood AK, Lutgendorf SK. Stress influences on anoikis. Cancer Prev Res (Phila) 4(4):481-5, 2011. e-Pub 2011. PMID: 21464029.
Carroll AR, Coleman RL, Sood AK. Therapeutic advances in women's cancers. Front Biosci (Schol Ed) 3(1):82-97, 2011. e-Pub 2011. PMID: 21196359.
Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11(1):59-67, 2011. e-Pub 2011. PMID: 21160526.
Jackson DB, Sood AK. Personalized cancer medicine: Advances and socioeconomic challenges. Nature Reviews Clinical Oncology 8:735-741, 2011. e-Pub 2011.
Schauer IG, Sood AK, Mok S, Liu J. The functional role of activated fibroblasts in ovarian cancer development. Neoplasia 13(5):393-405, 2011. e-Pub 2011.
Stany M, Ozbun L, Vathipadiekal V, Stone RL, Mok S, Xue H, Kagami T, Wang Y, McAlpine JN, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Y-Z W, Vivas Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Genomic analysis of microdissected ovarian clear cell cancers identifies histotype specific therapeutic targets. PLoS One 6(7):e21121, 2011. e-Pub 2011.
Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer 1(6):277-90, 2010. e-Pub 2010. PMID: 21761359.
Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol 6(12):1863-81, 2010. e-Pub 2010. PMID: 21142861.
Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: Biobehavioral signaling pathways and interventions. J Clin Oncol 28(26):4094-9, 2010. e-Pub 2010. PMID: 20644093.
Merritt WM, Bar-Eli M, Sood AK. The dicey role of Dicer: implications for RNAi therapy. Cancer Res 70(7):2571-4, 2010. e-Pub 2010. PMID: 20179193.
Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 10(3):431-7, 2010. e-Pub 2010. PMID: 20092424.
Stone RL, Sood AK. Ovarian Cancer: Collateral damage of targeted therapy. Lancet Oncology 11:465-475, 2010. e-Pub 2010. PMID: 20226736.
Shahzad MM, Lopez-Berestein G, Sood AK. Novel strategies for reversing platinum resistance. Drug Resist Updat 12(6):148-52, 2009. e-Pub 2009. PMID: 19805003.
Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK. Neuroendocrine modulation of cancer progression. Brain Behav Immun 23(1):10-5, 2009. e-Pub 2009. PMID: 18638541.
Ozpolat B, Sood AK, Lopez-Berestein G. Nanoparticle based systemic siRNA therapy for cancer. Journal of Internal Medicine 267(1):44-53, 2009. e-Pub 2009.
Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26(6):995-1005, 2008. e-Pub 2008. PMID: 18195328.
Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ. Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol 622:23-33, 2008. e-Pub 2008. PMID: 18546616.
Sanguino AM, Lopez-Berestein G, Sood AK. Strategies for in vivo siRNA delivery in cancer treatment. Mini Reviews in Medicinal Chemistry 8:248-255, 2008. e-Pub 2008.
Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nature Clinical Practice Oncology 5(4):194-204, 2008. e-Pub 2008. PMID: 18268546.
Thaker PH, Sood AK. Neuroendocrine influences on cancer biology. Seminars in Cancer Biology 18:164-170, 2008. e-Pub 2008. PMID: 18201896.
Merritt WM, Sood AK. Markers of angiogenesis in ovarian cancer. Dis Markers 23(5-6):419-31, 2007. e-Pub 2007. PMID: 18057525.
Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell Cycle 6(4):430-3, 2007. e-Pub 2007. PMID: 17312398.
Coleman RL, Sood AK. Historical progress in the initial management of ovarian cancer: Intraperitoneal therapy. Current Oncology Reports 8(6):455-64, 2006. e-Pub 2006.
Antoni MH, Lutgendorf SK, Cole S, Dhabhar F, Sephton S, McDonald PG, Stefanek M, Sood AK. The Influence of Biobehavioral Factors on Tumor Biology: Pathways and Mechanisms. Nature Reviews Cancer 6:240-248, 2006. e-Pub 2006. PMID: 16498446.
Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 9(6):1179-87, 2005. e-Pub 2005. PMID: 16300469.
Sharma NK, Sorosky JI, Bender D, Fletcher MS, Sood AK. Malignant mixed mullerian tumor (MMMT) of the cervix. Gynecol Oncol 97(2):442-5, 2005. e-Pub 2005. PMID: 15863143.
Kamat AA, AK S. The Merits of Vascular Targeting for Gynecologic Malignancies. Current Oncology Reports 7(6):444-450, 2005. e-Pub 2005. PMID: 16221381.
McDonald PG, Antoni MH, Lutgendorf SK, Cole S, Dhabhar F, Sephton S, Stefanek M, Sood AK. A biobehavioral perspective of tumor biology. Discovery Medicine 5(30):520-526, 2005. e-Pub 2005. PMID: 20704834.
Sood AK, Fletcher MS, Hendrix MJ. The embryonic-like properties of aggressive human tumor cells. J Soc Gynecol Investig 9(1):2-9, 2002. e-Pub 2002. PMID: 11839501.
Eichholz A, Mahavni V, Sood AK. Allopathic and complementary alternatives to hormone replacement therapy. Expert Opinion on Pharmacotherapy 3(7):949-955, 2002. e-Pub 2002.
Sood AK, Hendrix MJC. Angiogenesis and its implications for cancer treatment 7(3):2-3, 2001. e-Pub 2001.
Mahavni VM, Sood AK. Hormone replacement and cancer risk. Current Opinion in Oncology 13:384-389, 2001. e-Pub 2001.
Bender DP, Sood AK. Chemoradiation for the treatment of cervical cancer: A new paradigm. Postgraduate Obstetrics and Gynecology 21(19):1-5, 2001. e-Pub 2001.
Sood AK, Buller RE. Loss of Heterozygosity (LOH) as a prognostic factor in ovarian cancer. CME Journal of Gynecologic Oncology 4(2):189-191, 1999. e-Pub 1999.

Professional Educational Materials

Sood AK. Developed instructional videotapes and written materials for teaching operative dictations to residents and fellows, 2002.

Editorials

MNVR K, Sood AK. Editorial - Metronomic chemotherapy. Cancer Lett 400:203, 2017. PMID: 28315702.
Ravi Kumar MNV, Sood AK. Featuring the Guest Editors. Cancer Lett 400:204, 2017. PMID: 28315431.
Melhem-Bertrandt A, Sood AK. New directions in combating stress effects on cancer. Cancer Prevention Research 5(2):147-149, 2012.
Sood AK, Coleman RL, Ellis LM. Moving beyond anti-VEGF therapy in ovarian cancer. Journal of Clinical Oncology 30(4):345-347, 2012.
Sood AK, Coleman RL, Ellis LM. Moving beyond anti-VEGF therapy in ovarian cancer. Current Pharmaceutical Design 18:2713-2719, 2012.
Rupaimoole R, Han HD, Lopez-Berestein G, Sood AK. MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer 30(6):368-70, 2011. PMID: 21627858.
Sood AK, Wilson MT, Herzog TJ. Supporting gynecologic cancer research: the last 20 years and beyond. Gynecol Oncol 120(3):319-20, 2011. PMID: 21320669.
Sood AK, Coleman RL. Targeted therapy in gynecologic oncology: biology, strategy, and assessment. Gynecol Oncol 116(2):155-6, 2010. PMID: 20109724.
Nick AM, Sood AK. The ROC n' Role of the Multiplex Assay for Early Detection of Ovarian Cancer. [Commentary on article by Visintin I, et al. Diagnostic markers for early detection of ovarian cancer. Clinical Cancer Research 14(4):1065-72, 2008]. Nature Clinical Practice Oncology 5(10):568-569, 2008.
Sood AK. Cancer in surgical scar: insights and clinical challenges. Editorial for articles by Neumann et al., Cervical adenosquamous carcinoma: Tumor implantation in an episiotomy scar; Harry et al., Isolated clear cell adenocarcinoma in scar endometriosis mimicking an incisional hernia. Obstet Gynecol 110(2 Pt 2):453-4, 2007. PMID: 17666626.
Sood AK. Second look laparotomy for ovarian germ cell tumors: To do or not to do? Editorial for article by George et al., Laparotomy for post chemotherapy residue in ovarian germ cell tumors. Journal of Postgraduate Medicine 52(4):246-7, 2006.
Sood AK. Location matters. Editorial for articles by Solomon et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer; Alvarez-Secord et al., Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study. Gynecologic Oncology 101:378-9, 2006.
Sood AK, Hendrix MJ. The complexity of tumor vascularity. Cancer Biol Ther 2(3):257-8, 2003. PMID: 12878860.
Mayr NA, Sood AK. Chemo-Radiation Therapy in Cervical Cancer: Where do we go from here? Invited commentary for “Combined chemo-radiation for locally advanced cancer of the cervix”. Oncology:1336-1338, 2000.

Abstracts

Handley KF, Rodriguez-Aguayo C, Ma S, Kim MS, Ram PT, Sood AK. Rational combination approaches with CRM-1 inhibitor in ovarian cancer. AACR Annual Meeting, Philadelphia, PA, 2020. e-Pub 2020.
Handley KF, Moore KN, Burger RA, Dal Molin GZ, Stagg R, Sood AK, Coleman RL. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer (EOC): The SIERRA multi-institutional open-label phase Ib trial. Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer, 2020. e-Pub 2020.
Asare A, Wang Y, Lara OD, Zhang L, Sood AK. Understanding mechanisms of disparities in gynecologic malignancies. Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer, 2020. e-Pub 2020.
Naing A, Karp D, Piha-Paul SA, Pant S, Subbiah V, Bodurka DC, Fu S, Jazaeri A, Kato S, Schmeler K, Nick A, Yang Y, Akhmedzhanov FO, Fessahaye S, Gong J, Stephen B, Johnson AM, Soliman PT, Sood AK. Meric-Bernstam F. and Lu K.H. (2020). Temsirolimus in combinaton with metformin in patients with advanced or refractory endometrial cancers. AACR Annual Meeting, Philadelphia, PA, 2020. e-Pub 2020.
Lee S, Zhao L, Westin SN, Bateman NW, Jazaeri A, Fleming ND, Lu KH, Coleman RL, Mills GB, Zhang J, Conrads TP, Maxwell G, Futreal PA, Sood AK. High-depth whole genome sequencing of clinically-annotated high-grade serous ovarian cancers. AACR Annual Meeting, Philadelphia, PA, 2020. e-Pub 2020.
Lee S, Zhao L, Celestino J, Rangel KM, Hajek RH, Kim MS, Sharafi SE, Liu J, Fleming ND, Lu KH, Zhang J, Futreal PA, Mills GB, Westin SN, Sood AK, Jazaeri A, Coleman RL. Functional proteomic aberrations post-chemotherapy with paclitaxel and carboplatin in patients with advanced ovarian cancer. AACR Annual Meeting, Philadelphia, PA, 2020. e-Pub 2020.
Westin SN, Lee S, Zhao L, Yuan Y, Wu J, Hajek R, Sharafi S, Meyer LA, Fleming ND, Jazaer A, Coleman RL, Lu KH, Mills GB, Zhang J, Futreal A, Sood AK. Pharmacodynamic changes by durvalumab in combination with chemotherapy in women with untreated, advanced stage ovarian cancer. AACR Annual Meeting, Philadelphia, PA, 2020. e-Pub 2020.
Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Jazaeri AA, Liu J, Burks JK, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. A high-depth multi-omics analysis of clinically defined subsets of high-grade serous ovarian cancer. Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer, 2020. e-Pub 2020.
Chelariu-Raicu A, Stur E, Ivan C, Coleman RL, Sood AK, Yunfei W. Biological effects of a FRα-targeting antibody-drug conjugate, IMGN853 (mirvetuximab soravtansine) in high-grade serous ovarian cancer. AACR Annual Meeting, Philadelphia, PA, 2020. e-Pub 2020.
Ma S, Mangala LS, Hu W, Bayaktar E, Hu W, Jennings NB, Coleman RL, Lopez-Berestein G, Sood AK. Cloaking VEGF in small extracellular vesicles as a cause of adaptive resistance to anti-VEGF therapy. AACR Annual Meeting, Philadelphia, PA, 2020. e-Pub 2020.
Umamaheswaran S, Dasari SK, Yokoi A, Stur E, and Sood AK. Effect of sympathetic nervous system mediators on the tumor microenvironment via small extracellular vesicles in ovarian cancer. AACR Annual Meeting, Philadelphia, PA, 2020. e-Pub 2020.
Niu N, Li X, Yao J, Sood AK, Liu J. Polyploid giant cancer cells lead to evolution of drug resistance in high-grade ovarian cancer. AACR Special Conference on the Evolving Landscape of Cancer Modeling, San Diego, CA, 2020. e-Pub 2020.
LaFargue CJ, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawarad A, Home MS, Blake EA, Crim AK, Westin SN, Coleman RL, Matsuo K, Hasegawad K, Moore KN, Sood AK. Diamonds in the rough: An analysis of complete pathologic responders in ovarian cancer. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Cobb LP, Fellman B, Gershenson DM, Sood AK, Nick AM, Westin SN, Coleman RL, Fleming ND. The use of a laparoscopic surgical algorithm to triage the timing of cytoreductive surgery in patients with low grade serous ovarian and peritoneal cancer. Further evidence of relative chemoresistance. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Lara OD, Wang Y, Zhang L, Hu W, Rauh-Hain JA, Sood AK. Think outside the box: Pan-cancer molecular study of gynecologic disparities among African Americans. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
LaFargue CJ, Villar-Prados A, Ivana C, Strovel J, and Sood AK. Becoming a BET inhibitor 'sommelier': Identifying the best combinations for ovarian cancer. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Hu W, Ivan C, Sun Y, Ma S, Mangala LS, Coleman RL, Sood AK. A new epha 2 inhibitor for targeted therapy in uterine cancer. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Villar-Pradosa A, Mab S, LaFargue C, Roszik J, Sood AK. Predicting novel therapies and targets in ovarian and uterine cancers. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Labrie M, Jub Z, Litton JK, Kim TB, Lee S, Chen K, Soliman PT, Frumovitz, M Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB. Exploration of markers of synergistic lethality of PARP and PI3K-akt-mTOR inhibitors in women’s cancers. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Lara OD, Lyons YA, Dood RL, Wang Z, Pradeep S, Sood AK. Cut to the chase: Should we use tumor microarrays to evaluate the tumor microenvironment?. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Cobb LP, Suna CCL, Iyera R, Nick AM, Fleming ND, Sood AK, Wong KK, Silva EG, Gershenson DM. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Stur E, Zibetti Dal Molin G, Wu S, Baggerly K, Tworoger S, Levine D, Karlan B, Moore K, Lutgendorf S, and Sood AK. Molecular analysis of short- vs. long-term ovarian cancer survivors. AACR Special Conference on Advances in Ovarian Cancer Research, Atlanta, GA, 2019. e-Pub 2019.
Taki M, Noh KH, Mangala LS, Zhang N, An Z, Sood AK. he search for EGFL6 receptor: Implications for tumor angiogenesis. AACR Special Conference on Advances in Ovarian Cancer Research, Atlanta, GA, 2019. e-Pub 2019.
Joseph R, Soundararajan R, Vasaikar S, Yang F, Isgandarova S, Tian L, Haemmerle M, Mino B, Zhou T, Vidhya Raja G, Ramirez Pena E, Den Hollander P, Bhangre N, Shin C, Martinez M, Rodriguez Canales J, Chang J, Sood AK, Wistuba II, Gibbons DL, Rosen JM, Acharya G, Varadarajan N, Zhang XH, Mani SA. Regulation of metastasis by CD8 T lymphocytes. AACR Annual Meeting, Atlanta, GA, 2019. e-Pub 2019.
Lara OD, Wang Y, Hu W, Zhang L, Rauh-Hain A, and Sood AK. Pan-cancer molecular study of disparities among African Americans. AACR Annual Meeting, Atlanta, GA, 2019. e-Pub 2019.
Coleman RL, Hu W, Soliman PT, Nick AM, Ramirez PT, Westin SN, Zua Z, Schmeler KM, Bodurka DC, Meyer LA, Sood AK. Dasatinib, paclitaxel and carboplatin in women with advanced-stage and recurrent endometrial cancer: A pilot clinical and translational study. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Dal Molin GZ, Sood AK, Fellman B, Coleman RL, Westin SN, Meyer LA, Fleming ND. Assessment of survival after primary treatment in ovarian cancer patients using a modified frailty index. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Dal Molina GZ, Fleming ND, Westin SN, Fellman B, Coleman RL, Afshar-Kharghan V, Sood AK, Gunderson CC, Castellano T. A new risk model to predict venous thromboembolism in ovarian cancer. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Kurnita KC, Sinno AK, Fellman B, Stone RL, Sood AK, Gershenson DM, Schmeler KM, Fader AN, Frumovitz M. Gastrointestinal adjuvant chemotherapy regimens improve survival outcomes in women with mucinous ovarian cancer. 50th Annual Meeting of the Society of Gynecologic Oncology, Honolulu, HA, 2019. e-Pub 2019.
Ma S, McGuire MH, Stur E, Bayraktar E, Villar-Prados A, Wu SY, Yokoi A, Dasari SK, Rodriguez-Aguayo C, Liu J, Lopez-Berestein G, and Sood AK. Exosomal gain-of-function p53 protein promotes cancer-associated phenotype. AACR Annual Meeting, Atlanta, GA, 2019. e-Pub 2019.
Labrie M, Ju Z, Litton JK, Kim TB, Lee S, Chen K, Soliman PT, Frumovitz M, Meyer LA, Moulder S, Jazaeri AA, Lu KH, Sood AK, Coleman RL, Mills GB, Westin SN. Exploration of markers of synergistic lethality of PARP and PI3K-Akt-mTOR inhibitors in women's cancers. AACR Annual Meeting, Atlanta, GA, 2019. e-Pub 2019.
Kurnit KC, Meric-Bernstam F, Hess K, Coleman RL, Bhosale P, Savelieva K, Janku F, Hong D, Naing A, Pant S, Rodon J, Yap TA, Sood AK, Soliman PT, Gershenson DA, Mills GB, Westin SN. Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations. AACR Annual Meeting, Atlanta, GA, 2019. e-Pub 2019.
Yokoi K, Villar-Prados A, Oliphint PA, O'Halloran TJ, Roszik J, Sood AK. A novel approach for liquid biopsy by using nExo. AACR Annual Meeting, Atlanta, GA, 2019. e-Pub 2019.
Amero P, Rodriguez-Aguayo C, Chaudhari RR, Zhang S, Sood AK, Lopez-Berestein G. Next generation DNA aptamers with prolonged stability and antitumor activity. AACR Annual Meeting, Atlanta, GA, 2019. e-Pub 2019.
Kim MS, Ma S, Leuschner C, Lee S, Coleman RL, Sood AK. Targeting LHRH-R to improve immune response in ovarian cancer. AACR Annual Meeting, Atlanta, GA, 2019. e-Pub 2019.
Wen YF, Wang Y, Ma S, Raicu AC, Baggerly KA, Sood AK. Blockade of the short-form of prolactin receptor induces FOXO3a/EIF-4EBP1-mediated cell death in uterine cancer. AACR Annual Meeting, Atlanta, GA, 2019. e-Pub 2019.
Rodriguez-Aguayo C, Bayraktar E, Mangala LS, Ivan C, Lopez-Berestein G, and Sood AK. Long non-coding RNA ADAMTS9-AS2 inhibits ovarian tumor growth via Annexin A1. AACR Annual Meeting, Atlanta, GA, 2019. e-Pub 2019.
Dal Molina GZ, Fleming ND, Fellman B, Dood RL, Lara OD, LaFargue CJ, Coleman RL, Soliman PT, Schmeler KM, Westin SN, Sood AK. Venous thromboembolism (VTE) in ovarian cancer during neoadjuvant chemotherapy: Is it time to start prophylaxis?. 49th Annual Meeting of the Society of Gynecologic Oncology, New Orleans, LA, 2018. e-Pub 2018.
Hansen JM, Sood AK, Coleman RL, Westin SN, Ramirez PT, Fellman B, Soliman PT, Schmeler KM, Fleming ND. Concordance of laparoscopy in predicting intraperitoneal spread and residual disease at tumor reductive surgery in advanced ovarian cancer. 49th Annual Meeting of the Society of Gynecologic Oncology, New Orleans, LA, 2018. e-Pub 2018.
Fleming ND, Nick AM Coleman RL, Westin SN, Ramirez PT, Soliman P, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK. Personalized surgical algorithm for advanced ovarian cancer: Results from a prospective quality improvement project. 49th Annual Meeting of the Society of Gynecologic Oncology, New Orleans, LA, 2018. e-Pub 2018.
LaFargue CJ, Fleming ND Fellman B, Dood RL, Lara OD, Dal Molina GZ, Westin SN, Coleman RL, Sood AK. From unresectable to cancer-free at interval surgery: An evaluation of complete pathologic responders. 49th Annual Meeting of the Society of Gynecologic Oncology, New Orleans, LA, 2018. e-Pub 2018.
Lara OD Rodriguez-Aguayoa C, Bayraktara E, Ameroa P, Mangala S, LaFargue CJ, Sood AK. Grabbing the Grb2/GAB2 complex in ovarian cancer. 49th Annual Meeting of the Society of Gynecologic Oncology, New Orleans, LA, 2018. e-Pub 2018.
Dood RL, Zhao Y, Armbruster S, LaFargue CJ, Lara OD, Dal Molinb GZ, Sood AK, Baggerly KA. Come back in six months, or never? Defining surveillance and survivorship in gynecologic malignancies with an evidence-based approach. 49th Annual Meeting of the Society of Gynecologic Oncology, New Orleans, LA, 2018. e-Pub 2018.
Thiviyanathan V, Pi F, Zhang H, Li H, Wang H, Guo P, Sood AK. Aptamer conjugated nanoparticles for targeted drug delivery. AACR Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
Shuford S, Elder J, Puls L, Weroha J, Hou X, Zanfagnin V, Nick A, Stany MP, Maxwell L, Conrads T, Corless C, Sood AK, Gevaert M, Crosswell HE, DesRochers TM. Prospective clinical validation of EX VIVO, patient-specific response prediction to first-line chemotherapy. AACR Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
Wen Y, Nick AM, Lopez-Berestein G, Gallick GE, Coleman RL, Hung M, Sood AK. A Novel Target for overcoming adaptive resistance to anti-angiogenic therapy in ovarian cancer. AACR Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
Lara O, Rodriquez-Aguayo C, Bayrakter E, Amero P, Mangala S, LaFargue C, Tari-Ashizawa A, Lopez-Berestein G, Sood AK. Grabbing GRB2: The use of liposome-incorporated Grb2 antisense oligonucleotides as a novel therapy in gynecologic malignancies. AACR Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
Geethadevi A, Parashar D, Ragle-Aure M, Nair B, Lu Y, Kristensen VN, You M, Sood AK, Mills GM, Pradeep S, Chaluvally Raghavan P. MiR551b-mediated Oncostatin M signaling in breast cancer. AACR Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
Huang T, Sood AK, Tworoger S. Antihypertensive medication use and ovarian cancer survival. AACR Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
Ma S, Pradeep S, Wu S, Kim MS, Hu W, Mangala S, Coleman RL, Sood AK. EP-100 sensitizes BRCA wild-type ovarian cancer cells to PARP inhibitor. AACR Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
Villar-Prados A, Wu, SY, Roszik J, Engelhardt MI, Sood, AK. ). Systematic approach for identifying and validating novel therapies and targets for ovarian cancer. AACR Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, Pittsburgh, PA, 2017. e-Pub 2017.
Harjes U, Bridges E, Gharpure K, Roxannis I, Sheldon H, Miranda F, Mangala LS, Pradeep S, Lopez-Berestein, Ahmed A, Fielding B, Sood AK, Harris A. FABP4 in endothelial cells is a key link between metabolism and angiogenesis and regulates tumour growth. Oncogene 36:912-921, 2017. e-Pub 2017.
Lyons YA, Pradeep S, Hansen JM, Dood RL, Wu S, Wagner MJ, Previs RA, Hu W, Coleman RLand Sood AK. Less is more: Macrophage depletion after adaptive resistance improves anti-VEGF therapy. SGO Annual Meeting, National Arbor, MD, 2017. e-Pub 2017.
Thaker PH, Kuroki LM Hu W, Zighelboim I, Ramondetta LM, Hagemann AR, Massad LS, Powell MA, Mutch DG, and Sood AK. Overcoming stress effects: A prospective feasibility trial of beta-blockers with upfront ovarian cancer therapy. SGO Annual Meeting, National Arbor, MD, 2017. e-Pub 2017.
Dood RL, Nagaraja AS, Lyons YA, Hansen JM Previs RA, Jackson DB, Coleman RL, and Sood AK. Knocking out stress: A systems-based identification of optimal drug combinations to improve ovarian cancer outcome. SGO Annual Meeting, National Arbor, MD, 2017. e-Pub 2017.
Previs, RA, Moss TJ, Zand, B, Hansen, JM, Dood RL, Armaiz-Pena GN, Lyons YA, Coleman, RL, Sood, AK. Pretty fly for GPI: Altered carbohydrate metabolism in ovarian cancer. SGO Annual Meeting, National Arbor, MD, 2017. e-Pub 2017.
McGuire MH, Herbrich S, Wu S, Wang Y, Rupaimoole R, Yao H, Gharpure K, Lopez-Berestein K, Baggerly K, Sood AK. Intragenic DNA methylation and increased gene expression: New directions from pan-cancer analysis. AACR Special Conference: AACR Annual Meeting, Pittsburgh, PA, 2017. e-Pub 2017.
Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Noh K, Filant J, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Bartholomeusz GA, Ivan C, Seong Lee J, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein Gand Sood AK. PRKRA/PACT expression promotes chemoresistance in mucinous ovarian cancer. AACR Special Conference: AACR Annual Meeting, Pittsburgh, PA, 2017. e-Pub 2017.
Kheder E, Huang HJ, Wu A, Hong DS, Piha-Paul SA, Karp DD, Fu S, Subbiah V, Tsimberidou AP, Naing A, Diab A, Javle M, Kopetz S, Sood AK, Kurie JM, Meric-Bernstam F, Gleeson M, Janku F. Detection of circulating antibodies against KRAS in patients with advanced cancers. AACR Special Conference: AACR Annual Meeting, Pittsburgh, PA, 2017. e-Pub 2017.
Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Dorniak PL, Mangala LS, Petrillo M, Torres-Lugo M, Rodland KD, Fagotti A, Lopez-Berestein G, Li C, Sood, AK. Role of CTGF in hyperthermia resistance in ovarian and uterine cancers. AACR Special Conference: AACR Annual Meeting, Pittsburgh, PA, 2017. e-Pub 2017.
Lyons YA, Pradeep S, Hansen JM, Wagner MJ, Dood RL, Wu SY, Previs RA, Hu W, Coleman RL, Sood AK. Less is more: macrophage depletion via CSF1/CSF1R pathway improves anti-VEGF therapy after adaptive resistance. AACR Special Conference: AACR Annual Meeting, Pittsburgh, PA, 2017. e-Pub 2017.
Yang H, Zhang S, Mao W, Ahmed A, Jennings NA, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Le XF, Lu Z, and Bast RC. Silencing pfkfb2 enhances paclitaxel sensitivity by modulating metabolism of p53 wt ovarian and breast cancer cells and xenografts. AACR Special Conference: AACR Annual Meeting, Pittsburgh, PA, 2017. e-Pub 2017.
Kanlikilicer P, Bayraktar R, Rashed M, Aslan B, Calin GA, Sood AK, Lopez-Berestein G. Exosome-mediated ovarian cancer tumorigenesis mediated by miR1246/Rb/Cav1 axis. AACR Special Conference. AACR Special Conference: AACR Annual Meeting, Washington, DC, 2017. e-Pub 2017.
Villar-Prados A, Wu SY, Roszik J, Sood AK, Engelhardt MI. Forecasting novel therapies by understanding the role BRD4 in regulating the Notch3 signaling in ovarian cancer. AACR Special Conference: AACR Annual Meeting, Washington, DC, 2017. e-Pub 2017.
Zuo X, Xu W, Xu M, Tian R, Moussalli J, Mao F, Gagea M, Wei D, Sood AK, and Shureiqi I. PPARD downregulation in cancer cells suppresses metastases by inhibiting tumor angiogenesis and EMT. AACR Special Conference: AACR Annual Meeting, 2017. e-Pub 2017.
Nick AM, Ganeshan D, Iyer R, Bhosale P, Munsell MF, Schmeler KM, Burzawa JK, Soliman PT, Coleman RL, Sood AK. Poster Personalizing surgical therapy for advanced ovarian cancer: CT imaging may not predict disease resectability. The 47th Annual Meeting of the Society of Gynecologic Oncology, San Diego, CA, 2016. e-Pub 2016.
Dalton HJ, Pradeep S, Previs RA, Hansen JM, Rupaimoole R, Zand B, Nick AM, Hu W, Coleman RL, Sood AK. Featured Poster Session Modeling bad behavior: Overcoming anti-VEGF resistance in vivo. The 47th Annual Meeting of the Society of Gynecologic Oncology, San Diego, CA, 2016. e-Pub 2016.
Dao F, Schlappe B, Tseng JH, Lester J, Lutgendorf S, McMeekin DS, Coleman RL, Nick AM, Moore KN, Karlan BY, Sood AK, Levin DA. Featured Poster Session Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.2. The 47th Annual Meeting of the Society of Gynecologic Oncology, San Diego, CA, 2016. e-Pub 2016.
Sood AK, Pradeep S, Huang J, Nick AM, Brock S, Hansen J, Previs RA, Hu W, Coleman RL, Jackson DB. Featured Poster Session Off-target effects of erythropoietin stimulate ovarian cancer via EphB4. The 47th Annual Meeting of the Society of Gynecologic Oncology, San Diego, CA, 2016. e-Pub 2016.
Matsuo K, Cahoon SS, Kakuda M, Adachi S, Moeini A, Machida H, Garcia J, Ueda Y, Roman LD, and Sood AK. Focused Plenary Effect of low-dose aspirin on survival outcome of endometrial cancer. The 47th Annual Meeting of the Society of Gynecologic Oncology, San Diego, CA, 2016. e-Pub 2016.
Huang Y, Hu W, Huang J, Pradeep S, Dalton HJ, Previs RA, Hansen JM, Nick AM, Coleman RL, Sood AK. Focused Plenary Improving hormonal therapy in uterine cancer: Efficacy of onapristone (phosphor-PR) and trametinib. The 47th Annual Meeting of the Society of Gynecologic Oncology, San Diego, CA, 2016. e-Pub 2016.
Hansen JM, Previs RA, Lyons YA, Wang Y, Ivan C, Hu W, Baggerly KA, Sood AK. Scientific Plenary PTEN loss predicts response to Notch pathway inhibition in endometrial cancer. The 47th Annual Meeting of the Society of Gynecologic Oncology, San Diego, CA, 2016. e-Pub 2016.
Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Huang J, Hansen JM, Hu W, Coleman RL, Sood AK. Scientific Plenary Two to tango: Biological activity and companion predictive markers for a novel dual AKT and P70S6K inhibitor in ovarian and uterine malignancies. The 47th Annual Meeting of the Society of Gynecologic Oncology, 2016. e-Pub 2016.
Shoshan E, Huang L, Vasquez ME, Lee HJ, Kim SJ, Ivan C, Calin GA, Sood AK, Hwu P, Gershenwald JE, Markel G, Fidler IJ, and Bar-Eli M. Control of the melanoma metastatic phenotype by A-to-I microRNA editing. AACR Special Conference: The Function of Tumor Microenvironment in Cancer Progression, San Diego, CA, 2016. e-Pub 2016.
Liang L, Mercado-Uribe I, Niu N, Jiang Y, Cheng W, Broaddus R, Bast R, Mills G, Sood AK, Liu J. Establishment of Patient-Derived Xenograft (PDX) Models of Ovarian Cancer. AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic, New Orleans, LA, 2016. e-Pub 2016.
Rashed MH, Kanlikilicer P, Rodriguez Aguayo C, Kabil NN, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Mitra R, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Lopez Berestein G. Ovarian cancer cells selectively release exosomes containing tumor suppressor miRNAs to maintain SRC-mediated oncogenic activities. AACR 107th Annual Meeting, New Orleans, LA, 2016. e-Pub 2016.
Bayraktar E, Rodriguez-Aguayo C, Mai J, Ivan C, Ivan C, Chavez-Reyes A, Sood AK, Ferrari M, Shen H, Lopez-Berestein G. Silencing PTGER3 enhances chemotherapeutic responses. AACR 107th Annual Meeting, New Orleans, LA, 2016. e-Pub 2016.
Lyons YA, Pradeep S, Hansen JA, Previs RA, Yao H, Baggerly KA, Sood AK. Distinguishing macrophages by a unique gene signature to measure response to treatment. AACR 107th Annual Meeting, New Orleans, LA, 2016. e-Pub 2016.
Kanlikilicer, P, Mohammed M, Rashed H S, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Rodriguez-Aguayo C, Bayraktar E, Picher M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein. Exosomal miR-6126 as a novel tumor suppressor in ovarian cancer. AACR 107th Annual Meeting, New Orleans, LA.2, 2016. e-Pub 2016.
Wagner Michael J, Rahul M, Wallace B, Kirstin B, Coleman Robert L, Gabriel L, Sood AK. Translating EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA) to the clinic. AACR 107th Annual Meeting, New Orleans, LA, 2016. e-Pub 2016.
Nick AM, Coleman RL, Ramirez PT, Lu KH, Schmeler KM, Burzawa JK, Soliman PT, Rangel KM, Munsell MF, Sood AK. Poster Personalized surgical therapy for advanced ovarian cancer: R0 resection after neoadjuvant chemotherapy is associated with decreased event-free survival compared with primary cytoreductive surgery. The 47th Annual Meeting of the Society of Gynecologic Oncology, San Diego, CA, 2016. e-Pub 2016.
Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Dorniak P, Previs R, Sadaoui N, Stone R, Matsuo K, Dalton HJ, Lutgendorf SK, Sood AK, Lopez-Berestein G. Adrenergic regulation of MCP-1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Nick AM, Coleman RL, Ramirez PT, Schmeler KM, Soliman PT, Lu K, Burzawa J, Sood AK. Personalized surgical therapy for advanced ovarian cancer. The 46th Annual Meeting of the Society of Gynecologic Oncology, Chicago, IL, 2015. e-Pub 2015.
Tworoger SS, Poole EM, Armaiz-Pena G, Kubzansky L, Hankinson SE, Sood AK, Patel C, Clish C. Metabolomic changes in response to chronic stress in healthy mice. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Raghavan PC, Pradeep S, Lu Y, Sood A, Mills G. Mir-551b amplification regulates STAT3 expression and resistance to anoikis of ovarian cancer cells. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Granados-Principal S, Liu Y, Rodriguez-Aguayo C, Sood AK, Chang JC. HMG Box domain containing 3 (HMGXB3), a novel TGFβ-induced cancer gene that influences cancer stem cells and metastasis in triple negative breast cancer. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Leung CS, Yeung TL, Yip KP, Wong KK, Sood AK, Birrer MJ, Mok SC. CAF-derived MFAP5 promotes tumor angiogenesis and confers paclitaxel resistance in high-grade serous ovarian cancer. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Wen YW, Sood AK. Suicidal autophagy induced by immunotherapy targeting folate receptor in ovarian cancer. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Rupaimoole R, Previs R, Lee J, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison J, Rodriguez-Aguayo C, Calin GA, Mills G, Zhang W, Lopez-Berestein G, Bhattacharya P, Sood AK. SiRNA therapy against novel lncRNA NRCP: Shutting down the fuel for cancer cells. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Wu SY, McGuire M, Rupaimoole R, Pradeep S, Unruh AK, Herbrich SM, Ivan C, Ruder D, Rodriguez-Aguayo C, Sehgal V, Miyake T, Nagaraja AS, Gharpure K, Armaiz-Pena G, Lopez-Berestein G, Ram P, Baggerly KA, Sood AK. Integrative TCGA analyses identify basonuclin1 (BNC1) as a key mediator for platinum resistance. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Gharpure KM, Tucker SL, Herbrich SM, Unruh AK, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Wu SY, Rupaimoole R, Lopez-Berestein G, Ozpolat B, Ivan C, Hu W, Baggerly KA, Sood AK. Mechanistic and functional implications of FABP4 in ovarian cancer metastasis. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Yang L, Achreja A, Moss T, Baddour J, Stilles K, Chiba L, Kim SH, Morse J, Marini J, Sood AK, Ram PT, Nagrath D. Glutamine modulates cellular NAD+/NADH homeostasis thereby regulating cancer metastasis, drug sensitivity in cancer cells. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Previs RA, Moss TJ, Zand B, Rupaimoole R, Dalton HJ, Hansen JM, Armaiz-Pena G, Lutgendorf S, Coleman RL, Bhattacharya P, Ram P, Sood AK. Systems-based approach identifies altered carbohydrate metabolism as a predictor of a malignant phenotype in ovarian cancer. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Napoli M, Venkatanarayan A, Raulji P, Abbas HA, Norton W, Sood AK, Lopez-Berestein G, Tsai KY, Coarfa C, Gunaratne PH, Flores ER. Pharmacologic inhibition of the ΔNp63/DGCR8 axis as a novel therapeutic strategy for p53-deficient and mutatnt tumors. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Pradeep S, Huang J, Mora E, Nick A, Cho M, Wu S, Rupaimoole R, Xiong C, Li C, Lopez-Berestein G, Jackson D, Sood AK. Adverse effects of erythropoietin stimulates tumor growth via EphB4. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Fleming ND, Coleman RL, Wolf J, Tung C, Munsell MF, Sood AK. Phase II trial of bevacizumab with dose-dense carboplatin and paclitaxel as first-line treatment in patients with advanced ovarian cancer. The 46th Annual Meeting of the Society of Gynecologic Oncology, Chicago, IL, 2015. e-Pub 2015.
Hansen JM, Baggerly KA, Wang Y, Ivan C, Wu S, Previs RA, Zand B, Dalton HJ, Hu W, Coleman RL, Sood AK. Homologous recombination deficiency in uterine cancer: an unrecognized phenomenon. The 46th Annual Meeting of the Society of Gynecologic Oncology, Chicago, IL, 2015. e-Pub 2015.
Matsuo K, Hasegawa K, Yoshino K, Murakami R, Hisamatsu T, Ikeda Y, Enomoto T, Roman LD, Fotopoulou C, Sood AK. IL-6, VTE, and ovarian clear cell carcinoma: A dangerous triad. The 46th Annual Meeting of the Society of Gynecologic Oncology, Chicago, IL, 2015. e-Pub 2015.
Previs RA, Moss TJ, Zand B, Rupaimoole R, Dalton HJ, Hansen JM, Lutgendorf SK, Coleman RL, Bhattacharya P, Ram P, Sood AK. Fuel for the fire: A new approach to understanding altered ovarian cancer metabolism. The 46th Annual Meeting of the Society of Gynecologic Oncology, Chicago, IL, 2015. e-Pub 2015.
Previs RA, Thanapprapasr D, Hu W, Rupaimoole R, Huang J, Hansen JM, Dalton HJ, Zand B, Ali R, Coleman RL, Sood AK. The FAK of uterine cancer: PTEN expression predicts response of uterine cancer to focal adhesion kinase inhibition. The 46th Annual Meeting of the Society of Gynecologic Oncology, Chicago, IL, 2015. e-Pub 2015.
Sood AK, Huang J, Hu W, Previs RA, Dalton HJ, Hansen JM, Sun Y, Nick AM, Broaddus R, Coleman RL. Molecular predictors of response to EphA2 targeted therapy in uterine cancer. The 46th Annual Meeting of the Society of Gynecologic Oncology, Chicago, IL, 2015. e-Pub 2015.
Zand B, Previs RA, Zacharias NM, Rupaimoole R, Nagaraja AS, Guindani M, Dalton HJ, Hu W, Hansen J, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Taylor M, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Bar Eli M, Lopez-Berestein G, Bhattacharya PK, Sood AK. Role of increased n-acetylaspartate levels in ovarian cancer. The 46th Annual Meeting of the Society of Gynecologic Oncology, Chicago, IL, 2015. e-Pub 2015.
Nagaraja AS, Dorniak PL, Sadaoui NC, Armaiz-Pena G, Zand B, Wu SY, Allen JK, Rupaimoole R, Rodriguez-Aguayo C, Pradeep S, Lin T, Previs R, Hansen JM, Yang P, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Sustained adrenergic signaling activates pro-inflammatory prostaglandin network in ovarian carcinoma. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Hansen JM, Baggerly KA, Wang Y, Ivan C, Wu S, Previs RA, Zand B, Dalton HJ, Hu W, Coleman RL, Sood AK. Concurrent BRCA2 and PTEN mutations are associated with improved survival in endometrioid uterine cancer. The 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 2015. e-Pub 2015.
Nagaraja AS, Armaiz-Pena G, Allen JK, Sadaoui NC, Zand B, Tan L, Yang P, Cole SW, Lutgendorf SK, Sood AK. Sustained adrenergic signaling activates pro-inflammatory networks in ovarian carcinoma. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Hu W, Liu T, Ivan C, Huang J, Dalton JH, Previs R, Nick AM, Lopez-Berestein G, Coleman RL, Sood AK. Selective activation of Notch3 in high grade serous ovarian cancer. The 45th Annual Meeting of the Society of Gynecologic Oncology, Tampa, FL, 2014. e-Pub 2014.
Tucker SL, Gharpure K, Herbrich SM, Nick AM, Crane EK, Coleman RL, Guenthoer J, Dalton HJ, Baggerly KA, Sood AK. Molecular predictors of residual disease in patients with ovarian cancer. The 45th Annual Meeting of the Society of Gynecologic Oncology, Tampa, FL, 2014. e-Pub 2014.
Previs RA, Ivan C, Dalton HJ, Davis AN, Bottsford-Miller J, Zand B, Coleman RL, Baggerly KA, Sood AK. Taking it up a Notch: Implication for outcomes in endometrial cancer. The 45th Annual Meeting of the Society of Gynecologic Oncology, Tampa, FL, 2014. e-Pub 2014.
Nick AM, Ramirez PT, Rangel K, Schmeler KM, Soliman PT, Burzawa JK, Lu K, Coleman RL, Sood AK. Launching personalized surgical therapy for advanced ovarian cancer. The 45th Annual Meeting of the Society of Gynecologic Oncology, Tampa, FL, 2014. e-Pub 2014.
Matsuo K, Yoshino K, Nishimura M, Hiramatsu K, Banzai C, Sheridan TB, Hasegawa K, Shiki Y, Enomoto T, Kimura T, Sood AK. Impact of lymphovascular space invasion on survival of stage I epithelial ovarian cancer. The 45th Annual Meeting of the Society of Gynecologic Oncology, Tampa, FL, 2014. e-Pub 2014.
Matsuo K, Sheridan TB, Nishimura M, Hasegawa K, Yoshino K, Im DD, Rosenshein NB, Muderspach LI, Sood AK. Significance of lymphovascular space invasion in survival of advanced-stage primary peritoneal carcinoma. The 45th Annual Meeting of the Society of Gynecologic Oncology, Tampa, FL, 2014. e-Pub 2014.
Bottsford-Miller J, Taylor M, Dalton HJ, Stone RL, Nick AM, Davis A, Zand B, Previs R, Afshar-Kharghan V, Sood AK. More is not always better: Thrombocytosis contributes to impaired chemotherapy response in ovarian cancer. The 45th Annual Meeting of the Society of Gynecologic Oncology, Tampa, FL, 2014. e-Pub 2014.
Dalton HJ, Reusser NM, Zien A, Previs R, Rupaimoole R, Zand B, Bottsford-Miller J, Nick AM, Coleman RL, Sood AK. Not your mother’s bisphosphonate: Targeting angiogenesis in ovarian cancer. The 45th Annual Meeting of the Society of Gynecologic Oncology, Tampa, FL, 2014. e-Pub 2014.
Crane EK, Coleman RL, Urbauer DL, Fellman B, Sood AK, Nick AM. Neoadjuvant chemotherapy in ovarian cancer: Changes and influences in practice patterns among SGO members. The 45th Annual Meeting of the Society of Gynecologic Oncology, Tampa, FL, 2014. e-Pub 2014.
Previs RA, Ivan C, Dalton HJ, Davis AN, Bottsford-Miller J, Zand B, McGuire MH, Armaiz-Pena G, Coleman RL, Baggerly KA, Sood AK. Exploiting the non-overlapping dysregulation of Notch and PI3K/Akt signaling pathways as a guide for personalizing uterine cancer therapy. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Rupaimoole R, Ivan C, Pecot CV, Wu SY, Pradeep S, Zand B, Nagaraja AS, Gharpure KM, Dalton HJ, Sadaoui NC, Zhang W, Lopez-Berestein G, Sood AK. Hypoxia is a master regulator of Drosha and Dicer dependent miRNA biogenesis in cancer. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Rodriguez-Aguayo C, Monroig P, Almeida MI, Ivan C, Gonzalez-Villasana V, Shah MY, Sood AK, Calin G, Lopez-Berestein G. Downregulation of hnRNP A1 as a new mechanism of survival in ovarian cancer. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Wu SY, Yang X, Egli M, Gharpure K, Hatakeyama H, McGuire M, Rupaimoole R, Miyake T, Taylor M, Pradeep S, Nagaraja AS, Sierant M, Sighania R, Rodriguez-Aguayo C, McMillan NAJ, Lopez-Berestein, Ram P, Nawrot B, Sood AK. Evoking potent RNAi response using novel 2’-OMe-phosphorodithioated modified siRNAs. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Wen Y, Graybill WS, Hu W, Bottsford-Miller J, Zand B, Mangala LS, Dalton HJ, Stone RL, Nick AM, Jennings NB, Ivan C, Liu T, Sehgal V, Ram P, Vivas-Mejia PE, Coleman RL, Sood AK. Immunotherapy targeting folate receptor induces autophagy in ovarian cancer. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Davis AN, Lin YG, Previs RA, Dalton HJ, Stone RL, Zand B, Bottsford-Miller J, Coleman RL, Sood AK. Metronomic albumin-bound paclitaxel and topotecan has potent anti-tumor activity in ovarian cancer. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Choi HJ, Kim SW, Dalton HJ, Rupaimoole R, Pradeep S, Lu C, Mangala LS, Lopez-Berestein G, Sood AK. Paxillin enhances angiogenesis through transcriptional regulation of src in ovarian cancer. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Mangala LS, Jiang D, Wang H, Wu SY, Rao LG, Rodriguez-Aguayo C, Pradeep S, Volk DE, Lopez-Berestein G, Gorenstein D, Sood AK. Tumor vasculature targeting using cell-specific thioaptamer decorated chitosan nanoparticle. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Dalton HJ, Pradeep S, Armaiz-Pena G, Previs R, Davis A, Rupaimoole R, Zand B, Hailemichael Y, Overwijk W, Lopez-Berestein G, Sood AK. Macrophages modulate adaptive resistance to anti-angiogenic therapy. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Huang J, Hu W, Dalton HJ, Bottsford-Miller B, Coleman RL, Jaffe RB, Sood AK. Dll4 inhibition plus aflibercept markedly reduces ovarian tumor burden and ascites. The 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2014. e-Pub 2014.
Coleman R, Hu W, Munsell M, Sood A. The lead-in phase I/II trial design to interrogate novel biological agents. The 44th Annual Meeting of the Society of Gynecologic Oncology, 2013. e-Pub 2013.
Matsuo K, Todd S, Yoshino K, Mabuchi S, Im D, Rosenshein N, Sood A, Roman L. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. The 44th Annual Meeting of the Society of Gynecologic Oncology, 2013. e-Pub 2013.
Thaker P, Cole S, Lutgendorf S, Bender D, Ahmed A, Goodheart M, Lucci J, Sood A. Spirituality, depression and interleukin-6 in ovarian cancer patients. The 44th Annual Meeting of the Society of Gynecologic Oncology, Los Angeles, CA, 2013. e-Pub 2013.
Watkins J, Thaker P, Nick A, Ramondetta L, Kumar S, Matsuo K, Lutgendorf S, Ramirez P, Sood A. Improved outcomes with beta blocker use in epithelial ovarian cancer patients. The 44th Annual Meeting of the Society of Gynecologic Oncology, Los Angeles, CA, 2013. e-Pub 2013.
Zand B, Ivan C, Pecot C, Rupaimoole R, Dalton H, Bottsford-Miller J, Hu W, Nick A, Sood A. Separating the good, the bad, and the ugly: New directions in genomic prediction of outcome in ovarian cancer. The 44th Annual Meeting of the Society of Gynecologic Oncology, Los Angeles, CA, 2013. e-Pub 2013.
Zand B, Ivan C, Pecot C, Rupaimoole R, Dalton H, Bottsford-Miller J, Hu W, Nick A, Sood A. Deception of suppression: Unexpected effects of tristetraprolin in ovarian cancer. The 44th Annual Meeting of the Society of Gynecologic Oncology, Los Angeles, CA, 2013. e-Pub 2013.
Ramondetta L, Kang Y, Hu W, Sun C, Kott M, Deavers M, Klopp A, Thaker P, Smith J, Sood A. The clinical significance of beta adrenergic receptor expression in cervical cancer tissue. The 44th Annual Meeting of the Society of Gynecologic Oncology, Los Angeles, CA, 2013. e-Pub 2013.
Dalton H, Ivan C, Pecot C, Rupaimoole R, Zand B, Bottsford-Miller J, Hu W, Nick A, Coleman R, Sood A. The Eph family: Not playing nice in uterine cancer. The 44th Annual Meeting of the Society of Gynecologic Oncology, Los Angeles, CA, 2013. e-Pub 2013.
Hu W, Ivan C, Bottsford-Miller J, Zand B, Dalton H, Nick A, Lopez-Berestein G, Coleman R, Baggerly K, Sood A. Comprehensive epigenetic analysis of Notch pathway in high-grade serous ovarian cancer. The 44th Annual Meeting of the Society of Gynecologic Oncology, Los Angeles, CA, 2013. e-Pub 2013.
Pecot CV, Maharaj A, Wu S, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Zand B, Arumugam T, Lopez G, Sood A. Silencing the elephant in the room: therapeutic KRAS targeting with siRNA. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Pradeep S, Kim SW, Nishimura M, Raghavan P, Pecot C, Lopez G, Fidler I, Sood A. Hematogenous metastasis in ovarian cancer: Importance of the ErbB3/NRG axis. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Raghavan P, Zhang F, Pradeep S, Lu Y, Borresen-Dale AL, Flores E, Sood A, Mills G. OncomiR 569 hits p53 pathway and deregulates proliferation of ovarian epithelial cells. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Wu S, Unruh AK, Rupaimoole R, Ivan C, Ruder D, Pradeep S, Sehgal V, Rodriguez-Aguayo C, Pecot C, Miyake T, Lopez-Berestein G, Ram P, Baggerly KA, Sood AK. Overcoming platinum-resistance in ovarian cancer via targeting basonuclin1 (BNC1). The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Saha S, Bhattacharyya S, Giri K, Lanza IR, Nair KS, Jennings NB, Kumar R, Sood AK, Bhattacharya R, Mukherjee P. (2013). Role of cystathionine beta-synthase in ovarian cancer growth, metastasis and drug sensitivity. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Rodriguez-Aguayo C, Shen H, Gonzalez-Villasana V, Zhang G, Deng X, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC 19(7):1806-15, 2013. e-Pub 2013.
Huang J, Hu W, Bottsford-Miller J, Liu T, Zand B, Coleman RL, Sood AK. Molecular determinants of dasatinib response in uterine carcinoma. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Rupaimoole R, Pradeep S, Unruh A, Nagaraja AS, Pecot CV, Wu SY, Zand B, Dalton HJ, Ivan C, Zhang W, Sood AK. A novel mechanism of hypoxia-mediated cell cycle dysregulation: miR-134 targets CDKN2A. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Dalton HJ, Ivan C, Pecot CV, Rupaimoole R, Zand B, Bottsford-Miller J, Hu W, Nick AM, Coleman RL, Sood AK. An integrated analysis of the eph/ephrin family: implications in endometrial cancer. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Zand B, Ivan C, Pecot CV, Rupaimoole R, Dalton HJ, Bottsford-Miller J, Hu W, Nick AM, Sood AK. Ten degrees of separation: novel genes affecting outcome in ovarian cancer. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Park YY, Kim SB, Han HD, Sohn BH, Liang J, Lu Y, Mills G, Sood A, Lee JS. TARDBP regulates glycolysis in hepatocellular carcinoma by regulating PFKP through miR-520. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Zhang S, Mao W, Sood AK, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Li ZF, Bast RC, Le XF. Knockdown of the glycolytic enzyme PFKFB2 induces growth inhibition and enhances paclitaxel sensitivity in ovarian cancer cells. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Miyake T, Pradeep S, Zand B, Dalton HJ, Wen Y, Armaiz-Pena GN, Kauffman M, McCauley D, Shacham S, Wiktorowicz JE, Sood AK. Therapeutic targeting of CRM1 in ovarian cancer. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Cho MS, Vasquez HG, Han HD, Pradeep S, Rupaimoole R, Zand B, Kroll M, Sood AK, Afshar-Kharghan V. Complement promotes growth of ovarian cancer. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Sood AK, Conner MG, Yang ES, Landen CN. Endoglin (CD105) is a target for ovarian cancer cell-specific therapy through induction of DNA damage. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Deng D, Fuentes-Mattei E, Hwang RF, Wang H, Armaiz-Pena GN, Aslan B, Gutierrez-Puente Y, Sood AK, Logsdon C, Lopez-Berestein G. Targeting pancreatic stellate cells (PSC) to treat pancreatic cancer. The 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2013. e-Pub 2013.
Wu SY, Unruh AK, Bartholomeusz G, Ivan C, Pecot CV, Rupaimoole R, Han HD, Bottsford-Miller J, Tucker SL, Coleman RL, Lopez-Berestein G, Baggerly KA, Sood AK. Bedside to bench and back: an integrative functional analysis of The Cancer Genome Atlas (TCGA) for novel target discovery for the treatment of ovarian cancer. The 103nd Annual Meeting of the American Association for Cancer Research, Chicago, IL, 2012. e-Pub 2012.
Bottsford-Miller J, Stone R, Zand B, Nick A, Pecot C, Vasquez H, Ivan C, Hu W, Afshar-Khargan V, Sood AK. Fuel on the fire: Contribution of thrombocytosis to ovarian cancer resistance to taxane-based chemotherapy. The 43nd Annual Meeting of the Society of Gynecologic Oncologists, Austin, TX, 2012. e-Pub 2012.
Stone RL, RLNick, Bottsford-Miller J, King ER, Matsuo K, Lutgendorf S, McNeish I, Afshar-Kharghan V, Sood AK. Unraveling the Century-Old Mystery of Paraneoplastic Thrombocytosis in Ovarian Cancer. The 43nd Annual Meeting of the Society of Gynecologic Oncologists, Austin, TX, 2012. e-Pub 2012.
Matsuo K, Stone RL, Shahzad MMK, Bottsford-Miller JN, Roh JW, Zand B, Ram PT, Coleman RL, Loizos N, Sood AK. Platelet-derived Growth Factor Receptor Alpha (PDGFRα) Targeting and Relevant Biomarkers in Ovarian Carcinoma. The 43nd Annual Meeting of the Society of Gynecologic Oncologists, Austin, TX, 2012. e-Pub 2012.
Matsuo K, Sheridan TB, Miyake T, Yoshino K, Hew KE, Im DD, Rosenshein NB, Enomoto T, Sood AK, Roman LD. Lymphovascular Space Invasion and Risk of Lymph Node Metastasis in Epithelial Ovarian Cancer. The 43nd Annual Meeting of the Society of Gynecologic Oncologists, Austin, TX, 2012. e-Pub 2012.
Leung CS, Yeung TL, Balasubramanian L, Yip KP, Liu J, Wong KK, Han HD, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Novel Stromal Angiogenic Factor MFAP5 in Ovarian Cancer Progression. The 103nd Annual Meeting of the American Association for Cancer Research, Chicago, IL, 2012. e-Pub 2012.
Matsuo K, Nishimura M, Bottsford-Miller J, Stone RL, Zand B, Shahzad MMK, Schmeler KM, Wong KK, Frumovitz M, Sood AK. Targeting Src in Mucinous Ovarian Carcinoma. The 43nd Annual Meeting of the Society of Gynecologic Oncologists, Austin, TX, 2012. e-Pub 2012.
Zand B, Bottsford-Miller J, Hu W, Stone R, Nick AM, Lutgendorf SK, Sood AK. Metabolism gone awry: How ovarian cancer’s metabolism differs from the normal ovary. The 43nd Annual Meeting of the Society of Gynecologic Oncologists, Austin, TX, 2012. e-Pub 2012.
Bottsford-Miller J, Stone R, Nick A, Zand B, Pecot C, Ivan C, Hu W, Coleman RL, Afshar-Khargan V, Sood AK. Contribution of malignant thrombocytosis to ovarian cancer proliferation and resistance to chemotherapy-induced-apoptosis through Platelet Derived Growth Factor Receptor-Alpha (PDGFRA) signaling. The 103nd Annual Meeting of the American Association for Cancer Research, Chicago, IL, 2012. e-Pub 2012.
Huang J, Hu W, Han HD, Bottsford-Miller J, Jennings NB, Shen DY, Lu C, Pecot CV, Rupaimoole R, Urbauer D, Kang Y, Liu T, Roh JW, Hong JH, Deavers MT, Coleman RL, Sood AK. EphA2 and its phosphorylation is a key determinant of dasatinib sensitivity in endometrial cancer. The 103nd Annual Meeting of the American Association for Cancer Research, Chicago, IL, 2012. e-Pub 2012.
Zand B, Bottsford-Miller J, Hu W, Stone R, Nick AM, Lutgendorf SK, Sood AK. Metabolic distinctions in high grade epithelial ovarian cancer. The 103nd Annual Meeting of the American Association for Cancer Research, Chicago, IL, 2012. e-Pub 2012.
Wen Y, Zand B, Kang Y, Bottsford-Miller J, Stone RL, Carroll A, Pradeep A, Wu S, Pecot CV, Hu W, Ozpolat B, Coleman R, Sood AK. Suicidal tendencies: The promotion of cell death by a prolactin antagonist through autophagy in ovarian cancer. The 103nd Annual Meeting of the American Association for Cancer Research, Chicago, IL, 2012. e-Pub 2012.
Rupaimoole R, Pecot CV, Wu SY, Bottsford-Miller J, Ivan C, Coleman RL, Zhang W, Sood AK. A novel mechanism of hypoxia mediated cell cycle dysregulation: miR-134 targets CDKN2A. The 103nd Annual Meeting of the American Association for Cancer Research, Chicago, IL, 2012. e-Pub 2012.
Semaan A, Mert I, Solomon L, Morris R, Munkarah A, Sood A, Ali-Fehmi R. Overexpression of Enhancer of Zeste Homolog 2 (EZH2), Focal Adhesion kinase (FAK), and pFAK in high grade endometrial carcinoma. The 43nd Annual Meeting of the Society of Gynecologic Oncologists, Austin, TX, 2012. e-Pub 2012.
Pecot CV, Akbani R, Ivan C, Unruh AK, Wu S, Rupaimoole R, Bottsford-Miller J, Zand B, Tucker SL, Coleman RL, Baggerly KA, Sood AK. Clinical Relevance of miR-200 Family Members in Various Cancers. The 103rd Annual Meeting of the American Association for Cancer Research, Chicago, IL, 2012. e-Pub 2012.
Rodriguez-Aguayo C, Shen H, Deng X, Gonzalez-Villasana V, Sakamoto J, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. Sustained Gene Silencing by Liposomal siRNA Incorporated Mesoporous Silicon Particles. The 103nd Annual Meeting of the American Association for Cancer Research, Chicago, IL, 2012. e-Pub 2012.
Hu W, Ivan C, Bottsford-Miller J, Zand B, Pecot CV, Nick AM, Stone RL, Coleman RL, Baggerly KA, Sood AK. Integrated analysis of Notch pathway in high grade serous ovarian cancer. The 43nd Annual Meeting of the Society of Gynecologic Oncologists, Austin, TX, 2012. e-Pub 2012.
Nick AM, Stone RL, Soliman PT, Sood AK, Gershenson DM, Coleman RL, Ramirez PT. Pressure to respond: Hypertension predicts clinical benefit from bevacizumab in recurrent ovarian cancer. The 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 2011. e-Pub 2011.
Allen JK, Armaiz-Pena G, Jennings NB, Lutgendorf SK, Cole SW, Sood AK. BDNF is involved in mediating stress-effects on ovarian cancer progression. The 18th Annual Psychoneuroimmunology Research Society Meeting, Chicago, IL, 2011. e-Pub 2011.
Lamkin DM, Lutgendorf SK, Lubaroff DM, Sood AK, Beltz TG, Johnson AK. Cancer induces inflammation and depressive-like behavior in the mouse: Exacerbation by social isolation. The 18th Annual Psychoneuroimmunology Research Society Meeting, Chicago, IL, 2011. e-Pub 2011.
Schrepf AD, Clevenger L, DeGeest K, Penedo F, Beneder D, Goodheart M, Kirschbaum C, Sood AK, Lutgendorf SK. Changes in diurnal cortisol rhythms in ovarian cancer patients undergoing primary treatment. The 69th Annual Scientific Meeting of the American Psychosomatic Society, San Antonio, TX, 2011. e-Pub 2011.
Cohen L, Cole SW, Kirschbaum C, Sood A, Scott S, Tannir N, Jonasch E, Radvanyi L, Vence L, Arevalo JM, Pisters L. Depressive symptoms and cortisol rhythmicity predict survival in patients with stage IV renal cell carcinoma: Role of systemic inflammatory signaling. The 69th Annual Scientific Meeting of the American Psychosomatic Society, San Antonio, TX, 2011. e-Pub 2011.
Shinn EH, Lenihan DJ, Urbauer DL, Woods ML, Nick AM, Basen-Engquist K, Sood AK. Impact of cardiovascular comorbidity on ovarian cancer outcome. The 69th Annual Scientific Meeting of the American Psychosomatic Society, San Antonio, TX, 2011. e-Pub 2011.
Coleman RL, Duska L, Ramirez P, Modesitt S, Schmeler K, Iyer R, Garcia M, Sood AK. Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC#724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer. The 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 2011. e-Pub 2011.
Lee SJ, Moreno-Smith M, Han HD, Lu C, Roh JW, Nishimura M, Allen JK, Jennings NB, Matsuo K, Shahzad MMK, Lutgendorf SK, Sood AK. Mechanisms of stress-buffering effects of dopamine on tumor vasculature. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Rodriguez-Ahuayo C, Vivas-Mejia PE, Han HD, Shahzad MMK, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing surviving splice variant 2B leads to antitumor activity in taxanes-resistant ovarian cancer. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Cortez VA, Suzuki T, Miyat N, Sood AK, Vadlamudi RK. Therapeutic significance of ERα-PELP1 axis in blocking endocrine therapy resistance. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Bevis KS, Stone RL, Nick AM, Goodman B, Jennings N, Sood AK, Landen CN. Sensitivity and limitations of bioluminescent imaging in ovarian cancer xenograft models. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Bottsford-Miller J, Sanguino A, Thanapprapasr D, Pecot CV, Stone RL, Auger K, Nick AM, Sood AK. Enhancing anti-angiogenic therapy by blocking focal adhesion kinase. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Nick AM, Stone RL, Chang B, Liu J, Urbauer D, Mora EM, Pecot CV, Mangala LS, Han HD, Vivas-Mejia P, Sung B, Nishimura M, Matsuo K, Kannan S, Zweidler-McKay PA, Alicea RN, Armaiz-Pena GN, Shahzad MMK, Haghpeykar S, Hu W, Aggarwal BB, Lopez-Berestein G, Stein MA, Brock S, Jackson D, Sood AK. In search of a novel EPO receptor: The clinical significance of the Eph connection. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Pecot CV, Bischoff FZ, Lin YG, Jaladurgam P, Merritt WM, Pircher T, Mikolajczyk S, Mayer JA, Wong K, Pham T, Bottsford-Miller J, Stone RL, Celestino J, Eng C, Sood AK. Redefining CTCs: Detection of cytokeratin-negative circulating tumor cells. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Mora EM, Pecot CV, Nick AM, Mangala LS, Han HD, Stein MA, Brock S, Vivas-Mejia P, Sung B, Nishimura M, Matsuo K, Kannan S, Zweidler-McKay PA, Alicea RN, Armaiz-Pena GN, Shahzad MMK, Haghpeykar S, Stone RL, Liu J, Hu W, Aggarwal BB, Lopez-Berestein G, Jackson D, Sood AK. Erythropoietin meets a new receptor. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Nishimura M, Jung EJ, Spizzo R, Shahzad MMK, Matsuo K, Bottsford-Miller JN, Stone RL, Nick AM, Lu C, Han HD, Jennings NB, Calin GA, Sood AK. miR520d-3p regulates EphA2 and inhibits ovarian cancer growth. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Matsuo K, Nishimura M, Stone RL, Shahzad MMK, Komurov K, Bottsford-Miller JN, Enomoto T, Kimura T, Ram PT, Schmeler KM, Frumovitz M, Gallick GE, Wong KK, Sood AK. Targeting src in mucinous ovarian carcinoma. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Armaiz-Pena GN, Stone RL, Nick AM, Allen JK, Villares GJ, Cruz A, Vivas-Mejias P, Wu Z, English RD, Soman KV, Deavers MT, Zien A, Soldatos T, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Lopez GE, Gallick GE, DeGeest K, Bar-Eli M, Lopez-Berestein G, Cole SW, Lutgendorf SK, Sood AK. Molecular dynamics of SrcS17 activation in chronic stress-induced tumor growth. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Bradley A, Zheng H, Ziebarth A, Sakati W, Eier S, Lopez-Berestein G, Sood AK, Landen C, Eblen ST. The E3 ubiquitin ligase EDD regulates platinum resistance and is a novel therapeutic target for epithelial ovarian cancer. The 102nd Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2011. e-Pub 2011.
Ali-Fehmi R, Al-Wahab Z, Semaan A, Seward S, Morris R, Munkarah A, Sood A. EZH2 expression correlates with increased angiogenesis in ovarian carcinoma. The 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 2011. e-Pub 2011.
Al-Wahab Z, Munkarah A, Munns S, Seward S, Sood A, Morris R, Ali-Fehmi R. EZH2 expression in triple negative breast carcinoma. The 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 2011. e-Pub 2011.
Bottsford-Miller J, Stone RL, Pecot C, Nick A, Matsuo K, King E, Ring K, DeGeest K, Lutgendorf S, Sood A. True blood: Platelets as a biomarker of ovarian cancer recurrence. The 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 2011. e-Pub 2011.
Hu W, Lu C, Stone R, Bottsford-Miller J, Nick A, Shahzad M, Matsuo K, Coleman R, Sood A. Biological roles of tumor and endothelial delta-like ligand 4 in ovarian cancer. The 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 2011. e-Pub 2011.
Nick AM, Stone RL, Bottsford-Miller J, Spannuth WA, Jennings NB, Bagri A, Coleman RL, Sood AK. Neuropilin-1 blockade in the tumor microenvironment reduces tumor growth. The 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 2011. e-Pub 2011.
Shahzad MMK, Arevalo JM, Stone RL, Armaiz-Pena GN, Bottsford-Miller J, Nick AM, Lutgendorf SK, Lopez-Berestein G, Cole SW, Sood AK. Stress and the metastatic switch in epithelial ovarian carcinoma. The 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 2011. e-Pub 2011.
Shahzad MMK, Matsuo K, Shin YH, Stone RL, Bottsford-Miller J, Lu C, Han HD, Rajkovic A, Sood AK. Horm-A domain containing protein-1 (HORMAD1) and outcomes in ovarian cancer patients. The 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 2011. e-Pub 2011.
Matsuo K, Stone RL, Shahzad MMK, Bottsford-Miller JN, Roh JW, Ram PT, Coleman RL, Loizos N, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. The 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 2011. e-Pub 2011.
Nick AM, Stone RL, Bottsford-Miller J, Ramirez PT, Tung C, Armaiz-Pena G, Felix E, Sood AK. Stop and smell the volatile organic compounds: A novel breath-based bioassay for detection of ovarian cancer. The 42nd Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 2011. e-Pub 2011.
McConnell K, Dempsey C, Judd J, Wei F, Sood A, Suh J. Directed evolution of virus nanoparticles for enhanced nucleic acid delivery to ovarian carcinoma. Annual Meeting of the Biomedical Engineering Society, Hartford, CT, 2011. e-Pub 2011.
Matsuo K, Stone RL, Shahzad MMK, Carroll AR, Nishimura M, H-D H, S-J L, Mora E, Lu C, Sood AK. Platelet-derived growth factor receptor alpha blockade significantly enhances sensitization to docetaxel in ovarian carcinoma. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Lu C, Shahzad MMK, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Hu W, Landen CN, Stone RL, Matsuo K, Coleman RL, Sood AK. Targeting pericytes in ovarian carcinoma. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Stone RL, Nick AM, Afshar-Karghan V, Vasquez HG, Landen CN, Carroll AR, Matsuo K, Shahzad MMK, Spannuth WA, Mora EM, King ER, DeGeest K, Lutgendorf S, Sood AK. Mechanisms of paraneoplastic thrombocytosis in ovarian carcinoma. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Fu S, Li Y, D-Y S, Zheng H, Kavanagh J, Bast RC, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Stone RL, Nick AM, Afshar-Karghan V, Vasquez HG, Landen CN, Carroll AR, Gershenson H, Matsuo K, Shahzad MMK, Spannuth WA, Mora EM, King ER, DeGeest K, Lutgendorf S, Sood AK. Bad blood: The role of platelets in ovarian carcinoma. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 2010. e-Pub 2010.
Vivas-Mejia P, Fernandez A, Nick AM, Stone RL, Carroll A, Lin YG, Bornmann W, Hennessy BTJ, Peng Z, Coleman RL, Lopez-Berestein G, Sood AK. Reengineering imatinib to make it safer and more effective. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 2010. e-Pub 2010.
Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sood AK, Brown J, Gershenson DM, Ramirez PT. Lymph node metastasis in primary mucinous ovarian carcinoma is rare. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 2010. e-Pub 2010.
Nick AM, Stone RL, Spannuth WA, Landen CN, Carroll AR, Han HD, Deavers M, Lopez-Berestein G, Coleman RL, Sood AK. P130Cas and tumor angiogenesis: Moving beyond bevacizumab. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 2010. e-Pub 2010.
Shahzad MMK, Mangala LS, Moreno-Smith M, Carroll AR, Stone RL, Allen JK, Haghpeykar SB, Smith J, Tekedereli I, Ozpolat B, Vivas-Mejia P, Armaiz-Pena G, Cole SW, Lopez-Berestein G, Lutgendorf SK, Sood AK. Stress reduces effectiveness of chemotherapy in ovarian carcinoma. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 2010. e-Pub 2010.
Shahzad MMK, Mangala LS, Lee JW, Nair MP, Han HD, Mora EM, Lu C, Matsuo K, Gaur P, Carroll AR, Stone RL, Nick AM, Lopez-Berestein G, Lacko AG, Sood AK. Reconstituted high density lipoprotein (rHDL) for targeted therapy in ovarian cancer. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 2010. e-Pub 2010.
Matsuo K, Eno ML, Shahzad MMK, Carroll AR, Stone RL, Im DD, Rosenshein NB, Sood AK. Multiple extreme resistance in in vivo drug assay and survival outcomes of ovarian cancer patients. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 2010. e-Pub 2010.
Stone RL, J-W L, Nam EJ, Nick AM, Han HD, Shahzad MMK, Kim HS, Mangala LS, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK. Improving delivery of cytotoxic payload to uterine cancer. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, 2010. e-Pub 2010.
Brown J, Sood AK, Ramirez PT, Ramondetta LM, Coleman RL, Levenback CF, Wolf JK. Combination gemcitabine and cisplatin are highly active in endometrial carcinoma: Results of a prospective phase II trial. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 2010. e-Pub 2010.
Carroll A, Kim SW, Nick A, Stone RL, Spannuth WA, Armaiz-Pena GN, Matsuo K, Vivas-Mejia P, Mangala S, Mora E, Shahzad M, Coleman R, Lopez-Berestein G, Sood AK. Breaking scaffolds: Targeting paxillin in ovarian cancer. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 2010. e-Pub 2010.
Lin YG, Stone RL, Merritt WM, Kamat AA, Spannuth WA, Nick AM, Carroll AR, Langley RR, Coleman RL, Sood AK. Dual metronomic chemotherapy results in potent antiangiogenic effects in ovarian carcinoma. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 2010. e-Pub 2010.
Landen CN, Goodman B, Han HD, Mangala S, Nick AM, Armaiz-Pena G, Stone RL, Jennings N, Alvarez R, Gershenson DM, Coleman R, Lopez-Berestein G, Sood AK. Targeting the Notch Ligand Jagged1 in Tumor and Stroma in Ovarian Cancer. The 41st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 2010. e-Pub 2010.
Schmeler K, Tao X, Sun C, Malpica A, Deavers M, Sood A, Coleman R, Bodurka D, Kavanagh J, Gershenson D. Encouraging responses with bevacizumab in recurrent low-grade serous ovarian cancer. 13th Biennial Meeting of the International Gynecologic Cancer Society, Prague, Czech Republic, 2010. e-Pub 2010.
Chakravarty D, Challa R, Dandamudi R, Vivas-Mejia P, Lopez-Berestein G, Tekmal RR, Sood AK, Vadlamudi RK. PELP1: A novel therapeutic target for ovarian cancer progression and metastasis. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Spannuth WA, Krasnoperov V, Liu R, Nick AM, Lin YG, Merritt WM, Coleman RL, Gill PS, Sood AK. Therapeutic targeting of EphB4 with a novel monoclonal antibody. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Stone RL, Nick AM, Afshar-Kharghan V, Vasquez HG, Landen CN, Carroll AR, Matsuo K, Shahzad MMK, Spannuth WA, Mora EM, King ER, DeGeest K, Lutgendorf S, Sood AK. The bloody truth about paraneoplastic thrombocytosis in ovarian cancer. Annual Meeting of the Western Association of Gynecologic Oncologists, Santa Barbara, CA, 2010. e-Pub 2010.
Schmeler KM, Jhingran A, Iyer RB, Munsell M, Kim E, Jimenez C, Sun CC, Moore CL, Kitaka S, Eifel PJ, Klopp AH, Sood AK. Significant decreases in bone mineral density associated with pelvic radiation therapy: Early results of the prospective BAR (Bone mineral density Associated with pelvic Radiation therapy) study. 13th Biennial Meeting of the International Gynecologic Cancer Society, Prague, Czech Republic, 2010. e-Pub 2010.
Sood AK, Armaiz-Pena G, Stone RL, Nick AM, Carroll AR, Shahzad M, Lin YG, Kamat AA, Merritt WM, Lopez-Berestein G, Cole SW, Lutgendorf SK. Stress modulation of anoikis in ovarian cancer. Annual Meeting of the Western Association of Gynecologic Oncologists, Santa Barbara, CA, 2010. e-Pub 2010.
Vivas PE, Rodriguez-Aguayo C, Han HD, Shahzad MMK, Sood AK, Lopez-Berestein G. Targeting the survivin splice variant 2β in taxane-resistant ovarian cancer. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Chakravarty D, Challa R, Dandamudi R, Vivas-Mejia P, Lopez-Berestein G, Tekmal RR, Sood AK, Vadlamudi RK. A novel therapeutic target for ovarian cancer progression and metastasis. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Landen CN, Goodman B, Nick AM, Stone RL, Vivas-Mejia P, Miller LD, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeted therapy against aldehyde dehydrogenase in ovarian cancer. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Rodriguez-Aguayo C, Vivas-Mejia P, Benito JM, Fernandez A, Claret FX, Chavez-Reyes A, Sood AK, Lopez-Berestein G. JNK-1 inhibition leads to antitumor activity in ovarian cancer. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Tanaka T, Mangala L, Nieves-Alicea R, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Ferrari M. Sustained siRNA delivery by mesoporous silicon particles. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Carroll A, Kim SW, Nick AM, Stone RL, Spannuth WA, Armaiz-Pena GN, Matsuo K, Vivas-Mejia PE, Mangala S, Mora EM, Shahzad M, Lopez-Berestein G, Sood AK. Breaking scaffolds: Targeting paxillin in ovarian cancer. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Armaiz-Pena G, Halder JB, Nick AM, Stone RL, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MMK, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK, Sood AK. Neuroendocrine modulation of anoikis. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
J-P G, Calcagno AM, Varma S, Davidson B, Elstrand MB, Ganapathi R, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM. Correlation of expression of MDR-associated genes with outcome in primary ovarian serous carcinoma. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Nick AM, Stone RL, Spannuth WA, Landen CN, Villares G, Armaiz-Pena G, Carroll A, Ozpolat B, Tekedereli I, Vivas-Mejia P, Coleman RL, Lopez-Berestein G, Sood AK. Silencing p130Cas in ovarian carcinoma induces autophagic cell death. The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Shahzad MMK, Mangala LS, J-W L, Matsuo, Han HD, Nair MP, Mora EM, Lu C, Gaur P, Carroll AR, Stone RL, Lopez-Berestein G, Lacko AG, Sood AK. Targeting anticancer therapeutics: A role for reconstituted high density lipoprotein (rHDL). The 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010. e-Pub 2010.
Armaiz-Pena GN, Villares GJ, Lin YG, Han LY, Allen JK, Sanguino AM, Deavers MT, Gallick GG, Bar-Eli M, Lopez-Berestein G, Cole SW, Lutgendorf SK, Sood AK. Src activation takes center stage in stress-induced tumor growth. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Lin YG, Merritt WM, Armaiz-Pena GN, Lu C, Jennings NB, Han LY, Kamat AA, Nick AA, Stone RL, Spannuth WA, Deavers MT, Urbauer DL, Bender DP, DeGeest K, Lutgendorf SK, Sood AK. Functional β2 adrenergic receptors (ADRB2) on human ovarian tumors portend worse clinical outcome. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Landen CN, Goodman B, Nick AM, Armaiz-Pena G, Stone RL, Danes C, Shahzad M, Jennings N, Markman M, Gershenson DM, Cooper L, Bast RC, Coleman RL, Sood AK. Isolation of potential ovarian tumor initiating cells by aldehyde dehydrogenase expression. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Han H, Mangala L, Lee JW, Kim HS, McMurtry V, Shahzad MMK, Nam EJ, Lu C, Stone RL, Nick AM, Lopez-Berestein G, Sood AK. Targeted gene silencing using RGD peptide labeled chitosan nanoparticles. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Feng S, Agoulnik I, Truong A, Li Z, Han HD, Lopez-Berestein G, Klonisch T, Ittmann M, Sood A, Agoulnik A. Suppression of relaxin receptor RXFP1 in prostate cancer cells decreases tumor growth and metastasis in vivo. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Nick AM, Spannuth W, Landen CN, Kamat A, Han L, Lin YG, Merritt WM, Stone RL, Jennings NB, Kim W, Mangala LS, Deavers M, Lopez-Berestein G, Coleman R, Sood AK. Therapeutic gene silencing in ovarian carcinoma: Making the case for p130Cas. The 40th Annual Meeting of the Society of Gynecologic Oncologists, 2009. e-Pub 2009.
Nick AM, Mangala LS, Zuzel V, Schmandt R, Halder JB, Armaiz-Pena GN, Spannuth WA, Lin YG, Kim SW, Shahzad MMK, J-W L, Vivas-Mejia PE, Wolf J, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic targeting of ATP7B: Novel mechanisms and reversing cisplatin resistance in ovarian carcinoma. The 40th Annual Meeting of the Society of Gynecologic Oncologists, 2009. e-Pub 2009.
Mora EM, Mangala LS, Armaiz-Pena GN, Nick AM, Stone RL, Jennings NB, Sood AK. CXCL12 stimulation of chemokines receptor-4 increases adhesion and migration of ovarian cancer cells through activation of focal adhesion kinase. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Lee JW, Han HD, Shahzad MMK, Kim SW, Mangala LS, Nick AM, Lu C, Schmandt R, Kim HS, Mao S, Fazenbaker C, Jackson D, Landen CN, Coleman RL, Sood AK. Molecularly targeted chemotherapy using a novel EphA2 immunoconjugate in ovarian carcinoma. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Stone RL, Nick AM, Spannuth Q, Bonome T, Lutgendorf S, DeGeest K, Merritt WM, Lin YG, Gershenson DM, Coleman RL, Birrer MJ, Sood AK. The clinical and biological significance of focal adhesion kinase activation in ovarian carcinoma. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Lee JW, Shahzad MMK, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder JB, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK. Surgical stress promotes tumor growth in ovarian carcinoma. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Moreno-Smith M, Armaiz-Pena GN, Allen JK, Nick AM, Stone RL, Shazad M, Lee JW, Lu C, Schmandt R, Sood AK. Dopamine blocks stress-mediated tumor growth in ovarian carcinoma. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Nick A, Spannuth WA, Landen CN, Kim HS, Kamat AA, Lin YG, Merritt WM, Stone RL, Mangala LS, Armaiz-Pena GN, Deavers M, Lopez-Berestein G, Birrer MJ, Coleman RL, Sood AK. Targeting p130Cas in ovarian carcinoma. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Shahzad MMK, Lu C, Lee JW, Danes CG, Mangala LS, Halder JB, Nick AM, Stone RL, Kim HS, Nam EJ, Mora EM, Landen CN, Coleman RL, Lopez-Berestein G, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. The 100th Annual Meeting of the American Association for Cancer Research, 2009. e-Pub 2009.
Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Gershenson DM, Brown J. Antiangiogenic therapy for granulosa cell tumors of the ovary. The 45th Annual meeting of the American Society of Clinical Oncology, 2009. e-Pub 2009.
Coleman RL, Kamat A, Iyer R, Kundra V, Garcia M, Jaffe RB, Sood AK. Phase I and pharmacokinetic study of the novel VEGF-direction fusion protein, aflibercept, in combination with docetaxel in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. J Clin Oncol 27:288S (Abstract 5549). The 45th Annual meeting of the American Society of Clinical Oncology, 2009. e-Pub 2009.
Brown J, Deavers MT, Nick AM, Milojevic L, Gershenson DM, Sood AK. Clinical relevance of angiogenesis and lymphangiogenesis in patients with sex cord-stromal ovarian tumors. J Clin Oncol 27:295S (Abstract 5575). The 45th Annual meeting of the American Society of Clinical Oncology, 2009. e-Pub 2009.
Armaiz-Pena GN, Villares GJ, Han LY, Lin YG, Sanguino AM, Deavers MT, Gallick GE, Bar-Eli M, Lopez Berestein G, Cole SW, Lutgendorf SK, Sood AK. Molecular mechanisms of Src activation in chronic stress-induced cancer growth. The 16th Annual Meeting of the Psychoneuroimmunology Research Society, 2009. e-Pub 2009.
Vivas-Mejía PE, Sood A, Lopez-Berestein G. Targeting survivin in taxane-resistant ovarian cancer using liposomal siRNA. The 100th Annual Meeting of the American Association for Cancer Research, Denver, 2009. e-Pub 2009.
Stone RL, Nick AM, Spannuth W, Bonome T, Lutgendorf S, DeGeest K, Merritt WM, Lin YG, Gershenson DM, Coleman RL, Birrer MJ, Sood AK. Focal adhesion kinase is a new focus for anti-angiogenesis therapy in ovarian cancer. The 40th Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, TX, 2009. e-Pub 2009.
Lutgendorf S, Weinrib A, Henderson P, DeGeest K, Penedo F, Torres C, Lucci JA, Sephton S, Rohleder N, Costanzo E, Cole S, Sood AK. Inflammatory processes, HPA, and vegetative depression in ovarian cancer patients. 66th Annual Scientific Conference of the American Psychosomatic Society. Baltimore, MD, 2008. e-Pub 2008.
Schmandt R, Sood AK, Lutgendorf SK, Mangala LS, Armaiz-Pena G. Exercise Therapy for Ovarian Cancer: How does exercise counteract stress-induced tumor growth?. The 15th Annual Meeting of the Psychoneuroimmunology Research Society, Madison, WI, 2008. e-Pub 2008.
Armaiz-Pena G, Mangala LS, Han LY, Lin YG, Schmandt R, Sanguino AM, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth through a Src-dependent mechanism in a mouse model of ovarian cancer. The 15th Annual Meeting of the Psychoneuroimmunology Research Society, Madison, WI, 2008. e-Pub 2008.
Nick AM, Spannuth W, Landen CN, Kamat A, Han L, Lin YG, Merritt W, Jennings NB, Fiterman DJ, Kim S, Mangala LS, Deavers M, Coleman R, Sood AK. Making the case for p130Cas in ovarian carcinoma. Joint Meeting of the Western Association of Gynecologic Oncologists and the Felix Rutledge Society, Sonoma, CA, 2008. e-Pub 2008.
Spannuth WA, Kumar SR, Masood R, Nick AM, Lin YG, Merritt WM, Coleman RL, Deavers M, Vivas-Majia P, Gill PS, Lopez-Berestein G, Sood AK. Clinical and Biological Significance of EphB4 in Ovarian Carcinoma. Joint Meeting of the Western Association of Gynecologic Oncologists and the Felix Rutledge Society, Sonoma, CA, 2008. e-Pub 2008.
Lin YG, Merritt WM, Spannuth WA, Nick AM, Birrer MJ, Tsinberg P, Coleman RL, Bischoff F, Sood AK. Efficient recovery of circulating tumor cell (CTC) using a novel micro-electro-mechanical systems (MEMS)-based platform. Late Breaking Abstract: The 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2008. e-Pub 2008.
Han LY, Armaiz-Pena G, Jennings NB, Sanguino A, Kamat AA, Lin YG, Merritt WM, Landen CN, Spannuth WA, Nick AM, Lutgendorf SK, Lopez-Berestein G, Sood AK. Characterizing the effectors of the angiogenic switch in chronic stress using a MMP-9 null mouse model. The 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2008. e-Pub 2008.
Mangala LS, Han HD, Lu C, Ali-Fehmi R, Munkarah A, Spannuth W, Armaiz-Pena G, Nick AM, Lee JW, Shahzad M, Ozturk E, Sanguino A, Denkbas E, Birrer MJ, Lopez-Berestein G, Sood AK. In vivo vascular and tumor cell gene silencing with chitosan nanoparticles in ovarian carcinoma. The 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2008. e-Pub 2008.
Spannuth WA, Nick AM, Jennings NB, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Ellis L, Coleman RL, Sood AK. The Clinical and Functional Relevance of VEGFR on Ovarian Cancer Cells. The 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2008. e-Pub 2008.
Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Pennacchio LA, Cheng JF, Zeidan A, Wang H, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Decreased Expression of RNA Intereference Machinery, Dicer and Drosha, May Impact the Efficacy of RNAi-targeted Therapies in Ovarian Cancer. The 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2008. e-Pub 2008.
Lin YG, Hwang JY, Mangala LS, Fok JY, Merritt WM, Spannuth WA, Nick AM, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Biological and therapeutic implications of tissue transglutaminase (TG2) silencing in advanced ovarian carcinoma. The 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2008. e-Pub 2008.
Levin PA, Arumugam T, Pan X, Sood AK, Lopez-Berestein G, Logsdon CD. Neutral liposome-coupled siRNA delivery against EphA2 receptor sensitizes gemcitabine resistant orthotopic pancreatic tumors in vivo. The 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2008. e-Pub 2008.
Kim SW, Nick AM, Mangala LS, Spannuth WA, J-W L, Shahzad M, Vivas-Mejia P, Coleman RL, Lopez-Berestein G, Sood AK. Biological significance of paxillin in ovarian carcinoma. The 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2008. e-Pub 2008.
Han LY, Armaiz-Pena G, Jennings N, Kamat A, Lin YG, Merritt WM, Landen CN, Spannuth W, Lutgendorf SK, Sood AK. Stress over-rides the critical effects of host MMP-9. The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, 2008. e-Pub 2008.
Kamat AA, Merritt WM, Lin YG, Coffey D, Nugent E, Han LY, Landen CN, Broaddus R, Gershenson DM, Sood AK. EphA2 overexpression is correlated with markers of angiogenesis and proliferation in endometrial cancer. The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, 2008. e-Pub 2008.
Landen CN, Kim TJ, Lin YG, Mangala LS, Lu C, Kamat AA, Han LY, Merritt WM, Spannuth WA, Nick A, Armaiz-Pena G, Jennings NB, Tice D, Sood AK. Rational combinatorial VEGF and alphavbeta3 targeting in ovarian carcinoma. The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, 2008. e-Pub 2008.
Lin YG, Immaneni A, Merritt WM, Landen CN, Armaiz-Pena GN, Han LY, Kamat AA, Spannuth WA, Coleman RL, Brinkley WR, Sood AK. Targeting Aurora Kinases Inhibits Tumor Growth in In Vivo Models of Ovarian Carcinoma. The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, 2008. e-Pub 2008.
Lin YG, Halder J, Merritt WM, Spannuth WA, Nick AM, Kamat AA, Han LY, Kim TJ, Lu C, Sood AK. FAK Inhibition with a Novel Small Molecule, TAE226, Demonstrates Anti-tumorigenic and Anti-angiogenic Effects in a Preclinical Model of Advanced Ovarian Cancer. The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, 2008. e-Pub 2008.
Merritt WM, Lin YG, Spannuth WA, Kamat AA, Han LY, Landen CN, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Novel Approach to Anti-Angiogenic Therapy through Interleukin-8 Silencing in Ovarian Cancer. The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, 2008. e-Pub 2008.
Nick AM, Spannuth W, Landen CN, Kamat A, Han L, Lin YG, Merritt W, Jennings NB, Fiterman DJ, Kim S, Mangala LS, Deavers M, Coleman RL, Gynecologic Oncologists SSTCSOPIOCTAMOTSO, Tampa, FL. The Clinical Significance of p130cas in Ovarian Carcinoma. The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, 2008. e-Pub 2008.
Spannuth WA, Lin YG, Merritt WM, Nick AM, Mangala LS, Armaiz-Pena GN, Landen CN, Grasso L, Phillips M, Coleman RL, SK S. Therapeutic efficacy of folate receptor α blockade with MORAb-003 in ovarian cancer. The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, 2008. e-Pub 2008.
Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PJ, Ramirez PT, Frumovitz M, Bodurka DC, Sood AK. Pelvic fractures following radiation therapy for cervical cancer: Implications for survivors. 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, 2008.(Abstract 5530, 2008 ASCO Proceedings, Page 300s), 2008. e-Pub 2008.
Spannuth WA, Jennings N, Lin Y, Merritt W, Thaker P, Kamat A, Han L, Ellis L, Coleman RL, Sood AK. The Clinical and Functional Relevance of VEGFR on Ovarian Cancer Cells. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Landen CN, Chavez-Reyes A, Coffman KT, Kamat AA, Han LY, Merritt WM, Lin YG, Lu C, Thaker P, Jennings N, Gershenson DM, Lopez-Berestein G, Kinch MS, Sood AK. Therapeutic targeting of EphA2 in ovarian cancer. The 37th Annual Meeting of the Felix Rutledge Society, Houston, TX, 2007. e-Pub 2007.
Sood AK, Nilsson MB, Takahashi R, Arevalo J, Gallick GG, Lutgendorf SK, Cole SW. Stress hormones regulate IL-6 expression in human ovarian carcinoma cells through a Src-dependent mechanism. The 14th Annual Meeting of the Psychoneuroimmunology Research Society, Arcachon, France, 2007. e-Pub 2007.
Lin YG, Merritt WM, Fiterman DJ, Armaiz-Pena G, Jennings NB, Spannuth WA, Immaneni A, Gershenson DM, Brinkley WR, Coleman RL, Sood AK. Targeting aurora kinase inhibits tumorigenesis in ovarian cancer. The Annual Meeting of the Western Association of Gynecologic Oncologists, Sun River, OR, 2007. e-Pub 2007.
Lamkin DM, Lutgendorf SK, Henderson PJ, Sood AK, Lubaroff DM. TNF-a and IL-6 expression in ovarian cancer: β-agonist affects carcinoma cells but not monocytes in vitro. The 14th Annual Meeting of the Psychoneuroimmunology Research Society, Arcachon, France, 2007. e-Pub 2007.
Ravoori M, Kim TJ, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Spannuth WA, Gershenson DM, Coleman RL, Sood AK, Kundra V. Efficacy and antitumor effects of AVE8062 in a mouse model of orthotopic ovarian cancer. Society of Nuclear Medicine, Washington, DC, 2007. e-Pub 2007.
Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Coleman RL, Mok S, Birrer M, Sood AK. Decreased Expression of RNA Interference Machinery, Dicer and Drosha, is Associated with Poor Outcome in Ovarian Cancer Patients. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Sood AK, Halder JB, Sanguino A, Kamat AA, Landen CN, Han LY, Lin YG, Merritt WM, Coleman RL, Lopez-Berestein GL. Characterization and safety of in vivo siRNA delivery in neutral nanoparticles. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Spannuth WA, Kumar SR, Masood R, Singh J, Scehnet J, Deavers M, Jennings N, Kleiber G, Dubeau L, Weaver FA, Gill PS, Sood AK. EphB4 Expression Is Associated with an Aggressive Phenotype in Ovarian Cancer. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Kamat A, Coffey D, Nugent E, Merritt WM, Landen CN, Han LY, Lin YG, Broaddus R, Gershenson DM, Sood AK. EphA2 overexpression predicts poor outcome in progesterone-receptor negative endometrial carcinoma. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Bennett M, Han LY, Lin Y, Merritt W, Gray JW, Sood AK, Schmandt R. Targeting cytoskeletal assembly as a strategy to overcome taxane resistance in ovarian cancer. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Han LY, Landen CN, Li Y, Kamat AA, Lin YG, Merritt WM, Pena-Armaiz G, Shakespeare WC, Sawyer TK, Coleman RL, Gallick GE, Sood AK. IL-8 and VEGF as biomarkers of response to Src-targeted therapy in ovarian carcinoma. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Han LY, Fletcher MS, Ferrone S, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Deavers MT, Schmandt R, Lutgendorf SK, Gershenson DM, Sood AK. Clinical significance of immune escape and its effect on intratumoral T-cells in ovarian carcinoma. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Landen CN, Kim TJ, Ravoori M, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Spannuth WA, Gershenson DM, Coleman RL, Kundra V, Sood AK. Anti-tumor and Anti-vascular Effects of AVE8062 in Ovarian Carcinoma. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Brown J, Sood A, Deavers M, Milojevic L, Gershenson DM. Lymph node metastasis in ovarian sex cord-stromal tumors. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Kamat AA, Merritt WM, Lin YG, Han LY, Broaddus R, Nugent E, Landen CN, Coleman RL, Gershenson DM, Sood AK. Clinical and biological significance of the vascular endothelial growth factor (VEGF) pathway in endometrial cancer. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Lin YG, Merritt WM, Han LY, Kamat AA, Spannuth WA, Gershenson DM, Deavers MT, Schmandt R, Lutgendorf SK, Sood AK. Prevalence and clinical significance of beta-adrenergic receptors (ADRB) on ovarian carcinoma. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Lin YG, Nair A, Merritt WM, Han LY, Kamat AA, Armaiz-Pena GN, Kunnumakkara AB, Spannuth WA, Gershenson DM, Aggarwal BB, Sood AK. Curcumin inhibits tumor growth and angiogenesis by therapeutic targeting of Nf-kB in ovarian carcinoma. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Merritt WM, Kamat AA, Lin YG, Han LY, Spannuth WA, Landen CN, Lu C, Coleman RL, Gershenson DM, Sood AK. Development and Characterization of an Orthotopic Murine Endometrial Cancer Model. The 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2007. e-Pub 2007.
Le X, Lu C, Mao W, Li Y, Sood AK, Bast RC. The 97th Annual Meeting of the American Association for Cancer Research, Washington, DC. Implication of platelet-derived growth factors (PDGFs) and their receptors in the angiogenesis of breast cancer cells that overexpress HER2, 2006. e-Pub 2006.
Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer, 2006. e-Pub 2006. PMID: 17154180.
Merritt WM, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Landen CN, Thaker PH, Schmandt R, Gershenson DM, Sood AK. p53 null mutations are highly associated with increased EphA2 expression in ovarian carcinomas. The 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2006. e-Pub 2006.
Kim TJ, Ravoori M, Landen CN, Lu C, Kamat AA, Han LY, Kundra V, Sood AK. Effects of AVE8062 plus docetaxel on tumor growth in an orthotopic model of ovarian cancer. The 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2006. e-Pub 2006.
Sood AK, Thaker PH, Jennings N, Kamat AA, Han LY, Armaiz-Pena G, Lopez-Berestein G, Lutgendorf SK, Cole SW. Tumor cell beta adrenergic receptor dependence for chronic stress effects on ovarian cancer growth. The 13th Annual Meeting of the Psychoneuroimmunology Research Society, Miami, FL, 2006. e-Pub 2006.
Halder JB, Landen CN, Lutgendorf SK, Li Y, Jennings NB, Kamat AA, Han L, Lin Y, Merritt WM, Schmandt R, Coleman RL, Sood AK. FAK silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Han LY, Fletcher MS, Landen CN, Kamat AA, Lin YG, Merritt WM, Lutgendorf SK, Ferrone S, Gershenson DM, Sood AK. Characterizing the clinical significance of immune escape in ovarian carcinoma: a novel approach through assessment of human leukocyte antigen (HLA) class I downregulation. The Annual Meeting of the Western Association of Gynecologic Oncologists, Lake Tahoe, CA, 2006. e-Pub 2006.
Levin PA, Arumugam T, Sood AK, Lopez-Berestein G, Logsdon CD. Liposomal delivery of EphA2 siRNA in combination with gemcitabine reduces pancreatic tumor growth and invasion. American Pancreatic Association, Chicago, IL, 2006. e-Pub 2006.
Thaker PH, Lu C, Landen CN, Han LY, Kamat AA, Coleman RL, Gershenson DM, Fidler IJ, Sood AK. Vascular Remodeling with Direct Intraovarian Injection of Tumor Cells. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Lin YG, Kamat AA, Merritt WM, Han LY, Shishodia S, Sethi G, Nair AH, Gershenson DM, Aggarwal BB, Sood AK. Therapeutic targeting of NF-κb in ovarian carcinoma with curcumin. The Annual Meeting of the Western Association of Gynecologic Oncologists, Lake Tahoe, CA, 2006. e-Pub 2006.
Kamat AA, Bischoff FZ, Baldwin M, Nugent E, Han L, Landen CN, Lin Y, Merritt W, Simpson JL, Gershenson DM, Sood AK. Circulating Plasma Cell-free DNA in Ovarian Cancer: A Novel Prognostic Biomarker. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Kamat AA, Kim TJ, Landen CN, Chunhua L, Han LY, Lin YG, Thaker PH, Merritt WM, Coleman R, Gershenson DM, Sood AK. Metronomic Chemotherapy Enhances the Efficacy of Anti-vascular Therapy in Ovarian Cancer. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Landen CN, Lin Y, Immaneni A, Deavers MT, Thornton A, Celestino J, Han L, Kamat AA, Schmandt R, Bodurka DC, Gershenson DM, Brinkley WR, Sood AK. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Landen CN, Kim TJ, Kamat AA, Han LY, Tice D, Kinch MS, Sood AK. Targeting the avB3 integrin with a fully humanized antibody in ovarian cancer. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Thaker PH, Jennings N, Kamat AA, Han LY, Armaiz-Pena G, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Beta-2 Adrenergic Receptor Dependence for Chronic Stress Effects on Ovarian Cancer Growth. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Milam MR, Ramirez PT, Lu KH, Bassett RL, Slomovitz BM, Coleman RL, Sood AK. Supracervical Hysterectomy Does Not Impact Clinical Outcome in Patients with Epithelial Ovarian Cancer: A Case-Control Analysis. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Thaker PH, Jennings N, Kamat AA, Han LY, Li Y, Lutgendorf SK, Cole SW, Sood AK. Cellular Mechanisms for Catecholamine-mediated VEGF Production by Ovarian Cancer Cells. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Han LY, Landen CN, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK. Validation of preoperative serum tissue factor (TF) levels as an independent prognostic factor in patients with ovarian carcinoma. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Lu C, Landen CN, Kim T, Kamat AA, Han LY, Li Y, Jennings N, Halder J, Coleman R, Jaffe R, Sood AK. Dual targeting of endothelial cells and pericytes in antivascular therapy for human ovarian cancer. The 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2006. e-Pub 2006.
Han LY, Trevino J, Landen CN, Kamat AA, Lin YG, Merritt WM, Shakespeare WC, Sawyer TK, Gallick G, Sood AK. Src as a novel therapeutic target in ovarian carcinoma. The 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2006. e-Pub 2006.
Guan H, Zhou Z, Gallick GE, Sood AK, Han LY, Sawyer TK, Shakespeare WC, Kleinerman ES. Lyn activation is necessary for Ewing's sarcoma tumor growth in a mouse model. The 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2006. e-Pub 2006.
Kamat AA, Bischoff FZ, Dang D, Han LY, Lin YG, Merritt WM, Gershenson DM, Simpson JL, Sood AK. Circulating cell-free DNA: a novel surrogate biomarker for response to therapy in an ovarian cancer model. The 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2006. e-Pub 2006.
Landen CN, Chavez-Reyes A, Bucana C, Han LY, Kamat AA, Lu C, Schmandt R, Lopez-Berestein G, Sood AK. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. The 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2006. e-Pub 2006.
Bennett M, Clifford SL, Thornton A, Broaddus RR, Gray JW, Jiang F, Lu KH, Sood AK, Gershenson DM, Schmandt RE. BRK/PTK6 is frequently amplified and promotes tumor growth in ovarian carcinoma. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Lin Y, Merritt WM, Thaker PH, Li Y, Gershenson DM, Lutgendorf SK, Cole SW. Stress hormone mediated invasion of ovarian cancer cells. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Han LY, Landen CN, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK. The diagnostic relevance of tissue factor (TF) and vascular endothelial growth factor (VEGF) in the detection of ovarian malignancies. The 37th Annual Meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, 2006. e-Pub 2006.
Yang EV, Sood AK, Chen M, Yeh PE, Glaser R. Expression of VEGF and MMPs in upregulated following sympathetic activation of nasopharyngeal carcinoma tumor cell lines. The 12th Annual Meeting of the Psychoneuroimmunology Research Society, Denver, CO, 2005. e-Pub 2005.
Halder JB, Landen C, Li Y, Jennings NB, Kamat A, Han L, Gershenson DM, Sood AK. FAK silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. The 96th Annual Meeting of the American Association for Cancer Research, Anaheim, CA, 2005. e-Pub 2005.
Han LY, Landen CN, Kamat A, Schmandt R, Mueller P, Gershenson DM, Sood AK. Preoperative serum tissue factor (TF): an independent predictor of poor outcome in ovarian carcinoma. The 36th Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2005. e-Pub 2005.
Han LY, Landen CN, Trevino J, Kamat AA, Jennings N, Gallick G, Sood AK. Role of Src as a therapeutic target in ovarian carcinoma. The Annual Meeting of the Western Association of Gynecologic Oncologists, Santa Fe, NM, 2005. e-Pub 2005.
Sood AK, Thaker PH, Lloyd M, Jennings N, Felix E, Newman R, Lutgendorf SK. Chronic Stress Promotes Angiogenesis in Ovarian Carcinoma. The 12th Annual Meeting of the Psychoneuroimmunology Research Society, Denver, CO, 2005. e-Pub 2005.
Kamat AA, Sood AK, Kheradmand F, Landen CN, Han L, Agoulnik AI. Relaxin promotes migration and invasion of endometrial carcinoma. The 36th Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2005. e-Pub 2005.
Thaker PH, Lloyd M, Jennings N, Felix E, Gershenson DM, Newman R, Lutgendorf SK, Sood AK. Chronic Stress Promotes Angiogenesis in Ovarian Carcinoma. The 36th Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2005. e-Pub 2005.
Kamat AA, Simpson JL, Sood AK, Gershenson DM, Bischoff FZ. Assessment of plasma cell-free DNA levels in ovarian cancer: A pilot study. he 52nd Annual Meeting of the Society for Gynecologic Investigation, Los Angeles, CA, 2005. e-Pub 2005.
Sood AK, Halder JB, Landen C, Li Y, Jennings NB, Kamat AA, Han L, Schmandt R, Gershenson DM. FAK silencing sensitizes ovarian cancer cells to docetaxel-mediated apoptosis. The Annual Meeting of the Western Association of Gynecologic Oncologists, Santa Fe, NM, 2005. e-Pub 2005.
Landen CN, Coffman K, Han L, Kamat A, Thaker P, Kinch MS, Sood AK. Anti-vascular therapy of ovarian cancer with an EphA2 agonistic monoclonal antibody. The 96th Annual Meeting of the American Association for Cancer Research, Anaheim, CA, 2005. e-Pub 2005.
Landen CN, Chavez-Reyes A, Bucana C, Kamat A, Han L, Thaker PH, Lopez-Berestein G, Sood AK. Small Interfering RNA (siRNA) in vivo therapy for ovarian carcinoma using a novel nano-particle. The 36th Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2005. e-Pub 2005.
Landen CN, Chavez-Reyes A, Bucana C, Kamat A, Han L, Thaker PH, Lopez-Berestein G, Sood AK. Therapeutic silencing of EphA2 by in vivo liposomal siRNA delivery. The 96th Annual Meeting of the American Association for Cancer Research, Anaheim, CA, 2005. e-Pub 2005.
Landen CN, Chavez-Reyes A, Bucana C, Kamat A, Han L, Thaker PH, Lopez-Berestein G, Sood AK. Therapeutic silencing of EphA2 by in vivo liposomal siRNA delivery. 13th SPORE Investigator’s Workshop, Washington, D.C, 2005. e-Pub 2005.
Sood AK, Fletcher MS, DeYoung B, Gruman LM, Thaker PH, Landen CN, Schmandt R, Gershenson DM. Biological and clinical significance of focal adhesion kinase (FAK) in ovarian cancer. The 36th Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2005. e-Pub 2005.
Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, DeGeest K, Lubaroff DM. Psychosocial factors and natural killer cell activity in the ovarian cancer microenvironment. The 36th Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2005. e-Pub 2005.
Sood AK, Lutgendorf SK, Cole SW, KeGeest K, Mueller P, Newman RA, Bhatty R, Landen C, Kamat A, Han L. Tumor metastasis: Biobehavioral mechanisms. NIH Mind-Body and Health Initiative Meeting. Bethesda, MD, 2005. e-Pub 2005.
Kamat A, Fletcher M, Gruman L, Mueller P, Yang Y, Landen CN, Han L, Gershenson DM, Sood AK. The clinical significance of stromal matrix metalloproteinase (MMP) expression in ovarian carcinoma. The 36th Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2005. e-Pub 2005.
Kamat A, Marsack K, Sangi-Haghpeykar H, Agoulnik A, Edwards C, Sood AK, Coffey D. Steroid receptor expression and grade predict survival in endometrioid endometrial adenocarcinoma. The 36th Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2005. e-Pub 2005.
Thaker P, Sood AK, Fidler IJ. Dual targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor for therapy of human ovarian carcinoma. The 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004. e-Pub 2004.
Thaker PH, Yokoi K, Rebhun RB, Fan D, Fidler IJ, Sood AK. Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist Nembutal. The 95th Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2004. e-Pub 2004.
Thaker P, Sood AK, Fidler I. Novel anti-vascular approach for therapy of ovarian carcinoma. Western Association of Gynecologic Oncologists and the Felix Rutledge Society, Monterey, CA, 2004. e-Pub 2004.
Thaker P, Sood AK, Fidler IJ. Dual targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor for therapy of human ovarian carcinoma. The 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004. e-Pub 2004.
Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sequential Intraperitoneal Topotecan and Oral Etoposide Chemotherapy in Recurrent Platinum-Resistant Ovarian Carcinoma: Results of a Phase II Trial. The 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004. e-Pub 2004.
Sood AK, Landen C, Bhatty R, Thaker P, Lutgendorf S. Stress hormone mediated invasion of ovarian cancer cells. 62nd Annual Scientific Meeting of the American Psychosomatic Society. Orlando, FL, 2004. e-Pub 2004.
Sood AK, Fletcher MS, DeYoung B, Gruman LM, Thaker P, Landen C, Schmandt R, Gershenson DM. Role of focal adhesion kinase (FAK) in ovarian cancer progression. Western Association of Gynecologic Oncologists and the Felix Rutledge Society, Monterey, CA, 2004. e-Pub 2004.
Sood AK, Cole S, Costanzo E, Yang M, Bradley S, Coffin J, Jabbari S, Rainwater K, Lutgendorf SK. VEGF stimulation by stress hormones in ovarian carcinoma cells. The 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004. e-Pub 2004.
Sood AK, Cooper BC, Ramirez P, Sorosky JI. Novel modification of the vertical rectus abdominis myocutaneous (VRAM) flap for neovagina creation. The 35th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2004. e-Pub 2004.
Nilsson MB Sood AK. Stress hormones stimulate secretion of interleukin-6 by human ovarian carcinoma cell lines. The 95th Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2004. e-Pub 2004.
Landen, JrCL, Klingelhutz A, Coffin J, Sood AK. Genomic instability is associated with lack of telomerase activation in ovarian cancer. The 95th Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2004. e-Pub 2004.
Landen CN, Das P, Lutgendorf S, Cole SC, Savary CA, Sood AK. Neuroendocrine modulation of STAT3 in ovarian cancer. Western Association of Gynecologic Oncologists and the Felix Rutledge Society, Monterey, CA, 2004. e-Pub 2004.
Thaker P, Kinch M, Sood AK. EphA2 expression is associated with aggressive features in ovarian carcinoma. The 44th Annual Clinical Conference on Molecular Therapeutics for Cancer Metastasis, Houston, TX, 2003. e-Pub 2003.
Sood AK, Coffin JE, Seftor EA, Hendrix MJC. Inhibition of ovarian tumor cell plasticity properties by MMP antagonists. The 94th Annual Meeting of the American Association for Cancer Research, Toronto, Canada, 2003. e-Pub 2003.
Sood AK, Coffin JE, Flectcher MS, Gruman LM, Heidger PM, Seftor EA, Hendrix MJC. Molecular determinants of ovarian cancer plasticity. The 9th Biennial Forum on Ovarian Cancer, Ettington Park, 2003. e-Pub 2003.
Geisler JP, Rose SL, Manahan KJ, Sorosky JI, Anderson B, Buller RE, Sood AK. Operative and short term complications of tunneled central venous catheters on a gynecologic oncology service. The 34rd Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA, 2003. e-Pub 2003.
Bender DP, Cooper BC, Sorosky JI, Sood AK. Placental growth factor (PlGF) is a novel prognostic marker in ovarian cancer. The 34rd Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA, 2003. e-Pub 2003.
Lutgendorf S, Cole S, Costanzo E, Rainwater K, Bradley S, Jabbari S, Sood AK. In vitro stimulation of VEGF by stress-related mediators in ovarian carcinoma. The 61st Annual Scientific Meeting of the American Psychosomatic Society, Phoenix, AZ, 2003. e-Pub 2003.
Sood AK, Thaker P, Ellis LM, Stoeltzing O, Rousseau D, Killion JJ, Fan D, Kruzel E, Fidler IJ. Inhibition of colon cancer metastasis by the GABA-receptor agonist Nembutol. The 44th Annual Clinical Conference on Molecular Therapeutics for Cancer Metastasis, Houston, TX, 2003. e-Pub 2003.
Sood AK, Coffin, Jabbari S, Buller RE, Hendrix MJC, Klingelhutz A. p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. The 34rd Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA, 2003. e-Pub 2003.
Lee CM, Slomovitz BM, Fletcher MS, M-C H, Lu KH, Sood AK. Maspin expression in endometrial carcinoma. The 94th Annual Meeting of the American Association for Cancer Research, Toronto, Canada, 2003. e-Pub 2003.
Sood AK, Cole S, Costanzo E, Yang M, Bradley S, Coffin J, Jabbari S, Rainwater K, Lutgendorf SK. Stress-related mediators stimulate VEGF secretion by ovarian cancer cells. The Annual Meeting of the Western Association of Gynecologic Oncologists, Steam Boat, CO, 2003. e-Pub 2003.
Eichholz A, Smith B, Sorosky JI, VanVoorhis B, Sood AK. Teaching operative dictations in U. S. residency programs. The 51st Annual College Meeting of the American College of Obstetricians and Gynecologists, New Orleans, LA, 2003. e-Pub 2003.
Cooper BC, Sorosky JI, Sood AK. Novel modification of the vertical rectus abdominis myocutaneous (VRAM) flap for neovagina creation. The Annual Meeting of the Western Association of Gynecologic Oncologists, Steam Boat Springs, CO, 2003. e-Pub 2003.
Costanzo ES, Lutgendorf SK, Sood AK, Dao M, Anderson B, Lubaroff DM. Biobehavioral factors associated with interleukin-6 in women with ovarian cancer. The 61st Annual Scientific Meeting of the American Psychosomatic Society, Phoenix, AZ, 2003. e-Pub 2003.
Sood AK, Fletcher MS, Zahn CM, Seftor EA, Hendrix MJC. Prognostic significance of tumor cell-lined vasculature and absence of necrosis in ovarian carcinoma. The 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2002. e-Pub 2002.
Mahavni V, Woltman M, Fletcher M, Sood AK. Perineural Invasion is an Adverse Prognostic factor in Invasive Squamous Cell Carcinoma of the Vulva. The 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2002. e-Pub 2002.
Sood AK, Fletcher MS, Gruman L, Coffin J, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA, Hendrix MJC. Maspin expression is associated with poor outcome in ovarian carcinoma. The 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2002. e-Pub 2002.
Sood AK, Fletcher MS, Gruman L, Coffin J, Jabbari S, Khalkhali-Ellis Z, Seftor EA, Hendrix MJC. Implications of subcellular maspin localization in ovarian tumors. The 49th Annual Meeting of the Society for Gynecologic Investigation, Los Angeles, CA, 2002. e-Pub 2002.
Gonda TA, Sood A, Walker R, Hendrix MJC, Meltzer PS. Gene expression profile of cisplatin resistance in ovarian cancer cell lines. Oncogenomics 2002: Dissecting Cancer through Genome Research, American Association for Cancer Research, Dublin, Ireland, 2002. e-Pub 2002.
Sood AK, Buller RE, Coffin J, Jabbari S, Hendrix MJC, Klingelhutz A. p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. The Annual Meeting of the Western Association of Gynecologic Oncologists, Newport Beach, CA, 2002. e-Pub 2002.
Gonda TA, Walker R, Sood A, Hendrix MJC, Meltzer PS. Gene expression of cisplatin resistance in ovarian cancer cell lines. Molecular targets and cancer therapeutics, Frankfurt, Germany, 2002. e-Pub 2002.
Sood AK, Coffin J, Fletcher MS, Arbour N, Khalkhali-Ellis Z, Seftor EA, Hendrix MJC. Wild-type maspin expression down-regulates invasion in ovarian carcinoma. The 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2002. e-Pub 2002.
Bender DP, Sood AK, Sorosky JI, Anderson B, Buller RE. Pretreatment Serum CA125 has Prognostic Value in Cervical Adenocarcinoma. The 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2002. e-Pub 2002.
Cooper BC, Ritchie J, Wieneke C, Coffin J, Sorosky JI, Anderson B, Buller RE, Sood AK. Preoperative serum vascular endothelial growth factor (VEGF) levels: significance in ovarian cancer. The 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami, FL, 2002. e-Pub 2002.
Geisler JP, Sorosky JI, Duong HL, Buekers, Geisler MJ, Sood AK, Anderson B, Buller RE. Papillary serous carcinoma of the uterus. Increased risk for subsequent or concurrent development of breast carcinoma. The 32nd Annual Meeting of the Society of Gynecologic Oncologists, Nashville, TN, 2001. e-Pub 2001.
Cooper BC, Lutgendorf S, Johnsen E, Anderson B, Buller RE, Sood AK. Vascular Endothelial Growth Factor (VEGF) and Correlation with Social Relationships in Ovarian Cancer. The Annual Meeting of the Western Association of Gynecologic Oncologists, Sun Valley, ID, 2001. e-Pub 2001.
Geisler JP, Sood AK, Zogg MA, Holmes RJ, Rathe JA, Buller RE. Ovarian cancer hMLH1 promoter methylation contributes to microsatellite instability. The Annual Meeting of the Western Association of Gynecologic Oncologists, Sun Valley, ID, 2001. e-Pub 2001.
Shahin MS, Sanders L, Sood AK. Phase II Study of ON-Q Pain Management System in Patients Undergoing Surgery for Gynecologic Malignancy. The Annual Meeting of the Western Association of Gynecologic Oncologists, Sun Valley, ID, 2001. e-Pub 2001.
Goodheart MJ, Sood AK, Vassef MA, Davis C, Buller RE. Ovarian Cancer P53 Gene Mutations Are Associated with Increased Microvessel Density. The 32nd Annual Meeting of the Society of Gynecologic Oncologists, Nashville, TN, 2001. e-Pub 2001.
Goodheart MJ, Sood AK, Kirby PA, Davis C, Buller RE. Ovarian Cancer VEGF Staining is Independent of p53 Mutation. The 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 2001. e-Pub 2001.
Sorosky JI, Sood AK, Shahin M, Anderson B. Medicinal leech therapy. The Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, Pittsburgh, PA, 2001. e-Pub 2001.
Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood A, Markman M, Benda J. Randomized trial of Cisplatin and Ifosfamide versus Cisplatin, Ifosfamide, and Bleomycin in advanced squamous cell carcinoma of the uterine cervix. The 32nd Annual Meeting of the Society of Gynecologic Oncologists, Nashville, TN, 2001. e-Pub 2001.
Sood AK, Shahin MS, Geisler JP, Sanders L, Sorosky JI, Anderson B, Buller RE. Sequential Intraperitoneal Topotecan and Oral Etoposide Chemotherapy in Recurrent Platinum-Resistant Ovarian Carcinoma: Results of a Phase II Trial. The Annual Meeting of the Western Association of Gynecologic Oncologists, Sun Valley, ID, 2001. e-Pub 2001.
Lutgendorf S, Sood AK, Johnsen E, Cooper B, Anderson, Sorosky J, Buller RE. Social relationships and tumor angiogenesis factors in ovarian cancer patients. Society of Behavioral Medicine, Seattle, WA, 2001. e-Pub 2001.
Sood AK, Seftor EA, Fletcher MS, Gardner LMG, Heidger PM, Buller RE, Seftor REB, Hendrix MJC. Molecular Determinants of Ovarian Cancer Plasticity. The 48th Annual Meeting of the Society for Gynecologic Investigation, Toronto, Canada 158(4), 2001. e-Pub 2001. PMID: 11290546.
Bender DP, Sood AK, Sorosky JI, Anderson B, Buller RE. The value of pretreatment CA-125 in cervical adenocarcinoma. The Annual Meeting of the Western Association of Gynecologic Oncologists, Sun Valley, ID, 2001. e-Pub 2001.
Sood AK, Rao SC, Nygaard IE, Sorosky JI. Effects of radical hysterectomy on anorectal function. The 31st Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2000. e-Pub 2000.
Shahin MS, Sood AK, Sorosky JI, Anderson BA, Buller RE. A case-matched molecular comparison of primary ovarian cancer versus primary peritoneal and fallopian tube carcinomas. The 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000. e-Pub 2000.
Shahin MS, Sood AK, Hughes JH, Sorosky JI, Anderson B, Buller RE. p53 tumor suppressor gene dysfunction is an important predictor of outcome in ovarian cancer. The 31st Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2000. e-Pub 2000.
Rao SSC, Sood AK, Kempf J, Sorosky JI, Nygaard I. Does radical hysterectomy affect anorectal function?. The Annual Meeting of the American Gastroenterological Association, San Diego, CA,, 2000. e-Pub 2000.
Sood AK, Seftor EA, Seftor RE, Buller RE, Hendrix MJC. Vasculogenic mimicry by human ovarian carcinoma cells. The 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000. e-Pub 2000.
Sood AK, Seftor EA, Meltzer PS, Seftor R, Buller RE, Hendrix MJC. Microarray analysis of genes involved in cisplatin resistance in ovarian cancer. The Annual Meeting of the Western Association of Gynecologic Oncologists, Monterey, CA, 2000. e-Pub 2000.
Lowe MP, Ault KA, Sood AK. Recurrent carcinoma in situ of neovagina. Mid Atlantic Gynecologic Oncology Society, Washington, D.C, 2000. e-Pub 2000.
Sood AK, Zhang S, Sorosky JI, Anderson B, Buller RE. Preservation of saphenous vein in inguinal lymphadenectomy decreases postoperative morbidity in vulvar cancer patients. The 31st Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2000. e-Pub 2000.
Cooper B, Sood AK, Davis C, Sorosky JI, Anderson B, Buller RE. Preoperative CA-125 Levels: An Independent Risk Factor in Ovarian Cancer. Mid Atlantic Gynecologic Oncology Society, Washington, D.C, 2000. e-Pub 2000.
Buller RE, Shahin MS, Holmes, Hatterman, Kirby PA, Sood AK. P53 mutations and microsatellite instability in ovarian cancer: Yin and Yang. American Gynecological and Obstetrical Society, Williamsburg, VA, 2000. e-Pub 2000.
Buller RE, Sood AK, Shahin MS, Anderson B, Sorosky JI. p53 null mutations: Further explorations. The 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2000. e-Pub 2000.
Sood AK, Holmes RW, Buller RE. Genomic instability in ovarian cancer: Application of the 1998 NCI international criteria. The 31st Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, 2000. e-Pub 2000.
Sood AK, Holmes R, Sorosky JI, Anderson, B, Buller RE. Preoperative serum vascular endothelial growth factor (VEGF) levels: Significance in ovarian cancer. The Annual Meeting of the Western Association of Gynecologic Oncologists, Victoria, BC, 1999. e-Pub 1999.
Shahin MS, Sood AK, Sorosky JI, Anderson B, Buller RE. Understanding ovarian cancer response to treatment utilizing a p53 molecular-structural analysis. The 30th Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 1999. e-Pub 1999.
Sood AK, Sorosky JI, Mayr NA, Anderson B, Buller RE, Niebyl JR. Cervical cancer after recent pregnancy: Does route of delivery influence survival?. The 30th Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 1999. e-Pub 1999.
Sood AK, Shahin MS, Buller RE. Correlation of p53 mutations with preoperative CA 125 levels in ovarian cancer. The 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 1999. e-Pub 1999.
Blackburn RR, Mayr NA, Sorosky JI, Barker J, Zhen W, Sood AK, Weidner GJ, Buekers T, Anderson B, Buller RE, Hussey DH. Adjuvant concurrent radiation therapy and cisplatin followed by post-radiation cisplatin and taxol in high-risk endometrial/cervical adenocarcinoma. The Annual Meeting of the American Radium Society, HI, 1999. e-Pub 1999.
Sood AK, Shahin MS, Buller RE. Molecular findings associated with preoperative CA 125 levels in ovarian cancer. The 30th Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, 1999. e-Pub 1999.
Minassian VA, Sood AK, Sorosky JI, Buller RE. Long term central venous access in gynecologic cancer patients. The Annual Meeting of the American College of Obstetricians and Gynecologists, District VI, Chicago, IL, 1998. e-Pub 1998.
Sood AK, Sorosky, JI, Squatrito RC, Skilling JS, Anderson B, Buller RE. Cyclosporin A: Role in reversal of chemoresistance in gynecologic malignancies. The 89th Annual Meeting of the American Association for Cancer Research, 1998. e-Pub 1998.
Sood AK, Lallas TA, Buekers TE, Buller RE. Ovarian cancer genomic instability correlates with BRCA1 mutations. The Fourth Joint Conference of the American Association for Cancer Research (AACR) and the Japanese Cancer Association Meeting, Maui, HI, 1998. e-Pub 1998.
Sood AK, Lallas TA, Buekers TE, fullenkamp, Buller RE. Undercurrents in ovarian carcinogenesis: The utility of a p53 probe. The 29th Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 1998. e-Pub 1998.
Buller RE, Lallas TA, Fullenkamp C, Sood AK, Anderson B, Sorosky JI. Selective X-chromosome inactivation (SXI) associated with BRCA1 loss of heterozygosity (LOH) is highly predictive of BRCA1 mutation in ovarian carcinoma. The 29th Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 1998. e-Pub 1998.
Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE. Distant metastases in ovarian cancer: Why do they occur? . The 29th Annual Meeting of the Society of Gynecologic Oncologists, Orlando, FL, 1998. e-Pub 1998.
Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, Benda JA, Morgan LS. Primary ovarian sarcoma: Analysis of prognostic variables and role of surgical cytoreduction. The Annual Meeting of the Western Association of Gynecologic Oncologists, Napa, CA, 1998. e-Pub 1998.
Sood AK, Buller RE, Burger R, Dawson JD, Sorosky JI, Berman M. Measurement of a preoperative CA125 level facilitates optimal management of uterine cancer and predicts clinical outcome. The 28th Annual Meeting of the Society of Gynecologic Oncologists, Phoenix, AZ, 1997. e-Pub 1997.
Sood AK, Sorosky JI, Mayr N, Krogman S, Anderson B, Buller RE, Hussey DH. Radiotherapeutic management of cervical cancer complicating pregnancy. The Annual Meeting of the American Radium Society, New York City, NY, 1997. e-Pub 1997.
Sood AK, Skilling JS, Buller RE. Genomic instability: Why the guardian fails in ovarian cancer. The 28th Annual Meeting of the Society of Gynecologic Oncologists, Phoenix, AZ, 1997. e-Pub 1997.
Mayr NA, Sood AK, To DA, Saw CB, Sorosky JI, Hussey DH. Ultra-late complications in cancer of the cervix treated with primary radiation therapy: 20-year follow-up. The 39th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Orlando, FL, 1997. e-Pub 1997.
Buller RE, Sood AK, Powills K, Fullenkamp C, Sorosky JI, Anderson BA. Evidence for additional hereditary breast/ovarian cancer syndromes: A novel LOH analysis. The 28th Annual Meeting of the Society of Gynecologic Oncologists, Phoenix, AZ, 1997. e-Pub 1997.
Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen R, Lager DJ. Field cancerization: Why late recurrent ovarian cancer isn't recurrent. American Gynecological and Obstetrical Society, Victoria B.C., Canada, 1997. e-Pub 1997.
Buller RE, Sood AK, Hodges K, Lager D. Avoiding misses: Understanding why a p53 target can be elusive. Cancer Gene Therapy: Conference Supplement 4(6):S19, 1997. e-Pub 1997.
Buller RE, Lallas TA, Fullenkamp C, Sood AK. Selective X-chromosome inactivation (SXI) associated with BRCA1 loss of heterozygosity (LOH) is highly predictive of BRCA1 mutation in ovarian carcinoma. Proceedings of the American Association for Cancer Research 38:167. Abstract #1121, 1997. e-Pub 1997.
Sood AK, Sorosky JI, Krogman S, Anderson B, Benda J, Buller RE. Surgical management of cervical cancer complicating pregnancy: A case-control study. The Annual Meeting of the Western Association of Gynecologic Oncologists, San Diego, CA, 1996. e-Pub 1996.
Sood AK, Knowlton S, Buller RE. Genomic instability in ovarian cancer: A reassessment using arbitrarily primed polymerase chain reaction. The Annual Meeting of the Western Association of Gynecologic Oncologists, San Diego, CA, 1996. e-Pub 1996.
Buller RE, Sood A, Fullenkamp C, Anderson B, Powills, Sorosky J. Ramifications of a shared BRCA1/CA125 promoter. Gynecologic Oncology 60:103, 1996. e-Pub 1996.
Signore CC, Sood AK, Richards DS. Second trimester vaginal bleeding: Correlation of ultrasound findings with perinatal outcome. The Annual Meeting of the American College of Obstetricians and Gynecologists, Denver, CO, 1996. e-Pub 1996.
Skilling JS, Sood AK, Plaxe S, Baergen R, Lager DJ, Buller RE. Late recurrent ovarian cancer: Tumor dormancy or new cancer?. Gynecologic Oncology 60:103, 1996. e-Pub 1996.
Sood AK, Knowlton S, Buller RE. Genomic instability in ovarian cancer: A reassessment using arbitrarily primed polymerase chain reaction. Proceedings of the American Association for Cancer Research 37:544. Abstract #3722, 1996. e-Pub 1996.
Sood AK, Yancey M, Richards D. Prediction of fetal macrosomia using humeral soft tissue thickness (HSTT). The Annual Meeting of the American College of Obstetricians and Gynecologists, District IV, Asheville, NC, 1994. e-Pub 1994.
Sood AK, Bahrani-Mostafavi Z, Stoerker J, Stone IK. Human papillomavirus DNA in LEEP plume. The Biennial Meeting of the American Society for Colposcopy and Cervical Pathology, Orlando, FL, 1994. e-Pub 1994.
Stoerker J, Sood A, Hackenwerth A, Allen JB, Reilly SS, Schwartz JN. Use of the polymerase chain reaction to diagnose related papillomavirus infections in archival cervical specimens. Journal of Cell. Biochem:197, 1989.
Lutgendorf SK, Thaker PH, Arevalo JMG, Goodheart MJ, Dahmoush L, Penedo F, Slavich GM, Sood AK, Cole SW. EMT polarization in ovarian carcinomas from patients with high social isolation. Cancer.
Kim O, Park EY, Kwon SY, Shin S, Emerson RE, Shin YH, DeMayo FJ, Lydon JP, Coffey DM, Hawkins SM, Quilliam LA, Cheon DJ, Karpf AR, Fernandez FM, Nephew KP, Sood AK, Bast RC, Widschwendter M, Godwin AK, Miller KD, Cho CH, Kim J. Ovarian progesterone is a crucial endogenous factor inducing ovarian cancer. Proceedings of the National Academy of Sciences.
Bateman NW, Abulez T, Soltis AR, McPherson A, Choi S, Garsed DW, Pandey A, Tian C, Hood BL, Conrads KA, P-N T, Oliver J, Gist G, Mitchell D, Litzi T, Tarney DM, Crothers BA, Mhawech-Fauceglia P, Dalgard CL, Wilkerson MD, Pierobon M, Petricoin EF, Yan C, Meerzaman D, Bodelon C, Wentzensen N, Lee JSH, The APOLLO Research Network, Huntsman DG, Shah S, Shriver CD, Phippen NT, Darcy KM, Bowtell D, Conrads TP, Maxwell GL. Proteogenomic alterations associated with immune infiltration and homologous recombination deficiency in high grade serous ovarian cancer identified in enriched tumor epithelium. NPJ Precis Oncol.
Sood AK. Proteome Changes Correlating with Neoadjuvant Chemotherapy Response and Residual Disease in Advanced Ovarian Cancers. ASMS Conference on Mass Spectrometry and Allied Topics.
Mostafa Eyada, Victoria Michael, Bryan M. Fellman, Shrina Patel, Pamela T. Soliman, Jeffrey Andrew How, Amir A. Jazaeri, Nicole D. Fleming, Shannon Neville Westin, Travis T. Sims. Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer. 2024 ASCO Annual Meeting.
Singh N, Goff M, Need E, Sood A, Mourtada F, Mastren T, Goel S, Shi S. Folate Receptor α-Targeted Alpha Therapy of Ovarian Cancer. 19th International Symposium on Recent Advances in Drug Delivery Systems.
Singh N, Goff M, Need E, Sood A, Mourtada F, Mastren T, Goel S, Shi S. Folate Receptor α-Targeted Alpha Therapy of Ovarian Cancer. Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting.

Book Chapters

Matsuo, K, Sood, AK, Gershenson, DM. MANAGEMENT OF EARLY-STAGE OVARIAN CANCER, 60-92, 2024.
Li Y, Yang S, Hu W, Sood AK. The roles of anoikis in cervical cancer. In: In: Anoikis: How the extracellular matrix regulates life-or-death decisions. Springer Nature, 127-136, 2021.
Coleman RL, Liu JS, Matsuo K, Thaker PH, Westin SN, Sood AK. Carcinoma of the ovaries and fallopian tubes. In: Abeloff’s Clinical Oncology, Sixth Edition. Elsevier, 1525 – 1543, 2020.
Oncul S, Amero P, Rodriguez-Aguayo C, Sood AK, Calin GA, Lopez-Berestein G. RNA delivery for cancer gene therapy. In: RNA Therapeutics. Elsevier, 2019.
Zhang J, Silva E, Sood AK, Liu J. Ovarian epithelial carcinogenesis. In: Gynecologic and Obstetric Pathology. Science Press & Springer Nature, Singapore Pte Ltd, 121-139, 2019.
Taki M, Rodriguez-Aguayo C, Mangala LS, Lopez-Berestein G, Sood AK. In: Avances in RNAi-based therapy for cancer, 2019.
Filant J, Nejad P, Paul A, Simonson B, Srinivasan S, Zhang X, Balaj L, Das S, Gandhi R, Laurent LC, Sood AK. Isolation of Extracellular RNA from Serum/Plasma. In: Methods Mol Biol, 43-57, 2018.
Kondetimmanahalli R, Gharpure KM, Wu SY, Lopez-Berestein G, Sood AK. In: Non-conding RNAs: Novel targets in anti-cancer drug development, 447-459, 2018.
Menter DG, Davis JS, Tucker SC, Hawk E, Crissman JD, Sood AK, Kopetz S, Honn KV. First responders” in cancer progression and metastasis. In: In- Platelets in Thrombotic and Non-thrombotic Disorders - Pathophysiology, Pharmacology and Therapeutics. Cambridge University Press, 1111-1132, 2017.
Zhang X, Lopez-Berestein G, Sood AK, Calin GA. Profiling long-non coding RNA expression using custom-designed microarray. In: Methods Mol Biol, 33-41, 2016.
Thaker PH, Sood AK. Molecular pathogenesis of ovarian cancer. In: Current Multidisciplinary Oncology: Gynecologic Cancer. Demos Medical Publishing, 95-104, 2015.
Taylor M, Coleman RL, Sood AK. The role of angiogenesis in cancer. In: Targeted Therapy in Translational Cancer Research. : JohnWiley & Sons, 64-71, 2015.
Jiang D, Mangala LS, Rodriguez-Aguayo C, Gorenstein D, Lopez-Berestein G, Sood AK. Targeting approaches for nanoparticles. In: Nanoparticles for Delivery of Biotherapeutics. In: Future Science Group. Future Science Group, 64-77, 2015.
Kanlikilicer P, Rashed M, Ozpolat B, Ivan C, Rodriguez-Aguayo C, Sood AK, Calin GA, Lopez-Berestein G. The “EX” and the “SOMA”: How they communicate. In: Nano-Oncologicals: New Targeting and Delivery Approaches. In: In: Nano-Oncologicals: New Targeting and Delivery Approaches. Springer, 47 – 66, 2014.
Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK. RNAi in Cancer Therapy. In: Advanced delivery and therapeutic applications of RNA interference. John Wiley & Sons, Inc, 271-307, 2013.
Westin SN, Sood AK, Coleman RL. Targeted therapy and molecular genetics (Chapter 19). In: Clinical Gynecologic Oncology. (8th edition). Elsevier, 539-560, 2012.
Thaker PH, Sood AK. Immunology and Molecular Oncology in Gynecologic Cancer: Immunologic Response, Cytokines, Oncogenes, and Tumor Suppressor Genes. In: Comprehensive Gynecology. Sixth. Elsevier, 623-634, 2012.
Costanzo ES, Sood AK, Lutgendorf SK. Biobehavioral influences on cancer progression. In: Immunol Allergy Clin North Am. 1, 109-32, 2011.
Ahmed AA, Knapp S, Sood AK, Bast RC. Targeting therapies in cancer: Opportunities in Ovarian cancer. In: Gynecological Cancers: Biology and Therapeutics. RCOG Press, 167-182, 2011.
Matsuo K, Lu C, Shahzad MMK, Coleman RL, Sood AK. Role of pericytes in resistance to anti-angiogenic therapy. In: The Tumor Microenvironment. Springer, 311-324, 2010.
Costanzo E, Sood AK, Lutgendorf SK. Biobehavioral influences on cancer progression. In: Stress and Inflammatory Diseases in Immunology and Allergy Clinics of North America, 31(1):109-132, 2010.
Allen JK, Allen JK, Armaiz-Pena G, Armaiz-Pena G, Sood AK, Sood AK. Stress and Cancer. In: The M.D. Anderson Manual of Psychosocial Oncology. McGraw Hill, 17-34, 2010.
Nick AM, Coleman RL, Sood AK. Molecular therapeutics in ovarian carcinoma. In: Ovarian Cancer: State of the Art. Remedica Medical Education and Publishing Limited, Chapter 5, pages 109-160, 2009.
Mangala LS, Han HD, Lopez-Berestein G, Sood AK. Liposomal siRNA for ovarian cancer. In: Methods Mol Biol. Humana Press, 29-42, 2009.
Maxwell GL, Berchuck A, Sood AK. Biology and Genetics. In: Practical Gynecologic Oncology. Fifth. Lippincott Williams & Wilkins, 2009.
Sood AK, Lin YG, Jaffe RB. Prognostic and predictive implications of angiogenesis in ovarian carcinoma. In: Prognostic and Predictive Factors in Gynecologic Cancers. Taylor & Francis Group, 2007.
Lu C, Sood AK. Role of pericytes in angiogenesis. In: Angiogenesis Agents in Cancer Therapy. Second. The Humana Press, Inc, 117-132, 2007.
Sood AK, Gershenson DM. Management of early-stage ovarian cancer (Chapter 3). In: Surgery for ovarian cancer: Principles and Practice. Parthenon Publishing, 57-86, 2006.
Sood AK, Lutgendorf SK, Ben-Eliyahu S. Neuroendocrine regulation of cancer progression: from mechanisms to clinical relevance. In: Psychoneuroimmunology. Fourth, 233-249, 2006.
Sood AK. Genetics and Cancer. In: Women's Cancer Network (on-line chapter), 2002.
Sood AK, Buller RE. SSCP and sequence analysis of p53 mutation in ovarian tumors. In: Methods in Molecular Medicine: Ovarian Cancer Methods and Protocols. Humana Press, 323-328, 2000.
Sood AK, Sorosky JI. Invasive cervical cancer complicating pregnancy: How to manage the dilemma. In: Obstetrics and Gynecology Clinics of North America, 343-52, 1998.
Sorosky JI, Sood AK, Buekers TE. The use of chemotherapeutic agents during pregnancy. In: Obstetrics and Gynecology Clinics of North America, 591-9, 1997.
Mangala LS, Rodriguez-Aguayo C, Bayraktar E, Jennings NB, Lopez-Berestein G, Sood AK. Assessment of in vivo siRNA delivery in cancer mouse models. In: Long non-coding RNAs: Methods and protocols, 2nd edition. Humana Press, 157-168.
Fleming ND, Coleman RL, Sood AK. Targeted therapies in ovarian cancer. In: Clinical Decisions Support Project.
Alpay SN, Ozpolat B, Han HD, Lopez-Berestein G, Sood AK, Pan HL. Regulation of cell signaling in the nervous system with nanoparticles containing siRNA. In: Nanomedicine and the Nervous System. Science Publishers.
Chen A, Zhaoxia D, Sood AK, Hu W. Hormonal therapy for ovarian cancer. In: Encyclopedia of Cancer. Springer.
Aslan B, Han HD, Lopez-Berestein G, Sood AK. Chitosan nanoparticles. In: Encyclopedia of Nanotechnology. Springer.
Lutgendorf SK, Costanzo E, Sood AK. Psychoneuroimmunology and cancer: Biobehavioral influences on tumor progression. In: The Oxford Handbook of Psychoneuroimmunology.
Mora EM, Mangala LS, Lopez-Berestein G, Sood AK. RNAi: A new paradigm in cancer gene therapy. In: Gene based therapies for Cancer. Springer.
Sood AK, Matsuo K, Gershenson DM. Management of early-stage ovarian cancer. In: Surgery for ovarian cancer: Principles and practice. Second. Parthenon Publishing.
Han LY, Sood AK. Inhibition of the Src Oncogene: Therapeutic potential in ovarian carcinoma. In: Emerging Therapeutics in Cancer.
Denizli M, Aslan B, Rodriguez-Aguayo C, Mangala LS, Jiang D, Lopez-Berestein G, Sood AK. In: Chitosan nanoparticles for miRNA delivery. In: RNA Nanostructures. Methods in Molecular Biology. Humana.
Liang L, Mercado-Uribe I, Niu N, Jiang Y, Cheng W, Mills GB, Scott C, Sood AK, Liu J. Patient-derived xenograft models of ovarian/gynecologic tumors. In: In: Patient Derived Tumor Xenograft Model. Elsevier, 257-272.
Stone RL, Sood AK. Status of targeted/molecular therapy for ovarian cancer. In: Ovarian Cancer: Ask the Experts. Humana Press, Inc.
Menter DG, Fowlkes NW, Honn KV, Sood AK. The evolution and role of platelets in cancer biology and metastasis. In: Platelets in Disease: Thrombotic disorders and disorders not involving hemorrhage or thrombosis, Volume 4. 97. Springer Natuer, 1789-1806.
Alpay SN, Ozpolat B, Han HD, Lopez-Berestein G, Sood AK, Pan HL. Delivering siRNA using nanoparticles to the central nervous system. In: Nanomedicine and the Nervous System. Science Publishers, 228-249.

Books (edited and written)

Sood AK, Matsuo K. Management of early stage ovarian cancer - 2nd Edition.

Letters to the Editor

Thaker PH, Urbauer DL, Sood AK. Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?. Cancer 122: 325-6, 2016.
Zhang W, Yang D, Sood AK. Exploring clinical and molecular differences between BRCA1 and BRCA2 mutations in serous ovarian carcinoma. Reply to correspondence. Journal of the American Medical Association 307: 360-361, 2012.
Stone RL, Afshar-Kharghan V, AK S. Paraneoplastic thrombocytosis in ovarian cancer. Response to Naina HV, Harris S. The New England Journal of Medicine 366: 1840, 2012.
Merritt WM, Urbauer DL, Sood AK. Dicer and Drosha in ovarian cancer. Response to Correspondence from Kobel M, Gilks CB, Huntsman DG. The New England Journal of Medicine 360: 1150-1151, 2009.
Lowe MP, Sood AK. Response to Letter-to-the-Editor by Guvendag Guven et al regarding "Recurrent carcinoma in situ of a neovagina". Gynecologic Oncology 92: 728-729, 2004.

Patents

Delivery of siRNA by neutral lipid compositions. Patent Number: 60/671,641 (filing date: April 15, 2005). (Australian patent number 2006236453 issued February 23, 2012; U.S. patent number 8,895,717 issued November 25, 2014).
Novel tissue protective erythropoietin receptor (NEPOR) and methods of use. Patent Number: 2 109 690.
Pro-angiogenic gene in ovarian tumor endothelial cell isolates. Patent Number: (filed: December, 2006; Issued: May 14, 2013; Patent number 8440393).
Vivas-Mejia PE, Reyes Gonzalez JM, Sood AK. Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer. Patent Number: 11090266.
Methods and Composition of Matter Related to Wrapping of Dehydrons (filed: October, 2007; Issued: June 18, 2013; U.S. Patent Number 8,466,154 B2). Patent Number: U.S. Patent Number 8,466,154 B2.
HDL nanoparticles for delivery of nucleic acids. Patent Number: (filed: December, 2007; Issued: May 27, 2014; U.S. Patent Number 8,734,853).
Methods for treating cancer targeting transglutaminase. Patent Number: (filed October 5, 2007; Issued: October 30, 2012; Patent number 8299040).
Sood AK. Therapeutic peptides. Patent Number: 12,448,425.
Therapeutic targeting of Interleukins using siRNA in neutral liposomes. Patent Number: US 8,067,390 B2.
Sood AK. DNA aptamers and use thereof for the treatment of cancer. Patent Number: 12,077,760.